id	sid	tid	token	lemma	pos
fnp-6382	1	1	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	1	2	mechanisms	mechanism	NOUN
fnp-6382	1	3	may	may	AUX
fnp-6382	1	4	help	help	VERB
fnp-6382	1	5	identify	identify	VERB
fnp-6382	1	6	candidate	candidate	NOUN
fnp-6382	1	7	biomarkers	biomarker	NOUN
fnp-6382	1	8	in	in	ADP
fnp-6382	1	9	chronic	chronic	ADJ
fnp-6382	1	10	traumatic	traumatic	ADJ
fnp-6382	1	11	encephalopathy	encephalopathy	NOUN
fnp-6382	1	12	(	(	PUNCT
fnp-6382	1	13	cte	cte	NOUN
fnp-6382	1	14	)	)	PUNCT
fnp-6382	1	15	feel	feel	VERB
fnp-6382	1	16	free	free	ADJ
fnp-6382	1	17	to	to	PART
fnp-6382	1	18	add	add	VERB
fnp-6382	1	19	comments	comment	NOUN
fnp-6382	1	20	by	by	ADP
fnp-6382	1	21	clicking	click	VERB
fnp-6382	1	22	these	these	DET
fnp-6382	1	23	icons	icon	NOUN
fnp-6382	1	24	on	on	ADP
fnp-6382	1	25	the	the	DET
fnp-6382	1	26	sidebar	sidebar	NOUN
fnp-6382	1	27	free	free	ADJ
fnp-6382	1	28	neuropathology	neuropathology	NOUN
fnp-6382	1	29	6:15	6:15	NUM
fnp-6382	1	30	(	(	PUNCT
fnp-6382	1	31	2025	2025	NUM
fnp-6382	1	32	)	)	PUNCT
fnp-6382	1	33	review	review	VERB
fnp-6382	1	34	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	1	35	mechanisms	mechanism	NOUN
fnp-6382	1	36	may	may	AUX
fnp-6382	1	37	help	help	VERB
fnp-6382	1	38	identify	identify	VERB
fnp-6382	1	39	candidate	candidate	NOUN
fnp-6382	1	40	biomarkers	biomarker	NOUN
fnp-6382	1	41	in	in	ADP
fnp-6382	1	42	chronic	chronic	ADJ
fnp-6382	1	43	traumatic	traumatic	ADJ
fnp-6382	1	44	encephalopathy	encephalopathy	NOUN
fnp-6382	2	1	(	(	PUNCT
fnp-6382	2	2	cte	cte	NOUN
fnp-6382	2	3	)	)	PUNCT
fnp-6382	2	4	guneet	guneet	PROPN
fnp-6382	2	5	s.	s.	PROPN
fnp-6382	2	6	bindra1,2	bindra1,2	PROPN
fnp-6382	2	7	,	,	PUNCT
fnp-6382	2	8	shaheryar	shaheryar	NOUN
fnp-6382	2	9	asad1	asad1	PROPN
fnp-6382	2	10	,	,	PUNCT
fnp-6382	2	11	jean	jean	PROPN
fnp-6382	2	12	shanaa1	shanaa1	PROPN
fnp-6382	2	13	,	,	PUNCT
fnp-6382	2	14	forshing	forshe	VERB
fnp-6382	2	15	lui1	lui1	PROPN
fnp-6382	2	16	,	,	PUNCT
fnp-6382	2	17	andrew	andrew	PROPN
fnp-6382	2	18	e.	e.	PROPN
fnp-6382	2	19	budson2,3,4	budson2,3,4	PROPN
fnp-6382	2	20	,	,	PUNCT
fnp-6382	2	21	katherine	katherine	PROPN
fnp-6382	2	22	w.	w.	PROPN
fnp-6382	2	23	turk2,3,4	turk2,3,4	PROPN
fnp-6382	2	24	,	,	PUNCT
fnp-6382	2	25	jonathan	jonathan	PROPN
fnp-6382	2	26	d.	d.	PROPN
fnp-6382	2	27	cherry2,3,4,5,6	cherry2,3,4,5,6	PROPN
fnp-6382	2	28	california	california	PROPN
fnp-6382	2	29	northstate	northstate	PROPN
fnp-6382	2	30	university	university	PROPN
fnp-6382	2	31	college	college	PROPN
fnp-6382	2	32	of	of	ADP
fnp-6382	2	33	medicine	medicine	NOUN
fnp-6382	2	34	,	,	PUNCT
fnp-6382	2	35	elk	elk	PROPN
fnp-6382	2	36	grove	grove	PROPN
fnp-6382	2	37	,	,	PUNCT
fnp-6382	2	38	usa	usa	PROPN
fnp-6382	2	39	va	va	PROPN
fnp-6382	2	40	boston	boston	PROPN
fnp-6382	2	41	healthcare	healthcare	PROPN
fnp-6382	2	42	system	system	PROPN
fnp-6382	2	43	,	,	PUNCT
fnp-6382	2	44	boston	boston	PROPN
fnp-6382	2	45	,	,	PUNCT
fnp-6382	2	46	usa	usa	PROPN
fnp-6382	2	47	boston	boston	PROPN
fnp-6382	2	48	university	university	PROPN
fnp-6382	2	49	alzheimer	alzheimer	PROPN
fnp-6382	2	50	's	's	PART
fnp-6382	2	51	disease	disease	NOUN
fnp-6382	2	52	and	and	CCONJ
fnp-6382	2	53	cte	cte	NOUN
fnp-6382	2	54	centers	center	NOUN
fnp-6382	2	55	,	,	PUNCT
fnp-6382	2	56	boston	boston	PROPN
fnp-6382	2	57	university	university	PROPN
fnp-6382	2	58	school	school	NOUN
fnp-6382	2	59	of	of	ADP
fnp-6382	2	60	medicine	medicine	NOUN
fnp-6382	2	61	,	,	PUNCT
fnp-6382	2	62	boston	boston	PROPN
fnp-6382	2	63	,	,	PUNCT
fnp-6382	2	64	usa	usa	PROPN
fnp-6382	2	65	department	department	PROPN
fnp-6382	2	66	of	of	ADP
fnp-6382	2	67	neurology	neurology	PROPN
fnp-6382	2	68	,	,	PUNCT
fnp-6382	2	69	boston	boston	PROPN
fnp-6382	2	70	university	university	PROPN
fnp-6382	2	71	school	school	NOUN
fnp-6382	2	72	of	of	ADP
fnp-6382	2	73	medicine	medicine	NOUN
fnp-6382	2	74	,	,	PUNCT
fnp-6382	2	75	boston	boston	PROPN
fnp-6382	2	76	,	,	PUNCT
fnp-6382	2	77	usa	usa	PROPN
fnp-6382	2	78	department	department	PROPN
fnp-6382	2	79	of	of	ADP
fnp-6382	2	80	pathology	pathology	PROPN
fnp-6382	2	81	and	and	CCONJ
fnp-6382	2	82	laboratory	laboratory	NOUN
fnp-6382	2	83	medicine	medicine	NOUN
fnp-6382	2	84	,	,	PUNCT
fnp-6382	2	85	boston	boston	PROPN
fnp-6382	2	86	university	university	PROPN
fnp-6382	2	87	school	school	NOUN
fnp-6382	2	88	of	of	ADP
fnp-6382	2	89	medicine	medicine	NOUN
fnp-6382	2	90	,	,	PUNCT
fnp-6382	2	91	boston	boston	PROPN
fnp-6382	2	92	,	,	PUNCT
fnp-6382	2	93	usa	usa	PROPN
fnp-6382	2	94	department	department	PROPN
fnp-6382	2	95	of	of	ADP
fnp-6382	2	96	anatomy	anatomy	NOUN
fnp-6382	2	97	and	and	CCONJ
fnp-6382	2	98	neurobiology	neurobiology	NOUN
fnp-6382	2	99	,	,	PUNCT
fnp-6382	2	100	boston	boston	PROPN
fnp-6382	2	101	university	university	PROPN
fnp-6382	2	102	school	school	NOUN
fnp-6382	2	103	of	of	ADP
fnp-6382	2	104	medicine	medicine	NOUN
fnp-6382	2	105	,	,	PUNCT
fnp-6382	2	106	boston	boston	PROPN
fnp-6382	2	107	,	,	PUNCT
fnp-6382	2	108	usa	usa	PROPN
fnp-6382	2	109	corresponding	corresponding	PROPN
fnp-6382	2	110	author	author	NOUN
fnp-6382	2	111	:	:	PUNCT
fnp-6382	2	112	jonathan	jonathan	PROPN
fnp-6382	2	113	d.	d.	PROPN
fnp-6382	2	114	cherry	cherry	PROPN
fnp-6382	2	115	·	·	PROPN
fnp-6382	2	116	va	va	PROPN
fnp-6382	2	117	boston	boston	PROPN
fnp-6382	2	118	healthcare	healthcare	PROPN
fnp-6382	2	119	system	system	NOUN
fnp-6382	2	120	·	·	PUNCT
fnp-6382	2	121	150	150	NUM
fnp-6382	2	122	south	south	PROPN
fnp-6382	2	123	huntington	huntington	PROPN
fnp-6382	2	124	avenue	avenue	PROPN
fnp-6382	2	125	·	·	PUNCT
fnp-6382	2	126	ma	ma	PROPN
fnp-6382	2	127	02130	02130	NUM
fnp-6382	2	128	·	·	PUNCT
fnp-6382	2	129	boston	boston	PROPN
fnp-6382	2	130	·	·	PUNCT
fnp-6382	2	131	usa	usa	PROPN
fnp-6382	2	132	·	·	PUNCT
fnp-6382	2	133	jdcherry@bu.edu	jdcherry@bu.edu	PROPN
fnp-6382	2	134	submitted	submit	VERB
fnp-6382	2	135	:	:	PUNCT
fnp-6382	2	136	14	14	NUM
fnp-6382	2	137	march	march	NOUN
fnp-6382	2	138	2025	2025	NUM
fnp-6382	2	139	accepted	accept	VERB
fnp-6382	2	140	:	:	PUNCT
fnp-6382	2	141	29	29	NUM
fnp-6382	2	142	june	june	PROPN
fnp-6382	2	143	2025	2025	NUM
fnp-6382	2	144	copyedited	copyedit	VERB
fnp-6382	2	145	by	by	ADP
fnp-6382	2	146	:	:	PUNCT
fnp-6382	2	147	georg	georg	NOUN
fnp-6382	2	148	haase	haase	NOUN
fnp-6382	2	149	published	publish	VERB
fnp-6382	2	150	:	:	PUNCT
fnp-6382	2	151	14	14	NUM
fnp-6382	2	152	july	july	PROPN
fnp-6382	2	153	2025	2025	NUM
fnp-6382	2	154	https://doi.org/10.17879/freeneuropathology-2025-6832	https://doi.org/10.17879/freeneuropathology-2025-6832	PROPN
fnp-6382	2	155	keywords	keyword	NOUN
fnp-6382	2	156	:	:	PUNCT
fnp-6382	3	1	chronic	chronic	ADJ
fnp-6382	3	2	traumatic	traumatic	ADJ
fnp-6382	3	3	encephalopathy	encephalopathy	NOUN
fnp-6382	3	4	,	,	PUNCT
fnp-6382	3	5	repetitive	repetitive	ADJ
fnp-6382	3	6	head	head	NOUN
fnp-6382	3	7	impacts	impact	NOUN
fnp-6382	3	8	,	,	PUNCT
fnp-6382	3	9	traumatic	traumatic	ADJ
fnp-6382	3	10	brain	brain	NOUN
fnp-6382	3	11	injury	injury	NOUN
fnp-6382	3	12	,	,	PUNCT
fnp-6382	3	13	inflammatory	inflammatory	ADJ
fnp-6382	3	14	signature	signature	NOUN
fnp-6382	3	15	,	,	PUNCT
fnp-6382	3	16	biomarkers	biomarker	NOUN
fnp-6382	3	17	,	,	PUNCT
fnp-6382	3	18	neuroinflammation	neuroinflammation	NOUN
fnp-6382	3	19	abstract	abstract	ADJ
fnp-6382	3	20	chronic	chronic	ADJ
fnp-6382	3	21	traumatic	traumatic	ADJ
fnp-6382	3	22	encephalopathy	encephalopathy	NOUN
fnp-6382	3	23	(	(	PUNCT
fnp-6382	3	24	cte	cte	NOUN
fnp-6382	3	25	)	)	PUNCT
fnp-6382	3	26	is	be	AUX
fnp-6382	3	27	a	a	DET
fnp-6382	3	28	neurodegenerative	neurodegenerative	ADJ
fnp-6382	3	29	disease	disease	NOUN
fnp-6382	3	30	that	that	PRON
fnp-6382	3	31	can	can	AUX
fnp-6382	3	32	only	only	ADV
fnp-6382	3	33	be	be	AUX
fnp-6382	3	34	diagnosed	diagnose	VERB
fnp-6382	3	35	post	post	ADJ
fnp-6382	3	36	-	-	ADJ
fnp-6382	3	37	mortem	mortem	ADJ
fnp-6382	3	38	via	via	ADP
fnp-6382	3	39	pathological	pathological	ADJ
fnp-6382	3	40	autopsy	autopsy	NOUN
fnp-6382	3	41	.	.	PUNCT
fnp-6382	4	1	the	the	DET
fnp-6382	4	2	primary	primary	ADJ
fnp-6382	4	3	risk	risk	NOUN
fnp-6382	4	4	factor	factor	NOUN
fnp-6382	4	5	for	for	ADP
fnp-6382	4	6	cte	cte	NOUN
fnp-6382	4	7	is	be	AUX
fnp-6382	4	8	a	a	DET
fnp-6382	4	9	history	history	NOUN
fnp-6382	4	10	of	of	ADP
fnp-6382	4	11	repetitive	repetitive	ADJ
fnp-6382	4	12	head	head	NOUN
fnp-6382	4	13	impacts	impact	NOUN
fnp-6382	4	14	(	(	PUNCT
fnp-6382	4	15	rhi	rhi	NOUN
fnp-6382	4	16	)	)	PUNCT
fnp-6382	4	17	received	receive	VERB
fnp-6382	4	18	through	through	ADP
fnp-6382	4	19	contact	contact	NOUN
fnp-6382	4	20	sports	sport	NOUN
fnp-6382	4	21	including	include	VERB
fnp-6382	4	22	american	american	PROPN
fnp-6382	4	23	football	football	PROPN
fnp-6382	4	24	,	,	PUNCT
fnp-6382	4	25	hockey	hockey	NOUN
fnp-6382	4	26	or	or	CCONJ
fnp-6382	4	27	soccer	soccer	NOUN
fnp-6382	4	28	,	,	PUNCT
fnp-6382	4	29	military	military	NOUN
fnp-6382	4	30	-	-	PUNCT
fnp-6382	4	31	related	relate	VERB
fnp-6382	4	32	head	head	NOUN
fnp-6382	4	33	injuries	injury	NOUN
fnp-6382	4	34	,	,	PUNCT
fnp-6382	4	35	or	or	CCONJ
fnp-6382	4	36	intimate	intimate	ADJ
fnp-6382	4	37	partner	partner	NOUN
fnp-6382	4	38	violence	violence	NOUN
fnp-6382	4	39	.	.	PUNCT
fnp-6382	5	1	recent	recent	ADJ
fnp-6382	5	2	findings	finding	NOUN
fnp-6382	5	3	have	have	AUX
fnp-6382	5	4	demonstrated	demonstrate	VERB
fnp-6382	5	5	that	that	SCONJ
fnp-6382	5	6	neuroinflammation	neuroinflammation	NOUN
fnp-6382	5	7	is	be	AUX
fnp-6382	5	8	a	a	DET
fnp-6382	5	9	critical	critical	ADJ
fnp-6382	5	10	compo	compo	NOUN
fnp-6382	5	11	-	-	PUNCT
fnp-6382	5	12	nent	nent	NOUN
fnp-6382	5	13	of	of	ADP
fnp-6382	5	14	early	early	ADJ
fnp-6382	5	15	cte	cte	NOUN
fnp-6382	5	16	pathogenesis	pathogenesis	NOUN
fnp-6382	5	17	and	and	CCONJ
fnp-6382	5	18	is	be	AUX
fnp-6382	5	19	likely	likely	ADJ
fnp-6382	5	20	part	part	NOUN
fnp-6382	5	21	of	of	ADP
fnp-6382	5	22	the	the	DET
fnp-6382	5	23	mechanism	mechanism	NOUN
fnp-6382	5	24	driving	driving	NOUN
fnp-6382	5	25	disease	disease	NOUN
fnp-6382	5	26	onset	onset	NOUN
fnp-6382	5	27	and	and	CCONJ
fnp-6382	5	28	progression	progression	NOUN
fnp-6382	5	29	.	.	PUNCT
fnp-6382	6	1	additionally	additionally	ADV
fnp-6382	6	2	,	,	PUNCT
fnp-6382	6	3	the	the	DET
fnp-6382	6	4	innate	innate	ADJ
fnp-6382	6	5	specificity	specificity	NOUN
fnp-6382	6	6	,	,	PUNCT
fnp-6382	6	7	or	or	CCONJ
fnp-6382	6	8	‘	'	PUNCT
fnp-6382	6	9	signature	signature	NOUN
fnp-6382	6	10	’	'	PUNCT
fnp-6382	6	11	,	,	PUNCT
fnp-6382	6	12	of	of	ADP
fnp-6382	6	13	a	a	DET
fnp-6382	6	14	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	6	15	response	response	NOUN
fnp-6382	6	16	may	may	AUX
fnp-6382	6	17	function	function	VERB
fnp-6382	6	18	as	as	ADP
fnp-6382	6	19	a	a	DET
fnp-6382	6	20	dis	dis	NOUN
fnp-6382	6	21	-	-	PUNCT
fnp-6382	6	22	ease	ease	NOUN
fnp-6382	6	23	-	-	PUNCT
fnp-6382	6	24	specific	specific	ADJ
fnp-6382	6	25	marker	marker	NOUN
fnp-6382	6	26	for	for	ADP
fnp-6382	6	27	various	various	ADJ
fnp-6382	6	28	neurodegenerative	neurodegenerative	ADJ
fnp-6382	6	29	conditions	condition	NOUN
fnp-6382	6	30	.	.	PUNCT
fnp-6382	7	1	this	this	PRON
fnp-6382	7	2	would	would	AUX
fnp-6382	7	3	suggest	suggest	VERB
fnp-6382	7	4	an	an	DET
fnp-6382	7	5	enormous	enormous	ADJ
fnp-6382	7	6	repository	repository	NOUN
fnp-6382	7	7	of	of	ADP
fnp-6382	7	8	novel	novel	ADJ
fnp-6382	7	9	cte	cte	NOUN
fnp-6382	7	10	biomarker	biomarker	NOUN
fnp-6382	7	11	candidates	candidate	NOUN
fnp-6382	7	12	to	to	PART
fnp-6382	7	13	be	be	AUX
fnp-6382	7	14	added	add	VERB
fnp-6382	7	15	to	to	ADP
fnp-6382	7	16	ongoing	ongoing	ADJ
fnp-6382	7	17	clinical	clinical	ADJ
fnp-6382	7	18	trials	trial	NOUN
fnp-6382	7	19	,	,	PUNCT
fnp-6382	7	20	helping	helping	AUX
fnp-6382	7	21	bolster	bolster	VERB
fnp-6382	7	22	diagnosis	diagnosis	NOUN
fnp-6382	7	23	.	.	PUNCT
fnp-6382	8	1	however	however	ADV
fnp-6382	8	2	,	,	PUNCT
fnp-6382	8	3	few	few	ADJ
fnp-6382	8	4	studies	study	NOUN
fnp-6382	8	5	have	have	VERB
fnp-6382	8	6	truly	truly	ADV
fnp-6382	8	7	leveraged	leverage	VERB
fnp-6382	8	8	immune	immune	ADJ
fnp-6382	8	9	mediators	mediator	NOUN
fnp-6382	8	10	as	as	ADP
fnp-6382	8	11	candidate	candidate	NOUN
fnp-6382	8	12	cte	cte	PROPN
fnp-6382	8	13	markers	marker	NOUN
fnp-6382	8	14	.	.	PUNCT
fnp-6382	9	1	in	in	ADP
fnp-6382	9	2	this	this	DET
fnp-6382	9	3	review	review	NOUN
fnp-6382	9	4	,	,	PUNCT
fnp-6382	9	5	we	we	PRON
fnp-6382	9	6	argue	argue	VERB
fnp-6382	9	7	and	and	CCONJ
fnp-6382	9	8	provide	provide	VERB
fnp-6382	9	9	support	support	NOUN
fnp-6382	9	10	that	that	SCONJ
fnp-6382	9	11	inflammatory	inflammatory	ADJ
fnp-6382	9	12	mechanisms	mechanism	NOUN
fnp-6382	9	13	could	could	AUX
fnp-6382	9	14	serve	serve	VERB
fnp-6382	9	15	as	as	ADP
fnp-6382	9	16	a	a	DET
fnp-6382	9	17	viable	viable	ADJ
fnp-6382	9	18	source	source	NOUN
fnp-6382	9	19	for	for	ADP
fnp-6382	9	20	novel	novel	ADJ
fnp-6382	9	21	biomarkers	biomarker	NOUN
fnp-6382	9	22	that	that	PRON
fnp-6382	9	23	are	be	AUX
fnp-6382	9	24	specific	specific	ADJ
fnp-6382	9	25	to	to	ADP
fnp-6382	9	26	cte	cte	NOUN
fnp-6382	9	27	pathol	pathol	NOUN
fnp-6382	9	28	-	-	NOUN
fnp-6382	9	29	ogy	ogy	NOUN
fnp-6382	9	30	.	.	PUNCT
fnp-6382	10	1	this	this	PRON
fnp-6382	10	2	includes	include	VERB
fnp-6382	10	3	an	an	DET
fnp-6382	10	4	evaluation	evaluation	NOUN
fnp-6382	10	5	of	of	ADP
fnp-6382	10	6	inflammatory	inflammatory	ADJ
fnp-6382	10	7	or	or	CCONJ
fnp-6382	10	8	damage	damage	NOUN
fnp-6382	10	9	-	-	PUNCT
fnp-6382	10	10	related	relate	VERB
fnp-6382	10	11	markers	marker	NOUN
fnp-6382	10	12	such	such	ADJ
fnp-6382	10	13	as	as	ADP
fnp-6382	10	14	ccl11	ccl11	NOUN
fnp-6382	10	15	(	(	PUNCT
fnp-6382	10	16	c	c	NOUN
fnp-6382	10	17	-	-	PUNCT
fnp-6382	10	18	c	c	NOUN
fnp-6382	10	19	motif	motif	NOUN
fnp-6382	10	20	chem	chem	NOUN
fnp-6382	10	21	-	-	PUNCT
fnp-6382	10	22	okine	okine	NOUN
fnp-6382	10	23	ligand	ligand	NOUN
fnp-6382	10	24	11	11	NUM
fnp-6382	10	25	,	,	PUNCT
fnp-6382	10	26	also	also	ADV
fnp-6382	10	27	known	know	VERB
fnp-6382	10	28	as	as	ADP
fnp-6382	10	29	eotaxin-1	eotaxin-1	NOUN
fnp-6382	10	30	)	)	PUNCT
fnp-6382	10	31	,	,	PUNCT
fnp-6382	10	32	ccl21	ccl21	NOUN
fnp-6382	10	33	(	(	PUNCT
fnp-6382	10	34	c	c	NOUN
fnp-6382	10	35	-	-	PUNCT
fnp-6382	10	36	c	c	NOUN
fnp-6382	10	37	motif	motif	NOUN
fnp-6382	10	38	chemokine	chemokine	ADJ
fnp-6382	10	39	ligand	ligand	NOUN
fnp-6382	10	40	21	21	NUM
fnp-6382	10	41	)	)	PUNCT
fnp-6382	10	42	and	and	CCONJ
fnp-6382	10	43	gfap	gfap	ADJ
fnp-6382	10	44	(	(	PUNCT
fnp-6382	10	45	glial	glial	ADJ
fnp-6382	10	46	fibrillary	fibrillary	ADJ
fnp-6382	10	47	acidic	acidic	ADJ
fnp-6382	10	48	protein	protein	NOUN
fnp-6382	10	49	)	)	PUNCT
fnp-6382	10	50	.	.	PUNCT
fnp-6382	11	1	we	we	PRON
fnp-6382	11	2	discuss	discuss	VERB
fnp-6382	11	3	the	the	DET
fnp-6382	11	4	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	11	5	responses	response	NOUN
fnp-6382	11	6	that	that	PRON
fnp-6382	11	7	give	give	VERB
fnp-6382	11	8	rise	rise	NOUN
fnp-6382	11	9	to	to	ADP
fnp-6382	11	10	these	these	DET
fnp-6382	11	11	biomarkers	biomarker	NOUN
fnp-6382	11	12	in	in	ADP
fnp-6382	11	13	addition	addition	NOUN
fnp-6382	11	14	to	to	ADP
fnp-6382	11	15	the	the	DET
fnp-6382	11	16	advantages	advantage	NOUN
fnp-6382	11	17	and	and	CCONJ
fnp-6382	11	18	limitations	limitation	NOUN
fnp-6382	11	19	of	of	ADP
fnp-6382	11	20	using	use	VERB
fnp-6382	11	21	each	each	PRON
fnp-6382	11	22	to	to	PART
fnp-6382	11	23	diagnose	diagnose	VERB
fnp-6382	11	24	cte	cte	NOUN
fnp-6382	11	25	with	with	ADP
fnp-6382	11	26	particular	particular	ADJ
fnp-6382	11	27	attention	attention	NOUN
fnp-6382	11	28	to	to	ADP
fnp-6382	11	29	sensitivity	sensitivity	NOUN
fnp-6382	11	30	and	and	CCONJ
fnp-6382	11	31	specifici	specifici	PROPN
fnp-6382	11	32	-	-	PUNCT
fnp-6382	11	33	ty	ty	PROPN
fnp-6382	11	34	.	.	PUNCT
fnp-6382	12	1	although	although	SCONJ
fnp-6382	12	2	further	further	ADJ
fnp-6382	12	3	research	research	NOUN
fnp-6382	12	4	is	be	AUX
fnp-6382	12	5	necessary	necessary	ADJ
fnp-6382	12	6	to	to	PART
fnp-6382	12	7	validate	validate	VERB
fnp-6382	12	8	immune	immune	ADJ
fnp-6382	12	9	mediators	mediator	NOUN
fnp-6382	12	10	,	,	PUNCT
fnp-6382	12	11	the	the	DET
fnp-6382	12	12	latter	latter	ADJ
fnp-6382	12	13	show	show	NOUN
fnp-6382	12	14	promise	promise	NOUN
fnp-6382	12	15	as	as	ADP
fnp-6382	12	16	diagnos	diagnos	ADJ
fnp-6382	12	17	-	-	PUNCT
fnp-6382	12	18	tic	tic	ADJ
fnp-6382	12	19	biomarkers	biomarker	NOUN
fnp-6382	12	20	for	for	ADP
fnp-6382	12	21	cte	cte	NOUN
fnp-6382	12	22	and	and	CCONJ
fnp-6382	12	23	may	may	AUX
fnp-6382	12	24	also	also	ADV
fnp-6382	12	25	eventually	eventually	ADV
fnp-6382	12	26	serve	serve	VERB
fnp-6382	12	27	as	as	ADP
fnp-6382	12	28	therapeutic	therapeutic	ADJ
fnp-6382	12	29	targets	target	NOUN
fnp-6382	12	30	for	for	ADP
fnp-6382	12	31	mitigating	mitigate	VERB
fnp-6382	12	32	chronic	chronic	ADJ
fnp-6382	12	33	inflamma	inflamma	NOUN
fnp-6382	12	34	-	-	PUNCT
fnp-6382	12	35	tion	tion	NOUN
fnp-6382	12	36	in	in	ADP
fnp-6382	12	37	at	at	ADP
fnp-6382	12	38	-	-	PUNCT
fnp-6382	12	39	risk	risk	NOUN
fnp-6382	12	40	populations	population	NOUN
fnp-6382	12	41	.	.	PUNCT
fnp-6382	13	1	abbreviations	abbreviation	NOUN
fnp-6382	13	2	ad	ad	PROPN
fnp-6382	13	3	alzheimer	alzheimer	PROPN
fnp-6382	13	4	’s	’s	PART
fnp-6382	13	5	disease	disease	NOUN
fnp-6382	13	6	,	,	PUNCT
fnp-6382	13	7	bbb	bbb	PROPN
fnp-6382	13	8	blood	blood	NOUN
fnp-6382	13	9	-	-	PUNCT
fnp-6382	13	10	brain	brain	NOUN
fnp-6382	13	11	barrier	barrier	NOUN
fnp-6382	13	12	,	,	PUNCT
fnp-6382	13	13	ccl2	ccl2	PROPN
fnp-6382	13	14	chemokine	chemokine	PROPN
fnp-6382	13	15	ligand	ligand	PROPN
fnp-6382	13	16	2	2	NUM
fnp-6382	13	17	,	,	PUNCT
fnp-6382	13	18	ccl11	ccl11	PROPN
fnp-6382	13	19	eotaxin-1	eotaxin-1	PROPN
fnp-6382	13	20	,	,	PUNCT
fnp-6382	13	21	cns	cns	PROPN
fnp-6382	13	22	central	central	ADJ
fnp-6382	13	23	nervous	nervous	ADJ
fnp-6382	13	24	system	system	NOUN
fnp-6382	13	25	,	,	PUNCT
fnp-6382	13	26	crp	crp	PROPN
fnp-6382	13	27	c	c	NOUN
fnp-6382	13	28	-	-	PUNCT
fnp-6382	13	29	reactive	reactive	ADJ
fnp-6382	13	30	protein	protein	NOUN
fnp-6382	13	31	,	,	PUNCT
fnp-6382	13	32	csf	csf	ADJ
fnp-6382	13	33	cerebrospinal	cerebrospinal	ADJ
fnp-6382	13	34	fluid	fluid	NOUN
fnp-6382	13	35	,	,	PUNCT
fnp-6382	13	36	cte	cte	NOUN
fnp-6382	13	37	chronic	chronic	ADJ
fnp-6382	13	38	traumatic	traumatic	ADJ
fnp-6382	13	39	encephalopathy	encephalopathy	NOUN
fnp-6382	13	40	,	,	PUNCT
fnp-6382	13	41	damp	damp	VERB
fnp-6382	13	42	damage	damage	NOUN
fnp-6382	13	43	-	-	PUNCT
fnp-6382	13	44	associated	associate	VERB
fnp-6382	13	45	molecular	molecular	ADJ
fnp-6382	13	46	pattern	pattern	NOUN
fnp-6382	13	47	,	,	PUNCT
fnp-6382	13	48	dce	dce	PROPN
fnp-6382	13	49	-	-	PUNCT
fnp-6382	13	50	mri	mri	ADJ
fnp-6382	13	51	dynamic	dynamic	ADJ
fnp-6382	13	52	contrast	contrast	NOUN
fnp-6382	13	53	-	-	PUNCT
fnp-6382	13	54	enhanced	enhance	VERB
fnp-6382	13	55	magnetic	magnetic	ADJ
fnp-6382	13	56	resonance	resonance	NOUN
fnp-6382	13	57	imaging	imaging	NOUN
fnp-6382	13	58	,	,	PUNCT
fnp-6382	13	59	dti	dti	PROPN
fnp-6382	13	60	diffusion	diffusion	PROPN
fnp-6382	13	61	tensor	tensor	NOUN
fnp-6382	13	62	imaging	imaging	NOUN
fnp-6382	13	63	,	,	PUNCT
fnp-6382	13	64	elisa	elisa	VERB
fnp-6382	13	65	enzyme	enzyme	NOUN
fnp-6382	13	66	-	-	PUNCT
fnp-6382	13	67	linked	link	VERB
fnp-6382	13	68	immunosorbent	immunosorbent	NOUN
fnp-6382	13	69	assay	assay	PROPN
fnp-6382	13	70	,	,	PUNCT
fnp-6382	13	71	icam1	icam1	PROPN
fnp-6382	13	72	intercellular	intercellular	ADJ
fnp-6382	13	73	adhesion	adhesion	NOUN
fnp-6382	13	74	molecule-1	molecule-1	PROPN
fnp-6382	13	75	,	,	PUNCT
fnp-6382	13	76	fdg	fdg	PROPN
fnp-6382	13	77	–	–	PUNCT
fnp-6382	13	78	fluorodeoxyglucose	fluorodeoxyglucose	PROPN
fnp-6382	13	79	,	,	PUNCT
fnp-6382	13	80	ftd	ftd	PROPN
fnp-6382	13	81	frontotemporal	frontotemporal	ADJ
fnp-6382	13	82	dementia	dementia	NOUN
fnp-6382	13	83	,	,	PUNCT
fnp-6382	13	84	gfap	gfap	ADJ
fnp-6382	13	85	glial	glial	ADJ
fnp-6382	13	86	fibrillary	fibrillary	ADJ
fnp-6382	13	87	acidic	acidic	ADJ
fnp-6382	13	88	protein	protein	NOUN
fnp-6382	13	89	,	,	PUNCT
fnp-6382	13	90	hmgb1	hmgb1	PROPN
fnp-6382	13	91	high	high	ADJ
fnp-6382	13	92	mobility	mobility	PROPN
fnp-6382	13	93	group	group	PROPN
fnp-6382	13	94	box	box	PROPN
fnp-6382	13	95	protein	protein	NOUN
fnp-6382	13	96	,	,	PUNCT
fnp-6382	13	97	nbd	nbd	PROPN
fnp-6382	13	98	neurobehavioral	neurobehavioral	PROPN
fnp-6382	13	99	dysregulation	dysregulation	PROPN
fnp-6382	13	100	,	,	PUNCT
fnp-6382	13	101	nfl	nfl	PROPN
fnp-6382	13	102	neurofilament	neurofilament	VERB
fnp-6382	13	103	light	light	PROPN
fnp-6382	13	104	chain	chain	NOUN
fnp-6382	13	105	,	,	PUNCT
fnp-6382	13	106	opc	opc	PROPN
fnp-6382	13	107	oligodendrocyte	oligodendrocyte	ADJ
fnp-6382	13	108	precursor	precursor	NOUN
fnp-6382	13	109	cells	cell	NOUN
fnp-6382	13	110	,	,	PUNCT
fnp-6382	13	111	p	p	PROPN
fnp-6382	13	112	-	-	PUNCT
fnp-6382	13	113	tau	tau	PROPN
fnp-6382	13	114	phosphorylated	phosphorylate	VERB
fnp-6382	13	115	tau	tau	PROPN
fnp-6382	13	116	,	,	PUNCT
fnp-6382	13	117	rhi	rhi	PROPN
fnp-6382	13	118	repetitive	repetitive	ADJ
fnp-6382	13	119	head	head	NOUN
fnp-6382	13	120	impacts	impact	NOUN
fnp-6382	13	121	,	,	PUNCT
fnp-6382	13	122	tbi	tbi	NOUN
fnp-6382	13	123	traumatic	traumatic	ADJ
fnp-6382	13	124	brain	brain	NOUN
fnp-6382	13	125	injury	injury	NOUN
fnp-6382	13	126	,	,	PUNCT
fnp-6382	13	127	tes	tes	PROPN
fnp-6382	13	128	traumatic	traumatic	ADJ
fnp-6382	13	129	encephalopathy	encephalopathy	ADJ
fnp-6382	13	130	syndrome	syndrome	NOUN
fnp-6382	13	131	,	,	PUNCT
fnp-6382	13	132	tnf	tnf	PROPN
fnp-6382	13	133	-	-	PUNCT
fnp-6382	13	134	α	α	PROPN
fnp-6382	13	135	tumor	tumor	NOUN
fnp-6382	13	136	necrosis	necrosis	NOUN
fnp-6382	13	137	factor	factor	NOUN
fnp-6382	13	138	-	-	PUNCT
fnp-6382	13	139	alpha	alpha	NOUN
fnp-6382	13	140	,	,	PUNCT
fnp-6382	13	141	tspo	tspo	PROPN
fnp-6382	13	142	translocator	translocator	PROPN
fnp-6382	13	143	protein	protein	NOUN
fnp-6382	13	144	,	,	PUNCT
fnp-6382	13	145	trem2	trem2	NOUN
fnp-6382	13	146	triggering	trigger	VERB
fnp-6382	13	147	receptor	receptor	NOUN
fnp-6382	13	148	expressed	express	VERB
fnp-6382	13	149	on	on	ADP
fnp-6382	13	150	myeloid	myeloid	ADJ
fnp-6382	13	151	cells	cell	NOUN
fnp-6382	13	152	,	,	PUNCT
fnp-6382	13	153	vcam1	vcam1	NOUN
fnp-6382	13	154	vascular	vascular	ADJ
fnp-6382	13	155	cell	cell	NOUN
fnp-6382	13	156	adhesion	adhesion	NOUN
fnp-6382	13	157	molecule-1	molecule-1	PROPN
fnp-6382	13	158	,	,	PUNCT
fnp-6382	13	159	vegf	vegf	PROPN
fnp-6382	13	160	vasoactive	vasoactive	ADJ
fnp-6382	13	161	endothelial	endothelial	ADJ
fnp-6382	13	162	growth	growth	NOUN
fnp-6382	13	163	factor	factor	NOUN
fnp-6382	13	164	introduction	introduction	NOUN
fnp-6382	13	165	chronic	chronic	ADJ
fnp-6382	13	166	traumatic	traumatic	ADJ
fnp-6382	13	167	encephalopathy	encephalopathy	NOUN
fnp-6382	13	168	(	(	PUNCT
fnp-6382	13	169	cte	cte	NOUN
fnp-6382	13	170	)	)	PUNCT
fnp-6382	13	171	is	be	AUX
fnp-6382	13	172	a	a	DET
fnp-6382	13	173	progressive	progressive	ADJ
fnp-6382	13	174	neuropathological	neuropathological	ADJ
fnp-6382	13	175	disease	disease	NOUN
fnp-6382	13	176	characterized	characterize	VERB
fnp-6382	13	177	by	by	ADP
fnp-6382	13	178	the	the	DET
fnp-6382	13	179	perivascular	perivascular	ADJ
fnp-6382	13	180	accumulation	accumulation	NOUN
fnp-6382	13	181	of	of	ADP
fnp-6382	13	182	phosphorylated	phosphorylate	VERB
fnp-6382	13	183	tau	tau	PROPN
fnp-6382	13	184	(	(	PUNCT
fnp-6382	13	185	p	p	PROPN
fnp-6382	13	186	-	-	PUNCT
fnp-6382	13	187	tau	tau	NOUN
fnp-6382	13	188	)	)	PUNCT
fnp-6382	13	189	at	at	ADP
fnp-6382	13	190	the	the	DET
fnp-6382	13	191	depths	depth	NOUN
fnp-6382	13	192	of	of	ADP
fnp-6382	13	193	cerebral	cerebral	ADJ
fnp-6382	13	194	sulci	sulci	NOUN
fnp-6382	13	195	:	:	PUNCT
fnp-6382	13	196	(	(	PUNCT
fnp-6382	13	197	1	1	X
fnp-6382	13	198	)	)	PUNCT
fnp-6382	13	199	the	the	DET
fnp-6382	13	200	largest	large	ADJ
fnp-6382	13	201	risk	risk	NOUN
fnp-6382	13	202	factor	factor	NOUN
fnp-6382	13	203	for	for	ADP
fnp-6382	13	204	cte	cte	NOUN
fnp-6382	13	205	is	be	AUX
fnp-6382	13	206	exposure	exposure	NOUN
fnp-6382	13	207	to	to	ADP
fnp-6382	13	208	repetitive	repetitive	ADJ
fnp-6382	13	209	head	head	NOUN
fnp-6382	13	210	impacts	impact	NOUN
fnp-6382	13	211	(	(	PUNCT
fnp-6382	13	212	rhi	rhi	NOUN
fnp-6382	13	213	)	)	PUNCT
fnp-6382	13	214	,	,	PUNCT
fnp-6382	13	215	whether	whether	SCONJ
fnp-6382	13	216	concussive	concussive	ADJ
fnp-6382	13	217	or	or	CCONJ
fnp-6382	13	218	non	non	ADJ
fnp-6382	13	219	-	-	ADJ
fnp-6382	13	220	concussive	concussive	ADJ
fnp-6382	13	221	;	;	PUNCT
fnp-6382	13	222	(	(	PUNCT
fnp-6382	13	223	2	2	X
fnp-6382	13	224	)	)	PUNCT
fnp-6382	13	225	cte	cte	NOUN
fnp-6382	13	226	pathology	pathology	NOUN
fnp-6382	13	227	has	have	AUX
fnp-6382	13	228	been	be	AUX
fnp-6382	13	229	confirmed	confirm	VERB
fnp-6382	13	230	in	in	ADP
fnp-6382	13	231	patients	patient	NOUN
fnp-6382	13	232	with	with	ADP
fnp-6382	13	233	various	various	ADJ
fnp-6382	13	234	rhi	rhi	PROPN
fnp-6382	13	235	exposures	exposure	NOUN
fnp-6382	13	236	including	include	VERB
fnp-6382	13	237	contact	contact	NOUN
fnp-6382	13	238	sports	sport	NOUN
fnp-6382	13	239	such	such	ADJ
fnp-6382	13	240	as	as	ADP
fnp-6382	13	241	american	american	ADJ
fnp-6382	13	242	football	football	PROPN
fnp-6382	13	243	,	,	PUNCT
fnp-6382	13	244	hockey	hockey	NOUN
fnp-6382	13	245	,	,	PUNCT
fnp-6382	13	246	rugby	rugby	NOUN
fnp-6382	13	247	,	,	PUNCT
fnp-6382	13	248	boxing	boxing	NOUN
fnp-6382	13	249	,	,	PUNCT
fnp-6382	13	250	and	and	CCONJ
fnp-6382	13	251	soccer	soccer	NOUN
fnp-6382	13	252	(	(	PUNCT
fnp-6382	13	253	1,3,4	1,3,4	NUM
fnp-6382	13	254	)	)	PUNCT
fnp-6382	13	255	;	;	PUNCT
fnp-6382	13	256	(	(	PUNCT
fnp-6382	13	257	3	3	X
fnp-6382	13	258	)	)	PUNCT
fnp-6382	13	259	although	although	SCONJ
fnp-6382	13	260	sports	sport	NOUN
fnp-6382	13	261	-	-	PUNCT
fnp-6382	13	262	related	relate	VERB
fnp-6382	13	263	head	head	NOUN
fnp-6382	13	264	trauma	trauma	NOUN
fnp-6382	13	265	has	have	AUX
fnp-6382	13	266	been	be	AUX
fnp-6382	13	267	recognized	recognize	VERB
fnp-6382	13	268	as	as	ADP
fnp-6382	13	269	the	the	DET
fnp-6382	13	270	primary	primary	ADJ
fnp-6382	13	271	source	source	NOUN
fnp-6382	13	272	of	of	ADP
fnp-6382	13	273	cte	cte	NOUN
fnp-6382	13	274	cases	case	NOUN
fnp-6382	13	275	in	in	ADP
fnp-6382	13	276	the	the	DET
fnp-6382	13	277	literature	literature	NOUN
fnp-6382	13	278	,	,	PUNCT
fnp-6382	13	279	other	other	ADJ
fnp-6382	13	280	types	type	NOUN
fnp-6382	13	281	of	of	ADP
fnp-6382	13	282	exposure	exposure	NOUN
fnp-6382	13	283	have	have	AUX
fnp-6382	13	284	been	be	AUX
fnp-6382	13	285	shown	show	VERB
fnp-6382	13	286	to	to	PART
fnp-6382	13	287	be	be	AUX
fnp-6382	13	288	involved	involve	VERB
fnp-6382	13	289	as	as	ADV
fnp-6382	13	290	well	well	ADV
fnp-6382	13	291	.	.	PUNCT
fnp-6382	14	1	there	there	PRON
fnp-6382	14	2	is	be	VERB
fnp-6382	14	3	emerging	emerge	VERB
fnp-6382	14	4	evidence	evidence	NOUN
fnp-6382	14	5	of	of	ADP
fnp-6382	14	6	cte	cte	NOUN
fnp-6382	14	7	cases	case	NOUN
fnp-6382	14	8	in	in	ADP
fnp-6382	14	9	military	military	ADJ
fnp-6382	14	10	veterans	veteran	NOUN
fnp-6382	14	11	.	.	PUNCT
fnp-6382	15	1	premier	premier	PROPN
fnp-6382	15	2	et	et	PROPN
fnp-6382	15	3	al	al	PROPN
fnp-6382	15	4	.	.	PROPN
fnp-6382	15	5	demonstrated	demonstrate	VERB
fnp-6382	15	6	ten	ten	NUM
fnp-6382	15	7	out	out	ADP
fnp-6382	15	8	of	of	ADP
fnp-6382	15	9	225	225	NUM
fnp-6382	15	10	(	(	PUNCT
fnp-6382	15	11	4.4	4.4	NUM
fnp-6382	15	12	 	 	SPACE
fnp-6382	15	13	%	%	NOUN
fnp-6382	15	14	)	)	PUNCT
fnp-6382	15	15	veteran	veteran	NOUN
fnp-6382	15	16	brains	brain	NOUN
fnp-6382	15	17	had	have	VERB
fnp-6382	15	18	evidence	evidence	NOUN
fnp-6382	15	19	of	of	ADP
fnp-6382	15	20	cte	cte	NOUN
fnp-6382	15	21	(	(	PUNCT
fnp-6382	15	22	5	5	NUM
fnp-6382	15	23	)	)	PUNCT
fnp-6382	15	24	.	.	PUNCT
fnp-6382	16	1	although	although	SCONJ
fnp-6382	16	2	all	all	DET
fnp-6382	16	3	ten	ten	NUM
fnp-6382	16	4	of	of	ADP
fnp-6382	16	5	the	the	DET
fnp-6382	16	6	veterans	veteran	NOUN
fnp-6382	16	7	were	be	AUX
fnp-6382	16	8	found	find	VERB
fnp-6382	16	9	to	to	PART
fnp-6382	16	10	also	also	ADV
fnp-6382	16	11	play	play	VERB
fnp-6382	16	12	a	a	DET
fnp-6382	16	13	contact	contact	NOUN
fnp-6382	16	14	sports	sport	NOUN
fnp-6382	16	15	,	,	PUNCT
fnp-6382	16	16	other	other	ADJ
fnp-6382	16	17	studies	study	NOUN
fnp-6382	16	18	have	have	AUX
fnp-6382	16	19	observed	observe	VERB
fnp-6382	16	20	cte	cte	NOUN
fnp-6382	16	21	in	in	ADP
fnp-6382	16	22	veterans	veteran	NOUN
fnp-6382	16	23	without	without	ADP
fnp-6382	16	24	a	a	DET
fnp-6382	16	25	sports	sport	NOUN
fnp-6382	16	26	background	background	NOUN
fnp-6382	16	27	(	(	PUNCT
fnp-6382	16	28	6–9	6–9	NOUN
fnp-6382	16	29	)	)	PUNCT
fnp-6382	16	30	;	;	PUNCT
fnp-6382	16	31	(	(	PUNCT
fnp-6382	16	32	4	4	X
fnp-6382	16	33	)	)	PUNCT
fnp-6382	16	34	there	there	PRON
fnp-6382	16	35	has	have	AUX
fnp-6382	16	36	also	also	ADV
fnp-6382	16	37	been	be	AUX
fnp-6382	16	38	concern	concern	NOUN
fnp-6382	16	39	for	for	ADP
fnp-6382	16	40	cte	cte	NOUN
fnp-6382	16	41	in	in	ADP
fnp-6382	16	42	persons	person	NOUN
fnp-6382	16	43	who	who	PRON
fnp-6382	16	44	experience	experience	VERB
fnp-6382	16	45	long	long	ADJ
fnp-6382	16	46	-	-	PUNCT
fnp-6382	16	47	term	term	NOUN
fnp-6382	16	48	domestic	domestic	ADJ
fnp-6382	16	49	violence	violence	NOUN
fnp-6382	16	50	.	.	PUNCT
fnp-6382	17	1	dams	dam	NOUN
fnp-6382	17	2	-	-	PUNCT
fnp-6382	17	3	o’connor	o’connor	ADV
fnp-6382	17	4	et	et	PROPN
fnp-6382	17	5	al	al	PROPN
fnp-6382	17	6	.	.	PROPN
fnp-6382	17	7	examined	examine	VERB
fnp-6382	17	8	tissue	tissue	NOUN
fnp-6382	17	9	from	from	ADP
fnp-6382	17	10	individuals	individual	NOUN
fnp-6382	17	11	exposed	expose	VERB
fnp-6382	17	12	to	to	ADP
fnp-6382	17	13	intimate	intimate	ADJ
fnp-6382	17	14	partner	partner	NOUN
fnp-6382	17	15	violence	violence	NOUN
fnp-6382	17	16	and	and	CCONJ
fnp-6382	17	17	did	do	AUX
fnp-6382	17	18	not	not	PART
fnp-6382	17	19	observe	observe	VERB
fnp-6382	17	20	cte	cte	NOUN
fnp-6382	17	21	in	in	ADP
fnp-6382	17	22	their	their	PRON
fnp-6382	17	23	cohort	cohort	NOUN
fnp-6382	17	24	(	(	PUNCT
fnp-6382	17	25	10	10	NUM
fnp-6382	17	26	)	)	PUNCT
fnp-6382	17	27	;	;	PUNCT
fnp-6382	17	28	however	however	ADV
fnp-6382	17	29	,	,	PUNCT
fnp-6382	17	30	other	other	ADJ
fnp-6382	17	31	case	case	NOUN
fnp-6382	17	32	series	series	NOUN
fnp-6382	17	33	and	and	CCONJ
fnp-6382	17	34	autopsy	autopsy	ADJ
fnp-6382	17	35	studies	study	NOUN
fnp-6382	17	36	have	have	AUX
fnp-6382	17	37	identified	identify	VERB
fnp-6382	17	38	cte	cte	NOUN
fnp-6382	17	39	in	in	ADP
fnp-6382	17	40	individuals	individual	NOUN
fnp-6382	17	41	exposed	expose	VERB
fnp-6382	17	42	to	to	ADP
fnp-6382	17	43	domestic	domestic	ADJ
fnp-6382	17	44	abuse	abuse	NOUN
fnp-6382	17	45	,	,	PUNCT
fnp-6382	17	46	suggesting	suggest	VERB
fnp-6382	17	47	that	that	SCONJ
fnp-6382	17	48	while	while	SCONJ
fnp-6382	17	49	less	less	ADV
fnp-6382	17	50	common	common	ADJ
fnp-6382	17	51	,	,	PUNCT
fnp-6382	17	52	such	such	ADJ
fnp-6382	17	53	exposures	exposure	NOUN
fnp-6382	17	54	might	might	AUX
fnp-6382	17	55	still	still	ADV
fnp-6382	17	56	confer	confer	VERB
fnp-6382	17	57	risk	risk	NOUN
fnp-6382	17	58	(	(	PUNCT
fnp-6382	17	59	11,12	11,12	NUM
fnp-6382	17	60	)	)	PUNCT
fnp-6382	17	61	.	.	PUNCT
fnp-6382	18	1	overall	overall	ADV
fnp-6382	18	2	,	,	PUNCT
fnp-6382	18	3	while	while	SCONJ
fnp-6382	18	4	the	the	DET
fnp-6382	18	5	incidence	incidence	NOUN
fnp-6382	18	6	of	of	ADP
fnp-6382	18	7	cte	cte	NOUN
fnp-6382	18	8	is	be	AUX
fnp-6382	18	9	likely	likely	ADV
fnp-6382	18	10	much	much	ADV
fnp-6382	18	11	lower	low	ADJ
fnp-6382	18	12	in	in	ADP
fnp-6382	18	13	exposures	exposure	NOUN
fnp-6382	18	14	outside	outside	ADP
fnp-6382	18	15	of	of	ADP
fnp-6382	18	16	contact	contact	NOUN
fnp-6382	18	17	sports	sport	NOUN
fnp-6382	18	18	,	,	PUNCT
fnp-6382	18	19	the	the	DET
fnp-6382	18	20	risks	risk	NOUN
fnp-6382	18	21	are	be	AUX
fnp-6382	18	22	still	still	ADV
fnp-6382	18	23	not	not	PART
fnp-6382	18	24	zero	zero	NUM
fnp-6382	18	25	.	.	PUNCT
fnp-6382	19	1	however	however	ADV
fnp-6382	19	2	,	,	PUNCT
fnp-6382	19	3	a	a	DET
fnp-6382	19	4	major	major	ADJ
fnp-6382	19	5	limitation	limitation	NOUN
fnp-6382	19	6	in	in	ADP
fnp-6382	19	7	our	our	PRON
fnp-6382	19	8	understanding	understanding	NOUN
fnp-6382	19	9	of	of	ADP
fnp-6382	19	10	at	at	ADP
fnp-6382	19	11	-	-	PUNCT
fnp-6382	19	12	risk	risk	NOUN
fnp-6382	19	13	populations	population	NOUN
fnp-6382	19	14	is	be	AUX
fnp-6382	19	15	that	that	SCONJ
fnp-6382	19	16	cte	cte	PROPN
fnp-6382	19	17	can	can	AUX
fnp-6382	19	18	only	only	ADV
fnp-6382	19	19	be	be	AUX
fnp-6382	19	20	diagnosed	diagnose	VERB
fnp-6382	19	21	postmortem	postmortem	NOUN
fnp-6382	19	22	.	.	PUNCT
fnp-6382	20	1	although	although	SCONJ
fnp-6382	20	2	provisional	provisional	ADJ
fnp-6382	20	3	in	in	ADP
fnp-6382	20	4	-	-	PUNCT
fnp-6382	20	5	life	life	NOUN
fnp-6382	20	6	criteria	criterion	NOUN
fnp-6382	20	7	have	have	AUX
fnp-6382	20	8	been	be	AUX
fnp-6382	20	9	suggested	suggest	VERB
fnp-6382	20	10	,	,	PUNCT
fnp-6382	20	11	coining	coin	VERB
fnp-6382	20	12	the	the	DET
fnp-6382	20	13	term	term	NOUN
fnp-6382	20	14	traumatic	traumatic	ADJ
fnp-6382	20	15	encephalopathy	encephalopathy	ADJ
fnp-6382	20	16	syndrome	syndrome	NOUN
fnp-6382	20	17	(	(	PUNCT
fnp-6382	20	18	tes	tes	NOUN
fnp-6382	20	19	)	)	PUNCT
fnp-6382	20	20	,	,	PUNCT
fnp-6382	20	21	they	they	PRON
fnp-6382	20	22	has	have	AUX
fnp-6382	20	23	not	not	PART
fnp-6382	20	24	been	be	AUX
fnp-6382	20	25	fully	fully	ADV
fnp-6382	20	26	validated	validate	VERB
fnp-6382	20	27	and	and	CCONJ
fnp-6382	20	28	still	still	ADV
fnp-6382	20	29	remain	remain	VERB
fnp-6382	20	30	research	research	NOUN
fnp-6382	20	31	criteria	criterion	NOUN
fnp-6382	20	32	(	(	PUNCT
fnp-6382	20	33	3	3	NUM
fnp-6382	20	34	)	)	PUNCT
fnp-6382	20	35	.	.	PUNCT
fnp-6382	21	1	to	to	ADP
fnp-6382	21	2	date	date	NOUN
fnp-6382	21	3	,	,	PUNCT
fnp-6382	21	4	there	there	PRON
fnp-6382	21	5	is	be	VERB
fnp-6382	21	6	no	no	DET
fnp-6382	21	7	way	way	NOUN
fnp-6382	21	8	to	to	PART
fnp-6382	21	9	predict	predict	VERB
fnp-6382	21	10	if	if	SCONJ
fnp-6382	21	11	rhi	rhi	NOUN
fnp-6382	21	12	-	-	PUNCT
fnp-6382	21	13	exposed	expose	VERB
fnp-6382	21	14	individuals	individual	NOUN
fnp-6382	21	15	will	will	AUX
fnp-6382	21	16	develop	develop	VERB
fnp-6382	21	17	cte	cte	NOUN
fnp-6382	21	18	years	year	NOUN
fnp-6382	21	19	after	after	ADP
fnp-6382	21	20	exposure	exposure	NOUN
fnp-6382	21	21	,	,	PUNCT
fnp-6382	21	22	since	since	SCONJ
fnp-6382	21	23	not	not	PART
fnp-6382	21	24	all	all	DET
fnp-6382	21	25	individuals	individual	NOUN
fnp-6382	21	26	with	with	ADP
fnp-6382	21	27	rhi	rhi	PROPN
fnp-6382	21	28	exposure	exposure	NOUN
fnp-6382	21	29	go	go	VERB
fnp-6382	21	30	on	on	ADP
fnp-6382	21	31	to	to	PART
fnp-6382	21	32	acquire	acquire	VERB
fnp-6382	21	33	cte	cte	PROPN
fnp-6382	21	34	(	(	PUNCT
fnp-6382	21	35	13,14	13,14	NUM
fnp-6382	21	36	)	)	PUNCT
fnp-6382	21	37	.	.	PUNCT
fnp-6382	22	1	therefore	therefore	ADV
fnp-6382	22	2	,	,	PUNCT
fnp-6382	22	3	there	there	PRON
fnp-6382	22	4	is	be	VERB
fnp-6382	22	5	great	great	ADJ
fnp-6382	22	6	need	need	NOUN
fnp-6382	22	7	for	for	SCONJ
fnp-6382	22	8	biomarkers	biomarker	NOUN
fnp-6382	22	9	to	to	PART
fnp-6382	22	10	advance	advance	VERB
fnp-6382	22	11	ante	ante	NOUN
fnp-6382	22	12	-	-	PUNCT
fnp-6382	22	13	mortem	mortem	NOUN
fnp-6382	22	14	diagnosis	diagnosis	NOUN
fnp-6382	22	15	of	of	ADP
fnp-6382	22	16	cte	cte	NOUN
fnp-6382	22	17	.	.	PUNCT
fnp-6382	23	1	the	the	DET
fnp-6382	23	2	current	current	ADJ
fnp-6382	23	3	focus	focus	NOUN
fnp-6382	23	4	around	around	ADP
fnp-6382	23	5	cte	cte	NOUN
fnp-6382	23	6	biomarkers	biomarker	NOUN
fnp-6382	23	7	has	have	AUX
fnp-6382	23	8	primarily	primarily	ADV
fnp-6382	23	9	centered	center	VERB
fnp-6382	23	10	on	on	ADP
fnp-6382	23	11	structural	structural	ADJ
fnp-6382	23	12	protein	protein	NOUN
fnp-6382	23	13	markers	marker	NOUN
fnp-6382	23	14	,	,	PUNCT
fnp-6382	23	15	including	include	VERB
fnp-6382	23	16	tau	tau	PROPN
fnp-6382	23	17	proteins	protein	NOUN
fnp-6382	23	18	,	,	PUNCT
fnp-6382	23	19	neurofilament	neurofilament	ADJ
fnp-6382	23	20	light	light	ADJ
fnp-6382	23	21	protein	protein	NOUN
fnp-6382	23	22	(	(	PUNCT
fnp-6382	23	23	nfl	nfl	PROPN
fnp-6382	23	24	)	)	PUNCT
fnp-6382	23	25	and	and	CCONJ
fnp-6382	23	26	glial	glial	ADJ
fnp-6382	23	27	fibrillary	fibrillary	ADJ
fnp-6382	23	28	acidic	acidic	ADJ
fnp-6382	23	29	protein	protein	NOUN
fnp-6382	23	30	(	(	PUNCT
fnp-6382	23	31	gfap	gfap	ADJ
fnp-6382	23	32	)	)	PUNCT
fnp-6382	23	33	(	(	PUNCT
fnp-6382	23	34	15–18	15–18	NUM
fnp-6382	23	35	)	)	PUNCT
fnp-6382	23	36	.	.	PUNCT
fnp-6382	24	1	despite	despite	SCONJ
fnp-6382	24	2	some	some	DET
fnp-6382	24	3	promising	promising	ADJ
fnp-6382	24	4	evidence	evidence	NOUN
fnp-6382	24	5	,	,	PUNCT
fnp-6382	24	6	these	these	DET
fnp-6382	24	7	proteins	protein	NOUN
fnp-6382	24	8	are	be	AUX
fnp-6382	24	9	often	often	ADV
fnp-6382	24	10	associated	associate	VERB
fnp-6382	24	11	with	with	ADP
fnp-6382	24	12	other	other	ADJ
fnp-6382	24	13	neurodegenerative	neurodegenerative	ADJ
fnp-6382	24	14	conditions	condition	NOUN
fnp-6382	24	15	or	or	CCONJ
fnp-6382	24	16	acute	acute	NOUN
fnp-6382	24	17	injuries	injury	NOUN
fnp-6382	24	18	,	,	PUNCT
fnp-6382	24	19	hindering	hinder	VERB
fnp-6382	24	20	their	their	PRON
fnp-6382	24	21	specificity	specificity	NOUN
fnp-6382	24	22	to	to	PART
fnp-6382	24	23	cte	cte	PROPN
fnp-6382	24	24	(	(	PUNCT
fnp-6382	24	25	19,20	19,20	NOUN
fnp-6382	24	26	)	)	PUNCT
fnp-6382	24	27	.	.	PUNCT
fnp-6382	25	1	although	although	SCONJ
fnp-6382	25	2	certain	certain	ADJ
fnp-6382	25	3	phosphor	phosphor	NOUN
fnp-6382	25	4	epitopes	epitope	NOUN
fnp-6382	25	5	of	of	ADP
fnp-6382	25	6	tau	tau	PROPN
fnp-6382	25	7	may	may	AUX
fnp-6382	25	8	be	be	AUX
fnp-6382	25	9	useful	useful	ADJ
fnp-6382	25	10	,	,	PUNCT
fnp-6382	25	11	tau	tau	PROPN
fnp-6382	25	12	markers	marker	NOUN
fnp-6382	25	13	may	may	AUX
fnp-6382	25	14	not	not	PART
fnp-6382	25	15	generally	generally	ADV
fnp-6382	25	16	be	be	AUX
fnp-6382	25	17	ideal	ideal	ADJ
fnp-6382	25	18	for	for	ADP
fnp-6382	25	19	distinguishing	distinguish	VERB
fnp-6382	25	20	between	between	ADP
fnp-6382	25	21	alzheimer	alzheimer	PROPN
fnp-6382	25	22	’s	’s	PART
fnp-6382	25	23	disease	disease	NOUN
fnp-6382	25	24	(	(	PUNCT
fnp-6382	25	25	ad	ad	NOUN
fnp-6382	25	26	)	)	PUNCT
fnp-6382	25	27	and	and	CCONJ
fnp-6382	25	28	cte	cte	NOUN
fnp-6382	25	29	,	,	PUNCT
fnp-6382	25	30	as	as	SCONJ
fnp-6382	25	31	both	both	PRON
fnp-6382	25	32	are	be	AUX
fnp-6382	25	33	tauopathies	tauopathie	NOUN
fnp-6382	25	34	(	(	PUNCT
fnp-6382	25	35	21	21	NUM
fnp-6382	25	36	)	)	PUNCT
fnp-6382	25	37	.	.	PUNCT
fnp-6382	26	1	currently	currently	ADV
fnp-6382	26	2	,	,	PUNCT
fnp-6382	26	3	no	no	DET
fnp-6382	26	4	adequate	adequate	ADJ
fnp-6382	26	5	biomarkers	biomarker	NOUN
fnp-6382	26	6	exist	exist	VERB
fnp-6382	26	7	to	to	PART
fnp-6382	26	8	differentiate	differentiate	VERB
fnp-6382	26	9	cte	cte	NOUN
fnp-6382	26	10	from	from	ADP
fnp-6382	26	11	other	other	ADJ
fnp-6382	26	12	forms	form	NOUN
fnp-6382	26	13	of	of	ADP
fnp-6382	26	14	neurodegeneration	neurodegeneration	NOUN
fnp-6382	26	15	.	.	PUNCT
fnp-6382	27	1	interestingly	interestingly	ADV
fnp-6382	27	2	,	,	PUNCT
fnp-6382	27	3	recent	recent	ADJ
fnp-6382	27	4	studies	study	NOUN
fnp-6382	27	5	have	have	AUX
fnp-6382	27	6	suggested	suggest	VERB
fnp-6382	27	7	that	that	SCONJ
fnp-6382	27	8	the	the	DET
fnp-6382	27	9	neuroimmune	neuroimmune	ADJ
fnp-6382	27	10	response	response	NOUN
fnp-6382	27	11	might	might	AUX
fnp-6382	27	12	be	be	AUX
fnp-6382	27	13	distinct	distinct	ADJ
fnp-6382	27	14	among	among	ADP
fnp-6382	27	15	related	related	ADJ
fnp-6382	27	16	tauopathies	tauopathie	NOUN
fnp-6382	27	17	(	(	PUNCT
fnp-6382	27	18	22	22	NUM
fnp-6382	27	19	)	)	PUNCT
fnp-6382	27	20	.	.	PUNCT
fnp-6382	28	1	these	these	DET
fnp-6382	28	2	findings	finding	NOUN
fnp-6382	28	3	,	,	PUNCT
fnp-6382	28	4	coupled	couple	VERB
fnp-6382	28	5	with	with	ADP
fnp-6382	28	6	the	the	DET
fnp-6382	28	7	advent	advent	NOUN
fnp-6382	28	8	of	of	ADP
fnp-6382	28	9	high	high	ADJ
fnp-6382	28	10	-	-	PUNCT
fnp-6382	28	11	level	level	NOUN
fnp-6382	28	12	genomic	genomic	NOUN
fnp-6382	28	13	techniques	technique	NOUN
fnp-6382	28	14	like	like	ADP
fnp-6382	28	15	single	single	ADJ
fnp-6382	28	16	cell	cell	NOUN
fnp-6382	28	17	rna	rna	NOUN
fnp-6382	28	18	sequencing	sequencing	NOUN
fnp-6382	28	19	,	,	PUNCT
fnp-6382	28	20	have	have	AUX
fnp-6382	28	21	highlighted	highlight	VERB
fnp-6382	28	22	the	the	DET
fnp-6382	28	23	enormous	enormous	ADJ
fnp-6382	28	24	complexity	complexity	NOUN
fnp-6382	28	25	and	and	CCONJ
fnp-6382	28	26	flexibility	flexibility	NOUN
fnp-6382	28	27	of	of	ADP
fnp-6382	28	28	the	the	DET
fnp-6382	28	29	immune	immune	ADJ
fnp-6382	28	30	response	response	NOUN
fnp-6382	28	31	to	to	ADP
fnp-6382	28	32	repetitive	repetitive	ADJ
fnp-6382	28	33	head	head	NOUN
fnp-6382	28	34	trauma	trauma	NOUN
fnp-6382	28	35	.	.	PUNCT
fnp-6382	29	1	it	it	PRON
fnp-6382	29	2	may	may	AUX
fnp-6382	29	3	therefore	therefore	ADV
fnp-6382	29	4	be	be	AUX
fnp-6382	29	5	useful	useful	ADJ
fnp-6382	29	6	to	to	PART
fnp-6382	29	7	take	take	VERB
fnp-6382	29	8	advantage	advantage	NOUN
fnp-6382	29	9	of	of	ADP
fnp-6382	29	10	this	this	DET
fnp-6382	29	11	characteristic	characteristic	NOUN
fnp-6382	29	12	to	to	PART
fnp-6382	29	13	identify	identify	VERB
fnp-6382	29	14	novel	novel	ADJ
fnp-6382	29	15	sensitive	sensitive	ADJ
fnp-6382	29	16	and	and	CCONJ
fnp-6382	29	17	specific	specific	ADJ
fnp-6382	29	18	biomarkers	biomarker	NOUN
fnp-6382	29	19	that	that	PRON
fnp-6382	29	20	could	could	AUX
fnp-6382	29	21	effectively	effectively	ADV
fnp-6382	29	22	diagnose	diagnose	VERB
fnp-6382	29	23	cte	cte	NOUN
fnp-6382	29	24	in	in	ADP
fnp-6382	29	25	life	life	NOUN
fnp-6382	29	26	.	.	PUNCT
fnp-6382	30	1	herein	herein	NOUN
fnp-6382	30	2	we	we	PRON
fnp-6382	30	3	discuss	discuss	VERB
fnp-6382	30	4	neuroinflammation	neuroinflammation	NOUN
fnp-6382	30	5	in	in	ADP
fnp-6382	30	6	cte	cte	NOUN
fnp-6382	30	7	and	and	CCONJ
fnp-6382	30	8	examine	examine	VERB
fnp-6382	30	9	specific	specific	ADJ
fnp-6382	30	10	inflammatory	inflammatory	ADJ
fnp-6382	30	11	processes	process	NOUN
fnp-6382	30	12	that	that	PRON
fnp-6382	30	13	may	may	AUX
fnp-6382	30	14	involve	involve	VERB
fnp-6382	30	15	prospective	prospective	ADJ
fnp-6382	30	16	novel	novel	ADJ
fnp-6382	30	17	biomarkers	biomarker	NOUN
fnp-6382	30	18	.	.	PUNCT
fnp-6382	31	1	inflammation	inflammation	NOUN
fnp-6382	31	2	is	be	AUX
fnp-6382	31	3	strongly	strongly	ADV
fnp-6382	31	4	associated	associate	VERB
fnp-6382	31	5	with	with	ADP
fnp-6382	31	6	cte	cte	NOUN
fnp-6382	31	7	increasing	increase	VERB
fnp-6382	31	8	evidence	evidence	NOUN
fnp-6382	31	9	supports	support	VERB
fnp-6382	31	10	a	a	DET
fnp-6382	31	11	role	role	NOUN
fnp-6382	31	12	for	for	ADP
fnp-6382	31	13	inflammation	inflammation	NOUN
fnp-6382	31	14	as	as	ADP
fnp-6382	31	15	an	an	DET
fnp-6382	31	16	early	early	ADJ
fnp-6382	31	17	modifier	modifier	NOUN
fnp-6382	31	18	or	or	CCONJ
fnp-6382	31	19	initiator	initiator	NOUN
fnp-6382	31	20	of	of	ADP
fnp-6382	31	21	cte	cte	PROPN
fnp-6382	31	22	disease	disease	NOUN
fnp-6382	31	23	progression	progression	NOUN
fnp-6382	31	24	,	,	PUNCT
fnp-6382	31	25	consistent	consistent	ADJ
fnp-6382	31	26	with	with	ADP
fnp-6382	31	27	inflammation	inflammation	NOUN
fnp-6382	31	28	being	be	AUX
fnp-6382	31	29	a	a	DET
fnp-6382	31	30	mechanistic	mechanistic	ADJ
fnp-6382	31	31	driver	driver	NOUN
fnp-6382	31	32	of	of	ADP
fnp-6382	31	33	other	other	ADJ
fnp-6382	31	34	neurodegenerative	neurodegenerative	ADJ
fnp-6382	31	35	conditions	condition	NOUN
fnp-6382	31	36	.	.	PUNCT
fnp-6382	32	1	for	for	ADP
fnp-6382	32	2	instance	instance	NOUN
fnp-6382	32	3	,	,	PUNCT
fnp-6382	32	4	genomic	genomic	ADJ
fnp-6382	32	5	studies	study	NOUN
fnp-6382	32	6	have	have	AUX
fnp-6382	32	7	identified	identify	VERB
fnp-6382	32	8	risk	risk	NOUN
fnp-6382	32	9	-	-	PUNCT
fnp-6382	32	10	stratifying	stratify	VERB
fnp-6382	32	11	immune	immune	NOUN
fnp-6382	32	12	-	-	PUNCT
fnp-6382	32	13	related	relate	VERB
fnp-6382	32	14	loci	locus	NOUN
fnp-6382	32	15	in	in	ADP
fnp-6382	32	16	relation	relation	NOUN
fnp-6382	32	17	to	to	ADP
fnp-6382	32	18	ad	ad	NOUN
fnp-6382	32	19	,	,	PUNCT
fnp-6382	32	20	such	such	ADJ
fnp-6382	32	21	as	as	ADP
fnp-6382	32	22	trem2	trem2	NOUN
fnp-6382	32	23	(	(	PUNCT
fnp-6382	32	24	triggering	trigger	VERB
fnp-6382	32	25	receptor	receptor	NOUN
fnp-6382	32	26	expressed	express	VERB
fnp-6382	32	27	on	on	ADP
fnp-6382	32	28	myeloid	myeloid	ADJ
fnp-6382	32	29	cells	cell	NOUN
fnp-6382	32	30	2	2	NUM
fnp-6382	32	31	)	)	PUNCT
fnp-6382	32	32	and	and	CCONJ
fnp-6382	32	33	cd33	cd33	PROPN
fnp-6382	32	34	(	(	PUNCT
fnp-6382	32	35	cluster	cluster	NOUN
fnp-6382	32	36	of	of	ADP
fnp-6382	32	37	differentiation	differentiation	NOUN
fnp-6382	32	38	33	33	NUM
fnp-6382	32	39	)	)	PUNCT
fnp-6382	32	40	,	,	PUNCT
fnp-6382	32	41	(	(	PUNCT
fnp-6382	32	42	23,24	23,24	NOUN
fnp-6382	32	43	)	)	PUNCT
fnp-6382	32	44	,	,	PUNCT
fnp-6382	32	45	while	while	SCONJ
fnp-6382	32	46	tmem106b	tmem106b	PROPN
fnp-6382	32	47	(	(	PUNCT
fnp-6382	32	48	triggering	trigger	VERB
fnp-6382	32	49	receptor	receptor	NOUN
fnp-6382	32	50	expressed	express	VERB
fnp-6382	32	51	on	on	ADP
fnp-6382	32	52	myeloid	myeloid	NOUN
fnp-6382	32	53	cells	cell	NOUN
fnp-6382	32	54	106b	106b	PROPN
fnp-6382	32	55	)	)	PUNCT
fnp-6382	32	56	and	and	CCONJ
fnp-6382	32	57	lrrk2	lrrk2	NOUN
fnp-6382	32	58	(	(	PUNCT
fnp-6382	32	59	leucine	leucine	NOUN
fnp-6382	32	60	-	-	PUNCT
fnp-6382	32	61	rich	rich	ADJ
fnp-6382	32	62	repeat	repeat	NOUN
fnp-6382	32	63	kinase	kinase	NOUN
fnp-6382	32	64	2	2	X
fnp-6382	32	65	)	)	PUNCT
fnp-6382	32	66	have	have	AUX
fnp-6382	32	67	been	be	AUX
fnp-6382	32	68	detected	detect	VERB
fnp-6382	32	69	as	as	ADP
fnp-6382	32	70	immune	immune	NOUN
fnp-6382	32	71	-	-	PUNCT
fnp-6382	32	72	related	relate	VERB
fnp-6382	32	73	variants	variant	NOUN
fnp-6382	32	74	affecting	affect	VERB
fnp-6382	32	75	pathology	pathology	NOUN
fnp-6382	32	76	in	in	ADP
fnp-6382	32	77	frontotemporal	frontotemporal	ADJ
fnp-6382	32	78	dementia	dementia	NOUN
fnp-6382	32	79	(	(	PUNCT
fnp-6382	32	80	ftd	ftd	NOUN
fnp-6382	32	81	)	)	PUNCT
fnp-6382	32	82	(	(	PUNCT
fnp-6382	32	83	25,26	25,26	NUM
fnp-6382	32	84	)	)	PUNCT
fnp-6382	32	85	and	and	CCONJ
fnp-6382	32	86	parkinson	parkinson	NOUN
fnp-6382	32	87	’s	’s	PART
fnp-6382	32	88	disease	disease	NOUN
fnp-6382	32	89	(	(	PUNCT
fnp-6382	32	90	27,28	27,28	NOUN
fnp-6382	32	91	)	)	PUNCT
fnp-6382	32	92	,	,	PUNCT
fnp-6382	32	93	respectively	respectively	ADV
fnp-6382	32	94	.	.	PUNCT
fnp-6382	33	1	in	in	ADP
fnp-6382	33	2	fact	fact	NOUN
fnp-6382	33	3	,	,	PUNCT
fnp-6382	33	4	based	base	VERB
fnp-6382	33	5	on	on	ADP
fnp-6382	33	6	post	post	ADJ
fnp-6382	33	7	-	-	ADJ
fnp-6382	33	8	mortem	mortem	ADJ
fnp-6382	33	9	genomic	genomic	ADJ
fnp-6382	33	10	analysis	analysis	NOUN
fnp-6382	33	11	of	of	ADP
fnp-6382	33	12	cerebellum	cerebellum	ADJ
fnp-6382	33	13	tissue	tissue	NOUN
fnp-6382	33	14	,	,	PUNCT
fnp-6382	33	15	bieniek	bieniek	NOUN
fnp-6382	33	16	et	et	PROPN
fnp-6382	33	17	al	al	PROPN
fnp-6382	33	18	.	.	PROPN
fnp-6382	33	19	reported	report	VERB
fnp-6382	33	20	that	that	SCONJ
fnp-6382	33	21	donors	donor	NOUN
fnp-6382	33	22	with	with	ADP
fnp-6382	33	23	rhi	rhi	PROPN
fnp-6382	33	24	exposure	exposure	NOUN
fnp-6382	33	25	and	and	CCONJ
fnp-6382	33	26	cte	cte	NOUN
fnp-6382	33	27	diagnosis	diagnosis	NOUN
fnp-6382	33	28	at	at	ADP
fnp-6382	33	29	autopsy	autopsy	ADJ
fnp-6382	33	30	tended	tend	VERB
fnp-6382	33	31	to	to	PART
fnp-6382	33	32	have	have	VERB
fnp-6382	33	33	a	a	DET
fnp-6382	33	34	slight	slight	ADJ
fnp-6382	33	35	increase	increase	NOUN
fnp-6382	33	36	in	in	ADP
fnp-6382	33	37	the	the	DET
fnp-6382	33	38	mapt	mapt	NOUN
fnp-6382	33	39	 	 	SPACE
fnp-6382	33	40	h1	h1	NOUN
fnp-6382	33	41	haplotype	haplotype	NOUN
fnp-6382	33	42	,	,	PUNCT
fnp-6382	33	43	with	with	ADP
fnp-6382	33	44	less	less	ADV
fnp-6382	33	45	homozygous	homozygous	ADJ
fnp-6382	33	46	genotypes	genotype	NOUN
fnp-6382	33	47	of	of	ADP
fnp-6382	33	48	the	the	DET
fnp-6382	33	49	tmem106b	tmem106b	PROPN
fnp-6382	33	50	 	 	SPACE
fnp-6382	33	51	rs3173615	rs3173615	PROPN
fnp-6382	33	52	minor	minor	ADJ
fnp-6382	33	53	allele	allele	NOUN
fnp-6382	33	54	compared	compare	VERB
fnp-6382	33	55	to	to	ADP
fnp-6382	33	56	non	non	ADJ
fnp-6382	33	57	-	-	ADJ
fnp-6382	33	58	cte	cte	ADJ
fnp-6382	33	59	controls	control	NOUN
fnp-6382	33	60	.	.	PUNCT
fnp-6382	34	1	furthermore	furthermore	ADV
fnp-6382	34	2	,	,	PUNCT
fnp-6382	34	3	immune	immune	ADJ
fnp-6382	34	4	signaling	signal	VERB
fnp-6382	34	5	,	,	PUNCT
fnp-6382	34	6	such	such	ADJ
fnp-6382	34	7	as	as	ADP
fnp-6382	34	8	through	through	ADP
fnp-6382	34	9	cytokine	cytokine	ADJ
fnp-6382	34	10	release	release	NOUN
fnp-6382	34	11	from	from	ADP
fnp-6382	34	12	activated	activate	VERB
fnp-6382	34	13	microglia	microglia	NOUN
fnp-6382	34	14	,	,	PUNCT
fnp-6382	34	15	has	have	AUX
fnp-6382	34	16	been	be	AUX
fnp-6382	34	17	reported	report	VERB
fnp-6382	34	18	to	to	PART
fnp-6382	34	19	promote	promote	VERB
fnp-6382	34	20	tau	tau	PROPN
fnp-6382	34	21	hyperphosphorylation	hyperphosphorylation	NOUN
fnp-6382	34	22	and	and	CCONJ
fnp-6382	34	23	to	to	PART
fnp-6382	34	24	impair	impair	VERB
fnp-6382	34	25	amyloid	amyloid	NOUN
fnp-6382	34	26	-	-	PUNCT
fnp-6382	34	27	β	β	NOUN
fnp-6382	34	28	clearance	clearance	NOUN
fnp-6382	34	29	(	(	PUNCT
fnp-6382	34	30	29–31	29–31	PROPN
fnp-6382	34	31	)	)	PUNCT
fnp-6382	34	32	.	.	PUNCT
fnp-6382	35	1	although	although	SCONJ
fnp-6382	35	2	the	the	DET
fnp-6382	35	3	absence	absence	NOUN
fnp-6382	35	4	of	of	ADP
fnp-6382	35	5	a	a	DET
fnp-6382	35	6	validated	validate	VERB
fnp-6382	35	7	longitudinal	longitudinal	ADJ
fnp-6382	35	8	or	or	CCONJ
fnp-6382	35	9	animal	animal	NOUN
fnp-6382	35	10	model	model	NOUN
fnp-6382	35	11	limits	limit	VERB
fnp-6382	35	12	the	the	DET
fnp-6382	35	13	ability	ability	NOUN
fnp-6382	35	14	to	to	PART
fnp-6382	35	15	experimentally	experimentally	ADV
fnp-6382	35	16	demonstrate	demonstrate	VERB
fnp-6382	35	17	that	that	SCONJ
fnp-6382	35	18	cte	cte	PROPN
fnp-6382	35	19	follows	follow	VERB
fnp-6382	35	20	a	a	DET
fnp-6382	35	21	similar	similar	ADJ
fnp-6382	35	22	pattern	pattern	NOUN
fnp-6382	35	23	as	as	ADP
fnp-6382	35	24	other	other	ADJ
fnp-6382	35	25	neurodegenerative	neurodegenerative	ADJ
fnp-6382	35	26	states	state	NOUN
fnp-6382	35	27	,	,	PUNCT
fnp-6382	35	28	post	post	ADJ
fnp-6382	35	29	-	-	ADJ
fnp-6382	35	30	mortem	mortem	ADJ
fnp-6382	35	31	transcriptomic	transcriptomic	ADJ
fnp-6382	35	32	and	and	CCONJ
fnp-6382	35	33	computational	computational	ADJ
fnp-6382	35	34	analyses	analysis	NOUN
fnp-6382	35	35	offer	offer	VERB
fnp-6382	35	36	evidence	evidence	NOUN
fnp-6382	35	37	that	that	SCONJ
fnp-6382	35	38	inflammation	inflammation	NOUN
fnp-6382	35	39	precedes	precede	VERB
fnp-6382	35	40	pathology	pathology	NOUN
fnp-6382	35	41	in	in	ADP
fnp-6382	35	42	cte	cte	PROPN
fnp-6382	35	43	.	.	PUNCT
fnp-6382	36	1	in	in	ADP
fnp-6382	36	2	a	a	DET
fnp-6382	36	3	large	large	ADJ
fnp-6382	36	4	-	-	PUNCT
fnp-6382	36	5	scale	scale	NOUN
fnp-6382	36	6	mrna	mrna	NOUN
fnp-6382	36	7	-	-	PUNCT
fnp-6382	36	8	sequencing	sequence	VERB
fnp-6382	36	9	analysis	analysis	NOUN
fnp-6382	36	10	of	of	ADP
fnp-6382	36	11	post	post	ADJ
fnp-6382	36	12	-	-	ADJ
fnp-6382	36	13	mortem	mortem	ADJ
fnp-6382	36	14	cte	cte	NOUN
fnp-6382	36	15	,	,	PUNCT
fnp-6382	36	16	labadorf	labadorf	PROPN
fnp-6382	36	17	et	et	PROPN
fnp-6382	36	18	al	al	PROPN
fnp-6382	36	19	.	.	PROPN
fnp-6382	36	20	reported	report	VERB
fnp-6382	36	21	upregulation	upregulation	NOUN
fnp-6382	36	22	of	of	ADP
fnp-6382	36	23	genes	gene	NOUN
fnp-6382	36	24	related	relate	VERB
fnp-6382	36	25	to	to	PART
fnp-6382	36	26	cytokine	cytokine	VERB
fnp-6382	36	27	signaling	signal	VERB
fnp-6382	36	28	,	,	PUNCT
fnp-6382	36	29	immune	immune	ADJ
fnp-6382	36	30	cell	cell	NOUN
fnp-6382	36	31	migration	migration	NOUN
fnp-6382	36	32	,	,	PUNCT
fnp-6382	36	33	and	and	CCONJ
fnp-6382	36	34	apoptosis	apoptosis	NOUN
fnp-6382	36	35	in	in	ADP
fnp-6382	36	36	late	late	ADJ
fnp-6382	36	37	stage	stage	NOUN
fnp-6382	36	38	cte	cte	NOUN
fnp-6382	36	39	,	,	PUNCT
fnp-6382	36	40	while	while	SCONJ
fnp-6382	36	41	these	these	DET
fnp-6382	36	42	same	same	ADJ
fnp-6382	36	43	categories	category	NOUN
fnp-6382	36	44	had	have	VERB
fnp-6382	36	45	inverse	inverse	NOUN
fnp-6382	36	46	or	or	CCONJ
fnp-6382	36	47	reduced	reduce	VERB
fnp-6382	36	48	expression	expression	NOUN
fnp-6382	36	49	in	in	ADP
fnp-6382	36	50	early	early	ADJ
fnp-6382	36	51	stage	stage	NOUN
fnp-6382	36	52	cte	cte	NOUN
fnp-6382	36	53	.	.	PUNCT
fnp-6382	37	1	this	this	PRON
fnp-6382	37	2	suggests	suggest	VERB
fnp-6382	37	3	that	that	SCONJ
fnp-6382	37	4	early	early	ADJ
fnp-6382	37	5	inflammatory	inflammatory	ADJ
fnp-6382	37	6	responses	response	NOUN
fnp-6382	37	7	could	could	AUX
fnp-6382	37	8	have	have	VERB
fnp-6382	37	9	a	a	DET
fnp-6382	37	10	distinct	distinct	ADJ
fnp-6382	37	11	mechanistic	mechanistic	ADJ
fnp-6382	37	12	mechanistic	mechanistic	ADJ
fnp-6382	37	13	function	function	NOUN
fnp-6382	37	14	separate	separate	ADJ
fnp-6382	37	15	from	from	ADP
fnp-6382	37	16	the	the	DET
fnp-6382	37	17	response	response	NOUN
fnp-6382	37	18	to	to	ADP
fnp-6382	37	19	tauopathy	tauopathy	NOUN
fnp-6382	37	20	.	.	PUNCT
fnp-6382	38	1	notably	notably	ADV
fnp-6382	38	2	,	,	PUNCT
fnp-6382	38	3	activation	activation	NOUN
fnp-6382	38	4	of	of	ADP
fnp-6382	38	5	immune	immune	ADJ
fnp-6382	38	6	pathways	pathway	NOUN
fnp-6382	38	7	in	in	ADP
fnp-6382	38	8	early	early	ADJ
fnp-6382	38	9	stages	stage	NOUN
fnp-6382	38	10	of	of	ADP
fnp-6382	38	11	cte	cte	NOUN
fnp-6382	38	12	was	be	AUX
fnp-6382	38	13	positively	positively	ADV
fnp-6382	38	14	correlated	correlate	VERB
fnp-6382	38	15	with	with	ADP
fnp-6382	38	16	duration	duration	NOUN
fnp-6382	38	17	of	of	ADP
fnp-6382	38	18	rhi	rhi	PROPN
fnp-6382	38	19	exposure	exposure	NOUN
fnp-6382	38	20	,	,	PUNCT
fnp-6382	38	21	suggesting	suggest	VERB
fnp-6382	38	22	inflammation	inflammation	NOUN
fnp-6382	38	23	as	as	ADP
fnp-6382	38	24	an	an	DET
fnp-6382	38	25	initiating	initiate	VERB
fnp-6382	38	26	factor	factor	NOUN
fnp-6382	38	27	for	for	ADP
fnp-6382	38	28	cte	cte	NOUN
fnp-6382	38	29	pathogenesis	pathogenesis	NOUN
fnp-6382	38	30	(	(	PUNCT
fnp-6382	38	31	32	32	NUM
fnp-6382	38	32	)	)	PUNCT
fnp-6382	38	33	.	.	PUNCT
fnp-6382	39	1	similarly	similarly	ADV
fnp-6382	39	2	,	,	PUNCT
fnp-6382	39	3	cherry	cherry	PROPN
fnp-6382	39	4	et	et	PROPN
fnp-6382	39	5	al	al	PROPN
fnp-6382	39	6	.	.	PROPN
fnp-6382	39	7	found	find	VERB
fnp-6382	39	8	that	that	SCONJ
fnp-6382	39	9	in	in	ADP
fnp-6382	39	10	post	post	ADJ
fnp-6382	39	11	-	-	ADJ
fnp-6382	39	12	mortem	mortem	ADJ
fnp-6382	39	13	dorsolateral	dorsolateral	ADJ
fnp-6382	39	14	frontal	frontal	ADJ
fnp-6382	39	15	cortex	cortex	NOUN
fnp-6382	39	16	from	from	ADP
fnp-6382	39	17	donors	donor	NOUN
fnp-6382	39	18	with	with	ADP
fnp-6382	39	19	early	early	ADJ
fnp-6382	39	20	stage	stage	NOUN
fnp-6382	39	21	cte	cte	NOUN
fnp-6382	39	22	,	,	PUNCT
fnp-6382	39	23	immune	immune	NOUN
fnp-6382	39	24	-	-	PUNCT
fnp-6382	39	25	related	relate	VERB
fnp-6382	39	26	genes	gene	NOUN
fnp-6382	39	27	were	be	AUX
fnp-6382	39	28	upregulated	upregulate	VERB
fnp-6382	39	29	in	in	ADP
fnp-6382	39	30	sulci	sulci	NOUN
fnp-6382	39	31	compared	compare	VERB
fnp-6382	39	32	to	to	ADP
fnp-6382	39	33	neighboring	neighboring	NOUN
fnp-6382	39	34	gyri	gyri	NOUN
fnp-6382	39	35	compared	compare	VERB
fnp-6382	39	36	to	to	ADP
fnp-6382	39	37	rhi	rhi	PROPN
fnp-6382	39	38	donors	donor	NOUN
fnp-6382	39	39	without	without	ADP
fnp-6382	39	40	cte	cte	PROPN
fnp-6382	39	41	.	.	PUNCT
fnp-6382	40	1	these	these	DET
fnp-6382	40	2	sulcal	sulcal	ADJ
fnp-6382	40	3	alterations	alteration	NOUN
fnp-6382	40	4	in	in	ADP
fnp-6382	40	5	immune	immune	ADJ
fnp-6382	40	6	gene	gene	NOUN
fnp-6382	40	7	expression	expression	NOUN
fnp-6382	40	8	were	be	AUX
fnp-6382	40	9	also	also	ADV
fnp-6382	40	10	associated	associate	VERB
fnp-6382	40	11	with	with	ADP
fnp-6382	40	12	rhi	rhi	PROPN
fnp-6382	40	13	history	history	NOUN
fnp-6382	40	14	and	and	CCONJ
fnp-6382	40	15	did	do	AUX
fnp-6382	40	16	not	not	PART
fnp-6382	40	17	exclusively	exclusively	ADV
fnp-6382	40	18	co	co	VERB
fnp-6382	40	19	-	-	VERB
fnp-6382	40	20	occur	occur	VERB
fnp-6382	40	21	with	with	ADP
fnp-6382	40	22	pathology	pathology	NOUN
fnp-6382	40	23	,	,	PUNCT
fnp-6382	40	24	further	far	ADV
fnp-6382	40	25	suggesting	suggest	VERB
fnp-6382	40	26	inflammation	inflammation	NOUN
fnp-6382	40	27	to	to	PART
fnp-6382	40	28	occur	occur	VERB
fnp-6382	40	29	upstream	upstream	NOUN
fnp-6382	40	30	of	of	ADP
fnp-6382	40	31	tau	tau	PROPN
fnp-6382	40	32	deposition	deposition	NOUN
fnp-6382	40	33	(	(	PUNCT
fnp-6382	40	34	33	33	NUM
fnp-6382	40	35	)	)	PUNCT
fnp-6382	40	36	.	.	PUNCT
fnp-6382	41	1	additional	additional	ADJ
fnp-6382	41	2	support	support	NOUN
fnp-6382	41	3	comes	come	VERB
fnp-6382	41	4	from	from	ADP
fnp-6382	41	5	a	a	DET
fnp-6382	41	6	recent	recent	ADJ
fnp-6382	41	7	study	study	NOUN
fnp-6382	41	8	by	by	ADP
fnp-6382	41	9	butler	butler	PROPN
fnp-6382	41	10	et	et	PROPN
fnp-6382	41	11	al	al	PROPN
fnp-6382	41	12	.	.	PROPN
fnp-6382	41	13	who	who	PRON
fnp-6382	41	14	observed	observe	VERB
fnp-6382	41	15	that	that	SCONJ
fnp-6382	41	16	in	in	ADP
fnp-6382	41	17	individuals	individual	NOUN
fnp-6382	41	18	under	under	ADP
fnp-6382	41	19	the	the	DET
fnp-6382	41	20	age	age	NOUN
fnp-6382	41	21	of	of	ADP
fnp-6382	41	22	50	50	NUM
fnp-6382	41	23	years	year	NOUN
fnp-6382	41	24	with	with	ADP
fnp-6382	41	25	exposure	exposure	NOUN
fnp-6382	41	26	to	to	ADP
fnp-6382	41	27	contact	contact	NOUN
fnp-6382	41	28	sports	sport	NOUN
fnp-6382	41	29	,	,	PUNCT
fnp-6382	41	30	cases	case	NOUN
fnp-6382	41	31	that	that	PRON
fnp-6382	41	32	had	have	VERB
fnp-6382	41	33	exposure	exposure	NOUN
fnp-6382	41	34	to	to	ADP
fnp-6382	41	35	rhi	rhi	PROPN
fnp-6382	41	36	but	but	CCONJ
fnp-6382	41	37	no	no	DET
fnp-6382	41	38	cte	cte	NOUN
fnp-6382	41	39	pathology	pathology	NOUN
fnp-6382	41	40	still	still	ADV
fnp-6382	41	41	had	have	VERB
fnp-6382	41	42	significant	significant	ADJ
fnp-6382	41	43	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	41	44	changes	change	NOUN
fnp-6382	41	45	compared	compare	VERB
fnp-6382	41	46	to	to	ADP
fnp-6382	41	47	control	control	NOUN
fnp-6382	41	48	cases	case	NOUN
fnp-6382	41	49	.	.	PUNCT
fnp-6382	42	1	interestingly	interestingly	ADV
fnp-6382	42	2	,	,	PUNCT
fnp-6382	42	3	the	the	DET
fnp-6382	42	4	observed	observe	VERB
fnp-6382	42	5	inflammatory	inflammatory	ADJ
fnp-6382	42	6	changes	change	NOUN
fnp-6382	42	7	were	be	AUX
fnp-6382	42	8	similar	similar	ADJ
fnp-6382	42	9	to	to	ADP
fnp-6382	42	10	those	those	PRON
fnp-6382	42	11	seen	see	VERB
fnp-6382	42	12	in	in	ADP
fnp-6382	42	13	cases	case	NOUN
fnp-6382	42	14	with	with	ADP
fnp-6382	42	15	early	early	ADJ
fnp-6382	42	16	stage	stage	NOUN
fnp-6382	42	17	cte	cte	NOUN
fnp-6382	42	18	,	,	PUNCT
fnp-6382	42	19	suggesting	suggest	VERB
fnp-6382	42	20	that	that	SCONJ
fnp-6382	42	21	inflammation	inflammation	NOUN
fnp-6382	42	22	precedes	precede	VERB
fnp-6382	42	23	the	the	DET
fnp-6382	42	24	deposition	deposition	NOUN
fnp-6382	42	25	of	of	ADP
fnp-6382	42	26	p	p	PROPN
fnp-6382	42	27	-	-	PUNCT
fnp-6382	42	28	tau	tau	PROPN
fnp-6382	42	29	(	(	PUNCT
fnp-6382	42	30	34	34	NUM
fnp-6382	42	31	)	)	PUNCT
fnp-6382	42	32	.	.	PUNCT
fnp-6382	43	1	in	in	ADP
fnp-6382	43	2	addition	addition	NOUN
fnp-6382	43	3	,	,	PUNCT
fnp-6382	43	4	pet	pet	ADJ
fnp-6382	43	5	imaging	imaging	NOUN
fnp-6382	43	6	of	of	ADP
fnp-6382	43	7	translocator	translocator	NOUN
fnp-6382	43	8	protein	protein	NOUN
fnp-6382	43	9	(	(	PUNCT
fnp-6382	43	10	tspo	tspo	NOUN
fnp-6382	43	11	)	)	PUNCT
fnp-6382	43	12	,	,	PUNCT
fnp-6382	43	13	which	which	PRON
fnp-6382	43	14	is	be	AUX
fnp-6382	43	15	expressed	express	VERB
fnp-6382	43	16	in	in	ADP
fnp-6382	43	17	the	the	DET
fnp-6382	43	18	mitochondria	mitochondria	NOUN
fnp-6382	43	19	of	of	ADP
fnp-6382	43	20	various	various	ADJ
fnp-6382	43	21	neural	neural	ADJ
fnp-6382	43	22	cells	cell	NOUN
fnp-6382	43	23	(	(	PUNCT
fnp-6382	43	24	i.e.	i.e.	X
fnp-6382	43	25	,	,	PUNCT
fnp-6382	43	26	microglia	microglia	ADJ
fnp-6382	43	27	,	,	PUNCT
fnp-6382	43	28	endothelial	endothelial	ADJ
fnp-6382	43	29	cells	cell	NOUN
fnp-6382	43	30	,	,	PUNCT
fnp-6382	43	31	astrocytes	astrocyte	NOUN
fnp-6382	43	32	)	)	PUNCT
fnp-6382	43	33	,	,	PUNCT
fnp-6382	43	34	showed	show	VERB
fnp-6382	43	35	increased	increase	VERB
fnp-6382	43	36	tspo	tspo	NOUN
fnp-6382	43	37	in	in	ADP
fnp-6382	43	38	regions	region	NOUN
fnp-6382	43	39	including	include	VERB
fnp-6382	43	40	right	right	ADJ
fnp-6382	43	41	amygdala	amygdala	NOUN
fnp-6382	43	42	and	and	CCONJ
fnp-6382	43	43	bilateral	bilateral	ADJ
fnp-6382	43	44	supramarginal	supramarginal	ADJ
fnp-6382	43	45	gyri	gyri	PROPN
fnp-6382	43	46	for	for	ADP
fnp-6382	43	47	rhi	rhi	NOUN
fnp-6382	43	48	-	-	PUNCT
fnp-6382	43	49	exposed	expose	VERB
fnp-6382	43	50	football	football	NOUN
fnp-6382	43	51	players	player	NOUN
fnp-6382	43	52	(	(	PUNCT
fnp-6382	43	53	35,36	35,36	NUM
fnp-6382	43	54	)	)	PUNCT
fnp-6382	43	55	.	.	PUNCT
fnp-6382	44	1	when	when	SCONJ
fnp-6382	44	2	examining	examine	VERB
fnp-6382	44	3	tspo	tspo	NOUN
fnp-6382	44	4	via	via	ADP
fnp-6382	44	5	post	post	ADJ
fnp-6382	44	6	-	-	ADJ
fnp-6382	44	7	mortem	mortem	ADJ
fnp-6382	44	8	immunoassay	immunoassay	NOUN
fnp-6382	44	9	,	,	PUNCT
fnp-6382	44	10	varlow	varlow	PROPN
fnp-6382	44	11	et	et	PROPN
fnp-6382	44	12	al	al	PROPN
fnp-6382	44	13	.	.	PROPN
fnp-6382	44	14	reported	report	VERB
fnp-6382	44	15	that	that	SCONJ
fnp-6382	44	16	despite	despite	SCONJ
fnp-6382	44	17	the	the	DET
fnp-6382	44	18	difference	difference	NOUN
fnp-6382	44	19	in	in	ADP
fnp-6382	44	20	tspo	tspo	NOUN
fnp-6382	44	21	density	density	NOUN
fnp-6382	44	22	between	between	ADP
fnp-6382	44	23	cte	cte	NOUN
fnp-6382	44	24	and	and	CCONJ
fnp-6382	44	25	controls	control	VERB
fnp-6382	44	26	not	not	PART
fnp-6382	44	27	reaching	reach	VERB
fnp-6382	44	28	statistical	statistical	ADJ
fnp-6382	44	29	significance	significance	NOUN
fnp-6382	44	30	,	,	PUNCT
fnp-6382	44	31	there	there	PRON
fnp-6382	44	32	was	be	VERB
fnp-6382	44	33	a	a	DET
fnp-6382	44	34	general	general	ADJ
fnp-6382	44	35	trend	trend	NOUN
fnp-6382	44	36	of	of	ADP
fnp-6382	44	37	increased	increase	VERB
fnp-6382	44	38	expression	expression	NOUN
fnp-6382	44	39	in	in	ADP
fnp-6382	44	40	cte	cte	PROPN
fnp-6382	44	41	(	(	PUNCT
fnp-6382	44	42	37	37	NUM
fnp-6382	44	43	)	)	PUNCT
fnp-6382	44	44	.	.	PUNCT
fnp-6382	45	1	taken	take	VERB
fnp-6382	45	2	together	together	ADV
fnp-6382	45	3	,	,	PUNCT
fnp-6382	45	4	these	these	DET
fnp-6382	45	5	findings	finding	NOUN
fnp-6382	45	6	highlight	highlight	VERB
fnp-6382	45	7	that	that	PRON
fnp-6382	45	8	inflammation	inflammation	NOUN
fnp-6382	45	9	has	have	VERB
fnp-6382	45	10	a	a	DET
fnp-6382	45	11	critical	critical	ADJ
fnp-6382	45	12	and	and	CCONJ
fnp-6382	45	13	variable	variable	ADJ
fnp-6382	45	14	role	role	NOUN
fnp-6382	45	15	across	across	ADP
fnp-6382	45	16	cte	cte	PROPN
fnp-6382	45	17	pathogenesis	pathogenesis	NOUN
fnp-6382	45	18	.	.	PUNCT
fnp-6382	46	1	future	future	ADJ
fnp-6382	46	2	studies	study	NOUN
fnp-6382	46	3	that	that	PRON
fnp-6382	46	4	more	more	ADV
fnp-6382	46	5	precisely	precisely	ADV
fnp-6382	46	6	target	target	VERB
fnp-6382	46	7	these	these	DET
fnp-6382	46	8	inflammatory	inflammatory	ADJ
fnp-6382	46	9	processes	process	NOUN
fnp-6382	46	10	and	and	CCONJ
fnp-6382	46	11	aim	aim	VERB
fnp-6382	46	12	to	to	PART
fnp-6382	46	13	better	well	ADV
fnp-6382	46	14	characterize	characterize	VERB
fnp-6382	46	15	the	the	DET
fnp-6382	46	16	cte	cte	PROPN
fnp-6382	46	17	immune	immune	ADJ
fnp-6382	46	18	signature	signature	NOUN
fnp-6382	46	19	may	may	AUX
fnp-6382	46	20	offer	offer	VERB
fnp-6382	46	21	clearer	clear	ADJ
fnp-6382	46	22	insight	insight	NOUN
fnp-6382	46	23	into	into	ADP
fnp-6382	46	24	disease	disease	NOUN
fnp-6382	46	25	progression	progression	NOUN
fnp-6382	46	26	during	during	ADP
fnp-6382	46	27	life	life	NOUN
fnp-6382	46	28	.	.	PUNCT
fnp-6382	47	1	this	this	PRON
fnp-6382	47	2	would	would	AUX
fnp-6382	47	3	consequently	consequently	ADV
fnp-6382	47	4	serve	serve	VERB
fnp-6382	47	5	as	as	ADP
fnp-6382	47	6	a	a	DET
fnp-6382	47	7	promising	promising	ADJ
fnp-6382	47	8	avenue	avenue	NOUN
fnp-6382	47	9	for	for	ADP
fnp-6382	47	10	identifying	identify	VERB
fnp-6382	47	11	cte	cte	NOUN
fnp-6382	47	12	-	-	PUNCT
fnp-6382	47	13	specific	specific	ADJ
fnp-6382	47	14	biomarkers	biomarker	NOUN
fnp-6382	47	15	.	.	PUNCT
fnp-6382	48	1	candidate	candidate	NOUN
fnp-6382	48	2	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	48	3	markers	marker	NOUN
fnp-6382	48	4	for	for	ADP
fnp-6382	48	5	cte	cte	NOUN
fnp-6382	48	6	from	from	ADP
fnp-6382	48	7	the	the	DET
fnp-6382	48	8	immune	immune	ADJ
fnp-6382	48	9	signature	signature	NOUN
fnp-6382	48	10	of	of	ADP
fnp-6382	48	11	cte	cte	PROPN
fnp-6382	48	12	,	,	PUNCT
fnp-6382	48	13	candidate	candidate	NOUN
fnp-6382	48	14	markers	marker	NOUN
fnp-6382	48	15	may	may	AUX
fnp-6382	48	16	emerge	emerge	VERB
fnp-6382	48	17	allowing	allow	VERB
fnp-6382	48	18	distinction	distinction	NOUN
fnp-6382	48	19	of	of	ADP
fnp-6382	48	20	cte	cte	NOUN
fnp-6382	48	21	from	from	ADP
fnp-6382	48	22	other	other	ADJ
fnp-6382	48	23	neurodegenerative	neurodegenerative	ADJ
fnp-6382	48	24	conditions	condition	NOUN
fnp-6382	48	25	.	.	PUNCT
fnp-6382	49	1	considering	consider	VERB
fnp-6382	49	2	the	the	DET
fnp-6382	49	3	preliminary	preliminary	ADJ
fnp-6382	49	4	evidence	evidence	NOUN
fnp-6382	49	5	that	that	SCONJ
fnp-6382	49	6	inflammation	inflammation	NOUN
fnp-6382	49	7	precedes	precede	VERB
fnp-6382	49	8	and	and	CCONJ
fnp-6382	49	9	contributes	contribute	VERB
fnp-6382	49	10	to	to	PART
fnp-6382	49	11	cte	cte	VERB
fnp-6382	49	12	pathology	pathology	PROPN
fnp-6382	49	13	,	,	PUNCT
fnp-6382	49	14	it	it	PRON
fnp-6382	49	15	could	could	AUX
fnp-6382	49	16	be	be	AUX
fnp-6382	49	17	worthwhile	worthwhile	ADJ
fnp-6382	49	18	to	to	PART
fnp-6382	49	19	evaluate	evaluate	VERB
fnp-6382	49	20	proteins	protein	NOUN
fnp-6382	49	21	involved	involve	VERB
fnp-6382	49	22	in	in	ADP
fnp-6382	49	23	the	the	DET
fnp-6382	49	24	cte	cte	NOUN
fnp-6382	49	25	immune	immune	ADJ
fnp-6382	49	26	profile	profile	NOUN
fnp-6382	49	27	for	for	ADP
fnp-6382	49	28	biomarker	biomarker	NOUN
fnp-6382	49	29	development	development	NOUN
fnp-6382	49	30	.	.	PUNCT
fnp-6382	50	1	here	here	ADV
fnp-6382	50	2	,	,	PUNCT
fnp-6382	50	3	we	we	PRON
fnp-6382	50	4	discuss	discuss	VERB
fnp-6382	50	5	current	current	ADJ
fnp-6382	50	6	prospective	prospective	ADJ
fnp-6382	50	7	neuroimmune	neuroimmune	NOUN
fnp-6382	50	8	biomarkers	biomarker	NOUN
fnp-6382	50	9	primarily	primarily	ADV
fnp-6382	50	10	derived	derive	VERB
fnp-6382	50	11	from	from	ADP
fnp-6382	50	12	studies	study	NOUN
fnp-6382	50	13	using	use	VERB
fnp-6382	50	14	postmortem	postmortem	NOUN
fnp-6382	50	15	fluids	fluid	NOUN
fnp-6382	50	16	in	in	ADP
fnp-6382	50	17	neuropathologically	neuropathologically	ADV
fnp-6382	50	18	confirmed	confirm	VERB
fnp-6382	50	19	cte	cte	NOUN
fnp-6382	50	20	or	or	CCONJ
fnp-6382	50	21	in	in	ADP
fnp-6382	50	22	fluids	fluid	NOUN
fnp-6382	50	23	from	from	ADP
fnp-6382	50	24	living	live	VERB
fnp-6382	50	25	individuals	individual	NOUN
fnp-6382	50	26	with	with	ADP
fnp-6382	50	27	a	a	DET
fnp-6382	50	28	history	history	NOUN
fnp-6382	50	29	of	of	ADP
fnp-6382	50	30	playing	play	VERB
fnp-6382	50	31	contact	contact	NOUN
fnp-6382	50	32	sports	sport	NOUN
fnp-6382	50	33	.	.	PUNCT
fnp-6382	51	1	as	as	SCONJ
fnp-6382	51	2	cte	cte	PROPN
fnp-6382	51	3	can	can	AUX
fnp-6382	51	4	only	only	ADV
fnp-6382	51	5	be	be	AUX
fnp-6382	51	6	diagnosed	diagnose	VERB
fnp-6382	51	7	after	after	ADP
fnp-6382	51	8	death	death	NOUN
fnp-6382	51	9	,	,	PUNCT
fnp-6382	51	10	the	the	DET
fnp-6382	51	11	postmortem	postmortem	NOUN
fnp-6382	51	12	studies	study	NOUN
fnp-6382	51	13	are	be	AUX
fnp-6382	51	14	the	the	DET
fnp-6382	51	15	only	only	ADJ
fnp-6382	51	16	way	way	NOUN
fnp-6382	51	17	to	to	PART
fnp-6382	51	18	directly	directly	ADV
fnp-6382	51	19	link	link	VERB
fnp-6382	51	20	a	a	DET
fnp-6382	51	21	protein	protein	NOUN
fnp-6382	51	22	to	to	PART
fnp-6382	51	23	confirmed	confirm	VERB
fnp-6382	51	24	cte	cte	PROPN
fnp-6382	51	25	.	.	PUNCT
fnp-6382	52	1	however	however	ADV
fnp-6382	52	2	,	,	PUNCT
fnp-6382	52	3	as	as	SCONJ
fnp-6382	52	4	past	past	ADJ
fnp-6382	52	5	work	work	NOUN
fnp-6382	52	6	has	have	AUX
fnp-6382	52	7	demonstrated	demonstrate	VERB
fnp-6382	52	8	a	a	DET
fnp-6382	52	9	strong	strong	ADJ
fnp-6382	52	10	correlation	correlation	NOUN
fnp-6382	52	11	between	between	ADP
fnp-6382	52	12	more	more	ADJ
fnp-6382	52	13	years	year	NOUN
fnp-6382	52	14	of	of	ADP
fnp-6382	52	15	contact	contact	NOUN
fnp-6382	52	16	sports	sport	NOUN
fnp-6382	52	17	play	play	NOUN
fnp-6382	52	18	and	and	CCONJ
fnp-6382	52	19	elevated	elevated	ADJ
fnp-6382	52	20	risk	risk	NOUN
fnp-6382	52	21	of	of	ADP
fnp-6382	52	22	cte	cte	NOUN
fnp-6382	52	23	(	(	PUNCT
fnp-6382	52	24	4	4	NUM
fnp-6382	52	25	)	)	PUNCT
fnp-6382	52	26	,	,	PUNCT
fnp-6382	52	27	the	the	DET
fnp-6382	52	28	prospective	prospective	ADJ
fnp-6382	52	29	human	human	ADJ
fnp-6382	52	30	studies	study	NOUN
fnp-6382	52	31	offer	offer	VERB
fnp-6382	52	32	additional	additional	ADJ
fnp-6382	52	33	insight	insight	NOUN
fnp-6382	52	34	into	into	ADP
fnp-6382	52	35	other	other	ADJ
fnp-6382	52	36	targets	target	NOUN
fnp-6382	52	37	that	that	PRON
fnp-6382	52	38	are	be	AUX
fnp-6382	52	39	likely	likely	ADJ
fnp-6382	52	40	to	to	PART
fnp-6382	52	41	be	be	AUX
fnp-6382	52	42	involved	involve	VERB
fnp-6382	52	43	in	in	ADP
fnp-6382	52	44	the	the	DET
fnp-6382	52	45	cte	cte	NOUN
fnp-6382	52	46	process	process	NOUN
fnp-6382	52	47	,	,	PUNCT
fnp-6382	52	48	pending	pende	VERB
fnp-6382	52	49	neuropathologic	neuropathologic	ADJ
fnp-6382	52	50	follow	follow	NOUN
fnp-6382	52	51	ups	up	NOUN
fnp-6382	52	52	.	.	PUNCT
fnp-6382	53	1	prospective	prospective	ADJ
fnp-6382	53	2	markers	marker	NOUN
fnp-6382	53	3	are	be	AUX
fnp-6382	53	4	summarized	summarize	VERB
fnp-6382	53	5	in	in	ADP
fnp-6382	53	6	table	table	NOUN
fnp-6382	53	7	 	 	SPACE
fnp-6382	53	8	1	1	NUM
fnp-6382	53	9	.	.	PUNCT
fnp-6382	53	10	table	table	NOUN
fnp-6382	53	11	1	1	NUM
fnp-6382	53	12	:	:	PUNCT
fnp-6382	53	13	overview	overview	NOUN
fnp-6382	53	14	of	of	ADP
fnp-6382	53	15	human	human	NOUN
fnp-6382	53	16	-	-	PUNCT
fnp-6382	53	17	based	base	VERB
fnp-6382	53	18	studies	study	NOUN
fnp-6382	53	19	on	on	ADP
fnp-6382	53	20	prospective	prospective	ADJ
fnp-6382	53	21	immune	immune	ADJ
fnp-6382	53	22	markers	marker	NOUN
fnp-6382	53	23	study	study	NOUN
fnp-6382	53	24	immune	immune	ADJ
fnp-6382	53	25	protein(s	protein(s	PROPN
fnp-6382	53	26	)	)	PUNCT
fnp-6382	53	27	study	study	NOUN
fnp-6382	53	28	design	design	NOUN
fnp-6382	53	29	study	study	NOUN
fnp-6382	53	30	populations	population	NOUN
fnp-6382	53	31	and	and	CCONJ
fnp-6382	53	32	sample	sample	NOUN
fnp-6382	53	33	sizes	size	NOUN
fnp-6382	53	34	significant	significant	ADJ
fnp-6382	53	35	findings	finding	NOUN
fnp-6382	53	36	cherry	cherry	NOUN
fnp-6382	53	37	et	et	PROPN
fnp-6382	53	38	al	al	PROPN
fnp-6382	53	39	.	.	PROPN
fnp-6382	53	40	2017	2017	NUM
fnp-6382	53	41	(	(	PUNCT
fnp-6382	53	42	52	52	NUM
fnp-6382	53	43	)	)	PUNCT
fnp-6382	53	44	ccl11	ccl11	NOUN
fnp-6382	53	45	elisa	elisa	NOUN
fnp-6382	53	46	of	of	ADP
fnp-6382	53	47	postmortem	postmortem	NOUN
fnp-6382	53	48	dorsolateral	dorsolateral	ADJ
fnp-6382	53	49	frontal	frontal	ADJ
fnp-6382	53	50	cortex	cortex	NOUN
fnp-6382	53	51	(	(	PUNCT
fnp-6382	53	52	dlfc	dlfc	NOUN
fnp-6382	53	53	)	)	PUNCT
fnp-6382	53	54	and	and	CCONJ
fnp-6382	53	55	csf	csf	ADJ
fnp-6382	53	56	analysis	analysis	NOUN
fnp-6382	53	57	23	23	NUM
fnp-6382	53	58	cte	cte	NOUN
fnp-6382	53	59	,	,	PUNCT
fnp-6382	53	60	50	50	NUM
fnp-6382	53	61	ad	ad	NOUN
fnp-6382	53	62	,	,	PUNCT
fnp-6382	53	63	and	and	CCONJ
fnp-6382	53	64	18	18	NUM
fnp-6382	53	65	non	non	ADJ
fnp-6382	53	66	-	-	ADJ
fnp-6382	53	67	athlete	athlete	ADJ
fnp-6382	53	68	controls	control	NOUN
fnp-6382	53	69	.	.	PUNCT
fnp-6382	54	1	all	all	PRON
fnp-6382	54	2	were	be	AUX
fnp-6382	54	3	neuropathologically	neuropathologically	ADV
fnp-6382	54	4	confirmed	confirm	VERB
fnp-6382	54	5	.	.	PUNCT
fnp-6382	55	1	ccl11	ccl11	PROPN
fnp-6382	55	2	was	be	AUX
fnp-6382	55	3	elevated	elevate	VERB
fnp-6382	55	4	in	in	ADP
fnp-6382	55	5	dlfc	dlfc	NOUN
fnp-6382	55	6	of	of	ADP
fnp-6382	55	7	cte	cte	NOUN
fnp-6382	55	8	compared	compare	VERB
fnp-6382	55	9	to	to	ADP
fnp-6382	55	10	ad	ad	NOUN
fnp-6382	55	11	and	and	CCONJ
fnp-6382	55	12	controls	control	NOUN
fnp-6382	55	13	.	.	PUNCT
fnp-6382	56	1	same	same	ADJ
fnp-6382	56	2	results	result	NOUN
fnp-6382	56	3	seen	see	VERB
fnp-6382	56	4	upon	upon	SCONJ
fnp-6382	56	5	csf	csf	ADJ
fnp-6382	56	6	analysis	analysis	NOUN
fnp-6382	56	7	.	.	PUNCT
fnp-6382	57	1	receiver	receiver	ADJ
fnp-6382	57	2	operator	operator	NOUN
fnp-6382	57	3	characteristics	characteristic	NOUN
fnp-6382	57	4	(	(	PUNCT
fnp-6382	57	5	roc	roc	PROPN
fnp-6382	57	6	)	)	PUNCT
fnp-6382	57	7	curve	curve	NOUN
fnp-6382	57	8	analysis	analysis	NOUN
fnp-6382	57	9	showed	show	VERB
fnp-6382	57	10	specificity	specificity	NOUN
fnp-6382	57	11	of	of	ADP
fnp-6382	57	12	ccl11	ccl11	PROPN
fnp-6382	57	13	to	to	PART
fnp-6382	57	14	cte	cte	VERB
fnp-6382	57	15	.	.	PUNCT
fnp-6382	58	1	ccl11	ccl11	PROPN
fnp-6382	58	2	correlated	correlate	VERB
fnp-6382	58	3	with	with	ADP
fnp-6382	58	4	rhi	rhi	PROPN
fnp-6382	58	5	exposure	exposure	PROPN
fnp-6382	58	6	duration	duration	NOUN
fnp-6382	58	7	.	.	PUNCT
fnp-6382	59	1	cherry	cherry	NOUN
fnp-6382	59	2	et	et	PROPN
fnp-6382	59	3	al	al	PROPN
fnp-6382	59	4	.	.	PROPN
fnp-6382	59	5	2022	2022	NUM
fnp-6382	59	6	(	(	PUNCT
fnp-6382	59	7	22	22	NUM
fnp-6382	59	8	)	)	PUNCT
fnp-6382	59	9	ccl21	ccl21	NOUN
fnp-6382	59	10	ccl11	ccl11	PROPN
fnp-6382	59	11	cxcl5	cxcl5	PROPN
fnp-6382	59	12	cxcl13	cxcl13	NOUN
fnp-6382	59	13	gmcsf	gmcsf	PROPN
fnp-6382	60	1	ccl17	ccl17	PROPN
fnp-6382	60	2	multiplex	multiplex	PROPN
fnp-6382	60	3	elisa	elisa	PROPN
fnp-6382	60	4	of	of	ADP
fnp-6382	60	5	postmortem	postmortem	PROPN
fnp-6382	60	6	anterior	anterior	ADJ
fnp-6382	60	7	cingulate	cingulate	NOUN
fnp-6382	60	8	grey	grey	PROPN
fnp-6382	60	9	matter	matter	NOUN
fnp-6382	60	10	and	and	CCONJ
fnp-6382	60	11	csf	csf	VERB
fnp-6382	60	12	analysis	analysis	NOUN
fnp-6382	60	13	40	40	NUM
fnp-6382	60	14	cte	cte	NOUN
fnp-6382	60	15	,	,	PUNCT
fnp-6382	60	16	28	28	NUM
fnp-6382	60	17	ad	ad	NOUN
fnp-6382	60	18	,	,	PUNCT
fnp-6382	60	19	20	20	NUM
fnp-6382	60	20	progressive	progressive	ADJ
fnp-6382	60	21	supranuclear	supranuclear	ADJ
fnp-6382	60	22	palsy	palsy	ADJ
fnp-6382	60	23	,	,	PUNCT
fnp-6382	60	24	20	20	NUM
fnp-6382	60	25	corticobasal	corticobasal	NOUN
fnp-6382	60	26	degeneration	degeneration	NOUN
fnp-6382	60	27	,	,	PUNCT
fnp-6382	60	28	19	19	NUM
fnp-6382	60	29	argyrophilic	argyrophilic	ADJ
fnp-6382	60	30	grain	grain	NOUN
fnp-6382	60	31	disease	disease	NOUN
fnp-6382	60	32	.	.	PUNCT
fnp-6382	61	1	all	all	PRON
fnp-6382	61	2	were	be	AUX
fnp-6382	61	3	neuropathologically	neuropathologically	ADV
fnp-6382	61	4	confirmed	confirm	VERB
fnp-6382	61	5	.	.	PUNCT
fnp-6382	62	1	from	from	ADP
fnp-6382	62	2	71	71	NUM
fnp-6382	62	3	immune	immune	ADJ
fnp-6382	62	4	proteins	protein	NOUN
fnp-6382	62	5	,	,	PUNCT
fnp-6382	62	6	ccl21	ccl21	NOUN
fnp-6382	62	7	had	have	VERB
fnp-6382	62	8	the	the	DET
fnp-6382	62	9	strongest	strong	ADJ
fnp-6382	62	10	correlation	correlation	NOUN
fnp-6382	62	11	with	with	ADP
fnp-6382	62	12	cte	cte	PROPN
fnp-6382	62	13	.	.	PUNCT
fnp-6382	63	1	cxcl5	cxcl5	PROPN
fnp-6382	63	2	,	,	PUNCT
fnp-6382	63	3	cxcl13	cxcl13	PROPN
fnp-6382	63	4	,	,	PUNCT
fnp-6382	63	5	gmcsf	gmcsf	PROPN
fnp-6382	63	6	,	,	PUNCT
fnp-6382	63	7	and	and	CCONJ
fnp-6382	63	8	ccl17	ccl17	PROPN
fnp-6382	63	9	had	have	VERB
fnp-6382	63	10	significant	significant	ADJ
fnp-6382	63	11	association	association	NOUN
fnp-6382	63	12	with	with	ADP
fnp-6382	63	13	cte	cte	PROPN
fnp-6382	63	14	based	base	VERB
fnp-6382	63	15	on	on	ADP
fnp-6382	63	16	roc	roc	PROPN
fnp-6382	63	17	analysis	analysis	NOUN
fnp-6382	63	18	.	.	PUNCT
fnp-6382	64	1	csf	csf	ADJ
fnp-6382	64	2	analysis	analysis	NOUN
fnp-6382	64	3	showed	show	VERB
fnp-6382	64	4	ccl21	ccl21	NOUN
fnp-6382	64	5	to	to	PART
fnp-6382	64	6	be	be	AUX
fnp-6382	64	7	more	more	ADV
fnp-6382	64	8	significantly	significantly	ADV
fnp-6382	64	9	increased	increase	VERB
fnp-6382	64	10	in	in	ADP
fnp-6382	64	11	cte	cte	NOUN
fnp-6382	64	12	samples	sample	NOUN
fnp-6382	64	13	than	than	ADP
fnp-6382	64	14	in	in	ADP
fnp-6382	64	15	ad	ad	NOUN
fnp-6382	64	16	samples	sample	NOUN
fnp-6382	64	17	.	.	PUNCT
fnp-6382	65	1	vig	vig	PROPN
fnp-6382	65	2	et	et	PROPN
fnp-6382	65	3	al	al	PROPN
fnp-6382	65	4	.	.	PROPN
fnp-6382	65	5	2023	2023	NUM
fnp-6382	65	6	(	(	PUNCT
fnp-6382	65	7	59	59	NUM
fnp-6382	65	8	)	)	PUNCT
fnp-6382	65	9	ccl11	ccl11	NOUN
fnp-6382	65	10	immunoassay	immunoassay	NOUN
fnp-6382	65	11	of	of	ADP
fnp-6382	65	12	postmortem	postmortem	PROPN
fnp-6382	65	13	vitreous	vitreous	ADJ
fnp-6382	65	14	humor	humor	NOUN
fnp-6382	65	15	15	15	NUM
fnp-6382	65	16	cte	cte	NOUN
fnp-6382	65	17	,	,	PUNCT
fnp-6382	65	18	7	7	NUM
fnp-6382	65	19	ad	ad	NOUN
fnp-6382	65	20	,	,	PUNCT
fnp-6382	65	21	10	10	NUM
fnp-6382	65	22	with	with	ADP
fnp-6382	65	23	both	both	CCONJ
fnp-6382	65	24	ad	ad	NOUN
fnp-6382	65	25	and	and	CCONJ
fnp-6382	65	26	cte	cte	NOUN
fnp-6382	65	27	,	,	PUNCT
fnp-6382	65	28	9	9	NUM
fnp-6382	65	29	controls	control	NOUN
fnp-6382	65	30	.	.	PUNCT
fnp-6382	66	1	all	all	PRON
fnp-6382	66	2	were	be	AUX
fnp-6382	66	3	neuropathologically	neuropathologically	ADV
fnp-6382	66	4	confirmed	confirm	VERB
fnp-6382	66	5	.	.	PUNCT
fnp-6382	67	1	ccl11	ccl11	NOUN
fnp-6382	67	2	levels	level	NOUN
fnp-6382	67	3	trended	trend	VERB
fnp-6382	67	4	towards	towards	ADP
fnp-6382	67	5	significance	significance	NOUN
fnp-6382	67	6	only	only	ADV
fnp-6382	67	7	in	in	ADP
fnp-6382	67	8	samples	sample	NOUN
fnp-6382	67	9	with	with	ADP
fnp-6382	67	10	both	both	CCONJ
fnp-6382	67	11	ad	ad	NOUN
fnp-6382	67	12	and	and	CCONJ
fnp-6382	67	13	cte	cte	NOUN
fnp-6382	67	14	,	,	PUNCT
fnp-6382	67	15	compared	compare	VERB
fnp-6382	67	16	to	to	ADP
fnp-6382	67	17	controls	control	NOUN
fnp-6382	67	18	(	(	PUNCT
fnp-6382	67	19	p	p	X
fnp-6382	67	20	 	 	SPACE
fnp-6382	67	21	=	=	NOUN
fnp-6382	67	22	 	 	SPACE
fnp-6382	67	23	0.09	0.09	NUM
fnp-6382	67	24	)	)	PUNCT
fnp-6382	67	25	.	.	PUNCT
fnp-6382	68	1	cherry	cherry	NOUN
fnp-6382	68	2	et	et	PROPN
fnp-6382	68	3	al	al	PROPN
fnp-6382	68	4	.	.	PROPN
fnp-6382	68	5	2020	2020	NUM
fnp-6382	68	6	(	(	PUNCT
fnp-6382	68	7	41	41	NUM
fnp-6382	68	8	)	)	PUNCT
fnp-6382	68	9	ccl2	ccl2	NOUN
fnp-6382	68	10	immunoassay	immunoassay	PROPN
fnp-6382	68	11	and	and	CCONJ
fnp-6382	68	12	staining	stain	VERB
fnp-6382	68	13	of	of	ADP
fnp-6382	68	14	postmortem	postmortem	NOUN
fnp-6382	68	15	dlfc	dlfc	NOUN
fnp-6382	68	16	and	and	CCONJ
fnp-6382	68	17	calcarine	calcarine	VERB
fnp-6382	68	18	cortex	cortex	NOUN
fnp-6382	68	19	94	94	NUM
fnp-6382	68	20	rhi	rhi	NOUN
fnp-6382	68	21	-	-	PUNCT
fnp-6382	68	22	exposed	expose	VERB
fnp-6382	68	23	(	(	PUNCT
fnp-6382	68	24	20	20	NUM
fnp-6382	68	25	without	without	ADP
fnp-6382	68	26	cte	cte	NOUN
fnp-6382	68	27	,	,	PUNCT
fnp-6382	68	28	27	27	NUM
fnp-6382	68	29	low	low	ADJ
fnp-6382	68	30	cte	cte	NOUN
fnp-6382	68	31	,	,	PUNCT
fnp-6382	68	32	47	47	NUM
fnp-6382	68	33	high	high	ADJ
fnp-6382	68	34	cte	cte	NOUN
fnp-6382	68	35	)	)	PUNCT
fnp-6382	68	36	;	;	PUNCT
fnp-6382	68	37	112	112	NUM
fnp-6382	68	38	ad	ad	NOUN
fnp-6382	68	39	(	(	PUNCT
fnp-6382	68	40	60	60	NUM
fnp-6382	68	41	low	low	ADJ
fnp-6382	68	42	,	,	PUNCT
fnp-6382	68	43	28	28	NUM
fnp-6382	68	44	intermediate	intermediate	ADJ
fnp-6382	68	45	,	,	PUNCT
fnp-6382	68	46	24	24	NUM
fnp-6382	68	47	high	high	ADJ
fnp-6382	68	48	)	)	PUNCT
fnp-6382	68	49	;	;	PUNCT
fnp-6382	68	50	18	18	NUM
fnp-6382	68	51	non	non	ADJ
fnp-6382	68	52	-	-	PROPN
fnp-6382	68	53	rhi	rhi	ADJ
fnp-6382	68	54	controls	control	NOUN
fnp-6382	68	55	.	.	PUNCT
fnp-6382	69	1	all	all	PRON
fnp-6382	69	2	neuropathologically	neuropathologically	ADV
fnp-6382	69	3	confirmed	confirm	VERB
fnp-6382	69	4	.	.	PUNCT
fnp-6382	70	1	ccl2	ccl2	PROPN
fnp-6382	70	2	correlated	correlate	VERB
fnp-6382	70	3	with	with	ADP
fnp-6382	70	4	increased	increase	VERB
fnp-6382	70	5	cte	cte	NOUN
fnp-6382	70	6	severity	severity	NOUN
fnp-6382	70	7	(	(	PUNCT
fnp-6382	70	8	p	p	X
fnp-6382	70	9	 	 	SPACE
fnp-6382	70	10	<	<	X
fnp-6382	70	11	 	 	SPACE
fnp-6382	70	12	0.001	0.001	NUM
fnp-6382	70	13	)	)	PUNCT
fnp-6382	70	14	and	and	CCONJ
fnp-6382	70	15	with	with	ADP
fnp-6382	70	16	increased	increase	VERB
fnp-6382	70	17	football	football	NOUN
fnp-6382	70	18	career	career	NOUN
fnp-6382	70	19	length	length	NOUN
fnp-6382	70	20	(	(	PUNCT
fnp-6382	70	21	p	p	X
fnp-6382	70	22	 	 	SPACE
fnp-6382	70	23	<	<	X
fnp-6382	70	24	 	 	SPACE
fnp-6382	70	25	0.005	0.005	NUM
fnp-6382	70	26	)	)	PUNCT
fnp-6382	70	27	.	.	PUNCT
fnp-6382	71	1	ccl2	ccl2	PROPN
fnp-6382	71	2	has	have	VERB
fnp-6382	71	3	a	a	DET
fnp-6382	71	4	correlation	correlation	NOUN
fnp-6382	71	5	with	with	ADP
fnp-6382	71	6	p	p	NOUN
fnp-6382	71	7	-	-	PUNCT
fnp-6382	71	8	tau	tau	PROPN
fnp-6382	71	9	,	,	PUNCT
fnp-6382	71	10	which	which	PRON
fnp-6382	71	11	was	be	AUX
fnp-6382	71	12	independent	independent	ADJ
fnp-6382	71	13	of	of	ADP
fnp-6382	71	14	aβ42	aβ42	PROPN
fnp-6382	71	15	-	-	PUNCT
fnp-6382	71	16	status	status	NOUN
fnp-6382	71	17	or	or	CCONJ
fnp-6382	71	18	age	age	NOUN
fnp-6382	71	19	.	.	PUNCT
fnp-6382	72	1	van	van	PROPN
fnp-6382	72	2	amerongen	amerongen	PROPN
fnp-6382	72	3	et	et	PROPN
fnp-6382	72	4	al	al	PROPN
fnp-6382	72	5	.	.	PROPN
fnp-6382	72	6	2024	2024	NUM
fnp-6382	72	7	(	(	PUNCT
fnp-6382	72	8	66	66	NUM
fnp-6382	72	9	)	)	PUNCT
fnp-6382	72	10	il-6	il-6	NOUN
fnp-6382	72	11	csf	csf	ADJ
fnp-6382	72	12	analysis	analysis	NOUN
fnp-6382	72	13	from	from	ADP
fnp-6382	72	14	retired	retire	VERB
fnp-6382	72	15	football	football	NOUN
fnp-6382	72	16	players	player	NOUN
fnp-6382	72	17	104	104	NUM
fnp-6382	72	18	retired	retire	VERB
fnp-6382	72	19	athletes	athlete	NOUN
fnp-6382	72	20	with	with	ADP
fnp-6382	72	21	nbd	nbd	PROPN
fnp-6382	72	22	diagnosis	diagnosis	NOUN
fnp-6382	72	23	,	,	PUNCT
fnp-6382	72	24	76	76	NUM
fnp-6382	72	25	retired	retire	VERB
fnp-6382	72	26	athletes	athlete	NOUN
fnp-6382	72	27	without	without	ADP
fnp-6382	72	28	nbd	nbd	PROPN
fnp-6382	72	29	diagnosis	diagnosis	PROPN
fnp-6382	72	30	il-6	il-6	NUM
fnp-6382	72	31	was	be	AUX
fnp-6382	72	32	significantly	significantly	ADV
fnp-6382	72	33	elevated	elevate	VERB
fnp-6382	72	34	in	in	ADP
fnp-6382	72	35	subjects	subject	NOUN
fnp-6382	72	36	with	with	ADP
fnp-6382	72	37	nbd	nbd	PROPN
fnp-6382	72	38	diagnosis	diagnosis	NOUN
fnp-6382	72	39	.	.	PUNCT
fnp-6382	73	1	il-6	il-6	NOUN
fnp-6382	73	2	levels	level	NOUN
fnp-6382	73	3	correlated	correlate	VERB
fnp-6382	73	4	with	with	ADP
fnp-6382	73	5	various	various	ADJ
fnp-6382	73	6	measures	measure	NOUN
fnp-6382	73	7	of	of	ADP
fnp-6382	73	8	nbd	nbd	PROPN
fnp-6382	73	9	.	.	PROPN
fnp-6382	74	1	gard	gard	PROPN
fnp-6382	74	2	et	et	PROPN
fnp-6382	74	3	al	al	PROPN
fnp-6382	74	4	.	.	PROPN
fnp-6382	74	5	2023	2023	NUM
fnp-6382	74	6	(	(	PUNCT
fnp-6382	74	7	103	103	NUM
fnp-6382	74	8	)	)	PUNCT
fnp-6382	74	9	il-2	il-2	NUM
fnp-6382	74	10	il-15	il-15	NOUN
fnp-6382	74	11	tnf	tnf	PROPN
fnp-6382	74	12	-	-	PUNCT
fnp-6382	74	13	α	α	PROPN
fnp-6382	74	14	tnf	tnf	PROPN
fnp-6382	74	15	-	-	PUNCT
fnp-6382	74	16	β	β	PROPN
fnp-6382	74	17	eotaxin	eotaxin	PROPN
fnp-6382	74	18	tarc	tarc	PROPN
fnp-6382	74	19	vegf	vegf	PROPN
fnp-6382	74	20	cxcl10	cxcl10	PROPN
fnp-6382	74	21	csf	csf	VERB
fnp-6382	74	22	analysis	analysis	NOUN
fnp-6382	74	23	from	from	ADP
fnp-6382	74	24	living	live	VERB
fnp-6382	74	25	athletes	athlete	NOUN
fnp-6382	74	26	24	24	NUM
fnp-6382	74	27	symptomatic	symptomatic	ADJ
fnp-6382	74	28	athletes	athlete	NOUN
fnp-6382	74	29	with	with	ADP
fnp-6382	74	30	sports	sport	NOUN
fnp-6382	74	31	related	relate	VERB
fnp-6382	74	32	concussions	concussion	NOUN
fnp-6382	74	33	(	(	PUNCT
fnp-6382	74	34	src	src	NOUN
fnp-6382	74	35	)	)	PUNCT
fnp-6382	74	36	,	,	PUNCT
fnp-6382	74	37	12	12	NUM
fnp-6382	74	38	healthy	healthy	ADJ
fnp-6382	74	39	controls	control	NOUN
fnp-6382	74	40	.	.	PUNCT
fnp-6382	75	1	levels	level	NOUN
fnp-6382	75	2	of	of	ADP
fnp-6382	75	3	il-2	il-2	NUM
fnp-6382	75	4	,	,	PUNCT
fnp-6382	75	5	il-15	il-15	PRON
fnp-6382	75	6	,	,	PUNCT
fnp-6382	75	7	tnf	tnf	PROPN
fnp-6382	75	8	-	-	PUNCT
fnp-6382	75	9	α	α	PROPN
fnp-6382	75	10	,	,	PUNCT
fnp-6382	75	11	tnf	tnf	PROPN
fnp-6382	75	12	-	-	PUNCT
fnp-6382	75	13	β	β	PROPN
fnp-6382	75	14	,	,	PUNCT
fnp-6382	75	15	eotaxin	eotaxin	PROPN
fnp-6382	75	16	,	,	PUNCT
fnp-6382	75	17	and	and	CCONJ
fnp-6382	75	18	tarc	tarc	PROPN
fnp-6382	75	19	were	be	AUX
fnp-6382	75	20	all	all	PRON
fnp-6382	75	21	elevated	elevate	VERB
fnp-6382	75	22	in	in	ADP
fnp-6382	75	23	src	src	NOUN
fnp-6382	75	24	-	-	PUNCT
fnp-6382	75	25	exposed	expose	VERB
fnp-6382	75	26	athletes	athlete	NOUN
fnp-6382	75	27	compared	compare	VERB
fnp-6382	75	28	to	to	ADP
fnp-6382	75	29	controls	control	NOUN
fnp-6382	75	30	.	.	PUNCT
fnp-6382	76	1	vegf	vegf	PROPN
fnp-6382	76	2	levels	level	NOUN
fnp-6382	76	3	were	be	AUX
fnp-6382	76	4	significantly	significantly	ADV
fnp-6382	76	5	elevated	elevate	VERB
fnp-6382	76	6	in	in	ADP
fnp-6382	76	7	athletes	athlete	NOUN
fnp-6382	76	8	with	with	ADP
fnp-6382	76	9	src	src	NOUN
fnp-6382	76	10	history	history	NOUN
fnp-6382	76	11	.	.	PUNCT
fnp-6382	77	1	cxcl10	cxcl10	NOUN
fnp-6382	77	2	was	be	AUX
fnp-6382	77	3	increased	increase	VERB
fnp-6382	77	4	in	in	ADP
fnp-6382	77	5	athletes	athlete	NOUN
fnp-6382	77	6	compared	compare	VERB
fnp-6382	77	7	to	to	ADP
fnp-6382	77	8	controls	control	NOUN
fnp-6382	77	9	.	.	PUNCT
fnp-6382	78	1	asken	asken	VERB
fnp-6382	78	2	et	et	PROPN
fnp-6382	78	3	al	al	PROPN
fnp-6382	78	4	.	.	PROPN
fnp-6382	78	5	2023	2023	NUM
fnp-6382	78	6	(	(	PUNCT
fnp-6382	78	7	68	68	NUM
fnp-6382	78	8	)	)	PUNCT
fnp-6382	78	9	il-6	il-6	NOUN
fnp-6382	79	1	ifn	ifn	PROPN
fnp-6382	79	2	-	-	PUNCT
fnp-6382	79	3	γ	γ	PROPN
fnp-6382	79	4	ykl-40	ykl-40	NOUN
fnp-6382	79	5	plasma	plasma	NOUN
fnp-6382	79	6	analysis	analysis	NOUN
fnp-6382	79	7	from	from	ADP
fnp-6382	79	8	living	live	VERB
fnp-6382	79	9	subjects	subject	NOUN
fnp-6382	79	10	33	33	NUM
fnp-6382	79	11	rhi	rhi	NOUN
fnp-6382	79	12	/	/	SYM
fnp-6382	79	13	tes	tes	NOUN
fnp-6382	80	1	[	[	X
fnp-6382	80	2	11	11	NUM
fnp-6382	80	3	aβ+	aβ+	NOUN
fnp-6382	80	4	,	,	PUNCT
fnp-6382	80	5	22	22	NUM
fnp-6382	80	6	aβ-	aβ-	X
fnp-6382	80	7	]	]	X
fnp-6382	80	8	,	,	PUNCT
fnp-6382	80	9	62	62	NUM
fnp-6382	80	10	ad	ad	NOUN
fnp-6382	80	11	(	(	PUNCT
fnp-6382	80	12	rhi-	rhi-	NOUN
fnp-6382	80	13	)	)	PUNCT
fnp-6382	80	14	,	,	PUNCT
fnp-6382	80	15	59	59	NUM
fnp-6382	80	16	healthy	healthy	ADJ
fnp-6382	80	17	controls	control	NOUN
fnp-6382	80	18	(	(	PUNCT
fnp-6382	80	19	rhi-	rhi-	NOUN
fnp-6382	80	20	)	)	PUNCT
fnp-6382	80	21	rhi	rhi	PROPN
fnp-6382	80	22	/	/	SYM
fnp-6382	80	23	tes	tes	PROPN
fnp-6382	80	24	had	have	VERB
fnp-6382	80	25	significantly	significantly	ADV
fnp-6382	80	26	higher	high	ADJ
fnp-6382	80	27	il-6	il-6	NOUN
fnp-6382	80	28	concentrations	concentration	NOUN
fnp-6382	80	29	compared	compare	VERB
fnp-6382	80	30	to	to	ADP
fnp-6382	80	31	controls	control	NOUN
fnp-6382	80	32	(	(	PUNCT
fnp-6382	80	33	effect	effect	NOUN
fnp-6382	80	34	size	size	NOUN
fnp-6382	80	35	,	,	PUNCT
fnp-6382	80	36	d	d	X
fnp-6382	80	37	 	 	SPACE
fnp-6382	80	38	=	=	NOUN
fnp-6382	80	39	 	 	SPACE
fnp-6382	80	40	0.67	0.67	NUM
fnp-6382	80	41	)	)	PUNCT
fnp-6382	80	42	,	,	PUNCT
fnp-6382	80	43	and	and	CCONJ
fnp-6382	80	44	ad	ad	NOUN
fnp-6382	80	45	participants	participant	NOUN
fnp-6382	80	46	(	(	PUNCT
fnp-6382	80	47	d	d	X
fnp-6382	80	48	 	 	SPACE
fnp-6382	80	49	=	=	NOUN
fnp-6382	80	50	 	 	SPACE
fnp-6382	80	51	0.68	0.68	NUM
fnp-6382	80	52	)	)	PUNCT
fnp-6382	80	53	.	.	PUNCT
fnp-6382	81	1	aβrhi	aβrhi	NOUN
fnp-6382	81	2	/	/	SYM
fnp-6382	81	3	tes	tes	PROPN
fnp-6382	81	4	had	have	VERB
fnp-6382	81	5	significantly	significantly	ADV
fnp-6382	81	6	higher	high	ADJ
fnp-6382	81	7	il-6	il-6	NOUN
fnp-6382	81	8	compared	compare	VERB
fnp-6382	81	9	to	to	ADP
fnp-6382	81	10	aβ+	aβ+	ADJ
fnp-6382	81	11	rhi	rhi	PROPN
fnp-6382	81	12	(	(	PUNCT
fnp-6382	81	13	d	d	NOUN
fnp-6382	81	14	 	 	SPACE
fnp-6382	81	15	=	=	NOUN
fnp-6382	81	16	 	 	SPACE
fnp-6382	81	17	1.2	1.2	NUM
fnp-6382	81	18	)	)	PUNCT
fnp-6382	81	19	,	,	PUNCT
fnp-6382	81	20	ad	ad	NOUN
fnp-6382	81	21	(	(	PUNCT
fnp-6382	81	22	d	d	NOUN
fnp-6382	81	23	 	 	SPACE
fnp-6382	81	24	=	=	NOUN
fnp-6382	81	25	 	 	SPACE
fnp-6382	81	26	1.1	1.1	NUM
fnp-6382	81	27	)	)	PUNCT
fnp-6382	81	28	,	,	PUNCT
fnp-6382	81	29	or	or	CCONJ
fnp-6382	81	30	controls	control	NOUN
fnp-6382	81	31	(	(	PUNCT
fnp-6382	81	32	d	d	X
fnp-6382	81	33	 	 	SPACE
fnp-6382	81	34	=	=	NOUN
fnp-6382	81	35	 	 	SPACE
fnp-6382	81	36	1.1	1.1	NUM
fnp-6382	81	37	)	)	PUNCT
fnp-6382	81	38	.	.	PUNCT
fnp-6382	82	1	di	di	PROPN
fnp-6382	82	2	battista	battista	PROPN
fnp-6382	82	3	,	,	PUNCT
fnp-6382	82	4	rhind	rhind	NOUN
fnp-6382	82	5	,	,	PUNCT
fnp-6382	82	6	richards	richard	NOUN
fnp-6382	82	7	et	et	PROPN
fnp-6382	82	8	al	al	PROPN
fnp-6382	82	9	.	.	PROPN
fnp-6382	82	10	2016	2016	NUM
fnp-6382	82	11	(	(	PUNCT
fnp-6382	82	12	42	42	NUM
fnp-6382	82	13	)	)	PUNCT
fnp-6382	82	14	ccl2	ccl2	NOUN
fnp-6382	82	15	ccl11	ccl11	PROPN
fnp-6382	82	16	il-8	il-8	PROPN
fnp-6382	82	17	,	,	PUNCT
fnp-6382	82	18	il-12	il-12	PRON
fnp-6382	82	19	il-15	il-15	NOUN
fnp-6382	82	20	,	,	PUNCT
fnp-6382	82	21	il-4	il-4	PROPN
fnp-6382	82	22	,	,	PUNCT
fnp-6382	82	23	il-10	il-10	PRON
fnp-6382	82	24	,	,	PUNCT
fnp-6382	82	25	il-13	il-13	CCONJ
fnp-6382	82	26	immunoassay	immunoassay	NOUN
fnp-6382	82	27	of	of	ADP
fnp-6382	82	28	blood	blood	NOUN
fnp-6382	82	29	from	from	ADP
fnp-6382	82	30	living	live	VERB
fnp-6382	82	31	athletes	athlete	NOUN
fnp-6382	82	32	87	87	NUM
fnp-6382	82	33	college	college	NOUN
fnp-6382	82	34	-	-	PUNCT
fnp-6382	82	35	level	level	NOUN
fnp-6382	82	36	athletes	athlete	NOUN
fnp-6382	82	37	including	include	VERB
fnp-6382	82	38	football	football	NOUN
fnp-6382	82	39	,	,	PUNCT
fnp-6382	82	40	field	field	NOUN
fnp-6382	82	41	hockey	hockey	NOUN
fnp-6382	82	42	,	,	PUNCT
fnp-6382	82	43	rugby	rugby	NOUN
fnp-6382	82	44	,	,	PUNCT
fnp-6382	82	45	basketball	basketball	NOUN
fnp-6382	82	46	,	,	PUNCT
fnp-6382	82	47	and	and	CCONJ
fnp-6382	82	48	baseball	baseball	NOUN
fnp-6382	82	49	.	.	PUNCT
fnp-6382	83	1	of	of	ADP
fnp-6382	83	2	these	these	PRON
fnp-6382	83	3	,	,	PUNCT
fnp-6382	83	4	40	40	NUM
fnp-6382	83	5	participated	participate	VERB
fnp-6382	83	6	in	in	ADP
fnp-6382	83	7	collision	collision	NOUN
fnp-6382	83	8	sports	sport	NOUN
fnp-6382	83	9	.	.	PUNCT
fnp-6382	84	1	ccl2	ccl2	PROPN
fnp-6382	84	2	,	,	PUNCT
fnp-6382	84	3	ccl11	ccl11	NOUN
fnp-6382	84	4	,	,	PUNCT
fnp-6382	84	5	il-8	il-8	PRON
fnp-6382	84	6	,	,	PUNCT
fnp-6382	84	7	il-12	il-12	NOUN
fnp-6382	84	8	,	,	PUNCT
fnp-6382	84	9	il-15	il-15	PRON
fnp-6382	84	10	,	,	PUNCT
fnp-6382	84	11	were	be	AUX
fnp-6382	84	12	quantifiable	quantifiable	ADJ
fnp-6382	84	13	in	in	ADP
fnp-6382	84	14	majority	majority	NOUN
fnp-6382	84	15	of	of	ADP
fnp-6382	84	16	participants	participant	NOUN
fnp-6382	84	17	,	,	PUNCT
fnp-6382	84	18	ranging	range	VERB
fnp-6382	84	19	from	from	ADP
fnp-6382	84	20	77	77	NUM
fnp-6382	84	21	 	 	SPACE
fnp-6382	84	22	%	%	NOUN
fnp-6382	84	23	to	to	PART
fnp-6382	84	24	100	100	NUM
fnp-6382	84	25	 	 	SPACE
fnp-6382	84	26	%	%	NOUN
fnp-6382	84	27	.	.	PUNCT
fnp-6382	85	1	begum	begum	VERB
fnp-6382	85	2	et	et	PROPN
fnp-6382	85	3	al	al	PROPN
fnp-6382	85	4	.	.	PROPN
fnp-6382	85	5	2020	2020	NUM
fnp-6382	86	1	(	(	PUNCT
fnp-6382	86	2	43	43	NUM
fnp-6382	86	3	)	)	PUNCT
fnp-6382	86	4	ccl2	ccl2	NOUN
fnp-6382	86	5	tnfsf14	tnfsf14	NOUN
fnp-6382	86	6	cx3cl1	cx3cl1	VERB
fnp-6382	86	7	il-7	il-7	VERB
fnp-6382	86	8	plasma	plasma	VERB
fnp-6382	86	9	analysis	analysis	NOUN
fnp-6382	86	10	of	of	ADP
fnp-6382	86	11	living	live	VERB
fnp-6382	86	12	professional	professional	ADJ
fnp-6382	86	13	rugby	rugby	NOUN
fnp-6382	86	14	players	player	NOUN
fnp-6382	86	15	18	18	NUM
fnp-6382	86	16	athletes	athlete	NOUN
fnp-6382	86	17	with	with	ADP
fnp-6382	86	18	single	single	ADJ
fnp-6382	86	19	concussion	concussion	NOUN
fnp-6382	86	20	,	,	PUNCT
fnp-6382	86	21	5	5	NUM
fnp-6382	86	22	who	who	PRON
fnp-6382	86	23	were	be	AUX
fnp-6382	86	24	repetitively	repetitively	ADV
fnp-6382	86	25	-	-	PUNCT
fnp-6382	86	26	concussed	concuss	VERB
fnp-6382	86	27	,	,	PUNCT
fnp-6382	86	28	12	12	NUM
fnp-6382	86	29	healthy	healthy	ADJ
fnp-6382	86	30	controls	control	NOUN
fnp-6382	86	31	reduced	reduce	VERB
fnp-6382	86	32	ccl2	ccl2	NOUN
fnp-6382	86	33	was	be	AUX
fnp-6382	86	34	associated	associate	VERB
fnp-6382	86	35	with	with	ADP
fnp-6382	86	36	severity	severity	NOUN
fnp-6382	86	37	of	of	ADP
fnp-6382	86	38	symptoms	symptom	NOUN
fnp-6382	86	39	(	(	PUNCT
fnp-6382	86	40	p	p	X
fnp-6382	86	41	 	 	SPACE
fnp-6382	86	42	=	=	NOUN
fnp-6382	86	43	 	 	SPACE
fnp-6382	86	44	0.043	0.043	NUM
fnp-6382	86	45	)	)	PUNCT
fnp-6382	86	46	and	and	CCONJ
fnp-6382	86	47	increase	increase	VERB
fnp-6382	86	48	in	in	ADP
fnp-6382	86	49	number	number	NOUN
fnp-6382	86	50	of	of	ADP
fnp-6382	86	51	symptoms	symptom	NOUN
fnp-6382	86	52	(	(	PUNCT
fnp-6382	86	53	p	p	X
fnp-6382	86	54	 	 	SPACE
fnp-6382	86	55	=	=	NOUN
fnp-6382	86	56	 	 	SPACE
fnp-6382	86	57	0.013	0.013	NUM
fnp-6382	86	58	)	)	PUNCT
fnp-6382	86	59	.	.	PUNCT
fnp-6382	87	1	tnfsf14	tnfsf14	NOUN
fnp-6382	87	2	levels	level	NOUN
fnp-6382	87	3	were	be	AUX
fnp-6382	87	4	reduced	reduce	VERB
fnp-6382	87	5	in	in	ADP
fnp-6382	87	6	concussed	concuss	VERB
fnp-6382	87	7	subjects	subject	NOUN
fnp-6382	87	8	compared	compare	VERB
fnp-6382	87	9	to	to	ADP
fnp-6382	87	10	repetitively	repetitively	ADV
fnp-6382	87	11	-	-	PUNCT
fnp-6382	87	12	concussed	concuss	VERB
fnp-6382	87	13	subjects	subject	NOUN
fnp-6382	87	14	.	.	PUNCT
fnp-6382	88	1	il-7	il-7	PART
fnp-6382	89	1	levels	level	NOUN
fnp-6382	89	2	were	be	AUX
fnp-6382	89	3	higher	high	ADJ
fnp-6382	89	4	in	in	ADP
fnp-6382	89	5	repetitivelyconcussed	repetitivelyconcusse	VERB
fnp-6382	89	6	subjects	subject	NOUN
fnp-6382	89	7	compared	compare	VERB
fnp-6382	89	8	to	to	ADP
fnp-6382	89	9	concussed	concussed	ADJ
fnp-6382	89	10	subjects	subject	NOUN
fnp-6382	89	11	.	.	PUNCT
fnp-6382	90	1	cxcl3	cxcl3	PROPN
fnp-6382	90	2	was	be	AUX
fnp-6382	90	3	increased	increase	VERB
fnp-6382	90	4	less	less	ADJ
fnp-6382	90	5	than	than	ADP
fnp-6382	90	6	one	one	NUM
fnp-6382	90	7	week	week	NOUN
fnp-6382	90	8	after	after	ADP
fnp-6382	90	9	concussion	concussion	NOUN
fnp-6382	90	10	.	.	PUNCT
fnp-6382	91	1	huibregtse	huibregtse	X
fnp-6382	91	2	et	et	PROPN
fnp-6382	91	3	al	al	PROPN
fnp-6382	91	4	.	.	PROPN
fnp-6382	91	5	2020	2020	NUM
fnp-6382	91	6	(	(	PUNCT
fnp-6382	91	7	54	54	NUM
fnp-6382	91	8	)	)	PUNCT
fnp-6382	91	9	ccl11	ccl11	NOUN
fnp-6382	91	10	il-10	il-10	PRON
fnp-6382	91	11	plasma	plasma	NOUN
fnp-6382	91	12	analysis	analysis	NOUN
fnp-6382	91	13	of	of	ADP
fnp-6382	91	14	39	39	NUM
fnp-6382	91	15	living	live	VERB
fnp-6382	91	16	soccer	soccer	NOUN
fnp-6382	91	17	players	player	NOUN
fnp-6382	91	18	with	with	ADP
fnp-6382	91	19	heading	head	VERB
fnp-6382	91	20	experience	experience	NOUN
fnp-6382	91	21	22	22	NUM
fnp-6382	91	22	soccer	soccer	NOUN
fnp-6382	91	23	players	player	NOUN
fnp-6382	91	24	who	who	PRON
fnp-6382	91	25	underwent	undergo	VERB
fnp-6382	91	26	a	a	DET
fnp-6382	91	27	repetitive	repetitive	ADV
fnp-6382	91	28	-	-	PUNCT
fnp-6382	91	29	heading	head	VERB
fnp-6382	91	30	event	event	NOUN
fnp-6382	91	31	,	,	PUNCT
fnp-6382	91	32	and	and	CCONJ
fnp-6382	91	33	17	17	NUM
fnp-6382	91	34	soccer	soccer	NOUN
fnp-6382	91	35	players	player	NOUN
fnp-6382	91	36	who	who	PRON
fnp-6382	91	37	underwent	undergo	VERB
fnp-6382	91	38	a	a	DET
fnp-6382	91	39	repetitive	repetitive	ADJ
fnp-6382	91	40	-	-	PUNCT
fnp-6382	91	41	kicking	kick	VERB
fnp-6382	91	42	event	event	NOUN
fnp-6382	91	43	no	no	DET
fnp-6382	91	44	significant	significant	ADJ
fnp-6382	91	45	increase	increase	NOUN
fnp-6382	91	46	in	in	ADP
fnp-6382	91	47	ccl11	ccl11	NOUN
fnp-6382	91	48	occurred	occur	VERB
fnp-6382	91	49	after	after	ADP
fnp-6382	91	50	repeated	repeat	VERB
fnp-6382	91	51	-	-	PUNCT
fnp-6382	91	52	heading	head	VERB
fnp-6382	91	53	event	event	NOUN
fnp-6382	91	54	.	.	PUNCT
fnp-6382	92	1	increases	increase	NOUN
fnp-6382	92	2	in	in	ADP
fnp-6382	92	3	ccl11	ccl11	PROPN
fnp-6382	92	4	were	be	AUX
fnp-6382	92	5	significantly	significantly	ADV
fnp-6382	92	6	correlated	correlate	VERB
fnp-6382	92	7	with	with	ADP
fnp-6382	92	8	years	year	NOUN
fnp-6382	92	9	of	of	ADP
fnp-6382	92	10	heading	head	VERB
fnp-6382	92	11	experience	experience	NOUN
fnp-6382	92	12	(	(	PUNCT
fnp-6382	92	13	p	p	X
fnp-6382	92	14	 	 	SPACE
fnp-6382	92	15	=	=	NOUN
fnp-6382	92	16	 	 	SPACE
fnp-6382	92	17	0.01	0.01	NUM
fnp-6382	92	18	)	)	PUNCT
fnp-6382	92	19	.	.	PUNCT
fnp-6382	93	1	miner	miner	NOUN
fnp-6382	93	2	et	et	PROPN
fnp-6382	93	3	al	al	PROPN
fnp-6382	93	4	.	.	PROPN
fnp-6382	93	5	2024	2024	NUM
fnp-6382	93	6	(	(	PUNCT
fnp-6382	93	7	74	74	NUM
fnp-6382	93	8	)	)	PUNCT
fnp-6382	93	9	il-6	il-6	NOUN
fnp-6382	93	10	plasma	plasma	NOUN
fnp-6382	93	11	analysis	analysis	NOUN
fnp-6382	93	12	of	of	ADP
fnp-6382	93	13	living	living	NOUN
fnp-6382	93	14	subjects	subject	NOUN
fnp-6382	93	15	180	180	NUM
fnp-6382	93	16	former	former	ADJ
fnp-6382	93	17	football	football	NOUN
fnp-6382	93	18	players	player	NOUN
fnp-6382	93	19	,	,	PUNCT
fnp-6382	93	20	60	60	NUM
fnp-6382	93	21	asymptomatic	asymptomatic	ADJ
fnp-6382	93	22	unexposed	unexposed	ADJ
fnp-6382	93	23	male	male	ADJ
fnp-6382	93	24	subjects	subject	NOUN
fnp-6382	93	25	il-6	il-6	NOUN
fnp-6382	93	26	levels	level	NOUN
fnp-6382	93	27	did	do	AUX
fnp-6382	93	28	not	not	PART
fnp-6382	93	29	significantly	significantly	ADV
fnp-6382	93	30	differ	differ	VERB
fnp-6382	93	31	between	between	ADP
fnp-6382	93	32	rhi	rhi	NOUN
fnp-6382	93	33	-	-	PUNCT
fnp-6382	93	34	exposed	expose	VERB
fnp-6382	93	35	symptomatic	symptomatic	ADJ
fnp-6382	93	36	subjects	subject	NOUN
fnp-6382	93	37	and	and	CCONJ
fnp-6382	93	38	unexposed	unexposed	ADJ
fnp-6382	93	39	asymptomatic	asymptomatic	ADJ
fnp-6382	93	40	controls	control	NOUN
fnp-6382	93	41	.	.	PUNCT
fnp-6382	94	1	nitta	nitta	PROPN
fnp-6382	94	2	et	et	PROPN
fnp-6382	94	3	al	al	PROPN
fnp-6382	94	4	.	.	PROPN
fnp-6382	94	5	2019	2019	NUM
fnp-6382	94	6	(	(	PUNCT
fnp-6382	94	7	67	67	NUM
fnp-6382	94	8	)	)	PUNCT
fnp-6382	94	9	il-6	il-6	NOUN
fnp-6382	95	1	serum	serum	NOUN
fnp-6382	95	2	analysis	analysis	NOUN
fnp-6382	95	3	of	of	ADP
fnp-6382	95	4	football	football	NOUN
fnp-6382	95	5	players	player	NOUN
fnp-6382	95	6	857	857	NUM
fnp-6382	95	7	high	high	ADJ
fnp-6382	95	8	school	school	NOUN
fnp-6382	95	9	and	and	CCONJ
fnp-6382	95	10	collegiate	collegiate	ADJ
fnp-6382	95	11	football	football	NOUN
fnp-6382	95	12	players	player	NOUN
fnp-6382	95	13	il-6	il-6	NOUN
fnp-6382	95	14	levels	level	NOUN
fnp-6382	95	15	increased	increase	VERB
fnp-6382	95	16	within	within	ADP
fnp-6382	95	17	six	six	NUM
fnp-6382	95	18	hours	hour	NOUN
fnp-6382	95	19	after	after	ADP
fnp-6382	95	20	single	single	ADJ
fnp-6382	95	21	concussion	concussion	NOUN
fnp-6382	95	22	.	.	PUNCT
fnp-6382	96	1	levels	level	NOUN
fnp-6382	96	2	of	of	ADP
fnp-6382	96	3	il-6	il-6	NOUN
fnp-6382	96	4	at	at	ADP
fnp-6382	96	5	six	six	NUM
fnp-6382	96	6	hours	hour	NOUN
fnp-6382	96	7	after	after	SCONJ
fnp-6382	96	8	concussion	concussion	NOUN
fnp-6382	96	9	were	be	AUX
fnp-6382	96	10	associated	associate	VERB
fnp-6382	96	11	with	with	ADP
fnp-6382	96	12	duration	duration	NOUN
fnp-6382	96	13	of	of	ADP
fnp-6382	96	14	symptoms	symptom	NOUN
fnp-6382	96	15	(	(	PUNCT
fnp-6382	96	16	p	p	X
fnp-6382	96	17	 	 	SPACE
fnp-6382	96	18	=	=	NOUN
fnp-6382	96	19	 	 	SPACE
fnp-6382	96	20	0.031	0.031	NUM
fnp-6382	96	21	)	)	PUNCT
fnp-6382	96	22	.	.	PUNCT
fnp-6382	97	1	alosco	alosco	PROPN
fnp-6382	97	2	et	et	PROPN
fnp-6382	97	3	al	al	PROPN
fnp-6382	97	4	.	.	PROPN
fnp-6382	97	5	2018	2018	NUM
fnp-6382	97	6	(	(	PUNCT
fnp-6382	97	7	15	15	NUM
fnp-6382	97	8	)	)	PUNCT
fnp-6382	97	9	strem2	strem2	NOUN
fnp-6382	97	10	immunoassay	immunoassay	NOUN
fnp-6382	97	11	of	of	ADP
fnp-6382	97	12	csf	csf	PROPN
fnp-6382	97	13	from	from	ADP
fnp-6382	97	14	former	former	ADJ
fnp-6382	97	15	nfl	nfl	PROPN
fnp-6382	97	16	players	player	NOUN
fnp-6382	97	17	68	68	NUM
fnp-6382	97	18	former	former	ADJ
fnp-6382	97	19	nfl	nfl	PROPN
fnp-6382	97	20	players	player	NOUN
fnp-6382	97	21	,	,	PUNCT
fnp-6382	97	22	21	21	NUM
fnp-6382	97	23	non	non	ADJ
fnp-6382	97	24	-	-	PROPN
fnp-6382	97	25	rhi	rhi	ADJ
fnp-6382	97	26	controls	control	NOUN
fnp-6382	97	27	levels	level	NOUN
fnp-6382	97	28	of	of	ADP
fnp-6382	97	29	strem2	strem2	NOUN
fnp-6382	97	30	were	be	AUX
fnp-6382	97	31	significantly	significantly	ADV
fnp-6382	97	32	associated	associate	VERB
fnp-6382	97	33	with	with	ADP
fnp-6382	97	34	t	t	PROPN
fnp-6382	97	35	-	-	PUNCT
fnp-6382	97	36	tau	tau	PROPN
fnp-6382	97	37	.	.	PUNCT
fnp-6382	98	1	strem2	strem2	PROPN
fnp-6382	98	2	strengthened	strengthen	VERB
fnp-6382	98	3	the	the	DET
fnp-6382	98	4	relation	relation	NOUN
fnp-6382	98	5	between	between	ADP
fnp-6382	98	6	amount	amount	NOUN
fnp-6382	98	7	of	of	ADP
fnp-6382	98	8	rhi	rhi	PROPN
fnp-6382	98	9	exposure	exposure	NOUN
fnp-6382	98	10	and	and	CCONJ
fnp-6382	98	11	t	t	PROPN
fnp-6382	98	12	-	-	PUNCT
fnp-6382	98	13	tau	tau	PROPN
fnp-6382	98	14	levels	level	NOUN
fnp-6382	98	15	asken	asken	VERB
fnp-6382	98	16	et	et	PROPN
fnp-6382	98	17	al	al	PROPN
fnp-6382	98	18	.	.	PROPN
fnp-6382	98	19	2022	2022	NUM
fnp-6382	98	20	(	(	PUNCT
fnp-6382	98	21	84	84	NUM
fnp-6382	98	22	)	)	PUNCT
fnp-6382	98	23	nfl	nfl	PROPN
fnp-6382	98	24	gfap	gfap	PROPN
fnp-6382	98	25	ante	ante	NOUN
fnp-6382	98	26	-	-	PUNCT
fnp-6382	98	27	mortem	mortem	NOUN
fnp-6382	98	28	plasma	plasma	NOUN
fnp-6382	98	29	analysis	analysis	NOUN
fnp-6382	98	30	from	from	ADP
fnp-6382	98	31	rhi	rhi	NOUN
fnp-6382	98	32	-	-	PUNCT
fnp-6382	98	33	exposed	expose	VERB
fnp-6382	98	34	subjects	subject	NOUN
fnp-6382	98	35	,	,	PUNCT
fnp-6382	98	36	with	with	ADP
fnp-6382	98	37	postmortem	postmortem	NOUN
fnp-6382	98	38	evaluation	evaluation	NOUN
fnp-6382	98	39	9	9	NUM
fnp-6382	98	40	rhi	rhi	NOUN
fnp-6382	98	41	-	-	PUNCT
fnp-6382	98	42	exposed	expose	VERB
fnp-6382	98	43	subjects	subject	NOUN
fnp-6382	98	44	(	(	PUNCT
fnp-6382	98	45	5	5	NUM
fnp-6382	98	46	with	with	ADP
fnp-6382	98	47	confirmed	confirm	VERB
fnp-6382	98	48	cte	cte	NOUN
fnp-6382	98	49	)	)	PUNCT
fnp-6382	98	50	.	.	PUNCT
fnp-6382	99	1	plasma	plasma	NOUN
fnp-6382	99	2	levels	level	NOUN
fnp-6382	99	3	of	of	ADP
fnp-6382	99	4	gfap	gfap	NOUN
fnp-6382	99	5	generally	generally	ADV
fnp-6382	99	6	showed	show	VERB
fnp-6382	99	7	a	a	DET
fnp-6382	99	8	longitudinal	longitudinal	ADJ
fnp-6382	99	9	increase	increase	NOUN
fnp-6382	99	10	.	.	PUNCT
fnp-6382	100	1	baseline	baseline	PROPN
fnp-6382	100	2	levels	level	NOUN
fnp-6382	100	3	of	of	ADP
fnp-6382	100	4	gfap	gfap	PROPN
fnp-6382	100	5	were	be	AUX
fnp-6382	100	6	higher	high	ADJ
fnp-6382	100	7	for	for	ADP
fnp-6382	100	8	rhi	rhi	NOUN
fnp-6382	100	9	-	-	PUNCT
fnp-6382	100	10	exposed	expose	VERB
fnp-6382	100	11	subjects	subject	NOUN
fnp-6382	100	12	compared	compare	VERB
fnp-6382	100	13	to	to	ADP
fnp-6382	100	14	healthy	healthy	ADJ
fnp-6382	100	15	controls	control	NOUN
fnp-6382	100	16	.	.	PUNCT
fnp-6382	101	1	bernick	bernick	PROPN
fnp-6382	101	2	et	et	PROPN
fnp-6382	101	3	al	al	PROPN
fnp-6382	101	4	.	.	PROPN
fnp-6382	101	5	2023	2023	NUM
fnp-6382	101	6	(	(	PUNCT
fnp-6382	101	7	80	80	NUM
fnp-6382	101	8	)	)	PUNCT
fnp-6382	101	9	nfl	nfl	PROPN
fnp-6382	101	10	gfap	gfap	ADJ
fnp-6382	101	11	plasma	plasma	NOUN
fnp-6382	101	12	analysis	analysis	NOUN
fnp-6382	101	13	from	from	ADP
fnp-6382	101	14	retired	retired	ADJ
fnp-6382	101	15	athletes	athlete	NOUN
fnp-6382	101	16	,	,	PUNCT
fnp-6382	101	17	active	active	ADJ
fnp-6382	101	18	athletes	athlete	NOUN
fnp-6382	101	19	,	,	PUNCT
fnp-6382	101	20	and	and	CCONJ
fnp-6382	101	21	non	non	ADJ
fnp-6382	101	22	-	-	PROPN
fnp-6382	101	23	rhi	rhi	NOUN
fnp-6382	101	24	controls	control	VERB
fnp-6382	101	25	211	211	NUM
fnp-6382	101	26	active	active	ADJ
fnp-6382	101	27	martial	martial	ADJ
fnp-6382	101	28	arts	art	NOUN
fnp-6382	101	29	fighters	fighter	NOUN
fnp-6382	101	30	,	,	PUNCT
fnp-6382	101	31	140	140	NUM
fnp-6382	101	32	active	active	ADJ
fnp-6382	101	33	boxers	boxer	NOUN
fnp-6382	101	34	,	,	PUNCT
fnp-6382	101	35	69	69	NUM
fnp-6382	101	36	retired	retired	ADJ
fnp-6382	101	37	boxers	boxer	NOUN
fnp-6382	101	38	,	,	PUNCT
fnp-6382	101	39	52	52	NUM
fnp-6382	101	40	controls	control	NOUN
fnp-6382	101	41	gfap	gfap	ADJ
fnp-6382	101	42	levels	level	NOUN
fnp-6382	101	43	correlated	correlate	VERB
fnp-6382	101	44	with	with	ADP
fnp-6382	101	45	cortical	cortical	ADJ
fnp-6382	101	46	and	and	CCONJ
fnp-6382	101	47	sub	sub	ADJ
fnp-6382	101	48	-	-	ADJ
fnp-6382	101	49	cortical	cortical	ADJ
fnp-6382	101	50	atrophy	atrophy	NOUN
fnp-6382	101	51	on	on	ADP
fnp-6382	101	52	mri	mri	NOUN
fnp-6382	101	53	,	,	PUNCT
fnp-6382	101	54	and	and	CCONJ
fnp-6382	101	55	lower	low	ADJ
fnp-6382	101	56	cognitive	cognitive	ADJ
fnp-6382	101	57	scores	score	NOUN
fnp-6382	101	58	,	,	PUNCT
fnp-6382	101	59	for	for	ADP
fnp-6382	101	60	retired	retire	VERB
fnp-6382	101	61	boxers	boxer	NOUN
fnp-6382	101	62	.	.	PUNCT
fnp-6382	102	1	gfap	gfap	ADJ
fnp-6382	102	2	elevation	elevation	NOUN
fnp-6382	102	3	correlated	correlate	VERB
fnp-6382	102	4	with	with	ADP
fnp-6382	102	5	decreased	decrease	VERB
fnp-6382	102	6	corpus	corpus	NOUN
fnp-6382	102	7	callosum	callosum	NOUN
fnp-6382	102	8	and	and	CCONJ
fnp-6382	102	9	thalamic	thalamic	ADJ
fnp-6382	102	10	volumes	volume	NOUN
fnp-6382	102	11	on	on	ADP
fnp-6382	102	12	mri	mri	NOUN
fnp-6382	102	13	for	for	ADP
fnp-6382	102	14	active	active	ADJ
fnp-6382	102	15	boxers	boxer	NOUN
fnp-6382	102	16	.	.	PUNCT
fnp-6382	103	1	gfap	gfap	ADJ
fnp-6382	103	2	levels	level	NOUN
fnp-6382	103	3	were	be	AUX
fnp-6382	103	4	highest	high	ADJ
fnp-6382	103	5	among	among	ADP
fnp-6382	103	6	retired	retire	VERB
fnp-6382	103	7	boxers	boxer	NOUN
fnp-6382	103	8	compared	compare	VERB
fnp-6382	103	9	to	to	ADP
fnp-6382	103	10	active	active	ADJ
fnp-6382	103	11	boxers	boxer	NOUN
fnp-6382	103	12	,	,	PUNCT
fnp-6382	103	13	while	while	SCONJ
fnp-6382	103	14	nfl	nfl	PROPN
fnp-6382	103	15	levels	level	NOUN
fnp-6382	103	16	were	be	AUX
fnp-6382	103	17	highest	high	ADJ
fnp-6382	103	18	among	among	ADP
fnp-6382	103	19	active	active	ADJ
fnp-6382	103	20	boxers	boxer	NOUN
fnp-6382	103	21	compared	compare	VERB
fnp-6382	103	22	to	to	ADP
fnp-6382	103	23	mma	mma	PROPN
fnp-6382	103	24	fighters	fighter	NOUN
fnp-6382	103	25	.	.	PUNCT
fnp-6382	104	1	shahim	shahim	PROPN
fnp-6382	104	2	et	et	PROPN
fnp-6382	104	3	al	al	PROPN
fnp-6382	104	4	.	.	PROPN
fnp-6382	104	5	2022	2022	NUM
fnp-6382	104	6	(	(	PUNCT
fnp-6382	104	7	83	83	NUM
fnp-6382	104	8	)	)	PUNCT
fnp-6382	104	9	gfap	gfap	ADJ
fnp-6382	104	10	plasma	plasma	NOUN
fnp-6382	104	11	and	and	CCONJ
fnp-6382	104	12	csf	csf	ADJ
fnp-6382	104	13	analysis	analysis	NOUN
fnp-6382	104	14	of	of	ADP
fnp-6382	104	15	living	live	VERB
fnp-6382	104	16	,	,	PUNCT
fnp-6382	104	17	symptomatic	symptomatic	ADJ
fnp-6382	104	18	athletes	athlete	NOUN
fnp-6382	104	19	28	28	NUM
fnp-6382	104	20	rhi	rhi	NOUN
fnp-6382	104	21	-	-	PUNCT
fnp-6382	104	22	exposed	expose	VERB
fnp-6382	104	23	professional	professional	ADJ
fnp-6382	104	24	athletes	athlete	NOUN
fnp-6382	104	25	with	with	ADP
fnp-6382	104	26	persistent	persistent	ADJ
fnp-6382	104	27	postconcussive	postconcussive	ADJ
fnp-6382	104	28	symptoms	symptom	NOUN
fnp-6382	104	29	,	,	PUNCT
fnp-6382	104	30	19	19	NUM
fnp-6382	104	31	age	age	NOUN
fnp-6382	104	32	-	-	PUNCT
fnp-6382	104	33	matched	match	VERB
fnp-6382	104	34	unexposed	unexposed	ADJ
fnp-6382	104	35	controls	control	NOUN
fnp-6382	104	36	plasma	plasma	NOUN
fnp-6382	104	37	gfap	gfap	NOUN
fnp-6382	104	38	moderately	moderately	ADV
fnp-6382	104	39	correlated	correlate	VERB
fnp-6382	104	40	with	with	ADP
fnp-6382	104	41	csf	csf	ADJ
fnp-6382	104	42	gfap	gfap	NOUN
fnp-6382	104	43	(	(	PUNCT
fnp-6382	104	44	r	r	NOUN
fnp-6382	104	45	 	 	SPACE
fnp-6382	104	46	=	=	NOUN
fnp-6382	104	47	 	 	SPACE
fnp-6382	104	48	0.45	0.45	NUM
fnp-6382	104	49	,	,	PUNCT
fnp-6382	104	50	p	p	X
fnp-6382	104	51	 	 	SPACE
fnp-6382	104	52	=	=	NOUN
fnp-6382	104	53	 	 	SPACE
fnp-6382	104	54	0.02	0.02	NUM
fnp-6382	104	55	)	)	PUNCT
fnp-6382	104	56	bazarian	bazarian	NOUN
fnp-6382	104	57	et	et	PROPN
fnp-6382	104	58	al	al	PROPN
fnp-6382	104	59	.	.	PROPN
fnp-6382	104	60	2024	2024	NUM
fnp-6382	104	61	(	(	PUNCT
fnp-6382	104	62	81	81	NUM
fnp-6382	104	63	)	)	PUNCT
fnp-6382	104	64	gfap	gfap	ADJ
fnp-6382	104	65	plasma	plasma	NOUN
fnp-6382	104	66	analysis	analysis	NOUN
fnp-6382	104	67	of	of	ADP
fnp-6382	104	68	living	live	VERB
fnp-6382	104	69	football	football	NOUN
fnp-6382	104	70	players	player	NOUN
fnp-6382	104	71	30	30	NUM
fnp-6382	104	72	collegiate	collegiate	ADJ
fnp-6382	104	73	football	football	NOUN
fnp-6382	104	74	players	player	NOUN
fnp-6382	104	75	gfap	gfap	NOUN
fnp-6382	104	76	increased	increase	VERB
fnp-6382	104	77	from	from	ADP
fnp-6382	104	78	preto	preto	VERB
fnp-6382	104	79	post	post	NOUN
fnp-6382	104	80	-	-	NOUN
fnp-6382	104	81	game	game	NOUN
fnp-6382	104	82	,	,	PUNCT
fnp-6382	104	83	from	from	ADP
fnp-6382	104	84	79.69	79.69	NUM
fnp-6382	104	85	pg	pg	NOUN
fnp-6382	104	86	/	/	SYM
fnp-6382	104	87	ml	ml	NOUN
fnp-6382	104	88	to	to	ADP
fnp-6382	104	89	91.95	91.95	NUM
fnp-6382	104	90	pg	pg	NOUN
fnp-6382	104	91	/	/	SYM
fnp-6382	104	92	ml	ml	PROPN
fnp-6382	105	1	(	(	PUNCT
fnp-6382	105	2	p	p	X
fnp-6382	105	3	 	 	SPACE
fnp-6382	105	4	=	=	NOUN
fnp-6382	105	5	 	 	SPACE
fnp-6382	105	6	0.008	0.008	NUM
fnp-6382	105	7	)	)	PUNCT
fnp-6382	105	8	,	,	PUNCT
fnp-6382	105	9	then	then	ADV
fnp-6382	105	10	to	to	ADP
fnp-6382	105	11	99.21	99.21	NUM
fnp-6382	105	12	pg	pg	NOUN
fnp-6382	105	13	/	/	SYM
fnp-6382	105	14	ml	ml	PROPN
fnp-6382	105	15	(	(	PUNCT
fnp-6382	105	16	p	p	X
fnp-6382	105	17	 	 	SPACE
fnp-6382	105	18	<	<	X
fnp-6382	105	19	 	 	SPACE
fnp-6382	105	20	0.001	0.001	NUM
fnp-6382	105	21	)	)	PUNCT
fnp-6382	105	22	post	post	ADJ
fnp-6382	105	23	-	-	ADJ
fnp-6382	105	24	game	game	ADJ
fnp-6382	105	25	gfap	gfap	ADJ
fnp-6382	105	26	changes	change	NOUN
fnp-6382	105	27	correlated	correlate	VERB
fnp-6382	105	28	with	with	ADP
fnp-6382	105	29	reduced	reduced	ADJ
fnp-6382	105	30	functional	functional	ADJ
fnp-6382	105	31	anisotropy	anisotropy	NOUN
fnp-6382	105	32	in	in	ADP
fnp-6382	105	33	right	right	ADJ
fnp-6382	105	34	fornix	fornix	NOUN
fnp-6382	105	35	(	(	PUNCT
fnp-6382	105	36	r	r	NOUN
fnp-6382	105	37	 	 	SPACE
fnp-6382	105	38	=	=	NOUN
fnp-6382	105	39	 	 	SPACE
fnp-6382	105	40	-0.59	-0.59	NUM
fnp-6382	105	41	)	)	PUNCT
fnp-6382	105	42	,	,	PUNCT
fnp-6382	105	43	and	and	CCONJ
fnp-6382	105	44	adjusted	adjust	VERB
fnp-6382	105	45	correlations	correlation	NOUN
fnp-6382	105	46	with	with	ADP
fnp-6382	105	47	head	head	NOUN
fnp-6382	105	48	impact	impact	NOUN
fnp-6382	105	49	metrics	metric	NOUN
fnp-6382	105	50	(	(	PUNCT
fnp-6382	105	51	r	r	NOUN
fnp-6382	105	52	 	 	SPACE
fnp-6382	105	53	=	=	NOUN
fnp-6382	105	54	 	 	SPACE
fnp-6382	105	55	0.69–0.74	0.69–0.74	NOUN
fnp-6382	105	56	)	)	PUNCT
fnp-6382	105	57	.	.	PUNCT
fnp-6382	106	1	huibregtse	huibregtse	X
fnp-6382	106	2	et	et	PROPN
fnp-6382	106	3	al	al	PROPN
fnp-6382	106	4	.	.	PROPN
fnp-6382	106	5	2023	2023	NUM
fnp-6382	106	6	(	(	PUNCT
fnp-6382	106	7	82	82	NUM
fnp-6382	106	8	)	)	PUNCT
fnp-6382	106	9	gfap	gfap	NOUN
fnp-6382	106	10	serum	serum	NOUN
fnp-6382	106	11	analysis	analysis	NOUN
fnp-6382	106	12	of	of	ADP
fnp-6382	106	13	female	female	ADJ
fnp-6382	106	14	water	water	NOUN
fnp-6382	106	15	polo	polo	NOUN
fnp-6382	106	16	players	player	NOUN
fnp-6382	106	17	22	22	NUM
fnp-6382	106	18	female	female	ADJ
fnp-6382	106	19	collegiate	collegiate	ADJ
fnp-6382	106	20	water	water	NOUN
fnp-6382	106	21	polo	polo	NOUN
fnp-6382	106	22	players	player	NOUN
fnp-6382	106	23	gfap	gfap	PROPN
fnp-6382	106	24	increased	increase	VERB
fnp-6382	106	25	from	from	ADP
fnp-6382	106	26	week	week	NOUN
fnp-6382	106	27	1	1	NUM
fnp-6382	106	28	to	to	ADP
fnp-6382	106	29	week	week	NOUN
fnp-6382	106	30	8	8	NUM
fnp-6382	106	31	of	of	ADP
fnp-6382	106	32	preseason	preseason	NOUN
fnp-6382	106	33	(	(	PUNCT
fnp-6382	106	34	p	p	X
fnp-6382	106	35	 	 	SPACE
fnp-6382	106	36	=	=	NOUN
fnp-6382	106	37	 	 	SPACE
fnp-6382	106	38	0.002	0.002	NUM
fnp-6382	106	39	)	)	PUNCT
fnp-6382	106	40	cte	cte	NOUN
fnp-6382	106	41	,	,	PUNCT
fnp-6382	106	42	chronic	chronic	ADJ
fnp-6382	106	43	traumatic	traumatic	ADJ
fnp-6382	106	44	encephalopathy	encephalopathy	NOUN
fnp-6382	106	45	;	;	PUNCT
fnp-6382	107	1	tes	tes	NOUN
fnp-6382	107	2	,	,	PUNCT
fnp-6382	107	3	traumatic	traumatic	ADJ
fnp-6382	107	4	encephalopathy	encephalopathy	ADJ
fnp-6382	107	5	syndrome	syndrome	NOUN
fnp-6382	107	6	;	;	PUNCT
fnp-6382	107	7	ad	ad	NOUN
fnp-6382	107	8	,	,	PUNCT
fnp-6382	107	9	alzheimer	alzheimer	PROPN
fnp-6382	107	10	’s	’s	PART
fnp-6382	107	11	disease	disease	NOUN
fnp-6382	107	12	;	;	PUNCT
fnp-6382	107	13	rhi	rhi	PROPN
fnp-6382	107	14	,	,	PUNCT
fnp-6382	107	15	repetitive	repetitive	ADJ
fnp-6382	107	16	head	head	NOUN
fnp-6382	107	17	impacts	impact	NOUN
fnp-6382	107	18	;	;	PUNCT
fnp-6382	107	19	dlfc	dlfc	NOUN
fnp-6382	107	20	,	,	PUNCT
fnp-6382	107	21	dorsolateral	dorsolateral	ADJ
fnp-6382	107	22	frontal	frontal	ADJ
fnp-6382	107	23	cortex	cortex	NOUN
fnp-6382	107	24	;	;	PUNCT
fnp-6382	107	25	csf	csf	ADJ
fnp-6382	107	26	,	,	PUNCT
fnp-6382	107	27	cerebrospinal	cerebrospinal	ADJ
fnp-6382	107	28	fluid	fluid	NOUN
fnp-6382	107	29	;	;	PUNCT
fnp-6382	107	30	nbd	nbd	PROPN
fnp-6382	107	31	,	,	PUNCT
fnp-6382	107	32	neurobehavioral	neurobehavioral	ADJ
fnp-6382	107	33	dysregulation	dysregulation	NOUN
fnp-6382	107	34	;	;	PUNCT
fnp-6382	107	35	src	src	PROPN
fnp-6382	107	36	,	,	PUNCT
fnp-6382	107	37	sports	sport	NOUN
fnp-6382	107	38	-	-	PUNCT
fnp-6382	107	39	related	relate	VERB
fnp-6382	107	40	concussion	concussion	NOUN
fnp-6382	107	41	.	.	PUNCT
fnp-6382	108	1	ccl2	ccl2	PROPN
fnp-6382	108	2	ccl2	ccl2	PROPN
fnp-6382	108	3	is	be	AUX
fnp-6382	108	4	a	a	DET
fnp-6382	108	5	chemokine	chemokine	NOUN
fnp-6382	108	6	involved	involve	VERB
fnp-6382	108	7	in	in	ADP
fnp-6382	108	8	regulating	regulate	VERB
fnp-6382	108	9	monocyte	monocyte	NOUN
fnp-6382	108	10	infiltration	infiltration	NOUN
fnp-6382	108	11	through	through	ADP
fnp-6382	108	12	the	the	DET
fnp-6382	108	13	blood	blood	NOUN
fnp-6382	108	14	-	-	PUNCT
fnp-6382	108	15	brain	brain	NOUN
fnp-6382	108	16	barrier	barrier	NOUN
fnp-6382	108	17	(	(	PUNCT
fnp-6382	108	18	bbb	bbb	NOUN
fnp-6382	108	19	)	)	PUNCT
fnp-6382	108	20	in	in	ADP
fnp-6382	108	21	response	response	NOUN
fnp-6382	108	22	to	to	PART
fnp-6382	108	23	trauma	trauma	VERB
fnp-6382	108	24	,	,	PUNCT
fnp-6382	108	25	and	and	CCONJ
fnp-6382	108	26	it	it	PRON
fnp-6382	108	27	may	may	AUX
fnp-6382	108	28	be	be	AUX
fnp-6382	108	29	involved	involve	VERB
fnp-6382	108	30	in	in	ADP
fnp-6382	108	31	inducing	induce	VERB
fnp-6382	108	32	transcriptional	transcriptional	ADJ
fnp-6382	108	33	alterations	alteration	NOUN
fnp-6382	108	34	in	in	ADP
fnp-6382	108	35	microglia	microglia	NOUN
fnp-6382	108	36	(	(	PUNCT
fnp-6382	108	37	38	38	NUM
fnp-6382	108	38	)	)	PUNCT
fnp-6382	108	39	.	.	PUNCT
fnp-6382	109	1	ccr2	ccr2	NOUN
fnp-6382	109	2	deletion	deletion	NOUN
fnp-6382	109	3	or	or	CCONJ
fnp-6382	109	4	deficiency	deficiency	NOUN
fnp-6382	109	5	can	can	AUX
fnp-6382	109	6	also	also	ADV
fnp-6382	109	7	restrict	restrict	VERB
fnp-6382	109	8	the	the	DET
fnp-6382	109	9	degree	degree	NOUN
fnp-6382	109	10	of	of	ADP
fnp-6382	109	11	cognitive	cognitive	ADJ
fnp-6382	109	12	dysfunction	dysfunction	NOUN
fnp-6382	109	13	after	after	ADP
fnp-6382	109	14	tbi	tbi	PROPN
fnp-6382	109	15	(	(	PUNCT
fnp-6382	109	16	39,40	39,40	NUM
fnp-6382	109	17	)	)	PUNCT
fnp-6382	109	18	.	.	PUNCT
fnp-6382	110	1	despite	despite	SCONJ
fnp-6382	110	2	a	a	DET
fnp-6382	110	3	general	general	ADJ
fnp-6382	110	4	association	association	NOUN
fnp-6382	110	5	of	of	ADP
fnp-6382	110	6	ccl2	ccl2	PROPN
fnp-6382	110	7	with	with	ADP
fnp-6382	110	8	tau	tau	PROPN
fnp-6382	110	9	accumulation	accumulation	NOUN
fnp-6382	110	10	as	as	SCONJ
fnp-6382	110	11	seen	see	VERB
fnp-6382	110	12	in	in	ADP
fnp-6382	110	13	various	various	ADJ
fnp-6382	110	14	tauopathies	tauopathie	NOUN
fnp-6382	110	15	,	,	PUNCT
fnp-6382	110	16	cherry	cherry	PROPN
fnp-6382	110	17	et	et	PROPN
fnp-6382	110	18	al	al	PROPN
fnp-6382	110	19	.	.	PROPN
fnp-6382	110	20	reported	report	VERB
fnp-6382	110	21	evidence	evidence	NOUN
fnp-6382	110	22	of	of	ADP
fnp-6382	110	23	ccl2	ccl2	NOUN
fnp-6382	110	24	having	have	VERB
fnp-6382	110	25	a	a	DET
fnp-6382	110	26	vital	vital	ADJ
fnp-6382	110	27	role	role	NOUN
fnp-6382	110	28	in	in	ADP
fnp-6382	110	29	mediating	mediate	VERB
fnp-6382	110	30	cte	cte	NOUN
fnp-6382	110	31	pathogenesis	pathogenesis	NOUN
fnp-6382	110	32	through	through	ADP
fnp-6382	110	33	microglial	microglial	ADJ
fnp-6382	110	34	activation	activation	NOUN
fnp-6382	110	35	.	.	PUNCT
fnp-6382	111	1	by	by	ADP
fnp-6382	111	2	immunoassay	immunoassay	PROPN
fnp-6382	111	3	,	,	PUNCT
fnp-6382	111	4	ccl2	ccl2	NOUN
fnp-6382	111	5	in	in	ADP
fnp-6382	111	6	the	the	DET
fnp-6382	111	7	dorsolateral	dorsolateral	ADJ
fnp-6382	111	8	frontal	frontal	ADJ
fnp-6382	111	9	cortex	cortex	NOUN
fnp-6382	111	10	was	be	AUX
fnp-6382	111	11	found	find	VERB
fnp-6382	111	12	to	to	PART
fnp-6382	111	13	be	be	AUX
fnp-6382	111	14	elevated	elevate	VERB
fnp-6382	111	15	in	in	ADP
fnp-6382	111	16	both	both	CCONJ
fnp-6382	111	17	low	low	ADJ
fnp-6382	111	18	and	and	CCONJ
fnp-6382	111	19	high	high	ADJ
fnp-6382	111	20	-	-	PUNCT
fnp-6382	111	21	stage	stage	NOUN
fnp-6382	111	22	cte	cte	NOUN
fnp-6382	111	23	compared	compare	VERB
fnp-6382	111	24	to	to	ADP
fnp-6382	111	25	controls	control	NOUN
fnp-6382	111	26	,	,	PUNCT
fnp-6382	111	27	correlating	correlate	VERB
fnp-6382	111	28	with	with	ADP
fnp-6382	111	29	severity	severity	NOUN
fnp-6382	111	30	of	of	ADP
fnp-6382	111	31	cte	cte	PROPN
fnp-6382	111	32	pathology	pathology	PROPN
fnp-6382	111	33	.	.	PUNCT
fnp-6382	112	1	notably	notably	ADV
fnp-6382	112	2	,	,	PUNCT
fnp-6382	112	3	ccl2	ccl2	NOUN
fnp-6382	112	4	levels	level	NOUN
fnp-6382	112	5	correlated	correlate	VERB
fnp-6382	112	6	with	with	ADP
fnp-6382	112	7	football	football	NOUN
fnp-6382	112	8	career	career	NOUN
fnp-6382	112	9	length	length	NOUN
fnp-6382	112	10	,	,	PUNCT
fnp-6382	112	11	suggesting	suggest	VERB
fnp-6382	112	12	a	a	DET
fnp-6382	112	13	link	link	NOUN
fnp-6382	112	14	between	between	ADP
fnp-6382	112	15	ccl2	ccl2	NOUN
fnp-6382	112	16	signaling	signal	VERB
fnp-6382	112	17	and	and	CCONJ
fnp-6382	112	18	rhi	rhi	PROPN
fnp-6382	112	19	exposure	exposure	PROPN
fnp-6382	112	20	duration	duration	NOUN
fnp-6382	112	21	(	(	PUNCT
fnp-6382	112	22	41	41	NUM
fnp-6382	112	23	)	)	PUNCT
fnp-6382	112	24	.	.	PUNCT
fnp-6382	113	1	in	in	ADP
fnp-6382	113	2	fact	fact	NOUN
fnp-6382	113	3	,	,	PUNCT
fnp-6382	113	4	the	the	DET
fnp-6382	113	5	correlation	correlation	NOUN
fnp-6382	113	6	between	between	ADP
fnp-6382	113	7	ccl2	ccl2	NOUN
fnp-6382	113	8	and	and	CCONJ
fnp-6382	113	9	p	p	PROPN
fnp-6382	113	10	-	-	PUNCT
fnp-6382	113	11	tau	tau	PROPN
fnp-6382	113	12	,	,	PUNCT
fnp-6382	113	13	found	find	VERB
fnp-6382	113	14	in	in	ADP
fnp-6382	113	15	both	both	CCONJ
fnp-6382	113	16	cte	cte	NOUN
fnp-6382	113	17	and	and	CCONJ
fnp-6382	113	18	ad	ad	NOUN
fnp-6382	113	19	groups	group	NOUN
fnp-6382	113	20	,	,	PUNCT
fnp-6382	113	21	was	be	AUX
fnp-6382	113	22	independent	independent	ADJ
fnp-6382	113	23	of	of	ADP
fnp-6382	113	24	aβ42	aβ42	PROPN
fnp-6382	113	25	(	(	PUNCT
fnp-6382	113	26	amyloid	amyloid	NOUN
fnp-6382	113	27	beta	beta	PROPN
fnp-6382	113	28	1	1	NUM
fnp-6382	113	29	-	-	SYM
fnp-6382	113	30	42	42	NUM
fnp-6382	113	31	)	)	PUNCT
fnp-6382	113	32	levels	level	NOUN
fnp-6382	113	33	(	(	PUNCT
fnp-6382	113	34	41	41	NUM
fnp-6382	113	35	)	)	PUNCT
fnp-6382	113	36	.	.	PUNCT
fnp-6382	114	1	thus	thus	ADV
fnp-6382	114	2	,	,	PUNCT
fnp-6382	114	3	it	it	PRON
fnp-6382	114	4	is	be	AUX
fnp-6382	114	5	possible	possible	ADJ
fnp-6382	114	6	that	that	SCONJ
fnp-6382	114	7	the	the	DET
fnp-6382	114	8	tauopathy	tauopathy	NOUN
fnp-6382	114	9	in	in	ADP
fnp-6382	114	10	cte	cte	PROPN
fnp-6382	114	11	is	be	AUX
fnp-6382	114	12	more	more	ADV
fnp-6382	114	13	specifically	specifically	ADV
fnp-6382	114	14	driven	drive	VERB
fnp-6382	114	15	by	by	ADP
fnp-6382	114	16	ccl2	ccl2	PROPN
fnp-6382	114	17	.	.	PUNCT
fnp-6382	115	1	this	this	PRON
fnp-6382	115	2	is	be	AUX
fnp-6382	115	3	supported	support	VERB
fnp-6382	115	4	by	by	ADP
fnp-6382	115	5	the	the	DET
fnp-6382	115	6	finding	finding	NOUN
fnp-6382	115	7	that	that	SCONJ
fnp-6382	115	8	ccl2	ccl2	NOUN
fnp-6382	115	9	was	be	AUX
fnp-6382	115	10	significantly	significantly	ADV
fnp-6382	115	11	correlated	correlate	VERB
fnp-6382	115	12	with	with	ADP
fnp-6382	115	13	the	the	DET
fnp-6382	115	14	density	density	NOUN
fnp-6382	115	15	of	of	ADP
fnp-6382	115	16	iba1(ionized	iba1(ionize	VERB
fnp-6382	115	17	calcium	calcium	NOUN
fnp-6382	115	18	-	-	PUNCT
fnp-6382	115	19	binding	bind	VERB
fnp-6382	115	20	adapter	adapter	NOUN
fnp-6382	115	21	molecule	molecule	NOUN
fnp-6382	115	22	1	1	NUM
fnp-6382	115	23	)	)	PUNCT
fnp-6382	115	24	positive	positive	ADJ
fnp-6382	115	25	cells	cell	NOUN
fnp-6382	115	26	,	,	PUNCT
fnp-6382	115	27	which	which	PRON
fnp-6382	115	28	itself	itself	PRON
fnp-6382	115	29	was	be	AUX
fnp-6382	115	30	found	find	VERB
fnp-6382	115	31	to	to	PART
fnp-6382	115	32	be	be	AUX
fnp-6382	115	33	associated	associate	VERB
fnp-6382	115	34	with	with	ADP
fnp-6382	115	35	the	the	DET
fnp-6382	115	36	pathognomonic	pathognomonic	ADJ
fnp-6382	115	37	lesion	lesion	NOUN
fnp-6382	115	38	of	of	ADP
fnp-6382	115	39	perivascular	perivascular	ADJ
fnp-6382	115	40	tau	tau	PROPN
fnp-6382	115	41	(	(	PUNCT
fnp-6382	115	42	41	41	NUM
fnp-6382	115	43	)	)	PUNCT
fnp-6382	115	44	.	.	PUNCT
fnp-6382	116	1	support	support	NOUN
fnp-6382	116	2	for	for	ADP
fnp-6382	116	3	ccl2	ccl2	NOUN
fnp-6382	116	4	as	as	ADP
fnp-6382	116	5	a	a	DET
fnp-6382	116	6	marker	marker	NOUN
fnp-6382	116	7	of	of	ADP
fnp-6382	116	8	head	head	NOUN
fnp-6382	116	9	trauma	trauma	NOUN
fnp-6382	116	10	also	also	ADV
fnp-6382	116	11	comes	come	VERB
fnp-6382	116	12	from	from	ADP
fnp-6382	116	13	other	other	ADJ
fnp-6382	116	14	studies	study	NOUN
fnp-6382	116	15	.	.	PUNCT
fnp-6382	117	1	in	in	ADP
fnp-6382	117	2	a	a	DET
fnp-6382	117	3	blood	blood	NOUN
fnp-6382	117	4	-	-	PUNCT
fnp-6382	117	5	based	base	VERB
fnp-6382	117	6	biomarker	biomarker	NOUN
fnp-6382	117	7	analysis	analysis	NOUN
fnp-6382	117	8	of	of	ADP
fnp-6382	117	9	university	university	NOUN
fnp-6382	117	10	athletes	athlete	NOUN
fnp-6382	117	11	from	from	ADP
fnp-6382	117	12	various	various	ADJ
fnp-6382	117	13	contact	contact	NOUN
fnp-6382	117	14	sports	sport	NOUN
fnp-6382	117	15	at	at	ADP
fnp-6382	117	16	the	the	DET
fnp-6382	117	17	beginning	beginning	NOUN
fnp-6382	117	18	of	of	ADP
fnp-6382	117	19	competitive	competitive	ADJ
fnp-6382	117	20	season	season	NOUN
fnp-6382	117	21	,	,	PUNCT
fnp-6382	117	22	female	female	ADJ
fnp-6382	117	23	athletes	athlete	NOUN
fnp-6382	117	24	with	with	ADP
fnp-6382	117	25	prior	prior	ADJ
fnp-6382	117	26	exposure	exposure	NOUN
fnp-6382	117	27	to	to	ADP
fnp-6382	117	28	multiple	multiple	ADJ
fnp-6382	117	29	concussions	concussion	NOUN
fnp-6382	117	30	had	have	VERB
fnp-6382	117	31	elevated	elevate	VERB
fnp-6382	117	32	serum	serum	NOUN
fnp-6382	117	33	levels	level	NOUN
fnp-6382	117	34	of	of	ADP
fnp-6382	117	35	ccl2	ccl2	NOUN
fnp-6382	117	36	compared	compare	VERB
fnp-6382	117	37	to	to	ADP
fnp-6382	117	38	non	non	ADJ
fnp-6382	117	39	-	-	ADJ
fnp-6382	117	40	exposed	expose	VERB
fnp-6382	117	41	controls	control	NOUN
fnp-6382	117	42	.	.	PUNCT
fnp-6382	118	1	in	in	ADP
fnp-6382	118	2	fact	fact	NOUN
fnp-6382	118	3	,	,	PUNCT
fnp-6382	118	4	out	out	ADP
fnp-6382	118	5	of	of	ADP
fnp-6382	118	6	39	39	NUM
fnp-6382	118	7	markers	marker	NOUN
fnp-6382	118	8	including	include	VERB
fnp-6382	118	9	il-1β	il-1β	PROPN
fnp-6382	118	10	,	,	PUNCT
fnp-6382	118	11	il-6	il-6	NUM
fnp-6382	118	12	,	,	PUNCT
fnp-6382	118	13	ifn	ifn	PROPN
fnp-6382	118	14	-	-	PUNCT
fnp-6382	118	15	γ	γ	NOUN
fnp-6382	118	16	,	,	PUNCT
fnp-6382	118	17	il-10	il-10	PRON
fnp-6382	118	18	,	,	PUNCT
fnp-6382	118	19	and	and	CCONJ
fnp-6382	118	20	tnf	tnf	PROPN
fnp-6382	118	21	-	-	PUNCT
fnp-6382	118	22	α	α	PROPN
fnp-6382	118	23	,	,	PUNCT
fnp-6382	118	24	ccl2	ccl2	PROPN
fnp-6382	118	25	was	be	AUX
fnp-6382	118	26	the	the	DET
fnp-6382	118	27	only	only	ADJ
fnp-6382	118	28	protein	protein	NOUN
fnp-6382	118	29	that	that	PRON
fnp-6382	118	30	exhibited	exhibit	VERB
fnp-6382	118	31	a	a	DET
fnp-6382	118	32	significant	significant	ADJ
fnp-6382	118	33	relationship	relationship	NOUN
fnp-6382	118	34	with	with	ADP
fnp-6382	118	35	multiple	multiple	ADJ
fnp-6382	118	36	concussion	concussion	NOUN
fnp-6382	118	37	exposure	exposure	NOUN
fnp-6382	118	38	in	in	ADP
fnp-6382	118	39	this	this	DET
fnp-6382	118	40	group	group	NOUN
fnp-6382	118	41	(	(	PUNCT
fnp-6382	118	42	42	42	NUM
fnp-6382	118	43	)	)	PUNCT
fnp-6382	118	44	.	.	PUNCT
fnp-6382	119	1	interestingly	interestingly	ADV
fnp-6382	119	2	,	,	PUNCT
fnp-6382	119	3	begum	begum	AUX
fnp-6382	119	4	et	et	PROPN
fnp-6382	119	5	al	al	PROPN
fnp-6382	119	6	.	.	PROPN
fnp-6382	119	7	reported	report	VERB
fnp-6382	119	8	reduced	reduce	VERB
fnp-6382	119	9	ccl2	ccl2	PROPN
fnp-6382	119	10	serum	serum	PROPN
fnp-6382	119	11	levels	level	NOUN
fnp-6382	119	12	to	to	PART
fnp-6382	119	13	be	be	AUX
fnp-6382	119	14	associated	associate	VERB
fnp-6382	119	15	with	with	ADP
fnp-6382	119	16	an	an	DET
fnp-6382	119	17	increased	increase	VERB
fnp-6382	119	18	number	number	NOUN
fnp-6382	119	19	and	and	CCONJ
fnp-6382	119	20	severity	severity	NOUN
fnp-6382	119	21	of	of	ADP
fnp-6382	119	22	post	post	ADJ
fnp-6382	119	23	-	-	ADJ
fnp-6382	119	24	concussive	concussive	ADJ
fnp-6382	119	25	symptoms	symptom	NOUN
fnp-6382	119	26	in	in	ADP
fnp-6382	119	27	athletes	athlete	NOUN
fnp-6382	119	28	(	(	PUNCT
fnp-6382	119	29	43	43	NUM
fnp-6382	119	30	)	)	PUNCT
fnp-6382	119	31	.	.	PUNCT
fnp-6382	120	1	however	however	ADV
fnp-6382	120	2	,	,	PUNCT
fnp-6382	120	3	ccl2	ccl2	PROPN
fnp-6382	120	4	is	be	AUX
fnp-6382	120	5	also	also	ADV
fnp-6382	120	6	strongly	strongly	ADV
fnp-6382	120	7	associated	associate	VERB
fnp-6382	120	8	with	with	ADP
fnp-6382	120	9	ad	ad	NOUN
fnp-6382	120	10	pathology	pathology	NOUN
fnp-6382	120	11	(	(	PUNCT
fnp-6382	120	12	44–46	44–46	NUM
fnp-6382	120	13	)	)	PUNCT
fnp-6382	120	14	,	,	PUNCT
fnp-6382	120	15	in	in	ADP
fnp-6382	120	16	addition	addition	NOUN
fnp-6382	120	17	to	to	ADP
fnp-6382	120	18	multiple	multiple	ADJ
fnp-6382	120	19	sclerosis	sclerosis	NOUN
fnp-6382	120	20	(	(	PUNCT
fnp-6382	120	21	47	47	NUM
fnp-6382	120	22	)	)	PUNCT
fnp-6382	120	23	and	and	CCONJ
fnp-6382	120	24	stroke	stroke	NOUN
fnp-6382	120	25	(	(	PUNCT
fnp-6382	120	26	48,49	48,49	NOUN
fnp-6382	120	27	)	)	PUNCT
fnp-6382	120	28	.	.	PUNCT
fnp-6382	121	1	consequently	consequently	ADV
fnp-6382	121	2	,	,	PUNCT
fnp-6382	121	3	while	while	SCONJ
fnp-6382	121	4	ccl2	ccl2	PROPN
fnp-6382	121	5	may	may	AUX
fnp-6382	121	6	not	not	PART
fnp-6382	121	7	have	have	VERB
fnp-6382	121	8	the	the	DET
fnp-6382	121	9	specificity	specificity	NOUN
fnp-6382	121	10	to	to	PART
fnp-6382	121	11	cte	cte	VERB
fnp-6382	121	12	that	that	PRON
fnp-6382	121	13	would	would	AUX
fnp-6382	121	14	make	make	VERB
fnp-6382	121	15	it	it	PRON
fnp-6382	121	16	a	a	DET
fnp-6382	121	17	viable	viable	ADJ
fnp-6382	121	18	biomarker	biomarker	NOUN
fnp-6382	121	19	,	,	PUNCT
fnp-6382	121	20	its	its	PRON
fnp-6382	121	21	demonstrated	demonstrate	VERB
fnp-6382	121	22	involvement	involvement	NOUN
fnp-6382	121	23	in	in	ADP
fnp-6382	121	24	pathogenesis	pathogenesis	NOUN
fnp-6382	121	25	and	and	CCONJ
fnp-6382	121	26	possible	possible	ADJ
fnp-6382	121	27	sensitivity	sensitivity	NOUN
fnp-6382	121	28	to	to	ADP
fnp-6382	121	29	cte	cte	PROPN
fnp-6382	121	30	suggests	suggest	VERB
fnp-6382	121	31	that	that	SCONJ
fnp-6382	121	32	ccl2	ccl2	PROPN
fnp-6382	121	33	could	could	AUX
fnp-6382	121	34	instead	instead	ADV
fnp-6382	121	35	have	have	VERB
fnp-6382	121	36	value	value	NOUN
fnp-6382	121	37	as	as	ADP
fnp-6382	121	38	a	a	DET
fnp-6382	121	39	marker	marker	NOUN
fnp-6382	121	40	of	of	ADP
fnp-6382	121	41	disease	disease	NOUN
fnp-6382	121	42	progression	progression	NOUN
fnp-6382	121	43	.	.	PUNCT
fnp-6382	122	1	this	this	PRON
fnp-6382	122	2	is	be	AUX
fnp-6382	122	3	supported	support	VERB
fnp-6382	122	4	by	by	ADP
fnp-6382	122	5	the	the	DET
fnp-6382	122	6	findings	finding	NOUN
fnp-6382	122	7	of	of	ADP
fnp-6382	122	8	a	a	DET
fnp-6382	122	9	stepwise	stepwise	ADJ
fnp-6382	122	10	increase	increase	NOUN
fnp-6382	122	11	across	across	ADP
fnp-6382	122	12	rhi	rhi	PROPN
fnp-6382	122	13	exposure	exposure	NOUN
fnp-6382	122	14	and	and	CCONJ
fnp-6382	122	15	cte	cte	NOUN
fnp-6382	122	16	staging	staging	NOUN
fnp-6382	122	17	continuum	continuum	ADJ
fnp-6382	122	18	,	,	PUNCT
fnp-6382	122	19	although	although	SCONJ
fnp-6382	122	20	more	more	ADJ
fnp-6382	122	21	evidence	evidence	NOUN
fnp-6382	122	22	is	be	AUX
fnp-6382	122	23	required	require	VERB
fnp-6382	122	24	to	to	PART
fnp-6382	122	25	validate	validate	VERB
fnp-6382	122	26	these	these	DET
fnp-6382	122	27	results	result	NOUN
fnp-6382	122	28	.	.	PUNCT
fnp-6382	123	1	because	because	SCONJ
fnp-6382	123	2	of	of	ADP
fnp-6382	123	3	the	the	DET
fnp-6382	123	4	role	role	NOUN
fnp-6382	123	5	of	of	ADP
fnp-6382	123	6	ccl2	ccl2	NOUN
fnp-6382	123	7	in	in	ADP
fnp-6382	123	8	microglial	microglial	ADJ
fnp-6382	123	9	recruitment	recruitment	NOUN
fnp-6382	123	10	and	and	CCONJ
fnp-6382	123	11	subsequent	subsequent	ADJ
fnp-6382	123	12	tauopathy	tauopathy	NOUN
fnp-6382	123	13	,	,	PUNCT
fnp-6382	123	14	regulation	regulation	NOUN
fnp-6382	123	15	of	of	ADP
fnp-6382	123	16	this	this	DET
fnp-6382	123	17	signaling	signal	VERB
fnp-6382	123	18	pathway	pathway	NOUN
fnp-6382	123	19	may	may	AUX
fnp-6382	123	20	eventually	eventually	ADV
fnp-6382	123	21	serve	serve	VERB
fnp-6382	123	22	as	as	ADP
fnp-6382	123	23	a	a	DET
fnp-6382	123	24	therapeutic	therapeutic	ADJ
fnp-6382	123	25	target	target	NOUN
fnp-6382	123	26	in	in	ADP
fnp-6382	123	27	order	order	NOUN
fnp-6382	123	28	to	to	PART
fnp-6382	123	29	minimize	minimize	VERB
fnp-6382	123	30	the	the	DET
fnp-6382	123	31	degree	degree	NOUN
fnp-6382	123	32	of	of	ADP
fnp-6382	123	33	chronic	chronic	ADJ
fnp-6382	123	34	inflammation	inflammation	NOUN
fnp-6382	123	35	.	.	PUNCT
fnp-6382	124	1	however	however	ADV
fnp-6382	124	2	,	,	PUNCT
fnp-6382	124	3	future	future	ADJ
fnp-6382	124	4	investigations	investigation	NOUN
fnp-6382	124	5	should	should	AUX
fnp-6382	124	6	still	still	ADV
fnp-6382	124	7	aim	aim	VERB
fnp-6382	124	8	to	to	PART
fnp-6382	124	9	better	well	ADV
fnp-6382	124	10	characterize	characterize	VERB
fnp-6382	124	11	the	the	DET
fnp-6382	124	12	precise	precise	ADJ
fnp-6382	124	13	involvement	involvement	NOUN
fnp-6382	124	14	of	of	ADP
fnp-6382	124	15	this	this	DET
fnp-6382	124	16	signaling	signal	VERB
fnp-6382	124	17	pathway	pathway	NOUN
fnp-6382	124	18	in	in	ADP
fnp-6382	124	19	the	the	DET
fnp-6382	124	20	cte	cte	NOUN
fnp-6382	124	21	immune	immune	ADJ
fnp-6382	124	22	signature	signature	NOUN
fnp-6382	124	23	.	.	PUNCT
fnp-6382	125	1	ccl11	ccl11	PROPN
fnp-6382	125	2	ccl11	ccl11	PROPN
fnp-6382	125	3	,	,	PUNCT
fnp-6382	125	4	or	or	CCONJ
fnp-6382	125	5	eotaxin-1	eotaxin-1	NUM
fnp-6382	125	6	,	,	PUNCT
fnp-6382	125	7	is	be	AUX
fnp-6382	125	8	a	a	DET
fnp-6382	125	9	chemokine	chemokine	NOUN
fnp-6382	125	10	that	that	PRON
fnp-6382	125	11	is	be	AUX
fnp-6382	125	12	involved	involve	VERB
fnp-6382	125	13	in	in	ADP
fnp-6382	125	14	recruiting	recruit	VERB
fnp-6382	125	15	eosinophils	eosinophil	NOUN
fnp-6382	125	16	to	to	ADP
fnp-6382	125	17	sites	site	NOUN
fnp-6382	125	18	of	of	ADP
fnp-6382	125	19	inflammation	inflammation	NOUN
fnp-6382	125	20	to	to	PART
fnp-6382	125	21	trigger	trigger	VERB
fnp-6382	125	22	immune	immune	ADJ
fnp-6382	125	23	responses	response	NOUN
fnp-6382	125	24	(	(	PUNCT
fnp-6382	125	25	50	50	NUM
fnp-6382	125	26	)	)	PUNCT
fnp-6382	125	27	.	.	PUNCT
fnp-6382	126	1	due	due	ADP
fnp-6382	126	2	to	to	ADP
fnp-6382	126	3	its	its	PRON
fnp-6382	126	4	ability	ability	NOUN
fnp-6382	126	5	to	to	PART
fnp-6382	126	6	cross	cross	VERB
fnp-6382	126	7	the	the	DET
fnp-6382	126	8	blood	blood	NOUN
fnp-6382	126	9	-	-	PUNCT
fnp-6382	126	10	brain	brain	NOUN
fnp-6382	126	11	barrier	barrier	NOUN
fnp-6382	126	12	,	,	PUNCT
fnp-6382	126	13	ccl11	ccl11	PROPN
fnp-6382	126	14	can	can	AUX
fnp-6382	126	15	directly	directly	ADV
fnp-6382	126	16	contribute	contribute	VERB
fnp-6382	126	17	to	to	ADP
fnp-6382	126	18	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	126	19	mechanisms	mechanism	NOUN
fnp-6382	126	20	.	.	PUNCT
fnp-6382	127	1	in	in	ADP
fnp-6382	127	2	fact	fact	NOUN
fnp-6382	127	3	,	,	PUNCT
fnp-6382	127	4	neurons	neuron	NOUN
fnp-6382	127	5	,	,	PUNCT
fnp-6382	127	6	microglia	microglia	NOUN
fnp-6382	127	7	,	,	PUNCT
fnp-6382	127	8	and	and	CCONJ
fnp-6382	127	9	other	other	ADJ
fnp-6382	127	10	cns	cns	NOUN
fnp-6382	127	11	cell	cell	NOUN
fnp-6382	127	12	types	type	NOUN
fnp-6382	127	13	are	be	AUX
fnp-6382	127	14	known	know	VERB
fnp-6382	127	15	to	to	PART
fnp-6382	127	16	express	express	VERB
fnp-6382	127	17	receptors	receptor	NOUN
fnp-6382	127	18	for	for	ADP
fnp-6382	127	19	ccl11	ccl11	NOUN
fnp-6382	127	20	(	(	PUNCT
fnp-6382	127	21	51	51	NUM
fnp-6382	127	22	)	)	PUNCT
fnp-6382	127	23	.	.	PUNCT
fnp-6382	128	1	in	in	ADP
fnp-6382	128	2	a	a	DET
fnp-6382	128	3	study	study	NOUN
fnp-6382	128	4	that	that	PRON
fnp-6382	128	5	used	use	VERB
fnp-6382	128	6	enzyme	enzyme	NOUN
fnp-6382	128	7	-	-	PUNCT
fnp-6382	128	8	linked	link	VERB
fnp-6382	128	9	immunosorbent	immunosorbent	NOUN
fnp-6382	128	10	assay	assay	PROPN
fnp-6382	128	11	(	(	PUNCT
fnp-6382	128	12	elisa	elisa	NOUN
fnp-6382	128	13	)	)	PUNCT
fnp-6382	128	14	to	to	PART
fnp-6382	128	15	assess	assess	VERB
fnp-6382	128	16	csf	csf	ADJ
fnp-6382	128	17	levels	level	NOUN
fnp-6382	128	18	of	of	ADP
fnp-6382	128	19	ccl11	ccl11	PROPN
fnp-6382	128	20	in	in	ADP
fnp-6382	128	21	brain	brain	NOUN
fnp-6382	128	22	tissue	tissue	NOUN
fnp-6382	128	23	from	from	ADP
fnp-6382	128	24	football	football	NOUN
fnp-6382	128	25	players	player	NOUN
fnp-6382	128	26	,	,	PUNCT
fnp-6382	128	27	cherry	cherry	PROPN
fnp-6382	128	28	et	et	PROPN
fnp-6382	128	29	al	al	PROPN
fnp-6382	128	30	.	.	PROPN
fnp-6382	128	31	found	find	VERB
fnp-6382	128	32	a	a	DET
fnp-6382	128	33	significantly	significantly	ADV
fnp-6382	128	34	elevated	elevated	ADJ
fnp-6382	128	35	level	level	NOUN
fnp-6382	128	36	of	of	ADP
fnp-6382	128	37	ccl11	ccl11	NOUN
fnp-6382	128	38	in	in	ADP
fnp-6382	128	39	the	the	DET
fnp-6382	128	40	23	23	NUM
fnp-6382	128	41	cte	cte	NOUN
fnp-6382	128	42	-	-	PUNCT
fnp-6382	128	43	confirmed	confirm	VERB
fnp-6382	128	44	subjects	subject	NOUN
fnp-6382	128	45	compared	compare	VERB
fnp-6382	128	46	to	to	ADP
fnp-6382	128	47	the	the	DET
fnp-6382	128	48	50	50	NUM
fnp-6382	128	49	ad	ad	NOUN
fnp-6382	128	50	-	-	PUNCT
fnp-6382	128	51	confirmed	confirm	VERB
fnp-6382	128	52	subjects	subject	NOUN
fnp-6382	128	53	and	and	CCONJ
fnp-6382	128	54	18	18	NUM
fnp-6382	128	55	non	non	ADJ
fnp-6382	128	56	-	-	ADJ
fnp-6382	128	57	athlete	athlete	ADJ
fnp-6382	128	58	control	control	NOUN
fnp-6382	128	59	subjects	subject	NOUN
fnp-6382	128	60	.	.	PUNCT
fnp-6382	129	1	of	of	ADP
fnp-6382	129	2	note	note	NOUN
fnp-6382	129	3	,	,	PUNCT
fnp-6382	129	4	the	the	DET
fnp-6382	129	5	authors	author	NOUN
fnp-6382	129	6	determined	determine	VERB
fnp-6382	129	7	a	a	DET
fnp-6382	129	8	significant	significant	ADJ
fnp-6382	129	9	correlation	correlation	NOUN
fnp-6382	129	10	between	between	ADP
fnp-6382	129	11	ccl11	ccl11	PROPN
fnp-6382	129	12	levels	level	NOUN
fnp-6382	129	13	in	in	ADP
fnp-6382	129	14	cte	cte	PROPN
fnp-6382	129	15	subjects	subject	NOUN
fnp-6382	129	16	and	and	CCONJ
fnp-6382	129	17	football	football	NOUN
fnp-6382	129	18	career	career	NOUN
fnp-6382	129	19	length	length	NOUN
fnp-6382	129	20	.	.	PUNCT
fnp-6382	130	1	length	length	NOUN
fnp-6382	130	2	of	of	ADP
fnp-6382	130	3	rhi	rhi	PROPN
fnp-6382	130	4	exposure	exposure	NOUN
fnp-6382	130	5	and	and	CCONJ
fnp-6382	130	6	degree	degree	NOUN
fnp-6382	130	7	of	of	ADP
fnp-6382	130	8	tauopathy	tauopathy	NOUN
fnp-6382	130	9	in	in	ADP
fnp-6382	130	10	the	the	DET
fnp-6382	130	11	dorsolateral	dorsolateral	ADJ
fnp-6382	130	12	frontal	frontal	ADJ
fnp-6382	130	13	cortex	cortex	NOUN
fnp-6382	130	14	were	be	AUX
fnp-6382	130	15	more	more	ADV
fnp-6382	130	16	predictive	predictive	ADJ
fnp-6382	130	17	of	of	ADP
fnp-6382	130	18	cte	cte	NOUN
fnp-6382	130	19	diagnosis	diagnosis	NOUN
fnp-6382	130	20	compared	compare	VERB
fnp-6382	130	21	to	to	ADP
fnp-6382	130	22	age	age	NOUN
fnp-6382	130	23	(	(	PUNCT
fnp-6382	130	24	52	52	NUM
fnp-6382	130	25	)	)	PUNCT
fnp-6382	130	26	.	.	PUNCT
fnp-6382	131	1	however	however	ADV
fnp-6382	131	2	,	,	PUNCT
fnp-6382	131	3	this	this	DET
fnp-6382	131	4	study	study	NOUN
fnp-6382	131	5	did	do	AUX
fnp-6382	131	6	not	not	PART
fnp-6382	131	7	include	include	VERB
fnp-6382	131	8	rhi	rhi	NOUN
fnp-6382	131	9	-	-	PUNCT
fnp-6382	131	10	exposed	expose	VERB
fnp-6382	131	11	subjects	subject	NOUN
fnp-6382	131	12	without	without	ADP
fnp-6382	131	13	cte	cte	NOUN
fnp-6382	131	14	;	;	PUNCT
fnp-6382	131	15	therefore	therefore	ADV
fnp-6382	131	16	,	,	PUNCT
fnp-6382	131	17	it	it	PRON
fnp-6382	131	18	is	be	AUX
fnp-6382	131	19	unclear	unclear	ADJ
fnp-6382	131	20	at	at	ADP
fnp-6382	131	21	this	this	DET
fnp-6382	131	22	point	point	NOUN
fnp-6382	131	23	whether	whether	SCONJ
fnp-6382	131	24	ccl11	ccl11	NOUN
fnp-6382	131	25	reflects	reflect	VERB
fnp-6382	131	26	cte	cte	NOUN
fnp-6382	131	27	or	or	CCONJ
fnp-6382	131	28	rhi	rhi	PROPN
fnp-6382	131	29	exposure	exposure	PROPN
fnp-6382	131	30	independent	independent	ADJ
fnp-6382	131	31	of	of	ADP
fnp-6382	131	32	disease	disease	NOUN
fnp-6382	131	33	status	status	NOUN
fnp-6382	131	34	.	.	PUNCT
fnp-6382	132	1	furthermore	furthermore	ADV
fnp-6382	132	2	,	,	PUNCT
fnp-6382	132	3	no	no	DET
fnp-6382	132	4	notable	notable	ADJ
fnp-6382	132	5	increase	increase	NOUN
fnp-6382	132	6	in	in	ADP
fnp-6382	132	7	csf	csf	ADJ
fnp-6382	132	8	levels	level	NOUN
fnp-6382	132	9	of	of	ADP
fnp-6382	132	10	ccl11	ccl11	NOUN
fnp-6382	132	11	among	among	ADP
fnp-6382	132	12	the	the	DET
fnp-6382	132	13	ad	ad	NOUN
fnp-6382	132	14	subjects	subject	NOUN
fnp-6382	132	15	was	be	AUX
fnp-6382	132	16	determined	determine	VERB
fnp-6382	132	17	,	,	PUNCT
fnp-6382	132	18	which	which	PRON
fnp-6382	132	19	corroborates	corroborate	VERB
fnp-6382	132	20	results	result	NOUN
fnp-6382	132	21	from	from	ADP
fnp-6382	132	22	other	other	ADJ
fnp-6382	132	23	studies	study	NOUN
fnp-6382	132	24	(	(	PUNCT
fnp-6382	132	25	46,53	46,53	NOUN
fnp-6382	132	26	)	)	PUNCT
fnp-6382	132	27	.	.	PUNCT
fnp-6382	133	1	this	this	PRON
fnp-6382	133	2	would	would	AUX
fnp-6382	133	3	support	support	VERB
fnp-6382	133	4	ccl11	ccl11	NOUN
fnp-6382	133	5	as	as	ADP
fnp-6382	133	6	a	a	DET
fnp-6382	133	7	promising	promising	ADJ
fnp-6382	133	8	biomarker	biomarker	NOUN
fnp-6382	133	9	that	that	PRON
fnp-6382	133	10	may	may	AUX
fnp-6382	133	11	help	help	VERB
fnp-6382	133	12	differentiate	differentiate	VERB
fnp-6382	133	13	cte	cte	NOUN
fnp-6382	133	14	from	from	ADP
fnp-6382	133	15	other	other	ADJ
fnp-6382	133	16	pathologies	pathology	NOUN
fnp-6382	133	17	(	(	PUNCT
fnp-6382	133	18	52	52	NUM
fnp-6382	133	19	)	)	PUNCT
fnp-6382	133	20	.	.	PUNCT
fnp-6382	134	1	ccl11	ccl11	NOUN
fnp-6382	134	2	has	have	AUX
fnp-6382	134	3	been	be	AUX
fnp-6382	134	4	observed	observe	VERB
fnp-6382	134	5	in	in	ADP
fnp-6382	134	6	the	the	DET
fnp-6382	134	7	context	context	NOUN
fnp-6382	134	8	of	of	ADP
fnp-6382	134	9	sports	sport	NOUN
fnp-6382	134	10	injury	injury	NOUN
fnp-6382	134	11	in	in	ADP
fnp-6382	134	12	other	other	ADJ
fnp-6382	134	13	studies	study	NOUN
fnp-6382	134	14	as	as	ADV
fnp-6382	134	15	well	well	ADV
fnp-6382	134	16	.	.	PUNCT
fnp-6382	135	1	in	in	ADP
fnp-6382	135	2	the	the	DET
fnp-6382	135	3	study	study	NOUN
fnp-6382	135	4	from	from	ADP
fnp-6382	135	5	di	di	PROPN
fnp-6382	135	6	battista	battista	PROPN
fnp-6382	135	7	et	et	PROPN
fnp-6382	135	8	al	al	PROPN
fnp-6382	135	9	.	.	PROPN
fnp-6382	135	10	,	,	PUNCT
fnp-6382	135	11	ccl11	ccl11	PROPN
fnp-6382	135	12	was	be	AUX
fnp-6382	135	13	quantified	quantify	VERB
fnp-6382	135	14	in	in	ADP
fnp-6382	135	15	serum	serum	NOUN
fnp-6382	135	16	samples	sample	NOUN
fnp-6382	135	17	from	from	ADP
fnp-6382	135	18	college	college	NOUN
fnp-6382	135	19	-	-	PUNCT
fnp-6382	135	20	level	level	NOUN
fnp-6382	135	21	athletes	athlete	NOUN
fnp-6382	135	22	with	with	ADP
fnp-6382	135	23	and	and	CCONJ
fnp-6382	135	24	without	without	ADP
fnp-6382	135	25	a	a	DET
fnp-6382	135	26	history	history	NOUN
fnp-6382	135	27	of	of	ADP
fnp-6382	135	28	multiple	multiple	ADJ
fnp-6382	135	29	concussions	concussion	NOUN
fnp-6382	135	30	.	.	PUNCT
fnp-6382	136	1	although	although	SCONJ
fnp-6382	136	2	this	this	DET
fnp-6382	136	3	chemokine	chemokine	NOUN
fnp-6382	136	4	was	be	AUX
fnp-6382	136	5	detected	detect	VERB
fnp-6382	136	6	,	,	PUNCT
fnp-6382	136	7	there	there	PRON
fnp-6382	136	8	were	be	VERB
fnp-6382	136	9	no	no	DET
fnp-6382	136	10	significant	significant	ADJ
fnp-6382	136	11	differences	difference	NOUN
fnp-6382	136	12	in	in	ADP
fnp-6382	136	13	ccl11	ccl11	NOUN
fnp-6382	136	14	levels	level	NOUN
fnp-6382	136	15	between	between	ADP
fnp-6382	136	16	those	those	PRON
fnp-6382	136	17	with	with	ADP
fnp-6382	136	18	more	more	ADJ
fnp-6382	136	19	than	than	ADP
fnp-6382	136	20	three	three	NUM
fnp-6382	136	21	prior	prior	ADJ
fnp-6382	136	22	concussions	concussion	NOUN
fnp-6382	136	23	,	,	PUNCT
fnp-6382	136	24	and	and	CCONJ
fnp-6382	136	25	those	those	PRON
fnp-6382	136	26	with	with	ADP
fnp-6382	136	27	fewer	few	ADJ
fnp-6382	136	28	or	or	CCONJ
fnp-6382	136	29	none	none	NOUN
fnp-6382	136	30	,	,	PUNCT
fnp-6382	136	31	suggesting	suggest	VERB
fnp-6382	136	32	that	that	SCONJ
fnp-6382	136	33	peripheral	peripheral	ADJ
fnp-6382	136	34	ccl11	ccl11	NOUN
fnp-6382	136	35	is	be	AUX
fnp-6382	136	36	not	not	PART
fnp-6382	136	37	persistently	persistently	ADV
fnp-6382	136	38	elevated	elevate	VERB
fnp-6382	136	39	in	in	ADP
fnp-6382	136	40	young	young	ADJ
fnp-6382	136	41	,	,	PUNCT
fnp-6382	136	42	asymptomatic	asymptomatic	ADJ
fnp-6382	136	43	athletes	athlete	NOUN
fnp-6382	136	44	despite	despite	SCONJ
fnp-6382	136	45	concussion	concussion	NOUN
fnp-6382	136	46	exposure	exposure	NOUN
fnp-6382	136	47	.	.	PUNCT
fnp-6382	137	1	additionally	additionally	ADV
fnp-6382	137	2	,	,	PUNCT
fnp-6382	137	3	correlation	correlation	NOUN
fnp-6382	137	4	analyses	analysis	NOUN
fnp-6382	137	5	showed	show	VERB
fnp-6382	137	6	no	no	DET
fnp-6382	137	7	significant	significant	ADJ
fnp-6382	137	8	associations	association	NOUN
fnp-6382	137	9	between	between	ADP
fnp-6382	137	10	ccl11	ccl11	NOUN
fnp-6382	137	11	levels	level	NOUN
fnp-6382	137	12	and	and	CCONJ
fnp-6382	137	13	time	time	NOUN
fnp-6382	137	14	since	since	SCONJ
fnp-6382	137	15	last	last	ADJ
fnp-6382	137	16	concussion	concussion	NOUN
fnp-6382	137	17	,	,	PUNCT
fnp-6382	137	18	number	number	NOUN
fnp-6382	137	19	of	of	ADP
fnp-6382	137	20	prior	prior	ADJ
fnp-6382	137	21	concussions	concussion	NOUN
fnp-6382	137	22	,	,	PUNCT
fnp-6382	137	23	or	or	CCONJ
fnp-6382	137	24	self	self	NOUN
fnp-6382	137	25	-	-	PUNCT
fnp-6382	137	26	reported	report	VERB
fnp-6382	137	27	symptoms.(42	symptoms.(42	NOUN
fnp-6382	137	28	)	)	PUNCT
fnp-6382	137	29	.	.	PUNCT
fnp-6382	138	1	in	in	ADP
fnp-6382	138	2	soccer	soccer	NOUN
fnp-6382	138	3	players	player	NOUN
fnp-6382	138	4	,	,	PUNCT
fnp-6382	138	5	huibregtse	huibregtse	X
fnp-6382	138	6	et	et	PROPN
fnp-6382	138	7	al	al	PROPN
fnp-6382	138	8	.	.	PROPN
fnp-6382	139	1	(	(	PUNCT
fnp-6382	139	2	2020	2020	NUM
fnp-6382	139	3	)	)	PUNCT
fnp-6382	139	4	investigated	investigate	VERB
fnp-6382	139	5	acute	acute	ADJ
fnp-6382	139	6	changes	change	NOUN
fnp-6382	139	7	in	in	ADP
fnp-6382	139	8	ccl11	ccl11	NOUN
fnp-6382	139	9	following	follow	VERB
fnp-6382	139	10	repeated	repeat	VERB
fnp-6382	139	11	heading	heading	NOUN
fnp-6382	139	12	events	event	NOUN
fnp-6382	139	13	,	,	PUNCT
fnp-6382	139	14	finding	find	VERB
fnp-6382	139	15	no	no	DET
fnp-6382	139	16	significant	significant	ADJ
fnp-6382	139	17	increases	increase	NOUN
fnp-6382	139	18	in	in	ADP
fnp-6382	139	19	plasma	plasma	NOUN
fnp-6382	139	20	levels	level	NOUN
fnp-6382	139	21	after	after	ADP
fnp-6382	139	22	ten	ten	NUM
fnp-6382	139	23	head	head	NOUN
fnp-6382	139	24	traumas	trauma	NOUN
fnp-6382	139	25	.	.	PUNCT
fnp-6382	140	1	despite	despite	SCONJ
fnp-6382	140	2	no	no	DET
fnp-6382	140	3	group	group	NOUN
fnp-6382	140	4	-	-	PUNCT
fnp-6382	140	5	level	level	NOUN
fnp-6382	140	6	acute	acute	NOUN
fnp-6382	140	7	effects	effect	NOUN
fnp-6382	140	8	from	from	ADP
fnp-6382	140	9	intervention	intervention	NOUN
fnp-6382	140	10	,	,	PUNCT
fnp-6382	140	11	exposure	exposure	NOUN
fnp-6382	140	12	duration	duration	NOUN
fnp-6382	140	13	reportedly	reportedly	ADV
fnp-6382	140	14	contributed	contribute	VERB
fnp-6382	140	15	to	to	ADP
fnp-6382	140	16	individualized	individualized	ADJ
fnp-6382	140	17	differences	difference	NOUN
fnp-6382	140	18	in	in	ADP
fnp-6382	140	19	ccl11	ccl11	NOUN
fnp-6382	140	20	within	within	ADP
fnp-6382	140	21	the	the	DET
fnp-6382	140	22	head	head	NOUN
fnp-6382	140	23	trauma	trauma	NOUN
fnp-6382	140	24	group	group	NOUN
fnp-6382	140	25	.	.	PUNCT
fnp-6382	141	1	although	although	SCONJ
fnp-6382	141	2	not	not	PART
fnp-6382	141	3	elevated	elevate	VERB
fnp-6382	141	4	from	from	ADP
fnp-6382	141	5	baseline	baseline	NOUN
fnp-6382	141	6	,	,	PUNCT
fnp-6382	141	7	plasma	plasma	NOUN
fnp-6382	141	8	ccl11	ccl11	NOUN
fnp-6382	141	9	levels	level	NOUN
fnp-6382	141	10	at	at	ADP
fnp-6382	141	11	24	24	NUM
fnp-6382	141	12	hours	hour	NOUN
fnp-6382	141	13	post	post	ADJ
fnp-6382	141	14	-	-	ADJ
fnp-6382	141	15	exposure	exposure	NOUN
fnp-6382	141	16	were	be	AUX
fnp-6382	141	17	positively	positively	ADV
fnp-6382	141	18	associated	associate	VERB
fnp-6382	141	19	with	with	ADP
fnp-6382	141	20	years	year	NOUN
fnp-6382	141	21	of	of	ADP
fnp-6382	141	22	heading	head	VERB
fnp-6382	141	23	experience	experience	NOUN
fnp-6382	141	24	,	,	PUNCT
fnp-6382	141	25	with	with	ADP
fnp-6382	141	26	an	an	DET
fnp-6382	141	27	estimated	estimate	VERB
fnp-6382	141	28	2.0	2.0	NUM
fnp-6382	141	29	pg	pg	NOUN
fnp-6382	141	30	/	/	SYM
fnp-6382	141	31	ml	ml	NOUN
fnp-6382	141	32	increase	increase	VERB
fnp-6382	141	33	per	per	ADP
fnp-6382	141	34	year	year	NOUN
fnp-6382	141	35	of	of	ADP
fnp-6382	141	36	exposure	exposure	NOUN
fnp-6382	141	37	.	.	PUNCT
fnp-6382	142	1	this	this	PRON
fnp-6382	142	2	suggests	suggest	VERB
fnp-6382	142	3	a	a	DET
fnp-6382	142	4	unique	unique	ADJ
fnp-6382	142	5	sensitivity	sensitivity	NOUN
fnp-6382	142	6	to	to	PART
fnp-6382	142	7	cumulative	cumulative	VERB
fnp-6382	142	8	rather	rather	ADV
fnp-6382	142	9	than	than	ADP
fnp-6382	142	10	acute	acute	ADJ
fnp-6382	142	11	rhi	rhi	PROPN
fnp-6382	142	12	exposure	exposure	NOUN
fnp-6382	142	13	(	(	PUNCT
fnp-6382	142	14	54	54	NUM
fnp-6382	142	15	)	)	PUNCT
fnp-6382	142	16	.	.	PUNCT
fnp-6382	143	1	however	however	ADV
fnp-6382	143	2	,	,	PUNCT
fnp-6382	143	3	there	there	PRON
fnp-6382	143	4	are	be	VERB
fnp-6382	143	5	several	several	ADJ
fnp-6382	143	6	challenges	challenge	NOUN
fnp-6382	143	7	with	with	ADP
fnp-6382	143	8	using	use	VERB
fnp-6382	143	9	ccl11	ccl11	NOUN
fnp-6382	143	10	as	as	ADP
fnp-6382	143	11	a	a	DET
fnp-6382	143	12	biomarker	biomarker	NOUN
fnp-6382	143	13	for	for	ADP
fnp-6382	143	14	cte	cte	NOUN
fnp-6382	143	15	.	.	PUNCT
fnp-6382	144	1	while	while	SCONJ
fnp-6382	144	2	some	some	DET
fnp-6382	144	3	studies	study	NOUN
fnp-6382	144	4	have	have	AUX
fnp-6382	144	5	observed	observe	VERB
fnp-6382	144	6	more	more	ADV
fnp-6382	144	7	specific	specific	ADJ
fnp-6382	144	8	expression	expression	NOUN
fnp-6382	144	9	in	in	ADP
fnp-6382	144	10	the	the	DET
fnp-6382	144	11	context	context	NOUN
fnp-6382	144	12	of	of	ADP
fnp-6382	144	13	head	head	NOUN
fnp-6382	144	14	trauma	trauma	NOUN
fnp-6382	144	15	,	,	PUNCT
fnp-6382	144	16	other	other	ADJ
fnp-6382	144	17	studies	study	NOUN
fnp-6382	144	18	have	have	AUX
fnp-6382	144	19	demonstrated	demonstrate	VERB
fnp-6382	144	20	elevated	elevated	ADJ
fnp-6382	144	21	levels	level	NOUN
fnp-6382	144	22	in	in	ADP
fnp-6382	144	23	ad	ad	NOUN
fnp-6382	144	24	,	,	PUNCT
fnp-6382	144	25	huntington	huntington	PROPN
fnp-6382	144	26	’s	’s	PART
fnp-6382	144	27	disease	disease	NOUN
fnp-6382	144	28	,	,	PUNCT
fnp-6382	144	29	and	and	CCONJ
fnp-6382	144	30	stroke	stroke	NOUN
fnp-6382	144	31	(	(	PUNCT
fnp-6382	144	32	55–57	55–57	NUM
fnp-6382	144	33	)	)	PUNCT
fnp-6382	144	34	.	.	PUNCT
fnp-6382	145	1	additionally	additionally	ADV
fnp-6382	145	2	,	,	PUNCT
fnp-6382	145	3	ccl11	ccl11	PROPN
fnp-6382	145	4	has	have	AUX
fnp-6382	145	5	also	also	ADV
fnp-6382	145	6	been	be	AUX
fnp-6382	145	7	implicated	implicate	VERB
fnp-6382	145	8	in	in	ADP
fnp-6382	145	9	normal	normal	ADJ
fnp-6382	145	10	aging	aging	NOUN
fnp-6382	145	11	,	,	PUNCT
fnp-6382	145	12	which	which	PRON
fnp-6382	145	13	complicates	complicate	VERB
fnp-6382	145	14	its	its	PRON
fnp-6382	145	15	use	use	NOUN
fnp-6382	145	16	in	in	ADP
fnp-6382	145	17	older	old	ADJ
fnp-6382	145	18	subjects	subject	NOUN
fnp-6382	145	19	(	(	PUNCT
fnp-6382	145	20	58	58	NUM
fnp-6382	145	21	)	)	PUNCT
fnp-6382	145	22	.	.	PUNCT
fnp-6382	146	1	furthermore	furthermore	ADV
fnp-6382	146	2	,	,	PUNCT
fnp-6382	146	3	some	some	DET
fnp-6382	146	4	studies	study	NOUN
fnp-6382	146	5	have	have	AUX
fnp-6382	146	6	not	not	PART
fnp-6382	146	7	observed	observe	VERB
fnp-6382	146	8	increases	increase	NOUN
fnp-6382	146	9	in	in	ADP
fnp-6382	146	10	ccl11	ccl11	NOUN
fnp-6382	146	11	in	in	ADP
fnp-6382	146	12	the	the	DET
fnp-6382	146	13	context	context	NOUN
fnp-6382	146	14	of	of	ADP
fnp-6382	146	15	cte	cte	PROPN
fnp-6382	146	16	.	.	PUNCT
fnp-6382	147	1	in	in	ADP
fnp-6382	147	2	a	a	DET
fnp-6382	147	3	post	post	ADJ
fnp-6382	147	4	-	-	ADJ
fnp-6382	147	5	mortem	mortem	ADJ
fnp-6382	147	6	analysis	analysis	NOUN
fnp-6382	147	7	of	of	ADP
fnp-6382	147	8	vitreous	vitreous	ADJ
fnp-6382	147	9	humor	humor	NOUN
fnp-6382	147	10	,	,	PUNCT
fnp-6382	147	11	samples	sample	NOUN
fnp-6382	147	12	from	from	ADP
fnp-6382	147	13	cte	cte	NOUN
fnp-6382	147	14	subjects	subject	NOUN
fnp-6382	147	15	did	do	AUX
fnp-6382	147	16	not	not	PART
fnp-6382	147	17	show	show	VERB
fnp-6382	147	18	significantly	significantly	ADV
fnp-6382	147	19	elevated	elevated	ADJ
fnp-6382	147	20	levels	level	NOUN
fnp-6382	147	21	of	of	ADP
fnp-6382	147	22	ccl11	ccl11	NOUN
fnp-6382	147	23	compared	compare	VERB
fnp-6382	147	24	to	to	ADP
fnp-6382	147	25	ad	ad	NOUN
fnp-6382	147	26	or	or	CCONJ
fnp-6382	147	27	healthy	healthy	ADJ
fnp-6382	147	28	controls	control	NOUN
fnp-6382	147	29	,	,	PUNCT
fnp-6382	147	30	nor	nor	CCONJ
fnp-6382	147	31	were	be	AUX
fnp-6382	147	32	there	there	PRON
fnp-6382	147	33	differences	difference	NOUN
fnp-6382	147	34	in	in	ADP
fnp-6382	147	35	ccl11	ccl11	NOUN
fnp-6382	147	36	levels	level	NOUN
fnp-6382	147	37	across	across	ADP
fnp-6382	147	38	cte	cte	NOUN
fnp-6382	147	39	stages	stage	NOUN
fnp-6382	147	40	(	(	PUNCT
fnp-6382	147	41	59	59	NUM
fnp-6382	147	42	)	)	PUNCT
fnp-6382	147	43	.	.	PUNCT
fnp-6382	148	1	there	there	PRON
fnp-6382	148	2	was	be	VERB
fnp-6382	148	3	only	only	ADV
fnp-6382	148	4	a	a	DET
fnp-6382	148	5	significant	significant	ADJ
fnp-6382	148	6	increase	increase	NOUN
fnp-6382	148	7	of	of	ADP
fnp-6382	148	8	ccl11	ccl11	NOUN
fnp-6382	148	9	in	in	ADP
fnp-6382	148	10	samples	sample	NOUN
fnp-6382	148	11	from	from	ADP
fnp-6382	148	12	subjects	subject	NOUN
fnp-6382	148	13	with	with	ADP
fnp-6382	148	14	both	both	CCONJ
fnp-6382	148	15	ad	ad	NOUN
fnp-6382	148	16	and	and	CCONJ
fnp-6382	148	17	cte	cte	NOUN
fnp-6382	148	18	pathology	pathology	NOUN
fnp-6382	148	19	when	when	SCONJ
fnp-6382	148	20	compared	compare	VERB
fnp-6382	148	21	to	to	ADP
fnp-6382	148	22	controls	control	NOUN
fnp-6382	148	23	,	,	PUNCT
fnp-6382	148	24	suggesting	suggest	VERB
fnp-6382	148	25	possible	possible	ADJ
fnp-6382	148	26	synergistic	synergistic	ADJ
fnp-6382	148	27	effects	effect	NOUN
fnp-6382	148	28	when	when	SCONJ
fnp-6382	148	29	cte	cte	PROPN
fnp-6382	148	30	co	co	NOUN
fnp-6382	148	31	-	-	VERB
fnp-6382	148	32	occurs	occur	VERB
fnp-6382	148	33	with	with	ADP
fnp-6382	148	34	other	other	ADJ
fnp-6382	148	35	neurodegenerative	neurodegenerative	ADJ
fnp-6382	148	36	pathologies	pathology	NOUN
fnp-6382	148	37	.	.	PUNCT
fnp-6382	149	1	although	although	SCONJ
fnp-6382	149	2	these	these	DET
fnp-6382	149	3	results	result	NOUN
fnp-6382	149	4	were	be	AUX
fnp-6382	149	5	found	find	VERB
fnp-6382	149	6	in	in	ADP
fnp-6382	149	7	the	the	DET
fnp-6382	149	8	context	context	NOUN
fnp-6382	149	9	of	of	ADP
fnp-6382	149	10	vitreous	vitreous	ADJ
fnp-6382	149	11	humor	humor	NOUN
fnp-6382	149	12	,	,	PUNCT
fnp-6382	149	13	it	it	PRON
fnp-6382	149	14	will	will	AUX
fnp-6382	149	15	be	be	AUX
fnp-6382	149	16	important	important	ADJ
fnp-6382	149	17	to	to	PART
fnp-6382	149	18	validate	validate	VERB
fnp-6382	149	19	ccl11	ccl11	NOUN
fnp-6382	149	20	levels	level	NOUN
fnp-6382	149	21	in	in	ADP
fnp-6382	149	22	csf	csf	NOUN
fnp-6382	149	23	or	or	CCONJ
fnp-6382	149	24	plasma	plasma	NOUN
fnp-6382	149	25	in	in	ADP
fnp-6382	149	26	more	more	ADV
fnp-6382	149	27	independent	independent	ADJ
fnp-6382	149	28	cohorts	cohort	NOUN
fnp-6382	149	29	.	.	PUNCT
fnp-6382	150	1	ccl21	ccl21	NOUN
fnp-6382	150	2	ccl21	ccl21	NOUN
fnp-6382	150	3	or	or	CCONJ
fnp-6382	150	4	6ckine	6ckine	NUM
fnp-6382	150	5	,	,	PUNCT
fnp-6382	150	6	is	be	AUX
fnp-6382	150	7	a	a	DET
fnp-6382	150	8	chemokine	chemokine	ADJ
fnp-6382	150	9	involved	involve	VERB
fnp-6382	150	10	in	in	ADP
fnp-6382	150	11	mediating	mediate	VERB
fnp-6382	150	12	the	the	DET
fnp-6382	150	13	migration	migration	NOUN
fnp-6382	150	14	of	of	ADP
fnp-6382	150	15	ccr7	ccr7	NOUN
fnp-6382	150	16	-	-	PUNCT
fnp-6382	150	17	expressing	express	VERB
fnp-6382	150	18	immune	immune	ADJ
fnp-6382	150	19	cells	cell	NOUN
fnp-6382	150	20	i.e.	i.e.	X
fnp-6382	150	21	,	,	PUNCT
fnp-6382	150	22	t	t	NOUN
fnp-6382	150	23	-	-	PUNCT
fnp-6382	150	24	cells	cell	NOUN
fnp-6382	150	25	and	and	CCONJ
fnp-6382	150	26	dendritic	dendritic	ADJ
fnp-6382	150	27	cells	cell	NOUN
fnp-6382	150	28	to	to	PART
fnp-6382	150	29	lymphoid	lymphoid	VERB
fnp-6382	150	30	organs	organ	NOUN
fnp-6382	150	31	.	.	PUNCT
fnp-6382	151	1	in	in	ADP
fnp-6382	151	2	the	the	DET
fnp-6382	151	3	cns	cns	NOUN
fnp-6382	151	4	,	,	PUNCT
fnp-6382	151	5	ccl21	ccl21	PROPN
fnp-6382	151	6	may	may	AUX
fnp-6382	151	7	be	be	AUX
fnp-6382	151	8	upregulated	upregulate	VERB
fnp-6382	151	9	,	,	PUNCT
fnp-6382	151	10	facilitating	facilitate	VERB
fnp-6382	151	11	lymphocyte	lymphocyte	ADJ
fnp-6382	151	12	migration	migration	NOUN
fnp-6382	151	13	through	through	ADP
fnp-6382	151	14	the	the	DET
fnp-6382	151	15	bbb	bbb	PROPN
fnp-6382	151	16	(	(	PUNCT
fnp-6382	151	17	60	60	NUM
fnp-6382	151	18	)	)	PUNCT
fnp-6382	151	19	.	.	PUNCT
fnp-6382	152	1	using	use	VERB
fnp-6382	152	2	an	an	DET
fnp-6382	152	3	elisa	elisa	NOUN
fnp-6382	152	4	panel	panel	NOUN
fnp-6382	152	5	of	of	ADP
fnp-6382	152	6	71	71	NUM
fnp-6382	152	7	immune	immune	ADJ
fnp-6382	152	8	proteins	protein	NOUN
fnp-6382	152	9	to	to	PART
fnp-6382	152	10	examine	examine	VERB
fnp-6382	152	11	anterior	anterior	ADJ
fnp-6382	152	12	cingulate	cingulate	NOUN
fnp-6382	152	13	grey	grey	PROPN
fnp-6382	152	14	matter	matter	NOUN
fnp-6382	152	15	samples	sample	NOUN
fnp-6382	152	16	from	from	ADP
fnp-6382	152	17	patients	patient	NOUN
fnp-6382	152	18	with	with	ADP
fnp-6382	152	19	various	various	ADJ
fnp-6382	152	20	tauopathies	tauopathie	NOUN
fnp-6382	152	21	,	,	PUNCT
fnp-6382	152	22	cherry	cherry	PROPN
fnp-6382	152	23	et	et	PROPN
fnp-6382	152	24	al	al	AUX
fnp-6382	152	25	.	.	PROPN
fnp-6382	152	26	determined	determine	VERB
fnp-6382	152	27	that	that	SCONJ
fnp-6382	152	28	ccl21	ccl21	PROPN
fnp-6382	152	29	was	be	AUX
fnp-6382	152	30	most	most	ADV
fnp-6382	152	31	strongly	strongly	ADV
fnp-6382	152	32	correlated	correlate	VERB
fnp-6382	152	33	with	with	ADP
fnp-6382	152	34	the	the	DET
fnp-6382	152	35	cte	cte	NOUN
fnp-6382	152	36	-	-	PUNCT
fnp-6382	152	37	confirmed	confirm	VERB
fnp-6382	152	38	cases	case	NOUN
fnp-6382	152	39	,	,	PUNCT
fnp-6382	152	40	suggesting	suggest	VERB
fnp-6382	152	41	some	some	DET
fnp-6382	152	42	specificity	specificity	NOUN
fnp-6382	152	43	to	to	PART
fnp-6382	152	44	cte	cte	VERB
fnp-6382	152	45	pathogenesis	pathogenesis	NOUN
fnp-6382	152	46	(	(	PUNCT
fnp-6382	152	47	22	22	NUM
fnp-6382	152	48	)	)	PUNCT
fnp-6382	152	49	.	.	PUNCT
fnp-6382	153	1	cherry	cherry	NOUN
fnp-6382	153	2	et	et	PROPN
fnp-6382	153	3	al	al	PROPN
fnp-6382	153	4	.	.	PROPN
fnp-6382	153	5	also	also	ADV
fnp-6382	153	6	examined	examine	VERB
fnp-6382	153	7	ccl21	ccl21	NOUN
fnp-6382	153	8	levels	level	NOUN
fnp-6382	153	9	between	between	ADP
fnp-6382	153	10	cte	cte	NOUN
fnp-6382	153	11	-	-	PUNCT
fnp-6382	153	12	confirmed	confirm	VERB
fnp-6382	153	13	and	and	CCONJ
fnp-6382	153	14	ad	ad	NOUN
fnp-6382	153	15	-	-	PUNCT
fnp-6382	153	16	confirmed	confirm	VERB
fnp-6382	153	17	subjects	subject	NOUN
fnp-6382	153	18	via	via	ADP
fnp-6382	153	19	post	post	ADJ
fnp-6382	153	20	-	-	ADJ
fnp-6382	153	21	mortem	mortem	ADJ
fnp-6382	153	22	csf	csf	ADJ
fnp-6382	153	23	analysis	analysis	NOUN
fnp-6382	153	24	,	,	PUNCT
fnp-6382	153	25	showing	show	VERB
fnp-6382	153	26	that	that	SCONJ
fnp-6382	153	27	there	there	PRON
fnp-6382	153	28	was	be	VERB
fnp-6382	153	29	a	a	DET
fnp-6382	153	30	significant	significant	ADJ
fnp-6382	153	31	elevation	elevation	NOUN
fnp-6382	153	32	of	of	ADP
fnp-6382	153	33	ccl21	ccl21	NOUN
fnp-6382	153	34	levels	level	NOUN
fnp-6382	153	35	in	in	ADP
fnp-6382	153	36	ad	ad	NOUN
fnp-6382	153	37	(	(	PUNCT
fnp-6382	153	38	22	22	NUM
fnp-6382	153	39	)	)	PUNCT
fnp-6382	153	40	.	.	PUNCT
fnp-6382	154	1	an	an	DET
fnp-6382	154	2	important	important	ADJ
fnp-6382	154	3	caveat	caveat	NOUN
fnp-6382	154	4	of	of	ADP
fnp-6382	154	5	this	this	DET
fnp-6382	154	6	study	study	NOUN
fnp-6382	154	7	was	be	AUX
fnp-6382	154	8	that	that	SCONJ
fnp-6382	154	9	it	it	PRON
fnp-6382	154	10	only	only	ADV
fnp-6382	154	11	assessed	assess	VERB
fnp-6382	154	12	the	the	DET
fnp-6382	154	13	difference	difference	NOUN
fnp-6382	154	14	between	between	ADP
fnp-6382	154	15	different	different	ADJ
fnp-6382	154	16	types	type	NOUN
fnp-6382	154	17	of	of	ADP
fnp-6382	154	18	tauopathies	tauopathie	NOUN
fnp-6382	154	19	and	and	CCONJ
fnp-6382	154	20	did	do	AUX
fnp-6382	154	21	not	not	PART
fnp-6382	154	22	include	include	VERB
fnp-6382	154	23	non	non	ADJ
fnp-6382	154	24	-	-	ADJ
fnp-6382	154	25	disease	disease	ADJ
fnp-6382	154	26	control	control	NOUN
fnp-6382	154	27	cases	case	NOUN
fnp-6382	154	28	.	.	PUNCT
fnp-6382	155	1	however	however	ADV
fnp-6382	155	2	,	,	PUNCT
fnp-6382	155	3	the	the	DET
fnp-6382	155	4	findings	finding	NOUN
fnp-6382	155	5	suggest	suggest	VERB
fnp-6382	155	6	ccl21	ccl21	NOUN
fnp-6382	155	7	might	might	AUX
fnp-6382	155	8	be	be	AUX
fnp-6382	155	9	useful	useful	ADJ
fnp-6382	155	10	to	to	PART
fnp-6382	155	11	help	help	VERB
fnp-6382	155	12	better	well	ADV
fnp-6382	155	13	segregate	segregate	VERB
fnp-6382	155	14	related	related	ADJ
fnp-6382	155	15	neuropathologies	neuropathologie	NOUN
fnp-6382	155	16	.	.	PUNCT
fnp-6382	156	1	elevated	elevated	ADJ
fnp-6382	156	2	ccl21	ccl21	NOUN
fnp-6382	156	3	levels	level	NOUN
fnp-6382	156	4	may	may	AUX
fnp-6382	156	5	not	not	PART
fnp-6382	156	6	only	only	ADV
fnp-6382	156	7	assist	assist	VERB
fnp-6382	156	8	with	with	ADP
fnp-6382	156	9	determining	determine	VERB
fnp-6382	156	10	suspected	suspect	VERB
fnp-6382	156	11	cte	cte	NOUN
fnp-6382	156	12	,	,	PUNCT
fnp-6382	156	13	but	but	CCONJ
fnp-6382	156	14	can	can	AUX
fnp-6382	156	15	also	also	ADV
fnp-6382	156	16	be	be	AUX
fnp-6382	156	17	a	a	DET
fnp-6382	156	18	point	point	NOUN
fnp-6382	156	19	of	of	ADP
fnp-6382	156	20	future	future	ADJ
fnp-6382	156	21	investigation	investigation	NOUN
fnp-6382	156	22	in	in	ADP
fnp-6382	156	23	determining	determine	VERB
fnp-6382	156	24	how	how	SCONJ
fnp-6382	156	25	the	the	DET
fnp-6382	156	26	pathophysiology	pathophysiology	NOUN
fnp-6382	156	27	of	of	ADP
fnp-6382	156	28	cte	cte	NOUN
fnp-6382	156	29	might	might	AUX
fnp-6382	156	30	differ	differ	VERB
fnp-6382	156	31	from	from	ADP
fnp-6382	156	32	mechanisms	mechanism	NOUN
fnp-6382	156	33	seen	see	VERB
fnp-6382	156	34	in	in	ADP
fnp-6382	156	35	other	other	ADJ
fnp-6382	156	36	tauopathies	tauopathie	NOUN
fnp-6382	156	37	.	.	PUNCT
fnp-6382	157	1	given	give	VERB
fnp-6382	157	2	its	its	PRON
fnp-6382	157	3	known	know	VERB
fnp-6382	157	4	role	role	NOUN
fnp-6382	157	5	in	in	ADP
fnp-6382	157	6	trafficking	traffic	VERB
fnp-6382	157	7	immune	immune	ADJ
fnp-6382	157	8	cells	cell	NOUN
fnp-6382	157	9	across	across	ADP
fnp-6382	157	10	the	the	DET
fnp-6382	157	11	bbb	bbb	NOUN
fnp-6382	157	12	to	to	PART
fnp-6382	157	13	propagate	propagate	VERB
fnp-6382	157	14	inflammation	inflammation	NOUN
fnp-6382	157	15	,	,	PUNCT
fnp-6382	157	16	in	in	ADP
fnp-6382	157	17	addition	addition	NOUN
fnp-6382	157	18	to	to	ADP
fnp-6382	157	19	its	its	PRON
fnp-6382	157	20	demonstrated	demonstrate	VERB
fnp-6382	157	21	specificity	specificity	NOUN
fnp-6382	157	22	to	to	ADP
fnp-6382	157	23	cte	cte	PROPN
fnp-6382	157	24	,	,	PUNCT
fnp-6382	157	25	ccl21	ccl21	PROPN
fnp-6382	157	26	may	may	AUX
fnp-6382	157	27	contribute	contribute	VERB
fnp-6382	157	28	directly	directly	ADV
fnp-6382	157	29	to	to	ADP
fnp-6382	157	30	early	early	ADJ
fnp-6382	157	31	immune	immune	ADJ
fnp-6382	157	32	activation	activation	NOUN
fnp-6382	157	33	and	and	CCONJ
fnp-6382	157	34	subsequent	subsequent	ADJ
fnp-6382	157	35	cte	cte	NOUN
fnp-6382	157	36	pathogenesis	pathogenesis	NOUN
fnp-6382	157	37	.	.	PUNCT
fnp-6382	158	1	as	as	SCONJ
fnp-6382	158	2	such	such	ADJ
fnp-6382	158	3	,	,	PUNCT
fnp-6382	158	4	future	future	ADJ
fnp-6382	158	5	research	research	NOUN
fnp-6382	158	6	should	should	AUX
fnp-6382	158	7	investigate	investigate	VERB
fnp-6382	158	8	whether	whether	SCONJ
fnp-6382	158	9	ccl21	ccl21	NOUN
fnp-6382	158	10	expression	expression	NOUN
fnp-6382	158	11	is	be	AUX
fnp-6382	158	12	elevated	elevate	VERB
fnp-6382	158	13	during	during	ADP
fnp-6382	158	14	early	early	ADJ
fnp-6382	158	15	stages	stage	NOUN
fnp-6382	158	16	of	of	ADP
fnp-6382	158	17	cte	cte	NOUN
fnp-6382	158	18	,	,	PUNCT
fnp-6382	158	19	as	as	SCONJ
fnp-6382	158	20	this	this	PRON
fnp-6382	158	21	could	could	AUX
fnp-6382	158	22	clarify	clarify	VERB
fnp-6382	158	23	its	its	PRON
fnp-6382	158	24	role	role	NOUN
fnp-6382	158	25	in	in	ADP
fnp-6382	158	26	initiating	initiate	VERB
fnp-6382	158	27	or	or	CCONJ
fnp-6382	158	28	sustaining	sustain	VERB
fnp-6382	158	29	pathology	pathology	NOUN
fnp-6382	158	30	.	.	PUNCT
fnp-6382	159	1	there	there	PRON
fnp-6382	159	2	are	be	VERB
fnp-6382	159	3	sparse	sparse	ADJ
fnp-6382	159	4	studies	study	NOUN
fnp-6382	159	5	examining	examine	VERB
fnp-6382	159	6	ccl21	ccl21	NOUN
fnp-6382	159	7	in	in	ADP
fnp-6382	159	8	the	the	DET
fnp-6382	159	9	specific	specific	ADJ
fnp-6382	159	10	context	context	NOUN
fnp-6382	159	11	of	of	ADP
fnp-6382	159	12	head	head	NOUN
fnp-6382	159	13	trauma	trauma	NOUN
fnp-6382	159	14	,	,	PUNCT
fnp-6382	159	15	especially	especially	ADV
fnp-6382	159	16	in	in	ADP
fnp-6382	159	17	humans	human	NOUN
fnp-6382	159	18	.	.	PUNCT
fnp-6382	160	1	in	in	ADP
fnp-6382	160	2	fact	fact	NOUN
fnp-6382	160	3	,	,	PUNCT
fnp-6382	160	4	the	the	DET
fnp-6382	160	5	existing	exist	VERB
fnp-6382	160	6	neurotrauma	neurotrauma	PROPN
fnp-6382	160	7	data	datum	NOUN
fnp-6382	160	8	on	on	ADP
fnp-6382	160	9	ccl21	ccl21	NOUN
fnp-6382	160	10	primarily	primarily	ADV
fnp-6382	160	11	stems	stem	VERB
fnp-6382	160	12	from	from	ADP
fnp-6382	160	13	animal	animal	NOUN
fnp-6382	160	14	model	model	NOUN
fnp-6382	160	15	studies	study	NOUN
fnp-6382	160	16	on	on	ADP
fnp-6382	160	17	spinal	spinal	ADJ
fnp-6382	160	18	cord	cord	NOUN
fnp-6382	160	19	injury	injury	NOUN
fnp-6382	160	20	(	(	PUNCT
fnp-6382	160	21	sci	sci	PROPN
fnp-6382	160	22	)	)	PUNCT
fnp-6382	160	23	(	(	PUNCT
fnp-6382	160	24	61,62	61,62	NOUN
fnp-6382	160	25	)	)	PUNCT
fnp-6382	160	26	.	.	PUNCT
fnp-6382	161	1	of	of	ADP
fnp-6382	161	2	note	note	NOUN
fnp-6382	161	3	,	,	PUNCT
fnp-6382	161	4	one	one	NUM
fnp-6382	161	5	human	human	NOUN
fnp-6382	161	6	-	-	PUNCT
fnp-6382	161	7	based	base	VERB
fnp-6382	161	8	study	study	NOUN
fnp-6382	161	9	on	on	ADP
fnp-6382	161	10	sci	sci	PROPN
fnp-6382	161	11	exists	exist	VERB
fnp-6382	161	12	to	to	ADP
fnp-6382	161	13	date	date	NOUN
fnp-6382	161	14	,	,	PUNCT
fnp-6382	161	15	reporting	report	VERB
fnp-6382	161	16	a	a	DET
fnp-6382	161	17	negative	negative	ADJ
fnp-6382	161	18	correlation	correlation	NOUN
fnp-6382	161	19	between	between	ADP
fnp-6382	161	20	serum	serum	NOUN
fnp-6382	161	21	levels	level	NOUN
fnp-6382	161	22	of	of	ADP
fnp-6382	161	23	ccl21	ccl21	PROPN
fnp-6382	161	24	and	and	CCONJ
fnp-6382	161	25	neuropsychological	neuropsychological	ADJ
fnp-6382	161	26	test	test	NOUN
fnp-6382	161	27	scores	score	NOUN
fnp-6382	161	28	in	in	ADP
fnp-6382	161	29	sci	sci	PROPN
fnp-6382	161	30	patients	patient	NOUN
fnp-6382	161	31	,	,	PUNCT
fnp-6382	161	32	suggesting	suggest	VERB
fnp-6382	161	33	ccl21	ccl21	NOUN
fnp-6382	161	34	as	as	ADP
fnp-6382	161	35	a	a	DET
fnp-6382	161	36	possible	possible	ADJ
fnp-6382	161	37	correlate	correlate	NOUN
fnp-6382	161	38	for	for	ADP
fnp-6382	161	39	post	post	ADJ
fnp-6382	161	40	-	-	ADJ
fnp-6382	161	41	injury	injury	ADJ
fnp-6382	161	42	cognitive	cognitive	ADJ
fnp-6382	161	43	dysfunction	dysfunction	NOUN
fnp-6382	161	44	(	(	PUNCT
fnp-6382	161	45	63	63	NUM
fnp-6382	161	46	)	)	PUNCT
fnp-6382	161	47	.	.	PUNCT
fnp-6382	162	1	consequently	consequently	ADV
fnp-6382	162	2	,	,	PUNCT
fnp-6382	162	3	this	this	DET
fnp-6382	162	4	gap	gap	NOUN
fnp-6382	162	5	in	in	ADP
fnp-6382	162	6	the	the	DET
fnp-6382	162	7	literature	literature	NOUN
fnp-6382	162	8	highlights	highlight	NOUN
fnp-6382	162	9	the	the	DET
fnp-6382	162	10	need	need	NOUN
fnp-6382	162	11	for	for	ADP
fnp-6382	162	12	future	future	ADJ
fnp-6382	162	13	studies	study	NOUN
fnp-6382	162	14	assessing	assess	VERB
fnp-6382	162	15	bio	bio	ADJ
fnp-6382	162	16	-	-	ADJ
fnp-6382	162	17	fluid	fluid	ADJ
fnp-6382	162	18	levels	level	NOUN
fnp-6382	162	19	of	of	ADP
fnp-6382	162	20	ccl21	ccl21	NOUN
fnp-6382	162	21	in	in	ADP
fnp-6382	162	22	relation	relation	NOUN
fnp-6382	162	23	to	to	PART
fnp-6382	162	24	head	head	VERB
fnp-6382	162	25	trauma	trauma	NOUN
fnp-6382	162	26	,	,	PUNCT
fnp-6382	162	27	particularly	particularly	ADV
fnp-6382	162	28	in	in	ADP
fnp-6382	162	29	living	live	VERB
fnp-6382	162	30	subjects	subject	NOUN
fnp-6382	162	31	with	with	ADP
fnp-6382	162	32	rhi	rhi	PROPN
fnp-6382	162	33	exposure	exposure	NOUN
fnp-6382	162	34	and	and	CCONJ
fnp-6382	162	35	during	during	ADP
fnp-6382	162	36	post	post	ADJ
fnp-6382	162	37	-	-	ADJ
fnp-6382	162	38	mortem	mortem	ADJ
fnp-6382	162	39	evaluation	evaluation	NOUN
fnp-6382	162	40	.	.	PUNCT
fnp-6382	163	1	il-6	il-6	PRON
fnp-6382	164	1	il-6	il-6	NOUN
fnp-6382	164	2	is	be	AUX
fnp-6382	164	3	a	a	DET
fnp-6382	164	4	multifunctional	multifunctional	ADJ
fnp-6382	164	5	cytokine	cytokine	NOUN
fnp-6382	164	6	critically	critically	ADV
fnp-6382	164	7	involved	involve	VERB
fnp-6382	164	8	in	in	ADP
fnp-6382	164	9	the	the	DET
fnp-6382	164	10	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	164	11	cascade	cascade	NOUN
fnp-6382	164	12	.	.	PUNCT
fnp-6382	165	1	in	in	ADP
fnp-6382	165	2	the	the	DET
fnp-6382	165	3	cns	cns	NOUN
fnp-6382	165	4	,	,	PUNCT
fnp-6382	165	5	il-6	il-6	PRON
fnp-6382	165	6	is	be	AUX
fnp-6382	165	7	produced	produce	VERB
fnp-6382	165	8	primarily	primarily	ADV
fnp-6382	165	9	by	by	ADP
fnp-6382	165	10	activated	activate	VERB
fnp-6382	165	11	microglia	microglia	NOUN
fnp-6382	165	12	and	and	CCONJ
fnp-6382	165	13	astrocytes	astrocyte	NOUN
fnp-6382	165	14	following	follow	VERB
fnp-6382	165	15	trauma	trauma	NOUN
fnp-6382	165	16	,	,	PUNCT
fnp-6382	165	17	where	where	SCONJ
fnp-6382	165	18	it	it	PRON
fnp-6382	165	19	promotes	promote	VERB
fnp-6382	165	20	leukocyte	leukocyte	NOUN
fnp-6382	165	21	migration	migration	NOUN
fnp-6382	165	22	and	and	CCONJ
fnp-6382	165	23	cytokine	cytokine	NOUN
fnp-6382	165	24	signaling	signal	VERB
fnp-6382	165	25	(	(	PUNCT
fnp-6382	165	26	64,65	64,65	NOUN
fnp-6382	165	27	)	)	PUNCT
fnp-6382	165	28	.	.	PUNCT
fnp-6382	166	1	a	a	DET
fnp-6382	166	2	recent	recent	ADJ
fnp-6382	166	3	investigation	investigation	NOUN
fnp-6382	166	4	used	use	VERB
fnp-6382	166	5	a	a	DET
fnp-6382	166	6	csf	csf	ADJ
fnp-6382	166	7	immunoassay	immunoassay	NOUN
fnp-6382	166	8	on	on	ADP
fnp-6382	166	9	retired	retire	VERB
fnp-6382	166	10	football	football	NOUN
fnp-6382	166	11	players	player	NOUN
fnp-6382	166	12	for	for	ADP
fnp-6382	166	13	inflammatory	inflammatory	ADJ
fnp-6382	166	14	proteins	protein	NOUN
fnp-6382	166	15	including	include	VERB
fnp-6382	166	16	il-1β	il-1β	PROPN
fnp-6382	166	17	,	,	PUNCT
fnp-6382	166	18	il-6	il-6	NOUN
fnp-6382	166	19	,	,	PUNCT
fnp-6382	166	20	il-8	il-8	NOUN
fnp-6382	166	21	,	,	PUNCT
fnp-6382	166	22	il-10	il-10	PRON
fnp-6382	166	23	,	,	PUNCT
fnp-6382	166	24	tnf	tnf	PROPN
fnp-6382	166	25	-	-	PUNCT
fnp-6382	166	26	α	α	PROPN
fnp-6382	166	27	,	,	PUNCT
fnp-6382	166	28	and	and	CCONJ
fnp-6382	166	29	c	c	NOUN
fnp-6382	166	30	-	-	PUNCT
fnp-6382	166	31	reactive	reactive	ADJ
fnp-6382	166	32	protein	protein	NOUN
fnp-6382	166	33	.	.	PUNCT
fnp-6382	167	1	of	of	ADP
fnp-6382	167	2	these	these	DET
fnp-6382	167	3	markers	marker	NOUN
fnp-6382	167	4	,	,	PUNCT
fnp-6382	167	5	only	only	ADV
fnp-6382	167	6	il-6	il-6	NUM
fnp-6382	167	7	was	be	AUX
fnp-6382	167	8	significantly	significantly	ADV
fnp-6382	167	9	elevated	elevate	VERB
fnp-6382	167	10	in	in	ADP
fnp-6382	167	11	subjects	subject	NOUN
fnp-6382	167	12	who	who	PRON
fnp-6382	167	13	had	have	VERB
fnp-6382	167	14	neurobehavioral	neurobehavioral	ADJ
fnp-6382	167	15	dysregulation	dysregulation	NOUN
fnp-6382	167	16	(	(	PUNCT
fnp-6382	167	17	nbd	nbd	PROPN
fnp-6382	167	18	)	)	PUNCT
fnp-6382	167	19	,	,	PUNCT
fnp-6382	167	20	compared	compare	VERB
fnp-6382	167	21	to	to	ADP
fnp-6382	167	22	retired	retire	VERB
fnp-6382	167	23	players	player	NOUN
fnp-6382	167	24	without	without	ADP
fnp-6382	167	25	an	an	DET
fnp-6382	167	26	nbd	nbd	PROPN
fnp-6382	167	27	diagnosis	diagnosis	NOUN
fnp-6382	167	28	(	(	PUNCT
fnp-6382	167	29	66	66	NUM
fnp-6382	167	30	)	)	PUNCT
fnp-6382	167	31	.	.	PUNCT
fnp-6382	168	1	this	this	PRON
fnp-6382	168	2	is	be	AUX
fnp-6382	168	3	noteworthy	noteworthy	ADJ
fnp-6382	168	4	since	since	SCONJ
fnp-6382	168	5	nbd	nbd	PROPN
fnp-6382	168	6	,	,	PUNCT
fnp-6382	168	7	referring	refer	VERB
fnp-6382	168	8	to	to	ADP
fnp-6382	168	9	behavioral	behavioral	ADJ
fnp-6382	168	10	changes	change	NOUN
fnp-6382	168	11	and	and	CCONJ
fnp-6382	168	12	dysregulation	dysregulation	NOUN
fnp-6382	168	13	of	of	ADP
fnp-6382	168	14	emotion	emotion	NOUN
fnp-6382	168	15	,	,	PUNCT
fnp-6382	168	16	is	be	AUX
fnp-6382	168	17	a	a	DET
fnp-6382	168	18	prominent	prominent	ADJ
fnp-6382	168	19	clinical	clinical	ADJ
fnp-6382	168	20	finding	finding	NOUN
fnp-6382	168	21	in	in	ADP
fnp-6382	168	22	the	the	DET
fnp-6382	168	23	proposed	propose	VERB
fnp-6382	168	24	criteria	criterion	NOUN
fnp-6382	168	25	for	for	ADP
fnp-6382	168	26	tes	tes	NOUN
fnp-6382	168	27	(	(	PUNCT
fnp-6382	168	28	traumatic	traumatic	ADJ
fnp-6382	168	29	encephalopathy	encephalopathy	ADJ
fnp-6382	168	30	syndrome	syndrome	NOUN
fnp-6382	168	31	)	)	PUNCT
fnp-6382	168	32	.	.	PUNCT
fnp-6382	169	1	van	van	PROPN
fnp-6382	169	2	amerongen	amerongen	PROPN
fnp-6382	169	3	et	et	PROPN
fnp-6382	169	4	al	al	PROPN
fnp-6382	169	5	.	.	PROPN
fnp-6382	169	6	found	find	VERB
fnp-6382	169	7	il-6	il-6	PRON
fnp-6382	169	8	to	to	PART
fnp-6382	169	9	be	be	AUX
fnp-6382	169	10	correlated	correlate	VERB
fnp-6382	169	11	with	with	ADP
fnp-6382	169	12	the	the	DET
fnp-6382	169	13	overall	overall	ADJ
fnp-6382	169	14	nbd	nbd	PROPN
fnp-6382	169	15	score	score	NOUN
fnp-6382	169	16	,	,	PUNCT
fnp-6382	169	17	as	as	ADV
fnp-6382	169	18	well	well	ADV
fnp-6382	169	19	as	as	ADP
fnp-6382	169	20	with	with	ADP
fnp-6382	169	21	subdomains	subdomain	NOUN
fnp-6382	169	22	including	include	VERB
fnp-6382	169	23	impulsivity	impulsivity	NOUN
fnp-6382	169	24	,	,	PUNCT
fnp-6382	169	25	emotional	emotional	ADJ
fnp-6382	169	26	dysregulation	dysregulation	NOUN
fnp-6382	169	27	,	,	PUNCT
fnp-6382	169	28	and	and	CCONJ
fnp-6382	169	29	affective	affective	ADJ
fnp-6382	169	30	lability	lability	NOUN
fnp-6382	169	31	.	.	PUNCT
fnp-6382	170	1	interestingly	interestingly	ADV
fnp-6382	170	2	,	,	PUNCT
fnp-6382	170	3	il-6	il-6	NUM
fnp-6382	170	4	appeared	appear	VERB
fnp-6382	170	5	to	to	PART
fnp-6382	170	6	have	have	VERB
fnp-6382	170	7	a	a	DET
fnp-6382	170	8	selective	selective	ADJ
fnp-6382	170	9	relationship	relationship	NOUN
fnp-6382	170	10	with	with	ADP
fnp-6382	170	11	certain	certain	ADJ
fnp-6382	170	12	behavioral	behavioral	ADJ
fnp-6382	170	13	traits	trait	NOUN
fnp-6382	170	14	,	,	PUNCT
fnp-6382	170	15	as	as	SCONJ
fnp-6382	170	16	it	it	PRON
fnp-6382	170	17	did	do	AUX
fnp-6382	170	18	not	not	PART
fnp-6382	170	19	correlate	correlate	VERB
fnp-6382	170	20	with	with	ADP
fnp-6382	170	21	the	the	DET
fnp-6382	170	22	explosiveness	explosiveness	PROPN
fnp-6382	170	23	domain	domain	NOUN
fnp-6382	170	24	of	of	ADP
fnp-6382	170	25	nbd	nbd	PROPN
fnp-6382	170	26	or	or	CCONJ
fnp-6382	170	27	with	with	ADP
fnp-6382	170	28	measures	measure	NOUN
fnp-6382	170	29	of	of	ADP
fnp-6382	170	30	cognitive	cognitive	ADJ
fnp-6382	170	31	performance	performance	NOUN
fnp-6382	170	32	.	.	PUNCT
fnp-6382	171	1	none	none	NOUN
fnp-6382	171	2	of	of	ADP
fnp-6382	171	3	the	the	DET
fnp-6382	171	4	tested	test	VERB
fnp-6382	171	5	markers	marker	NOUN
fnp-6382	171	6	in	in	ADP
fnp-6382	171	7	the	the	DET
fnp-6382	171	8	csf	csf	NOUN
fnp-6382	171	9	,	,	PUNCT
fnp-6382	171	10	including	include	VERB
fnp-6382	171	11	il-6	il-6	NUM
fnp-6382	171	12	,	,	PUNCT
fnp-6382	171	13	were	be	AUX
fnp-6382	171	14	associated	associate	VERB
fnp-6382	171	15	with	with	ADP
fnp-6382	171	16	rhi	rhi	PROPN
fnp-6382	171	17	proxies	proxy	NOUN
fnp-6382	171	18	i.e.	i.e.	X
fnp-6382	171	19	,	,	PUNCT
fnp-6382	171	20	football	football	NOUN
fnp-6382	171	21	career	career	NOUN
fnp-6382	171	22	length	length	NOUN
fnp-6382	171	23	(	(	PUNCT
fnp-6382	171	24	66	66	NUM
fnp-6382	171	25	)	)	PUNCT
fnp-6382	171	26	.	.	PUNCT
fnp-6382	172	1	this	this	PRON
fnp-6382	172	2	points	point	VERB
fnp-6382	172	3	to	to	ADP
fnp-6382	172	4	il-6	il-6	NOUN
fnp-6382	172	5	as	as	ADP
fnp-6382	172	6	a	a	DET
fnp-6382	172	7	potential	potential	ADJ
fnp-6382	172	8	sensitive	sensitive	ADJ
fnp-6382	172	9	marker	marker	NOUN
fnp-6382	172	10	,	,	PUNCT
fnp-6382	172	11	particularly	particularly	ADV
fnp-6382	172	12	compared	compare	VERB
fnp-6382	172	13	to	to	ADP
fnp-6382	172	14	other	other	ADJ
fnp-6382	172	15	inflammatory	inflammatory	ADJ
fnp-6382	172	16	cytokines	cytokine	NOUN
fnp-6382	172	17	,	,	PUNCT
fnp-6382	172	18	for	for	ADP
fnp-6382	172	19	monitoring	monitor	VERB
fnp-6382	172	20	progression	progression	NOUN
fnp-6382	172	21	of	of	ADP
fnp-6382	172	22	nbd	nbd	PROPN
fnp-6382	172	23	symptoms	symptom	NOUN
fnp-6382	172	24	in	in	ADP
fnp-6382	172	25	those	those	DET
fnp-6382	172	26	persons	person	NOUN
fnp-6382	172	27	at	at	ADP
fnp-6382	172	28	risk	risk	NOUN
fnp-6382	172	29	for	for	ADP
fnp-6382	172	30	cte	cte	NOUN
fnp-6382	172	31	.	.	PUNCT
fnp-6382	173	1	similarly	similarly	ADV
fnp-6382	173	2	,	,	PUNCT
fnp-6382	173	3	serum	serum	NOUN
fnp-6382	173	4	levels	level	NOUN
fnp-6382	173	5	of	of	ADP
fnp-6382	173	6	il-6	il-6	NUM
fnp-6382	173	7	were	be	AUX
fnp-6382	173	8	found	find	VERB
fnp-6382	173	9	to	to	PART
fnp-6382	173	10	correlate	correlate	VERB
fnp-6382	173	11	with	with	ADP
fnp-6382	173	12	clinical	clinical	ADJ
fnp-6382	173	13	symptom	symptom	NOUN
fnp-6382	173	14	severity	severity	NOUN
fnp-6382	173	15	after	after	ADP
fnp-6382	173	16	a	a	DET
fnp-6382	173	17	sports	sport	NOUN
fnp-6382	173	18	-	-	PUNCT
fnp-6382	173	19	related	relate	VERB
fnp-6382	173	20	concussion	concussion	NOUN
fnp-6382	173	21	,	,	PUNCT
fnp-6382	173	22	as	as	SCONJ
fnp-6382	173	23	it	it	PRON
fnp-6382	173	24	remained	remain	VERB
fnp-6382	173	25	elevated	elevated	ADJ
fnp-6382	173	26	at	at	ADP
fnp-6382	173	27	14	14	NUM
fnp-6382	173	28	days	day	NOUN
fnp-6382	173	29	post	post	ADJ
fnp-6382	173	30	-	-	NOUN
fnp-6382	173	31	injury	injury	ADJ
fnp-6382	173	32	(	(	PUNCT
fnp-6382	173	33	67	67	NUM
fnp-6382	173	34	)	)	PUNCT
fnp-6382	173	35	.	.	PUNCT
fnp-6382	174	1	additionally	additionally	ADV
fnp-6382	174	2	,	,	PUNCT
fnp-6382	174	3	il-6	il-6	NUM
fnp-6382	174	4	levels	level	NOUN
fnp-6382	174	5	in	in	ADP
fnp-6382	174	6	the	the	DET
fnp-6382	174	7	plasma	plasma	NOUN
fnp-6382	174	8	were	be	AUX
fnp-6382	174	9	significantly	significantly	ADV
fnp-6382	174	10	elevated	elevate	VERB
fnp-6382	174	11	in	in	ADP
fnp-6382	174	12	rhi	rhi	PROPN
fnp-6382	174	13	/	/	SYM
fnp-6382	174	14	tes	tes	NOUN
fnp-6382	174	15	patients	patient	NOUN
fnp-6382	174	16	compared	compare	VERB
fnp-6382	174	17	to	to	ADP
fnp-6382	174	18	healthy	healthy	ADJ
fnp-6382	174	19	controls	control	NOUN
fnp-6382	174	20	and	and	CCONJ
fnp-6382	174	21	ad	ad	NOUN
fnp-6382	174	22	patients	patient	NOUN
fnp-6382	174	23	without	without	ADP
fnp-6382	174	24	rhi	rhi	PROPN
fnp-6382	174	25	exposure	exposure	NOUN
fnp-6382	174	26	.	.	PUNCT
fnp-6382	175	1	furthermore	furthermore	ADV
fnp-6382	175	2	,	,	PUNCT
fnp-6382	175	3	rhi	rhi	PROPN
fnp-6382	175	4	/	/	SYM
fnp-6382	175	5	tes	tes	NOUN
fnp-6382	175	6	patients	patient	NOUN
fnp-6382	175	7	who	who	PRON
fnp-6382	175	8	were	be	AUX
fnp-6382	175	9	negative	negative	ADJ
fnp-6382	175	10	for	for	ADP
fnp-6382	175	11	aβ	aβ	NOUN
fnp-6382	175	12	-	-	PUNCT
fnp-6382	175	13	pet	pet	NOUN
fnp-6382	175	14	negative	negative	ADJ
fnp-6382	175	15	,	,	PUNCT
fnp-6382	175	16	i.e.	i.e.	X
fnp-6382	175	17	negative	negative	ADJ
fnp-6382	175	18	for	for	ADP
fnp-6382	175	19	aβ	aβ	PRON
fnp-6382	175	20	in	in	ADP
fnp-6382	175	21	positron	positron	NOUN
fnp-6382	175	22	-	-	PUNCT
fnp-6382	175	23	emission	emission	NOUN
fnp-6382	175	24	tomography	tomography	NOUN
fnp-6382	175	25	,	,	PUNCT
fnp-6382	175	26	still	still	ADV
fnp-6382	175	27	had	have	VERB
fnp-6382	175	28	significantly	significantly	ADV
fnp-6382	175	29	higher	high	ADJ
fnp-6382	175	30	il-6	il-6	NOUN
fnp-6382	175	31	levels	level	NOUN
fnp-6382	175	32	than	than	ADP
fnp-6382	175	33	rhi	rhi	PROPN
fnp-6382	175	34	/	/	SYM
fnp-6382	175	35	tes	tes	NOUN
fnp-6382	175	36	patients	patient	NOUN
fnp-6382	175	37	with	with	ADP
fnp-6382	175	38	aβ+	aβ+	ADJ
fnp-6382	175	39	status	status	NOUN
fnp-6382	175	40	and	and	CCONJ
fnp-6382	175	41	all	all	DET
fnp-6382	175	42	other	other	ADJ
fnp-6382	175	43	groups	group	NOUN
fnp-6382	175	44	,	,	PUNCT
fnp-6382	175	45	suggesting	suggest	VERB
fnp-6382	175	46	that	that	SCONJ
fnp-6382	175	47	il-6	il-6	NOUN
fnp-6382	175	48	elevation	elevation	NOUN
fnp-6382	175	49	is	be	AUX
fnp-6382	175	50	more	more	ADV
fnp-6382	175	51	reflective	reflective	ADJ
fnp-6382	175	52	of	of	ADP
fnp-6382	175	53	chronic	chronic	ADJ
fnp-6382	175	54	rhi	rhi	NOUN
fnp-6382	175	55	-	-	PUNCT
fnp-6382	175	56	induced	induce	VERB
fnp-6382	175	57	inflammation	inflammation	NOUN
fnp-6382	175	58	than	than	ADP
fnp-6382	175	59	of	of	ADP
fnp-6382	175	60	any	any	DET
fnp-6382	175	61	potential	potential	ADJ
fnp-6382	175	62	co	co	ADJ
fnp-6382	175	63	-	-	ADJ
fnp-6382	175	64	morbid	morbid	ADJ
fnp-6382	175	65	alzheimer	alzheimer	NOUN
fnp-6382	175	66	’s	’s	PART
fnp-6382	175	67	pathology	pathology	NOUN
fnp-6382	175	68	(	(	PUNCT
fnp-6382	175	69	68	68	NUM
fnp-6382	175	70	)	)	PUNCT
fnp-6382	175	71	.	.	PUNCT
fnp-6382	176	1	while	while	SCONJ
fnp-6382	176	2	tes	tes	PROPN
fnp-6382	176	3	criteria	criterion	NOUN
fnp-6382	176	4	have	have	AUX
fnp-6382	176	5	not	not	PART
fnp-6382	176	6	been	be	AUX
fnp-6382	176	7	pathologically	pathologically	ADV
fnp-6382	176	8	validated	validate	VERB
fnp-6382	176	9	,	,	PUNCT
fnp-6382	176	10	these	these	DET
fnp-6382	176	11	findings	finding	NOUN
fnp-6382	176	12	suggest	suggest	VERB
fnp-6382	176	13	that	that	SCONJ
fnp-6382	176	14	il-6	il-6	PRON
fnp-6382	176	15	might	might	AUX
fnp-6382	176	16	play	play	VERB
fnp-6382	176	17	a	a	DET
fnp-6382	176	18	role	role	NOUN
fnp-6382	176	19	in	in	ADP
fnp-6382	176	20	neuropsychiatric	neuropsychiatric	ADJ
fnp-6382	176	21	symptoms	symptom	NOUN
fnp-6382	176	22	observed	observe	VERB
fnp-6382	176	23	in	in	ADP
fnp-6382	176	24	patients	patient	NOUN
fnp-6382	176	25	with	with	ADP
fnp-6382	176	26	rhi	rhi	PROPN
fnp-6382	176	27	exposure	exposure	NOUN
fnp-6382	176	28	,	,	PUNCT
fnp-6382	176	29	including	include	VERB
fnp-6382	176	30	those	those	PRON
fnp-6382	176	31	who	who	PRON
fnp-6382	176	32	may	may	AUX
fnp-6382	176	33	eventually	eventually	ADV
fnp-6382	176	34	develop	develop	VERB
fnp-6382	176	35	cte	cte	NOUN
fnp-6382	176	36	.	.	PUNCT
fnp-6382	177	1	however	however	ADV
fnp-6382	177	2	,	,	PUNCT
fnp-6382	177	3	il-6	il-6	NOUN
fnp-6382	177	4	plasma	plasma	NOUN
fnp-6382	177	5	levels	level	NOUN
fnp-6382	177	6	have	have	AUX
fnp-6382	177	7	also	also	ADV
fnp-6382	177	8	been	be	AUX
fnp-6382	177	9	previously	previously	ADV
fnp-6382	177	10	linked	link	VERB
fnp-6382	177	11	to	to	ADP
fnp-6382	177	12	disinhibition	disinhibition	NOUN
fnp-6382	177	13	in	in	ADP
fnp-6382	177	14	frontotemporal	frontotemporal	ADJ
fnp-6382	177	15	dementia	dementia	NOUN
fnp-6382	177	16	(	(	PUNCT
fnp-6382	177	17	ftd	ftd	NOUN
fnp-6382	177	18	)	)	PUNCT
fnp-6382	177	19	(	(	PUNCT
fnp-6382	177	20	69	69	NUM
fnp-6382	177	21	)	)	PUNCT
fnp-6382	177	22	,	,	PUNCT
fnp-6382	177	23	apathy	apathy	NOUN
fnp-6382	177	24	in	in	ADP
fnp-6382	177	25	ad	ad	NOUN
fnp-6382	177	26	(	(	PUNCT
fnp-6382	177	27	70,71	70,71	NUM
fnp-6382	177	28	)	)	PUNCT
fnp-6382	177	29	,	,	PUNCT
fnp-6382	177	30	and	and	CCONJ
fnp-6382	177	31	manic	manic	ADJ
fnp-6382	177	32	symptoms	symptom	NOUN
fnp-6382	177	33	in	in	ADP
fnp-6382	177	34	bipolar	bipolar	ADJ
fnp-6382	177	35	disorder	disorder	NOUN
fnp-6382	177	36	(	(	PUNCT
fnp-6382	177	37	72	72	NUM
fnp-6382	177	38	)	)	PUNCT
fnp-6382	177	39	.	.	PUNCT
fnp-6382	178	1	thus	thus	ADV
fnp-6382	178	2	,	,	PUNCT
fnp-6382	178	3	il-6	il-6	PRON
fnp-6382	178	4	may	may	AUX
fnp-6382	178	5	non	non	ADJ
fnp-6382	178	6	-	-	ADJ
fnp-6382	178	7	specifically	specifically	ADV
fnp-6382	178	8	contribute	contribute	ADJ
fnp-6382	178	9	to	to	ADP
fnp-6382	178	10	nbd	nbd	PROPN
fnp-6382	178	11	symptoms	symptom	NOUN
fnp-6382	178	12	in	in	ADP
fnp-6382	178	13	various	various	ADJ
fnp-6382	178	14	neurologic	neurologic	ADJ
fnp-6382	178	15	or	or	CCONJ
fnp-6382	178	16	psychiatric	psychiatric	ADJ
fnp-6382	178	17	conditions	condition	NOUN
fnp-6382	178	18	,	,	PUNCT
fnp-6382	178	19	including	include	VERB
fnp-6382	178	20	cte	cte	NOUN
fnp-6382	178	21	.	.	PUNCT
fnp-6382	179	1	future	future	ADJ
fnp-6382	179	2	investigations	investigation	NOUN
fnp-6382	179	3	could	could	AUX
fnp-6382	179	4	benefit	benefit	VERB
fnp-6382	179	5	from	from	ADP
fnp-6382	179	6	directly	directly	ADV
fnp-6382	179	7	assessing	assess	VERB
fnp-6382	179	8	il-6	il-6	NOUN
fnp-6382	179	9	as	as	ADP
fnp-6382	179	10	a	a	DET
fnp-6382	179	11	possible	possible	ADJ
fnp-6382	179	12	pathological	pathological	ADJ
fnp-6382	179	13	correlate	correlate	NOUN
fnp-6382	179	14	for	for	ADP
fnp-6382	179	15	nbd	nbd	PROPN
fnp-6382	179	16	in	in	ADP
fnp-6382	179	17	cte	cte	PROPN
fnp-6382	179	18	,	,	PUNCT
fnp-6382	179	19	such	such	ADJ
fnp-6382	179	20	as	as	ADP
fnp-6382	179	21	by	by	ADP
fnp-6382	179	22	comparing	compare	VERB
fnp-6382	179	23	postmortem	postmortem	NOUN
fnp-6382	179	24	findings	finding	NOUN
fnp-6382	179	25	with	with	ADP
fnp-6382	179	26	retrospective	retrospective	ADJ
fnp-6382	179	27	review	review	NOUN
fnp-6382	179	28	of	of	ADP
fnp-6382	179	29	clinical	clinical	ADJ
fnp-6382	179	30	symptoms	symptom	NOUN
fnp-6382	179	31	.	.	PUNCT
fnp-6382	180	1	however	however	ADV
fnp-6382	180	2	,	,	PUNCT
fnp-6382	180	3	not	not	PART
fnp-6382	180	4	all	all	DET
fnp-6382	180	5	studies	study	NOUN
fnp-6382	180	6	have	have	AUX
fnp-6382	180	7	found	find	VERB
fnp-6382	180	8	success	success	NOUN
fnp-6382	180	9	with	with	ADP
fnp-6382	180	10	il-6	il-6	NOUN
fnp-6382	180	11	as	as	ADP
fnp-6382	180	12	an	an	DET
fnp-6382	180	13	rhi	rhi	NOUN
fnp-6382	180	14	-	-	PUNCT
fnp-6382	180	15	related	relate	VERB
fnp-6382	180	16	biomarker	biomarker	NOUN
fnp-6382	180	17	.	.	PUNCT
fnp-6382	181	1	parkin	parkin	NOUN
fnp-6382	181	2	et	et	PROPN
fnp-6382	181	3	al	al	PROPN
fnp-6382	181	4	conducted	conduct	VERB
fnp-6382	181	5	an	an	DET
fnp-6382	181	6	immunoassay	immunoassay	NOUN
fnp-6382	181	7	of	of	ADP
fnp-6382	181	8	blood	blood	NOUN
fnp-6382	181	9	-	-	PUNCT
fnp-6382	181	10	based	base	VERB
fnp-6382	181	11	immune	immune	ADJ
fnp-6382	181	12	markers	marker	NOUN
fnp-6382	181	13	up	up	ADP
fnp-6382	181	14	to	to	PART
fnp-6382	181	15	3	3	NUM
fnp-6382	181	16	months	month	NOUN
fnp-6382	181	17	after	after	ADP
fnp-6382	181	18	pediatric	pediatric	ADJ
fnp-6382	181	19	concussion	concussion	NOUN
fnp-6382	181	20	,	,	PUNCT
fnp-6382	181	21	observing	observe	VERB
fnp-6382	181	22	that	that	SCONJ
fnp-6382	181	23	patients	patient	NOUN
fnp-6382	181	24	with	with	ADP
fnp-6382	181	25	normal	normal	ADJ
fnp-6382	181	26	recovery	recovery	NOUN
fnp-6382	181	27	exhibited	exhibit	VERB
fnp-6382	181	28	the	the	DET
fnp-6382	181	29	same	same	ADJ
fnp-6382	181	30	gradual	gradual	ADJ
fnp-6382	181	31	decrease	decrease	NOUN
fnp-6382	181	32	in	in	ADP
fnp-6382	181	33	il-6	il-6	NOUN
fnp-6382	181	34	expression	expression	NOUN
fnp-6382	181	35	as	as	ADP
fnp-6382	181	36	patients	patient	NOUN
fnp-6382	181	37	with	with	ADP
fnp-6382	181	38	persisting	persist	VERB
fnp-6382	181	39	symptoms	symptom	NOUN
fnp-6382	181	40	showing	show	VERB
fnp-6382	181	41	concentration	concentration	NOUN
fnp-6382	181	42	difficulty	difficulty	NOUN
fnp-6382	181	43	as	as	ADV
fnp-6382	181	44	well	well	ADV
fnp-6382	181	45	as	as	ADP
fnp-6382	181	46	cognitive	cognitive	ADJ
fnp-6382	181	47	and	and	CCONJ
fnp-6382	181	48	behavioral	behavioral	ADJ
fnp-6382	181	49	deficits	deficit	NOUN
fnp-6382	181	50	(	(	PUNCT
fnp-6382	181	51	73	73	NUM
fnp-6382	181	52	)	)	PUNCT
fnp-6382	181	53	.	.	PUNCT
fnp-6382	182	1	that	that	PRON
fnp-6382	182	2	said	say	VERB
fnp-6382	182	3	,	,	PUNCT
fnp-6382	182	4	the	the	DET
fnp-6382	182	5	symptom	symptom	NOUN
fnp-6382	182	6	categories	category	NOUN
fnp-6382	182	7	in	in	ADP
fnp-6382	182	8	this	this	DET
fnp-6382	182	9	study	study	NOUN
fnp-6382	182	10	were	be	AUX
fnp-6382	182	11	broadly	broadly	ADV
fnp-6382	182	12	defined	define	VERB
fnp-6382	182	13	and	and	CCONJ
fnp-6382	182	14	likely	likely	ADV
fnp-6382	182	15	included	include	VERB
fnp-6382	182	16	general	general	ADJ
fnp-6382	182	17	post	post	ADJ
fnp-6382	182	18	-	-	ADJ
fnp-6382	182	19	concussive	concussive	ADJ
fnp-6382	182	20	complaints	complaint	NOUN
fnp-6382	182	21	like	like	ADP
fnp-6382	182	22	dizziness	dizziness	NOUN
fnp-6382	182	23	and	and	CCONJ
fnp-6382	182	24	headache	headache	NOUN
fnp-6382	182	25	,	,	PUNCT
fnp-6382	182	26	rather	rather	ADV
fnp-6382	182	27	than	than	ADP
fnp-6382	182	28	specific	specific	ADJ
fnp-6382	182	29	components	component	NOUN
fnp-6382	182	30	of	of	ADP
fnp-6382	182	31	nbd	nbd	PROPN
fnp-6382	182	32	.	.	PUNCT
fnp-6382	183	1	non	non	ADJ
fnp-6382	183	2	-	-	ADJ
fnp-6382	183	3	specific	specific	ADJ
fnp-6382	183	4	symptom	symptom	NOUN
fnp-6382	183	5	classification	classification	NOUN
fnp-6382	183	6	may	may	AUX
fnp-6382	183	7	have	have	AUX
fnp-6382	183	8	obscured	obscure	VERB
fnp-6382	183	9	potential	potential	ADJ
fnp-6382	183	10	relationships	relationship	NOUN
fnp-6382	183	11	between	between	ADP
fnp-6382	183	12	il-6	il-6	NOUN
fnp-6382	183	13	and	and	CCONJ
fnp-6382	183	14	behavioral	behavioral	ADJ
fnp-6382	183	15	phenotypes	phenotype	NOUN
fnp-6382	183	16	when	when	SCONJ
fnp-6382	183	17	considering	consider	VERB
fnp-6382	183	18	the	the	DET
fnp-6382	183	19	findings	finding	NOUN
fnp-6382	183	20	from	from	ADP
fnp-6382	183	21	van	van	PROPN
fnp-6382	183	22	amerongen	amerongen	PROPN
fnp-6382	183	23	et	et	PROPN
fnp-6382	183	24	al	al	PROPN
fnp-6382	183	25	.	.	PUNCT
fnp-6382	184	1	that	that	PRON
fnp-6382	184	2	suggest	suggest	VERB
fnp-6382	184	3	il-6	il-6	NOUN
fnp-6382	184	4	to	to	PART
fnp-6382	184	5	have	have	VERB
fnp-6382	184	6	a	a	DET
fnp-6382	184	7	selective	selective	ADJ
fnp-6382	184	8	association	association	NOUN
fnp-6382	184	9	with	with	ADP
fnp-6382	184	10	nbd	nbd	PROPN
fnp-6382	184	11	subdomains	subdomain	NOUN
fnp-6382	184	12	(	(	PUNCT
fnp-6382	184	13	74	74	NUM
fnp-6382	184	14	)	)	PUNCT
fnp-6382	184	15	.	.	PUNCT
fnp-6382	185	1	additionally	additionally	ADV
fnp-6382	185	2	,	,	PUNCT
fnp-6382	185	3	il-6	il-6	NOUN
fnp-6382	185	4	plasma	plasma	NOUN
fnp-6382	185	5	levels	level	NOUN
fnp-6382	185	6	in	in	ADP
fnp-6382	185	7	former	former	ADJ
fnp-6382	185	8	football	football	NOUN
fnp-6382	185	9	athletes	athlete	NOUN
fnp-6382	185	10	did	do	AUX
fnp-6382	185	11	not	not	PART
fnp-6382	185	12	significantly	significantly	ADV
fnp-6382	185	13	differ	differ	VERB
fnp-6382	185	14	between	between	ADP
fnp-6382	185	15	rhi	rhi	NOUN
fnp-6382	185	16	-	-	PUNCT
fnp-6382	185	17	exposed	expose	VERB
fnp-6382	185	18	symptomatic	symptomatic	ADJ
fnp-6382	185	19	subjects	subject	NOUN
fnp-6382	185	20	and	and	CCONJ
fnp-6382	185	21	unexposed	unexposed	ADJ
fnp-6382	185	22	asymptomatic	asymptomatic	ADJ
fnp-6382	185	23	controls	control	NOUN
fnp-6382	185	24	.	.	PUNCT
fnp-6382	186	1	furthermore	furthermore	ADV
fnp-6382	186	2	,	,	PUNCT
fnp-6382	186	3	il-6	il-6	NOUN
fnp-6382	186	4	plasma	plasma	NOUN
fnp-6382	186	5	levels	level	NOUN
fnp-6382	186	6	were	be	AUX
fnp-6382	186	7	not	not	PART
fnp-6382	186	8	significantly	significantly	ADV
fnp-6382	186	9	associated	associate	VERB
fnp-6382	186	10	with	with	ADP
fnp-6382	186	11	rhi	rhi	PROPN
fnp-6382	186	12	proxies	proxy	NOUN
fnp-6382	186	13	including	include	VERB
fnp-6382	186	14	years	year	NOUN
fnp-6382	186	15	of	of	ADP
fnp-6382	186	16	play	play	NOUN
fnp-6382	186	17	and	and	CCONJ
fnp-6382	186	18	age	age	NOUN
fnp-6382	186	19	of	of	ADP
fnp-6382	186	20	first	first	ADJ
fnp-6382	186	21	exposure	exposure	NOUN
fnp-6382	186	22	(	(	PUNCT
fnp-6382	186	23	74	74	NUM
fnp-6382	186	24	)	)	PUNCT
fnp-6382	186	25	.	.	PUNCT
fnp-6382	187	1	to	to	PART
fnp-6382	187	2	address	address	VERB
fnp-6382	187	3	uncertainty	uncertainty	NOUN
fnp-6382	187	4	regarding	regard	VERB
fnp-6382	187	5	il-6	il-6	NOUN
fnp-6382	187	6	as	as	ADP
fnp-6382	187	7	a	a	DET
fnp-6382	187	8	viable	viable	ADJ
fnp-6382	187	9	marker	marker	NOUN
fnp-6382	187	10	for	for	ADP
fnp-6382	187	11	symptomology	symptomology	NOUN
fnp-6382	187	12	,	,	PUNCT
fnp-6382	187	13	future	future	ADJ
fnp-6382	187	14	examinations	examination	NOUN
fnp-6382	187	15	should	should	AUX
fnp-6382	187	16	longitudinally	longitudinally	ADV
fnp-6382	187	17	assess	assess	VERB
fnp-6382	187	18	il-6	il-6	NOUN
fnp-6382	187	19	in	in	ADP
fnp-6382	187	20	rhi	rhi	NOUN
fnp-6382	187	21	-	-	PUNCT
fnp-6382	187	22	exposed	expose	VERB
fnp-6382	187	23	subjects	subject	NOUN
fnp-6382	187	24	alongside	alongside	ADP
fnp-6382	187	25	clinical	clinical	ADJ
fnp-6382	187	26	phenotypes	phenotype	NOUN
fnp-6382	187	27	,	,	PUNCT
fnp-6382	187	28	aiming	aim	VERB
fnp-6382	187	29	to	to	PART
fnp-6382	187	30	determine	determine	VERB
fnp-6382	187	31	if	if	SCONJ
fnp-6382	187	32	il-6	il-6	NUM
fnp-6382	187	33	levels	level	NOUN
fnp-6382	187	34	reliably	reliably	ADV
fnp-6382	187	35	track	track	VERB
fnp-6382	187	36	symptom	symptom	NOUN
fnp-6382	187	37	onset	onset	NOUN
fnp-6382	187	38	,	,	PUNCT
fnp-6382	187	39	persist	persist	VERB
fnp-6382	187	40	independently	independently	ADV
fnp-6382	187	41	of	of	ADP
fnp-6382	187	42	clinical	clinical	ADJ
fnp-6382	187	43	progression	progression	NOUN
fnp-6382	187	44	,	,	PUNCT
fnp-6382	187	45	or	or	CCONJ
fnp-6382	187	46	reflect	reflect	VERB
fnp-6382	187	47	non	non	ADJ
fnp-6382	187	48	-	-	ADJ
fnp-6382	187	49	specific	specific	ADJ
fnp-6382	187	50	post	post	ADJ
fnp-6382	187	51	-	-	ADJ
fnp-6382	187	52	traumatic	traumatic	ADJ
fnp-6382	187	53	inflammation	inflammation	NOUN
fnp-6382	187	54	.	.	PUNCT
fnp-6382	188	1	gfap	gfap	ADJ
fnp-6382	188	2	considering	consider	VERB
fnp-6382	188	3	the	the	DET
fnp-6382	188	4	role	role	NOUN
fnp-6382	188	5	of	of	ADP
fnp-6382	188	6	astrocytes	astrocyte	NOUN
fnp-6382	188	7	in	in	ADP
fnp-6382	188	8	facilitating	facilitate	VERB
fnp-6382	188	9	neuroinflammation	neuroinflammation	NOUN
fnp-6382	188	10	,	,	PUNCT
fnp-6382	188	11	some	some	DET
fnp-6382	188	12	studies	study	NOUN
fnp-6382	188	13	have	have	AUX
fnp-6382	188	14	assessed	assess	VERB
fnp-6382	188	15	gfap	gfap	NOUN
fnp-6382	188	16	in	in	ADP
fnp-6382	188	17	relation	relation	NOUN
fnp-6382	188	18	to	to	ADP
fnp-6382	188	19	rhi	rhi	PROPN
fnp-6382	188	20	.	.	PUNCT
fnp-6382	189	1	gfap	gfap	NOUN
fnp-6382	189	2	is	be	AUX
fnp-6382	189	3	a	a	DET
fnp-6382	189	4	filament	filament	NOUN
fnp-6382	189	5	protein	protein	NOUN
fnp-6382	189	6	in	in	ADP
fnp-6382	189	7	the	the	DET
fnp-6382	189	8	cytoskeleton	cytoskeleton	NOUN
fnp-6382	189	9	of	of	ADP
fnp-6382	189	10	astrocytes	astrocyte	NOUN
fnp-6382	189	11	and	and	CCONJ
fnp-6382	189	12	provides	provide	VERB
fnp-6382	189	13	structural	structural	ADJ
fnp-6382	189	14	support	support	NOUN
fnp-6382	189	15	(	(	PUNCT
fnp-6382	189	16	75	75	NUM
fnp-6382	189	17	)	)	PUNCT
fnp-6382	189	18	.	.	PUNCT
fnp-6382	190	1	since	since	SCONJ
fnp-6382	190	2	gfap	gfap	NOUN
fnp-6382	190	3	is	be	AUX
fnp-6382	190	4	upregulated	upregulate	VERB
fnp-6382	190	5	during	during	ADP
fnp-6382	190	6	astrogliosis	astrogliosis	NOUN
fnp-6382	190	7	,	,	PUNCT
fnp-6382	190	8	elevated	elevated	ADJ
fnp-6382	190	9	gfap	gfap	ADJ
fnp-6382	190	10	levels	level	NOUN
fnp-6382	190	11	may	may	AUX
fnp-6382	190	12	indicate	indicate	VERB
fnp-6382	190	13	a	a	DET
fnp-6382	190	14	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	190	15	response	response	NOUN
fnp-6382	190	16	,	,	PUNCT
fnp-6382	190	17	or	or	CCONJ
fnp-6382	190	18	an	an	DET
fnp-6382	190	19	injury	injury	NOUN
fnp-6382	190	20	to	to	ADP
fnp-6382	190	21	astrocytes	astrocyte	NOUN
fnp-6382	190	22	(	(	PUNCT
fnp-6382	190	23	76	76	NUM
fnp-6382	190	24	)	)	PUNCT
fnp-6382	190	25	.	.	PUNCT
fnp-6382	191	1	gfap	gfap	NOUN
fnp-6382	191	2	is	be	AUX
fnp-6382	191	3	also	also	ADV
fnp-6382	191	4	a	a	DET
fnp-6382	191	5	potential	potential	ADJ
fnp-6382	191	6	predictor	predictor	NOUN
fnp-6382	191	7	of	of	ADP
fnp-6382	191	8	concussion	concussion	NOUN
fnp-6382	191	9	status	status	NOUN
fnp-6382	191	10	or	or	CCONJ
fnp-6382	191	11	increased	increase	VERB
fnp-6382	191	12	rhi	rhi	PROPN
fnp-6382	191	13	severity	severity	NOUN
fnp-6382	191	14	,	,	PUNCT
fnp-6382	191	15	albeit	albeit	SCONJ
fnp-6382	191	16	more	more	ADV
fnp-6382	191	17	-	-	PUNCT
fnp-6382	191	18	so	so	ADV
fnp-6382	191	19	in	in	ADP
fnp-6382	191	20	an	an	DET
fnp-6382	191	21	acute	acute	ADJ
fnp-6382	191	22	post	post	ADJ
fnp-6382	191	23	-	-	ADJ
fnp-6382	191	24	tbi	tbi	ADJ
fnp-6382	191	25	timeframe	timeframe	NOUN
fnp-6382	191	26	(	(	PUNCT
fnp-6382	191	27	77,78	77,78	PROPN
fnp-6382	191	28	)	)	PUNCT
fnp-6382	191	29	.	.	PUNCT
fnp-6382	192	1	although	although	SCONJ
fnp-6382	192	2	postmortem	postmortem	NOUN
fnp-6382	192	3	studies	study	NOUN
fnp-6382	192	4	provide	provide	VERB
fnp-6382	192	5	evidence	evidence	NOUN
fnp-6382	192	6	of	of	ADP
fnp-6382	192	7	altered	altered	ADJ
fnp-6382	192	8	gfap	gfap	ADJ
fnp-6382	192	9	expression	expression	NOUN
fnp-6382	192	10	in	in	ADP
fnp-6382	192	11	cte	cte	PROPN
fnp-6382	192	12	(	(	PUNCT
fnp-6382	192	13	16,79	16,79	NUM
fnp-6382	192	14	)	)	PUNCT
fnp-6382	192	15	,	,	PUNCT
fnp-6382	192	16	fluid	fluid	ADJ
fnp-6382	192	17	biomarker	biomarker	NOUN
fnp-6382	192	18	studies	study	NOUN
fnp-6382	192	19	in	in	ADP
fnp-6382	192	20	pathologically	pathologically	ADV
fnp-6382	192	21	confirmed	confirm	VERB
fnp-6382	192	22	cte	cte	PROPN
fnp-6382	192	23	are	be	AUX
fnp-6382	192	24	rather	rather	ADV
fnp-6382	192	25	limited	limited	ADJ
fnp-6382	192	26	.	.	PUNCT
fnp-6382	193	1	however	however	ADV
fnp-6382	193	2	,	,	PUNCT
fnp-6382	193	3	gfap	gfap	ADJ
fnp-6382	193	4	elevations	elevation	NOUN
fnp-6382	193	5	have	have	AUX
fnp-6382	193	6	been	be	AUX
fnp-6382	193	7	observed	observe	VERB
fnp-6382	193	8	in	in	ADP
fnp-6382	193	9	rhi	rhi	NOUN
fnp-6382	193	10	-	-	PUNCT
fnp-6382	193	11	exposed	expose	VERB
fnp-6382	193	12	populations	population	NOUN
fnp-6382	193	13	who	who	PRON
fnp-6382	193	14	may	may	AUX
fnp-6382	193	15	be	be	AUX
fnp-6382	193	16	susceptible	susceptible	ADJ
fnp-6382	193	17	to	to	ADP
fnp-6382	193	18	cte	cte	PROPN
fnp-6382	193	19	.	.	PUNCT
fnp-6382	194	1	in	in	ADP
fnp-6382	194	2	a	a	DET
fnp-6382	194	3	longitudinal	longitudinal	ADJ
fnp-6382	194	4	cohort	cohort	NOUN
fnp-6382	194	5	study	study	NOUN
fnp-6382	194	6	of	of	ADP
fnp-6382	194	7	professional	professional	ADJ
fnp-6382	194	8	boxers	boxer	NOUN
fnp-6382	194	9	and	and	CCONJ
fnp-6382	194	10	mixed	mixed	ADJ
fnp-6382	194	11	martial	martial	ADJ
fnp-6382	194	12	art	art	NOUN
fnp-6382	194	13	fighters	fighter	NOUN
fnp-6382	194	14	,	,	PUNCT
fnp-6382	194	15	bernick	bernick	PROPN
fnp-6382	194	16	et	et	PROPN
fnp-6382	194	17	al	al	PROPN
fnp-6382	194	18	.	.	PROPN
fnp-6382	195	1	(	(	PUNCT
fnp-6382	195	2	2023	2023	NUM
fnp-6382	195	3	)	)	PUNCT
fnp-6382	195	4	measured	measure	VERB
fnp-6382	195	5	plasma	plasma	NOUN
fnp-6382	195	6	levels	level	NOUN
fnp-6382	195	7	of	of	ADP
fnp-6382	195	8	gfap	gfap	NOUN
fnp-6382	195	9	annually	annually	ADV
fnp-6382	195	10	over	over	ADP
fnp-6382	195	11	one	one	NUM
fnp-6382	195	12	to	to	PART
fnp-6382	195	13	four	four	NUM
fnp-6382	195	14	years	year	NOUN
fnp-6382	195	15	of	of	ADP
fnp-6382	195	16	follow	follow	NOUN
fnp-6382	195	17	-	-	PUNCT
fnp-6382	195	18	up	up	NOUN
fnp-6382	195	19	,	,	PUNCT
fnp-6382	195	20	examining	examine	VERB
fnp-6382	195	21	the	the	DET
fnp-6382	195	22	association	association	NOUN
fnp-6382	195	23	of	of	ADP
fnp-6382	195	24	gfap	gfap	ADJ
fnp-6382	195	25	levels	level	NOUN
fnp-6382	195	26	with	with	ADP
fnp-6382	195	27	structural	structural	ADJ
fnp-6382	195	28	mri	mri	NOUN
fnp-6382	195	29	data	datum	NOUN
fnp-6382	195	30	and	and	CCONJ
fnp-6382	195	31	cognitive	cognitive	ADJ
fnp-6382	195	32	outcomes	outcome	NOUN
fnp-6382	195	33	.	.	PUNCT
fnp-6382	196	1	longitudinal	longitudinal	ADJ
fnp-6382	196	2	increases	increase	NOUN
fnp-6382	196	3	in	in	ADP
fnp-6382	196	4	gfap	gfap	ADJ
fnp-6382	196	5	levels	level	NOUN
fnp-6382	196	6	were	be	AUX
fnp-6382	196	7	significantly	significantly	ADV
fnp-6382	196	8	associated	associate	VERB
fnp-6382	196	9	with	with	ADP
fnp-6382	196	10	decreased	decrease	VERB
fnp-6382	196	11	volume	volume	NOUN
fnp-6382	196	12	of	of	ADP
fnp-6382	196	13	certain	certain	ADJ
fnp-6382	196	14	brain	brain	NOUN
fnp-6382	196	15	regions	region	NOUN
fnp-6382	196	16	on	on	ADP
fnp-6382	196	17	mri	mri	NOUN
fnp-6382	196	18	,	,	PUNCT
fnp-6382	196	19	including	include	VERB
fnp-6382	196	20	hippocampus	hippocampus	NOUN
fnp-6382	196	21	and	and	CCONJ
fnp-6382	196	22	thalamus	thalamus	NOUN
fnp-6382	196	23	,	,	PUNCT
fnp-6382	196	24	in	in	ADP
fnp-6382	196	25	addition	addition	NOUN
fnp-6382	196	26	to	to	ADP
fnp-6382	196	27	enlarged	enlarge	VERB
fnp-6382	196	28	lateral	lateral	ADJ
fnp-6382	196	29	ventricles	ventricle	NOUN
fnp-6382	196	30	.	.	PUNCT
fnp-6382	197	1	these	these	DET
fnp-6382	197	2	structural	structural	ADJ
fnp-6382	197	3	changes	change	NOUN
fnp-6382	197	4	also	also	ADV
fnp-6382	197	5	correlated	correlate	VERB
fnp-6382	197	6	with	with	ADP
fnp-6382	197	7	declines	decline	NOUN
fnp-6382	197	8	in	in	ADP
fnp-6382	197	9	processing	processing	NOUN
fnp-6382	197	10	speed	speed	NOUN
fnp-6382	197	11	,	,	PUNCT
fnp-6382	197	12	memory	memory	NOUN
fnp-6382	197	13	,	,	PUNCT
fnp-6382	197	14	and	and	CCONJ
fnp-6382	197	15	reaction	reaction	NOUN
fnp-6382	197	16	time	time	NOUN
fnp-6382	197	17	,	,	PUNCT
fnp-6382	197	18	suggesting	suggest	VERB
fnp-6382	197	19	that	that	SCONJ
fnp-6382	197	20	gfap	gfap	NOUN
fnp-6382	197	21	is	be	AUX
fnp-6382	197	22	a	a	DET
fnp-6382	197	23	viable	viable	ADJ
fnp-6382	197	24	marker	marker	NOUN
fnp-6382	197	25	for	for	ADP
fnp-6382	197	26	long	long	ADJ
fnp-6382	197	27	-	-	PUNCT
fnp-6382	197	28	term	term	NOUN
fnp-6382	197	29	neurodegenerative	neurodegenerative	ADJ
fnp-6382	197	30	progression	progression	NOUN
fnp-6382	197	31	in	in	ADP
fnp-6382	197	32	rhi	rhi	NOUN
fnp-6382	197	33	-	-	PUNCT
fnp-6382	197	34	exposed	expose	VERB
fnp-6382	197	35	populations	population	NOUN
fnp-6382	197	36	(	(	PUNCT
fnp-6382	197	37	80	80	NUM
fnp-6382	197	38	)	)	PUNCT
fnp-6382	197	39	.	.	PUNCT
fnp-6382	198	1	additional	additional	ADJ
fnp-6382	198	2	studies	study	NOUN
fnp-6382	198	3	further	far	ADV
fnp-6382	198	4	support	support	VERB
fnp-6382	198	5	the	the	DET
fnp-6382	198	6	relevance	relevance	NOUN
fnp-6382	198	7	of	of	ADP
fnp-6382	198	8	gfap	gfap	NOUN
fnp-6382	198	9	as	as	ADP
fnp-6382	198	10	a	a	DET
fnp-6382	198	11	marker	marker	NOUN
fnp-6382	198	12	of	of	ADP
fnp-6382	198	13	astroglial	astroglial	ADJ
fnp-6382	198	14	activation	activation	NOUN
fnp-6382	198	15	following	follow	VERB
fnp-6382	198	16	rhi	rhi	PROPN
fnp-6382	198	17	.	.	PUNCT
fnp-6382	199	1	in	in	ADP
fnp-6382	199	2	a	a	DET
fnp-6382	199	3	study	study	NOUN
fnp-6382	199	4	from	from	ADP
fnp-6382	199	5	bazarian	bazarian	PROPN
fnp-6382	199	6	et	et	PROPN
fnp-6382	199	7	al	al	PROPN
fnp-6382	199	8	.	.	PROPN
fnp-6382	199	9	,	,	PUNCT
fnp-6382	199	10	serum	serum	PROPN
fnp-6382	199	11	gfap	gfap	NOUN
fnp-6382	199	12	was	be	AUX
fnp-6382	199	13	measured	measure	VERB
fnp-6382	199	14	in	in	ADP
fnp-6382	199	15	collegiate	collegiate	ADJ
fnp-6382	199	16	football	football	NOUN
fnp-6382	199	17	players	player	NOUN
fnp-6382	199	18	before	before	ADV
fnp-6382	199	19	,	,	PUNCT
fnp-6382	199	20	immediately	immediately	ADV
fnp-6382	199	21	after	after	ADV
fnp-6382	199	22	,	,	PUNCT
fnp-6382	199	23	and	and	CCONJ
fnp-6382	199	24	45	45	NUM
fnp-6382	199	25	minutes	minute	NOUN
fnp-6382	199	26	post	post	ADJ
fnp-6382	199	27	-	-	NOUN
fnp-6382	199	28	game	game	NOUN
fnp-6382	199	29	.	.	PUNCT
fnp-6382	200	1	although	although	SCONJ
fnp-6382	200	2	no	no	DET
fnp-6382	200	3	athletes	athlete	NOUN
fnp-6382	200	4	sustained	sustain	VERB
fnp-6382	200	5	a	a	DET
fnp-6382	200	6	diagnosed	diagnose	VERB
fnp-6382	200	7	concussion	concussion	NOUN
fnp-6382	200	8	,	,	PUNCT
fnp-6382	200	9	gfap	gfap	ADJ
fnp-6382	200	10	levels	level	NOUN
fnp-6382	200	11	increased	increase	VERB
fnp-6382	200	12	significantly	significantly	ADV
fnp-6382	200	13	after	after	ADP
fnp-6382	200	14	the	the	DET
fnp-6382	200	15	game	game	NOUN
fnp-6382	200	16	,	,	PUNCT
fnp-6382	200	17	with	with	ADP
fnp-6382	200	18	magnitudes	magnitude	NOUN
fnp-6382	200	19	of	of	ADP
fnp-6382	200	20	increase	increase	NOUN
fnp-6382	200	21	correlating	correlate	VERB
fnp-6382	200	22	with	with	ADP
fnp-6382	200	23	both	both	CCONJ
fnp-6382	200	24	helmet	helmet	NOUN
fnp-6382	200	25	-	-	PUNCT
fnp-6382	200	26	recorded	record	VERB
fnp-6382	200	27	head	head	NOUN
fnp-6382	200	28	impact	impact	NOUN
fnp-6382	200	29	exposure	exposure	NOUN
fnp-6382	200	30	and	and	CCONJ
fnp-6382	200	31	reduced	reduce	VERB
fnp-6382	200	32	white	white	ADJ
fnp-6382	200	33	matter	matter	NOUN
fnp-6382	200	34	integrity	integrity	NOUN
fnp-6382	200	35	measured	measure	VERB
fnp-6382	200	36	via	via	ADP
fnp-6382	200	37	diffusion	diffusion	NOUN
fnp-6382	200	38	tensor	tensor	NOUN
fnp-6382	200	39	imaging	imaging	NOUN
fnp-6382	200	40	.	.	PUNCT
fnp-6382	201	1	these	these	DET
fnp-6382	201	2	associations	association	NOUN
fnp-6382	201	3	remained	remain	VERB
fnp-6382	201	4	significant	significant	ADJ
fnp-6382	201	5	even	even	ADV
fnp-6382	201	6	after	after	ADP
fnp-6382	201	7	adjusting	adjust	VERB
fnp-6382	201	8	for	for	ADP
fnp-6382	201	9	physical	physical	ADJ
fnp-6382	201	10	exertion	exertion	NOUN
fnp-6382	201	11	,	,	PUNCT
fnp-6382	201	12	suggesting	suggest	VERB
fnp-6382	201	13	that	that	SCONJ
fnp-6382	201	14	acute	acute	ADJ
fnp-6382	201	15	gfap	gfap	ADJ
fnp-6382	201	16	elevations	elevation	NOUN
fnp-6382	201	17	may	may	AUX
fnp-6382	201	18	reflect	reflect	VERB
fnp-6382	201	19	subclinical	subclinical	ADJ
fnp-6382	201	20	astrocytic	astrocytic	ADJ
fnp-6382	201	21	injury	injury	NOUN
fnp-6382	201	22	related	relate	VERB
fnp-6382	201	23	to	to	ADP
fnp-6382	201	24	repetitive	repetitive	ADJ
fnp-6382	201	25	,	,	PUNCT
fnp-6382	201	26	non	non	ADJ
fnp-6382	201	27	-	-	ADJ
fnp-6382	201	28	concussive	concussive	ADJ
fnp-6382	201	29	impacts	impact	NOUN
fnp-6382	201	30	sustained	sustain	VERB
fnp-6382	201	31	during	during	ADP
fnp-6382	201	32	a	a	DET
fnp-6382	201	33	single	single	ADJ
fnp-6382	201	34	game	game	NOUN
fnp-6382	201	35	(	(	PUNCT
fnp-6382	201	36	81	81	NUM
fnp-6382	201	37	)	)	PUNCT
fnp-6382	201	38	.	.	PUNCT
fnp-6382	202	1	furthermore	furthermore	ADV
fnp-6382	202	2	,	,	PUNCT
fnp-6382	202	3	in	in	ADP
fnp-6382	202	4	a	a	DET
fnp-6382	202	5	study	study	NOUN
fnp-6382	202	6	on	on	ADP
fnp-6382	202	7	collegiate	collegiate	ADJ
fnp-6382	202	8	women	woman	NOUN
fnp-6382	202	9	’s	’s	PART
fnp-6382	202	10	water	water	NOUN
fnp-6382	202	11	polo	polo	NOUN
fnp-6382	202	12	players	player	NOUN
fnp-6382	202	13	,	,	PUNCT
fnp-6382	202	14	serum	serum	NOUN
fnp-6382	202	15	gfap	gfap	ADJ
fnp-6382	202	16	concentrations	concentration	NOUN
fnp-6382	202	17	were	be	AUX
fnp-6382	202	18	assessed	assess	VERB
fnp-6382	202	19	over	over	ADP
fnp-6382	202	20	an	an	DET
fnp-6382	202	21	eight	eight	NUM
fnp-6382	202	22	-	-	PUNCT
fnp-6382	202	23	week	week	NOUN
fnp-6382	202	24	preseason	preseason	NOUN
fnp-6382	202	25	period	period	NOUN
fnp-6382	202	26	.	.	PUNCT
fnp-6382	203	1	the	the	DET
fnp-6382	203	2	authors	author	NOUN
fnp-6382	203	3	reported	report	VERB
fnp-6382	203	4	a	a	DET
fnp-6382	203	5	significant	significant	ADJ
fnp-6382	203	6	linear	linear	ADJ
fnp-6382	203	7	increase	increase	NOUN
fnp-6382	203	8	in	in	ADP
fnp-6382	203	9	gfap	gfap	NOUN
fnp-6382	203	10	over	over	ADP
fnp-6382	203	11	the	the	DET
fnp-6382	203	12	study	study	NOUN
fnp-6382	203	13	period	period	NOUN
fnp-6382	203	14	,	,	PUNCT
fnp-6382	203	15	while	while	SCONJ
fnp-6382	203	16	no	no	DET
fnp-6382	203	17	acute	acute	ADJ
fnp-6382	203	18	changes	change	NOUN
fnp-6382	203	19	in	in	ADP
fnp-6382	203	20	gfap	gfap	PROPN
fnp-6382	203	21	were	be	AUX
fnp-6382	203	22	observed	observe	VERB
fnp-6382	203	23	following	follow	VERB
fnp-6382	203	24	scrimmages	scrimmage	NOUN
fnp-6382	203	25	,	,	PUNCT
fnp-6382	203	26	suggesting	suggest	VERB
fnp-6382	203	27	that	that	SCONJ
fnp-6382	203	28	astroglial	astroglial	ADJ
fnp-6382	203	29	activation	activation	NOUN
fnp-6382	203	30	may	may	AUX
fnp-6382	203	31	accumulate	accumulate	VERB
fnp-6382	203	32	over	over	ADP
fnp-6382	203	33	time	time	NOUN
fnp-6382	203	34	even	even	ADV
fnp-6382	203	35	in	in	ADP
fnp-6382	203	36	the	the	DET
fnp-6382	203	37	absence	absence	NOUN
fnp-6382	203	38	of	of	ADP
fnp-6382	203	39	concussion	concussion	NOUN
fnp-6382	203	40	diagnoses	diagnosis	NOUN
fnp-6382	203	41	.	.	PUNCT
fnp-6382	204	1	however	however	ADV
fnp-6382	204	2	,	,	PUNCT
fnp-6382	204	3	this	this	DET
fnp-6382	204	4	longitudinal	longitudinal	ADJ
fnp-6382	204	5	gfap	gfap	ADJ
fnp-6382	204	6	increase	increase	NOUN
fnp-6382	204	7	was	be	AUX
fnp-6382	204	8	not	not	PART
fnp-6382	204	9	significantly	significantly	ADV
fnp-6382	204	10	associated	associate	VERB
fnp-6382	204	11	with	with	ADP
fnp-6382	204	12	cumulative	cumulative	ADJ
fnp-6382	204	13	head	head	NOUN
fnp-6382	204	14	impact	impact	NOUN
fnp-6382	204	15	burden	burden	NOUN
fnp-6382	204	16	calculated	calculate	VERB
fnp-6382	204	17	based	base	VERB
fnp-6382	204	18	on	on	ADP
fnp-6382	204	19	acceleration	acceleration	NOUN
fnp-6382	204	20	metrics	metric	NOUN
fnp-6382	204	21	from	from	ADP
fnp-6382	204	22	instrumented	instrumented	ADJ
fnp-6382	204	23	mouth	mouth	NOUN
fnp-6382	204	24	guards	guard	NOUN
fnp-6382	204	25	(	(	PUNCT
fnp-6382	204	26	82	82	NUM
fnp-6382	204	27	)	)	PUNCT
fnp-6382	204	28	.	.	PUNCT
fnp-6382	205	1	these	these	DET
fnp-6382	205	2	findings	finding	NOUN
fnp-6382	205	3	support	support	VERB
fnp-6382	205	4	the	the	DET
fnp-6382	205	5	notion	notion	NOUN
fnp-6382	205	6	that	that	SCONJ
fnp-6382	205	7	while	while	SCONJ
fnp-6382	205	8	gfap	gfap	NOUN
fnp-6382	205	9	can	can	AUX
fnp-6382	205	10	increase	increase	VERB
fnp-6382	205	11	longitudinally	longitudinally	ADV
fnp-6382	205	12	in	in	ADP
fnp-6382	205	13	rhi	rhi	NOUN
fnp-6382	205	14	-	-	PUNCT
fnp-6382	205	15	exposed	expose	VERB
fnp-6382	205	16	populations	population	NOUN
fnp-6382	205	17	,	,	PUNCT
fnp-6382	205	18	the	the	DET
fnp-6382	205	19	utility	utility	NOUN
fnp-6382	205	20	of	of	ADP
fnp-6382	205	21	gfap	gfap	NOUN
fnp-6382	205	22	as	as	ADP
fnp-6382	205	23	a	a	DET
fnp-6382	205	24	specific	specific	ADJ
fnp-6382	205	25	marker	marker	NOUN
fnp-6382	205	26	of	of	ADP
fnp-6382	205	27	head	head	NOUN
fnp-6382	205	28	impact	impact	NOUN
fnp-6382	205	29	burden	burden	NOUN
fnp-6382	205	30	,	,	PUNCT
fnp-6382	205	31	particularly	particularly	ADV
fnp-6382	205	32	in	in	ADP
fnp-6382	205	33	subconcussive	subconcussive	ADJ
fnp-6382	205	34	settings	setting	NOUN
fnp-6382	205	35	,	,	PUNCT
fnp-6382	205	36	may	may	AUX
fnp-6382	205	37	be	be	AUX
fnp-6382	205	38	limited	limit	VERB
fnp-6382	205	39	.	.	PUNCT
fnp-6382	206	1	shahim	shahim	PROPN
fnp-6382	206	2	et	et	PROPN
fnp-6382	206	3	al	al	PROPN
fnp-6382	206	4	.	.	PROPN
fnp-6382	206	5	evaluated	evaluate	VERB
fnp-6382	206	6	csf	csf	ADJ
fnp-6382	206	7	and	and	CCONJ
fnp-6382	206	8	plasma	plasma	NOUN
fnp-6382	206	9	levels	level	NOUN
fnp-6382	206	10	of	of	ADP
fnp-6382	206	11	gfap	gfap	NOUN
fnp-6382	206	12	in	in	ADP
fnp-6382	206	13	a	a	DET
fnp-6382	206	14	cohort	cohort	NOUN
fnp-6382	206	15	of	of	ADP
fnp-6382	206	16	rhi	rhi	NOUN
fnp-6382	206	17	-	-	PUNCT
fnp-6382	206	18	exposed	expose	VERB
fnp-6382	206	19	professional	professional	ADJ
fnp-6382	206	20	athletes	athlete	NOUN
fnp-6382	206	21	with	with	ADP
fnp-6382	206	22	persistent	persistent	ADJ
fnp-6382	206	23	symptoms	symptom	NOUN
fnp-6382	206	24	.	.	PUNCT
fnp-6382	207	1	plasma	plasma	NOUN
fnp-6382	207	2	gfap	gfap	ADJ
fnp-6382	207	3	levels	level	NOUN
fnp-6382	207	4	showed	show	VERB
fnp-6382	207	5	a	a	DET
fnp-6382	207	6	moderate	moderate	ADJ
fnp-6382	207	7	correlation	correlation	NOUN
fnp-6382	207	8	with	with	ADP
fnp-6382	207	9	csf	csf	ADJ
fnp-6382	207	10	gfap	gfap	ADJ
fnp-6382	207	11	levels	level	NOUN
fnp-6382	207	12	,	,	PUNCT
fnp-6382	207	13	but	but	CCONJ
fnp-6382	207	14	plasma	plasma	NOUN
fnp-6382	207	15	levels	level	NOUN
fnp-6382	207	16	did	do	AUX
fnp-6382	207	17	not	not	PART
fnp-6382	207	18	significantly	significantly	ADV
fnp-6382	207	19	correlate	correlate	VERB
fnp-6382	207	20	to	to	ADP
fnp-6382	207	21	symptom	symptom	NOUN
fnp-6382	207	22	severity	severity	NOUN
fnp-6382	207	23	or	or	CCONJ
fnp-6382	207	24	number	number	NOUN
fnp-6382	207	25	of	of	ADP
fnp-6382	207	26	prior	prior	ADJ
fnp-6382	207	27	concussions	concussion	NOUN
fnp-6382	207	28	.	.	PUNCT
fnp-6382	208	1	in	in	ADP
fnp-6382	208	2	addition	addition	NOUN
fnp-6382	208	3	,	,	PUNCT
fnp-6382	208	4	serum	serum	NOUN
fnp-6382	208	5	gfap	gfap	ADJ
fnp-6382	208	6	levels	level	NOUN
fnp-6382	208	7	did	do	AUX
fnp-6382	208	8	not	not	PART
fnp-6382	208	9	significantly	significantly	ADV
fnp-6382	208	10	differ	differ	VERB
fnp-6382	208	11	between	between	ADP
fnp-6382	208	12	rhi	rhi	NOUN
fnp-6382	208	13	-	-	PUNCT
fnp-6382	208	14	exposed	expose	VERB
fnp-6382	208	15	subjects	subject	NOUN
fnp-6382	208	16	and	and	CCONJ
fnp-6382	208	17	unexposed	unexposed	ADJ
fnp-6382	208	18	controls	control	NOUN
fnp-6382	208	19	,	,	PUNCT
fnp-6382	208	20	and	and	CCONJ
fnp-6382	208	21	serum	serum	NOUN
fnp-6382	208	22	gfap	gfap	ADJ
fnp-6382	208	23	levels	level	NOUN
fnp-6382	208	24	did	do	AUX
fnp-6382	208	25	not	not	PART
fnp-6382	208	26	relate	relate	VERB
fnp-6382	208	27	to	to	ADP
fnp-6382	208	28	bbb	bbb	PROPN
fnp-6382	208	29	integrity	integrity	NOUN
fnp-6382	208	30	measured	measure	VERB
fnp-6382	208	31	via	via	ADP
fnp-6382	208	32	the	the	DET
fnp-6382	208	33	csf	csf	PROPN
fnp-6382	208	34	/	/	SYM
fnp-6382	208	35	serum	serum	NOUN
fnp-6382	208	36	albumin	albumin	ADJ
fnp-6382	208	37	ratio	ratio	NOUN
fnp-6382	208	38	.	.	PUNCT
fnp-6382	209	1	thus	thus	ADV
fnp-6382	209	2	,	,	PUNCT
fnp-6382	209	3	gfap	gfap	NOUN
fnp-6382	209	4	may	may	AUX
fnp-6382	209	5	have	have	VERB
fnp-6382	209	6	limited	limit	VERB
fnp-6382	209	7	utility	utility	NOUN
fnp-6382	209	8	in	in	ADP
fnp-6382	209	9	the	the	DET
fnp-6382	209	10	later	later	ADJ
fnp-6382	209	11	stages	stage	NOUN
fnp-6382	209	12	of	of	ADP
fnp-6382	209	13	post	post	ADJ
fnp-6382	209	14	-	-	PROPN
fnp-6382	209	15	rhi	rhi	ADJ
fnp-6382	209	16	neurodegeneration	neurodegeneration	NOUN
fnp-6382	209	17	long	long	ADV
fnp-6382	209	18	after	after	ADP
fnp-6382	209	19	initial	initial	ADJ
fnp-6382	209	20	exposure	exposure	NOUN
fnp-6382	209	21	,	,	PUNCT
fnp-6382	209	22	suggesting	suggest	VERB
fnp-6382	209	23	a	a	DET
fnp-6382	209	24	temporal	temporal	ADJ
fnp-6382	209	25	window	window	NOUN
fnp-6382	209	26	where	where	SCONJ
fnp-6382	209	27	astrocytic	astrocytic	ADJ
fnp-6382	209	28	markers	marker	NOUN
fnp-6382	209	29	could	could	AUX
fnp-6382	209	30	be	be	AUX
fnp-6382	209	31	more	more	ADV
fnp-6382	209	32	sensitive	sensitive	ADJ
fnp-6382	209	33	to	to	ADP
fnp-6382	209	34	injury	injury	NOUN
fnp-6382	209	35	(	(	PUNCT
fnp-6382	209	36	83	83	NUM
fnp-6382	209	37	)	)	PUNCT
fnp-6382	209	38	.	.	PUNCT
fnp-6382	210	1	as	as	ADP
fnp-6382	210	2	such	such	ADJ
fnp-6382	210	3	,	,	PUNCT
fnp-6382	210	4	future	future	ADJ
fnp-6382	210	5	studies	study	NOUN
fnp-6382	210	6	may	may	AUX
fnp-6382	210	7	aim	aim	VERB
fnp-6382	210	8	to	to	PART
fnp-6382	210	9	better	well	ADV
fnp-6382	210	10	characterize	characterize	VERB
fnp-6382	210	11	the	the	DET
fnp-6382	210	12	long	long	ADJ
fnp-6382	210	13	-	-	PUNCT
fnp-6382	210	14	term	term	NOUN
fnp-6382	210	15	trajectory	trajectory	NOUN
fnp-6382	210	16	of	of	ADP
fnp-6382	210	17	serum	serum	NOUN
fnp-6382	210	18	gfap	gfap	PROPN
fnp-6382	210	19	from	from	ADP
fnp-6382	210	20	rhi	rhi	PROPN
fnp-6382	210	21	exposure	exposure	NOUN
fnp-6382	210	22	to	to	ADP
fnp-6382	210	23	post	post	ADJ
fnp-6382	210	24	-	-	ADJ
fnp-6382	210	25	mortem	mortem	ADJ
fnp-6382	210	26	evaluation	evaluation	NOUN
fnp-6382	210	27	.	.	PUNCT
fnp-6382	211	1	furthermore	furthermore	ADV
fnp-6382	211	2	,	,	PUNCT
fnp-6382	211	3	asken	asken	VERB
fnp-6382	211	4	et	et	PROPN
fnp-6382	211	5	al	al	PROPN
fnp-6382	211	6	.	.	PROPN
fnp-6382	212	1	(	(	PUNCT
fnp-6382	212	2	2022	2022	NUM
fnp-6382	212	3	)	)	PUNCT
fnp-6382	212	4	examined	examine	VERB
fnp-6382	212	5	plasma	plasma	NOUN
fnp-6382	212	6	gfap	gfap	ADJ
fnp-6382	212	7	levels	level	NOUN
fnp-6382	212	8	in	in	ADP
fnp-6382	212	9	a	a	DET
fnp-6382	212	10	clinicopathological	clinicopathological	ADJ
fnp-6382	212	11	cohort	cohort	NOUN
fnp-6382	212	12	of	of	ADP
fnp-6382	212	13	nine	nine	NUM
fnp-6382	212	14	rhi	rhi	NOUN
fnp-6382	212	15	-	-	PUNCT
fnp-6382	212	16	exposed	expose	VERB
fnp-6382	212	17	individuals	individual	NOUN
fnp-6382	212	18	who	who	PRON
fnp-6382	212	19	were	be	AUX
fnp-6382	212	20	followed	follow	VERB
fnp-6382	212	21	to	to	PART
fnp-6382	212	22	autopsy	autopsy	VERB
fnp-6382	212	23	.	.	PUNCT
fnp-6382	213	1	three	three	NUM
fnp-6382	213	2	out	out	ADP
fnp-6382	213	3	of	of	ADP
fnp-6382	213	4	five	five	NUM
fnp-6382	213	5	subjects	subject	NOUN
fnp-6382	213	6	with	with	ADP
fnp-6382	213	7	longitudinal	longitudinal	ADJ
fnp-6382	213	8	data	datum	NOUN
fnp-6382	213	9	had	have	VERB
fnp-6382	213	10	a	a	DET
fnp-6382	213	11	steady	steady	ADJ
fnp-6382	213	12	increase	increase	NOUN
fnp-6382	213	13	in	in	ADP
fnp-6382	213	14	gfap	gfap	ADJ
fnp-6382	213	15	concentration	concentration	NOUN
fnp-6382	213	16	over	over	ADP
fnp-6382	213	17	time	time	NOUN
fnp-6382	213	18	,	,	PUNCT
fnp-6382	213	19	ranging	range	VERB
fnp-6382	213	20	from	from	ADP
fnp-6382	213	21	two	two	NUM
fnp-6382	213	22	to	to	PART
fnp-6382	213	23	seven	seven	NUM
fnp-6382	213	24	years	year	NOUN
fnp-6382	213	25	,	,	PUNCT
fnp-6382	213	26	in	in	ADP
fnp-6382	213	27	addition	addition	NOUN
fnp-6382	213	28	to	to	ADP
fnp-6382	213	29	having	have	VERB
fnp-6382	213	30	higher	high	ADJ
fnp-6382	213	31	levels	level	NOUN
fnp-6382	213	32	at	at	ADP
fnp-6382	213	33	baseline	baseline	NOUN
fnp-6382	213	34	compared	compare	VERB
fnp-6382	213	35	to	to	ADP
fnp-6382	213	36	healthy	healthy	ADJ
fnp-6382	213	37	controls	control	NOUN
fnp-6382	213	38	.	.	PUNCT
fnp-6382	214	1	among	among	ADP
fnp-6382	214	2	the	the	DET
fnp-6382	214	3	five	five	NUM
fnp-6382	214	4	cases	case	NOUN
fnp-6382	214	5	with	with	ADP
fnp-6382	214	6	autopsy	autopsy	NOUN
fnp-6382	214	7	-	-	PUNCT
fnp-6382	214	8	confirmed	confirm	VERB
fnp-6382	214	9	cte	cte	NOUN
fnp-6382	214	10	,	,	PUNCT
fnp-6382	214	11	elevated	elevate	VERB
fnp-6382	214	12	gfap	gfap	ADJ
fnp-6382	214	13	levels	level	NOUN
fnp-6382	214	14	tended	tend	VERB
fnp-6382	214	15	to	to	PART
fnp-6382	214	16	co	co	VERB
fnp-6382	214	17	-	-	VERB
fnp-6382	214	18	occur	occur	VERB
fnp-6382	214	19	with	with	ADP
fnp-6382	214	20	imaging	imaging	NOUN
fnp-6382	214	21	evidence	evidence	NOUN
fnp-6382	214	22	of	of	ADP
fnp-6382	214	23	medial	medial	ADJ
fnp-6382	214	24	temporal	temporal	ADJ
fnp-6382	214	25	atrophy	atrophy	NOUN
fnp-6382	214	26	and	and	CCONJ
fnp-6382	214	27	cognitive	cognitive	ADJ
fnp-6382	214	28	decline	decline	NOUN
fnp-6382	214	29	.	.	PUNCT
fnp-6382	215	1	cte	cte	PROPN
fnp-6382	215	2	was	be	AUX
fnp-6382	215	3	the	the	DET
fnp-6382	215	4	primary	primary	ADJ
fnp-6382	215	5	neuropathological	neuropathological	ADJ
fnp-6382	215	6	diagnosis	diagnosis	NOUN
fnp-6382	215	7	in	in	ADP
fnp-6382	215	8	two	two	NUM
fnp-6382	215	9	cases	case	NOUN
fnp-6382	215	10	in	in	ADP
fnp-6382	215	11	which	which	PRON
fnp-6382	215	12	persistently	persistently	ADV
fnp-6382	215	13	high	high	ADJ
fnp-6382	215	14	gfap	gfap	ADJ
fnp-6382	215	15	levels	level	NOUN
fnp-6382	215	16	were	be	AUX
fnp-6382	215	17	observed	observe	VERB
fnp-6382	215	18	.	.	PUNCT
fnp-6382	216	1	while	while	SCONJ
fnp-6382	216	2	these	these	DET
fnp-6382	216	3	findings	finding	NOUN
fnp-6382	216	4	suggest	suggest	VERB
fnp-6382	216	5	a	a	DET
fnp-6382	216	6	possible	possible	ADJ
fnp-6382	216	7	association	association	NOUN
fnp-6382	216	8	between	between	ADP
fnp-6382	216	9	gfap	gfap	ADJ
fnp-6382	216	10	elevation	elevation	NOUN
fnp-6382	216	11	and	and	CCONJ
fnp-6382	216	12	cte	cte	PROPN
fnp-6382	216	13	pathology	pathology	PROPN
fnp-6382	216	14	,	,	PUNCT
fnp-6382	216	15	the	the	DET
fnp-6382	216	16	presence	presence	NOUN
fnp-6382	216	17	of	of	ADP
fnp-6382	216	18	frequent	frequent	ADJ
fnp-6382	216	19	co	co	NOUN
fnp-6382	216	20	-	-	NOUN
fnp-6382	216	21	pathologies	pathology	NOUN
fnp-6382	216	22	such	such	ADJ
fnp-6382	216	23	as	as	ADP
fnp-6382	216	24	ad	ad	NOUN
fnp-6382	216	25	or	or	CCONJ
fnp-6382	216	26	tdp-43	tdp-43	NOUN
fnp-6382	216	27	proteinopathy	proteinopathy	ADJ
fnp-6382	216	28	,	,	PUNCT
fnp-6382	216	29	underscores	underscore	VERB
fnp-6382	216	30	that	that	SCONJ
fnp-6382	216	31	gfap	gfap	NOUN
fnp-6382	216	32	is	be	AUX
fnp-6382	216	33	not	not	PART
fnp-6382	216	34	a	a	DET
fnp-6382	216	35	specific	specific	ADJ
fnp-6382	216	36	marker	marker	NOUN
fnp-6382	216	37	of	of	ADP
fnp-6382	216	38	cte	cte	NOUN
fnp-6382	216	39	and	and	CCONJ
fnp-6382	216	40	may	may	AUX
fnp-6382	216	41	instead	instead	ADV
fnp-6382	216	42	be	be	AUX
fnp-6382	216	43	implemented	implement	VERB
fnp-6382	216	44	as	as	ADP
fnp-6382	216	45	a	a	DET
fnp-6382	216	46	sensitive	sensitive	ADJ
fnp-6382	216	47	marker	marker	NOUN
fnp-6382	216	48	for	for	ADP
fnp-6382	216	49	astrocytic	astrocytic	ADJ
fnp-6382	216	50	activation	activation	NOUN
fnp-6382	216	51	in	in	ADP
fnp-6382	216	52	the	the	DET
fnp-6382	216	53	context	context	NOUN
fnp-6382	216	54	of	of	ADP
fnp-6382	216	55	neurodegeneration	neurodegeneration	NOUN
fnp-6382	216	56	(	(	PUNCT
fnp-6382	216	57	84	84	NUM
fnp-6382	216	58	)	)	PUNCT
fnp-6382	216	59	.	.	PUNCT
fnp-6382	217	1	taken	take	VERB
fnp-6382	217	2	together	together	ADV
fnp-6382	217	3	,	,	PUNCT
fnp-6382	217	4	these	these	DET
fnp-6382	217	5	findings	finding	NOUN
fnp-6382	217	6	underscore	underscore	VERB
fnp-6382	217	7	that	that	SCONJ
fnp-6382	217	8	while	while	SCONJ
fnp-6382	217	9	gfap	gfap	NOUN
fnp-6382	217	10	may	may	AUX
fnp-6382	217	11	be	be	AUX
fnp-6382	217	12	a	a	DET
fnp-6382	217	13	sensitive	sensitive	ADJ
fnp-6382	217	14	indicator	indicator	NOUN
fnp-6382	217	15	of	of	ADP
fnp-6382	217	16	acute	acute	ADJ
fnp-6382	217	17	astroglial	astroglial	ADJ
fnp-6382	217	18	responses	response	NOUN
fnp-6382	217	19	to	to	ADP
fnp-6382	217	20	rhi	rhi	PROPN
fnp-6382	217	21	,	,	PUNCT
fnp-6382	217	22	including	include	VERB
fnp-6382	217	23	subconcussive	subconcussive	ADJ
fnp-6382	217	24	impacts	impact	NOUN
fnp-6382	217	25	,	,	PUNCT
fnp-6382	217	26	it	it	PRON
fnp-6382	217	27	could	could	AUX
fnp-6382	217	28	be	be	AUX
fnp-6382	217	29	subject	subject	ADJ
fnp-6382	217	30	to	to	ADP
fnp-6382	217	31	temporal	temporal	ADJ
fnp-6382	217	32	and	and	CCONJ
fnp-6382	217	33	individual	individual	ADJ
fnp-6382	217	34	variability	variability	NOUN
fnp-6382	217	35	.	.	PUNCT
fnp-6382	218	1	although	although	SCONJ
fnp-6382	218	2	promising	promise	VERB
fnp-6382	218	3	,	,	PUNCT
fnp-6382	218	4	the	the	DET
fnp-6382	218	5	utility	utility	NOUN
fnp-6382	218	6	of	of	ADP
fnp-6382	218	7	gfap	gfap	NOUN
fnp-6382	218	8	as	as	ADP
fnp-6382	218	9	a	a	DET
fnp-6382	218	10	long	long	ADJ
fnp-6382	218	11	-	-	PUNCT
fnp-6382	218	12	term	term	NOUN
fnp-6382	218	13	biomarker	biomarker	NOUN
fnp-6382	218	14	of	of	ADP
fnp-6382	218	15	neurodegenerative	neurodegenerative	ADJ
fnp-6382	218	16	risk	risk	NOUN
fnp-6382	218	17	will	will	AUX
fnp-6382	218	18	likely	likely	ADV
fnp-6382	218	19	require	require	VERB
fnp-6382	218	20	longitudinal	longitudinal	ADJ
fnp-6382	218	21	tracking	tracking	NOUN
fnp-6382	218	22	and	and	CCONJ
fnp-6382	218	23	integration	integration	NOUN
fnp-6382	218	24	with	with	ADP
fnp-6382	218	25	symptom	symptom	NOUN
fnp-6382	218	26	trajectories	trajectory	NOUN
fnp-6382	218	27	and	and	CCONJ
fnp-6382	218	28	other	other	ADJ
fnp-6382	218	29	fluid	fluid	ADJ
fnp-6382	218	30	markers	marker	NOUN
fnp-6382	218	31	to	to	PART
fnp-6382	218	32	improve	improve	VERB
fnp-6382	218	33	specificity	specificity	NOUN
fnp-6382	218	34	for	for	ADP
fnp-6382	218	35	cte	cte	NOUN
fnp-6382	218	36	.	.	PUNCT
fnp-6382	219	1	additional	additional	ADJ
fnp-6382	219	2	prospective	prospective	ADJ
fnp-6382	219	3	markers	marker	NOUN
fnp-6382	219	4	of	of	ADP
fnp-6382	219	5	cte	cte	PROPN
fnp-6382	219	6	the	the	DET
fnp-6382	219	7	above	above	ADV
fnp-6382	219	8	mentioned	mention	VERB
fnp-6382	219	9	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	219	10	candidate	candidate	NOUN
fnp-6382	219	11	markers	marker	NOUN
fnp-6382	219	12	have	have	AUX
fnp-6382	219	13	been	be	AUX
fnp-6382	219	14	examined	examine	VERB
fnp-6382	219	15	to	to	ADP
fnp-6382	219	16	a	a	DET
fnp-6382	219	17	limited	limited	ADJ
fnp-6382	219	18	extent	extent	NOUN
fnp-6382	219	19	for	for	SCONJ
fnp-6382	219	20	their	their	PRON
fnp-6382	219	21	application	application	NOUN
fnp-6382	219	22	to	to	PART
fnp-6382	219	23	cte	cte	VERB
fnp-6382	219	24	pathology	pathology	NOUN
fnp-6382	219	25	.	.	PUNCT
fnp-6382	220	1	in	in	ADP
fnp-6382	220	2	addition	addition	NOUN
fnp-6382	220	3	,	,	PUNCT
fnp-6382	220	4	there	there	PRON
fnp-6382	220	5	are	be	VERB
fnp-6382	220	6	several	several	ADJ
fnp-6382	220	7	other	other	ADJ
fnp-6382	220	8	immune	immune	ADJ
fnp-6382	220	9	mediators	mediator	NOUN
fnp-6382	220	10	that	that	PRON
fnp-6382	220	11	may	may	AUX
fnp-6382	220	12	be	be	AUX
fnp-6382	220	13	considered	consider	VERB
fnp-6382	220	14	for	for	ADP
fnp-6382	220	15	future	future	ADJ
fnp-6382	220	16	post	post	ADJ
fnp-6382	220	17	-	-	ADJ
fnp-6382	220	18	mortem	mortem	ADJ
fnp-6382	220	19	investigations	investigation	NOUN
fnp-6382	220	20	.	.	PUNCT
fnp-6382	221	1	in	in	ADP
fnp-6382	221	2	general	general	ADJ
fnp-6382	221	3	,	,	PUNCT
fnp-6382	221	4	these	these	DET
fnp-6382	221	5	immune	immune	ADJ
fnp-6382	221	6	proteins	protein	NOUN
fnp-6382	221	7	have	have	AUX
fnp-6382	221	8	been	be	AUX
fnp-6382	221	9	primarily	primarily	ADV
fnp-6382	221	10	assessed	assess	VERB
fnp-6382	221	11	through	through	ADP
fnp-6382	221	12	mouse	mouse	NOUN
fnp-6382	221	13	models	model	NOUN
fnp-6382	221	14	,	,	PUNCT
fnp-6382	221	15	as	as	ADV
fnp-6382	221	16	well	well	ADV
fnp-6382	221	17	as	as	ADP
fnp-6382	221	18	in	in	ADP
fnp-6382	221	19	rhi	rhi	NOUN
fnp-6382	221	20	-	-	PUNCT
fnp-6382	221	21	exposed	expose	VERB
fnp-6382	221	22	living	living	NOUN
fnp-6382	221	23	subjects	subject	NOUN
fnp-6382	221	24	for	for	ADP
fnp-6382	221	25	some	some	DET
fnp-6382	221	26	cases	case	NOUN
fnp-6382	221	27	.	.	PUNCT
fnp-6382	222	1	yet	yet	ADV
fnp-6382	222	2	,	,	PUNCT
fnp-6382	222	3	there	there	PRON
fnp-6382	222	4	is	be	VERB
fnp-6382	222	5	limited	limited	ADJ
fnp-6382	222	6	understanding	understanding	NOUN
fnp-6382	222	7	of	of	ADP
fnp-6382	222	8	how	how	SCONJ
fnp-6382	222	9	exactly	exactly	ADV
fnp-6382	222	10	they	they	PRON
fnp-6382	222	11	fit	fit	VERB
fnp-6382	222	12	into	into	ADP
fnp-6382	222	13	the	the	DET
fnp-6382	222	14	signature	signature	NOUN
fnp-6382	222	15	for	for	ADP
fnp-6382	222	16	cte	cte	PROPN
fnp-6382	222	17	.	.	PUNCT
fnp-6382	223	1	future	future	ADJ
fnp-6382	223	2	investigations	investigation	NOUN
fnp-6382	223	3	could	could	AUX
fnp-6382	223	4	assess	assess	VERB
fnp-6382	223	5	the	the	DET
fnp-6382	223	6	specificity	specificity	NOUN
fnp-6382	223	7	of	of	ADP
fnp-6382	223	8	these	these	DET
fnp-6382	223	9	markers	marker	NOUN
fnp-6382	223	10	to	to	PART
fnp-6382	223	11	cte	cte	VERB
fnp-6382	223	12	by	by	ADP
fnp-6382	223	13	conducting	conduct	VERB
fnp-6382	223	14	comprehensive	comprehensive	ADJ
fnp-6382	223	15	panels	panel	NOUN
fnp-6382	223	16	of	of	ADP
fnp-6382	223	17	immune	immune	ADJ
fnp-6382	223	18	proteins	protein	NOUN
fnp-6382	223	19	in	in	ADP
fnp-6382	223	20	post	post	ADJ
fnp-6382	223	21	-	-	ADJ
fnp-6382	223	22	mortem	mortem	ADJ
fnp-6382	223	23	tissue	tissue	NOUN
fnp-6382	223	24	.	.	PUNCT
fnp-6382	224	1	it	it	PRON
fnp-6382	224	2	would	would	AUX
fnp-6382	224	3	be	be	AUX
fnp-6382	224	4	particularly	particularly	ADV
fnp-6382	224	5	beneficial	beneficial	ADJ
fnp-6382	224	6	to	to	PART
fnp-6382	224	7	directly	directly	ADV
fnp-6382	224	8	compare	compare	VERB
fnp-6382	224	9	csf	csf	ADJ
fnp-6382	224	10	or	or	CCONJ
fnp-6382	224	11	serum	serum	NOUN
fnp-6382	224	12	levels	level	NOUN
fnp-6382	224	13	of	of	ADP
fnp-6382	224	14	these	these	DET
fnp-6382	224	15	potential	potential	ADJ
fnp-6382	224	16	markers	marker	NOUN
fnp-6382	224	17	between	between	ADP
fnp-6382	224	18	cte	cte	NOUN
fnp-6382	224	19	and	and	CCONJ
fnp-6382	224	20	other	other	ADJ
fnp-6382	224	21	neurodegenerative	neurodegenerative	ADJ
fnp-6382	224	22	diseases	disease	NOUN
fnp-6382	224	23	that	that	PRON
fnp-6382	224	24	may	may	AUX
fnp-6382	224	25	result	result	VERB
fnp-6382	224	26	from	from	ADP
fnp-6382	224	27	head	head	NOUN
fnp-6382	224	28	trauma	trauma	NOUN
fnp-6382	224	29	i.e.	i.e.	X
fnp-6382	224	30	ad	ad	NOUN
fnp-6382	224	31	.	.	PUNCT
fnp-6382	225	1	the	the	DET
fnp-6382	225	2	prospective	prospective	ADJ
fnp-6382	225	3	markers	marker	NOUN
fnp-6382	225	4	are	be	AUX
fnp-6382	225	5	discussed	discuss	VERB
fnp-6382	225	6	below	below	ADV
fnp-6382	225	7	,	,	PUNCT
fnp-6382	225	8	with	with	ADP
fnp-6382	225	9	pertinent	pertinent	ADJ
fnp-6382	225	10	findings	finding	NOUN
fnp-6382	225	11	from	from	ADP
fnp-6382	225	12	human	human	NOUN
fnp-6382	225	13	-	-	PUNCT
fnp-6382	225	14	based	base	VERB
fnp-6382	225	15	studies	study	NOUN
fnp-6382	225	16	also	also	ADV
fnp-6382	225	17	included	include	VERB
fnp-6382	225	18	in	in	ADP
fnp-6382	225	19	table	table	NOUN
fnp-6382	225	20	 	 	SPACE
fnp-6382	225	21	1	1	NUM
fnp-6382	225	22	.	.	PUNCT
fnp-6382	225	23	because	because	SCONJ
fnp-6382	225	24	of	of	ADP
fnp-6382	225	25	the	the	DET
fnp-6382	225	26	limited	limited	ADJ
fnp-6382	225	27	literature	literature	NOUN
fnp-6382	225	28	of	of	ADP
fnp-6382	225	29	these	these	DET
fnp-6382	225	30	markers	marker	NOUN
fnp-6382	225	31	,	,	PUNCT
fnp-6382	225	32	we	we	PRON
fnp-6382	225	33	propose	propose	VERB
fnp-6382	225	34	novel	novel	ADJ
fnp-6382	225	35	proteins	protein	NOUN
fnp-6382	225	36	that	that	PRON
fnp-6382	225	37	could	could	AUX
fnp-6382	225	38	be	be	AUX
fnp-6382	225	39	worth	worth	ADJ
fnp-6382	225	40	examining	examine	VERB
fnp-6382	225	41	,	,	PUNCT
fnp-6382	225	42	as	as	SCONJ
fnp-6382	225	43	the	the	DET
fnp-6382	225	44	latter	latter	ADJ
fnp-6382	225	45	have	have	AUX
fnp-6382	225	46	not	not	PART
fnp-6382	225	47	yet	yet	ADV
fnp-6382	225	48	been	be	AUX
fnp-6382	225	49	applied	apply	VERB
fnp-6382	225	50	to	to	ADP
fnp-6382	225	51	rhi	rhi	PROPN
fnp-6382	225	52	at	at	ADP
fnp-6382	225	53	the	the	DET
fnp-6382	225	54	human	human	ADJ
fnp-6382	225	55	level	level	NOUN
fnp-6382	225	56	or	or	CCONJ
fnp-6382	225	57	to	to	ADP
fnp-6382	225	58	post	post	ADJ
fnp-6382	225	59	-	-	ADJ
fnp-6382	225	60	mortem	mortem	ADJ
fnp-6382	225	61	cte	cte	NOUN
fnp-6382	225	62	.	.	PUNCT
fnp-6382	226	1	strem2	strem2	PROPN
fnp-6382	226	2	based	base	VERB
fnp-6382	226	3	on	on	ADP
fnp-6382	226	4	the	the	DET
fnp-6382	226	5	vital	vital	ADJ
fnp-6382	226	6	role	role	NOUN
fnp-6382	226	7	of	of	ADP
fnp-6382	226	8	microgliosis	microgliosis	NOUN
fnp-6382	226	9	in	in	ADP
fnp-6382	226	10	neuroinflammation	neuroinflammation	NOUN
fnp-6382	226	11	,	,	PUNCT
fnp-6382	226	12	microglial	microglial	ADJ
fnp-6382	226	13	markers	marker	NOUN
fnp-6382	226	14	may	may	AUX
fnp-6382	226	15	have	have	VERB
fnp-6382	226	16	some	some	DET
fnp-6382	226	17	viability	viability	NOUN
fnp-6382	226	18	as	as	ADP
fnp-6382	226	19	diagnostic	diagnostic	ADJ
fnp-6382	226	20	or	or	CCONJ
fnp-6382	226	21	therapeutic	therapeutic	ADJ
fnp-6382	226	22	targets	target	NOUN
fnp-6382	226	23	for	for	ADP
fnp-6382	226	24	cte	cte	NOUN
fnp-6382	226	25	,	,	PUNCT
fnp-6382	226	26	such	such	ADJ
fnp-6382	226	27	as	as	ADP
fnp-6382	226	28	soluble	soluble	ADJ
fnp-6382	226	29	triggering	trigger	VERB
fnp-6382	226	30	receptor	receptor	NOUN
fnp-6382	226	31	expressed	express	VERB
fnp-6382	226	32	on	on	ADP
fnp-6382	226	33	myeloid	myeloid	ADJ
fnp-6382	226	34	cells	cell	NOUN
fnp-6382	226	35	2	2	NUM
fnp-6382	226	36	(	(	PUNCT
fnp-6382	226	37	strem2	strem2	NOUN
fnp-6382	226	38	)	)	PUNCT
fnp-6382	226	39	.	.	PUNCT
fnp-6382	227	1	this	this	DET
fnp-6382	227	2	receptor	receptor	NOUN
fnp-6382	227	3	,	,	PUNCT
fnp-6382	227	4	upregulated	upregulate	VERB
fnp-6382	227	5	in	in	ADP
fnp-6382	227	6	activated	activated	ADJ
fnp-6382	227	7	microglia	microglia	NOUN
fnp-6382	227	8	,	,	PUNCT
fnp-6382	227	9	has	have	AUX
fnp-6382	227	10	been	be	AUX
fnp-6382	227	11	implicated	implicate	VERB
fnp-6382	227	12	in	in	ADP
fnp-6382	227	13	various	various	ADJ
fnp-6382	227	14	neurodegenerative	neurodegenerative	ADJ
fnp-6382	227	15	diseases	disease	NOUN
fnp-6382	227	16	due	due	ADP
fnp-6382	227	17	to	to	ADP
fnp-6382	227	18	its	its	PRON
fnp-6382	227	19	role	role	NOUN
fnp-6382	227	20	in	in	ADP
fnp-6382	227	21	regulating	regulate	VERB
fnp-6382	227	22	microglial	microglial	ADJ
fnp-6382	227	23	survival	survival	NOUN
fnp-6382	227	24	,	,	PUNCT
fnp-6382	227	25	proliferation	proliferation	NOUN
fnp-6382	227	26	,	,	PUNCT
fnp-6382	227	27	and	and	CCONJ
fnp-6382	227	28	phagocytosis	phagocytosis	NOUN
fnp-6382	227	29	(	(	PUNCT
fnp-6382	227	30	85	85	NUM
fnp-6382	227	31	)	)	PUNCT
fnp-6382	227	32	.	.	PUNCT
fnp-6382	228	1	it	it	PRON
fnp-6382	228	2	is	be	AUX
fnp-6382	228	3	worth	worth	ADJ
fnp-6382	228	4	noting	note	VERB
fnp-6382	228	5	that	that	SCONJ
fnp-6382	228	6	triggering	trigger	VERB
fnp-6382	228	7	receptor	receptor	NOUN
fnp-6382	228	8	expressed	express	VERB
fnp-6382	228	9	on	on	ADP
fnp-6382	228	10	myeloid	myeloid	ADJ
fnp-6382	228	11	cells	cell	NOUN
fnp-6382	228	12	(	(	PUNCT
fnp-6382	228	13	trem2	trem2	NOUN
fnp-6382	228	14	)	)	PUNCT
fnp-6382	228	15	refers	refer	VERB
fnp-6382	228	16	to	to	ADP
fnp-6382	228	17	a	a	DET
fnp-6382	228	18	transmembrane	transmembrane	ADJ
fnp-6382	228	19	protein	protein	NOUN
fnp-6382	228	20	found	find	VERB
fnp-6382	228	21	in	in	ADP
fnp-6382	228	22	microglia	microglia	NOUN
fnp-6382	228	23	which	which	PRON
fnp-6382	228	24	is	be	AUX
fnp-6382	228	25	involved	involve	VERB
fnp-6382	228	26	in	in	ADP
fnp-6382	228	27	a	a	DET
fnp-6382	228	28	variety	variety	NOUN
fnp-6382	228	29	of	of	ADP
fnp-6382	228	30	functions	function	NOUN
fnp-6382	228	31	,	,	PUNCT
fnp-6382	228	32	such	such	ADJ
fnp-6382	228	33	as	as	ADP
fnp-6382	228	34	facilitating	facilitate	VERB
fnp-6382	228	35	microgliosis	microgliosis	NOUN
fnp-6382	228	36	and	and	CCONJ
fnp-6382	228	37	regulating	regulate	VERB
fnp-6382	228	38	lipid	lipid	NOUN
fnp-6382	228	39	metabolism	metabolism	NOUN
fnp-6382	228	40	(	(	PUNCT
fnp-6382	228	41	86	86	NUM
fnp-6382	228	42	)	)	PUNCT
fnp-6382	228	43	.	.	PUNCT
fnp-6382	229	1	proteolysis	proteolysis	NOUN
fnp-6382	229	2	leads	lead	VERB
fnp-6382	229	3	to	to	ADP
fnp-6382	229	4	release	release	NOUN
fnp-6382	229	5	of	of	ADP
fnp-6382	229	6	strem2	strem2	NOUN
fnp-6382	229	7	in	in	ADP
fnp-6382	229	8	csf	csf	PROPN
fnp-6382	229	9	.	.	PUNCT
fnp-6382	230	1	the	the	DET
fnp-6382	230	2	protein	protein	NOUN
fnp-6382	230	3	strem2	strem2	NOUN
fnp-6382	230	4	is	be	AUX
fnp-6382	230	5	generally	generally	ADV
fnp-6382	230	6	shown	show	VERB
fnp-6382	230	7	to	to	PART
fnp-6382	230	8	be	be	AUX
fnp-6382	230	9	associated	associate	VERB
fnp-6382	230	10	with	with	ADP
fnp-6382	230	11	tauopathy	tauopathy	NOUN
fnp-6382	230	12	and	and	CCONJ
fnp-6382	230	13	has	have	AUX
fnp-6382	230	14	been	be	AUX
fnp-6382	230	15	primarily	primarily	ADV
fnp-6382	230	16	studied	study	VERB
fnp-6382	230	17	in	in	ADP
fnp-6382	230	18	the	the	DET
fnp-6382	230	19	context	context	NOUN
fnp-6382	230	20	of	of	ADP
fnp-6382	230	21	ad	ad	NOUN
fnp-6382	230	22	,	,	PUNCT
fnp-6382	230	23	but	but	CCONJ
fnp-6382	230	24	its	its	PRON
fnp-6382	230	25	overall	overall	ADJ
fnp-6382	230	26	function	function	NOUN
fnp-6382	230	27	is	be	AUX
fnp-6382	230	28	less	less	ADV
fnp-6382	230	29	understood	understand	VERB
fnp-6382	230	30	(	(	PUNCT
fnp-6382	230	31	87	87	NUM
fnp-6382	230	32	)	)	PUNCT
fnp-6382	230	33	.	.	PUNCT
fnp-6382	231	1	by	by	ADP
fnp-6382	231	2	analyzing	analyze	VERB
fnp-6382	231	3	csf	csf	ADJ
fnp-6382	231	4	samples	sample	NOUN
fnp-6382	231	5	from	from	ADP
fnp-6382	231	6	rhi	rhi	NOUN
fnp-6382	231	7	-	-	PUNCT
fnp-6382	231	8	exposed	expose	VERB
fnp-6382	231	9	retired	retired	ADJ
fnp-6382	231	10	nfl	nfl	PROPN
fnp-6382	231	11	players	players	PROPN
fnp-6382	231	12	,	,	PUNCT
fnp-6382	231	13	alosco	alosco	PROPN
fnp-6382	231	14	et	et	PROPN
fnp-6382	231	15	al	al	PROPN
fnp-6382	231	16	.	.	PROPN
fnp-6382	231	17	determined	determine	VERB
fnp-6382	231	18	that	that	SCONJ
fnp-6382	231	19	levels	level	NOUN
fnp-6382	231	20	of	of	ADP
fnp-6382	231	21	strem2	strem2	NOUN
fnp-6382	231	22	significantly	significantly	ADV
fnp-6382	231	23	correlated	correlate	VERB
fnp-6382	231	24	with	with	ADP
fnp-6382	231	25	the	the	DET
fnp-6382	231	26	amount	amount	NOUN
fnp-6382	231	27	of	of	ADP
fnp-6382	231	28	total	total	ADJ
fnp-6382	231	29	tau	tau	PROPN
fnp-6382	231	30	(	(	PUNCT
fnp-6382	231	31	t	t	PROPN
fnp-6382	231	32	-	-	PUNCT
fnp-6382	231	33	tau	tau	PROPN
fnp-6382	231	34	)	)	PUNCT
fnp-6382	231	35	in	in	ADP
fnp-6382	231	36	the	the	DET
fnp-6382	231	37	rhi	rhi	NOUN
fnp-6382	231	38	-	-	PUNCT
fnp-6382	231	39	exposed	expose	VERB
fnp-6382	231	40	group	group	NOUN
fnp-6382	231	41	,	,	PUNCT
fnp-6382	231	42	despite	despite	SCONJ
fnp-6382	231	43	the	the	DET
fnp-6382	231	44	absence	absence	NOUN
fnp-6382	231	45	of	of	ADP
fnp-6382	231	46	group	group	NOUN
fnp-6382	231	47	-	-	PUNCT
fnp-6382	231	48	level	level	NOUN
fnp-6382	231	49	differences	difference	NOUN
fnp-6382	231	50	in	in	ADP
fnp-6382	231	51	strem2	strem2	NOUN
fnp-6382	231	52	levels	level	NOUN
fnp-6382	231	53	between	between	ADP
fnp-6382	231	54	the	the	DET
fnp-6382	231	55	athletes	athlete	NOUN
fnp-6382	231	56	and	and	CCONJ
fnp-6382	231	57	control	control	NOUN
fnp-6382	231	58	subjects	subject	NOUN
fnp-6382	231	59	(	(	PUNCT
fnp-6382	231	60	15	15	NUM
fnp-6382	231	61	)	)	PUNCT
fnp-6382	231	62	.	.	PUNCT
fnp-6382	232	1	despite	despite	SCONJ
fnp-6382	232	2	an	an	DET
fnp-6382	232	3	insignificant	insignificant	ADJ
fnp-6382	232	4	association	association	NOUN
fnp-6382	232	5	between	between	ADP
fnp-6382	232	6	strem2	strem2	PROPN
fnp-6382	232	7	and	and	CCONJ
fnp-6382	232	8	cumulative	cumulative	ADJ
fnp-6382	232	9	rhi	rhi	PROPN
fnp-6382	232	10	exposure	exposure	NOUN
fnp-6382	232	11	,	,	PUNCT
fnp-6382	232	12	regression	regression	VERB
fnp-6382	232	13	analysis	analysis	NOUN
fnp-6382	232	14	showed	show	VERB
fnp-6382	232	15	that	that	SCONJ
fnp-6382	232	16	strem2	strem2	NOUN
fnp-6382	232	17	levels	level	NOUN
fnp-6382	232	18	increased	increase	VERB
fnp-6382	232	19	the	the	DET
fnp-6382	232	20	strength	strength	NOUN
fnp-6382	232	21	of	of	ADP
fnp-6382	232	22	association	association	NOUN
fnp-6382	232	23	between	between	ADP
fnp-6382	232	24	rhi	rhi	PROPN
fnp-6382	232	25	exposure	exposure	NOUN
fnp-6382	232	26	and	and	CCONJ
fnp-6382	232	27	t	t	PROPN
fnp-6382	232	28	-	-	PUNCT
fnp-6382	232	29	tau	tau	PROPN
fnp-6382	232	30	levels	level	NOUN
fnp-6382	232	31	(	(	PUNCT
fnp-6382	232	32	15	15	NUM
fnp-6382	232	33	)	)	PUNCT
fnp-6382	232	34	.	.	PUNCT
fnp-6382	233	1	this	this	PRON
fnp-6382	233	2	suggests	suggest	VERB
fnp-6382	233	3	some	some	DET
fnp-6382	233	4	early	early	ADJ
fnp-6382	233	5	involvement	involvement	NOUN
fnp-6382	233	6	of	of	ADP
fnp-6382	233	7	strem2	strem2	NOUN
fnp-6382	233	8	in	in	ADP
fnp-6382	233	9	facilitating	facilitate	VERB
fnp-6382	233	10	cte	cte	NOUN
fnp-6382	233	11	pathology	pathology	NOUN
fnp-6382	233	12	in	in	ADP
fnp-6382	233	13	response	response	NOUN
fnp-6382	233	14	to	to	ADP
fnp-6382	233	15	rhi	rhi	PROPN
fnp-6382	233	16	.	.	PUNCT
fnp-6382	234	1	a	a	DET
fnp-6382	234	2	potential	potential	ADJ
fnp-6382	234	3	limitation	limitation	NOUN
fnp-6382	234	4	to	to	ADP
fnp-6382	234	5	implementing	implement	VERB
fnp-6382	234	6	strem2	strem2	NOUN
fnp-6382	234	7	as	as	ADP
fnp-6382	234	8	a	a	DET
fnp-6382	234	9	marker	marker	NOUN
fnp-6382	234	10	for	for	ADP
fnp-6382	234	11	cte	cte	NOUN
fnp-6382	234	12	is	be	AUX
fnp-6382	234	13	the	the	DET
fnp-6382	234	14	extensive	extensive	ADJ
fnp-6382	234	15	prior	prior	ADJ
fnp-6382	234	16	evidence	evidence	NOUN
fnp-6382	234	17	of	of	ADP
fnp-6382	234	18	strem2	strem2	NOUN
fnp-6382	234	19	having	have	VERB
fnp-6382	234	20	a	a	DET
fnp-6382	234	21	strong	strong	ADJ
fnp-6382	234	22	association	association	NOUN
fnp-6382	234	23	with	with	ADP
fnp-6382	234	24	ad	ad	NOUN
fnp-6382	234	25	pathology	pathology	NOUN
fnp-6382	234	26	(	(	PUNCT
fnp-6382	234	27	88–90	88–90	NUM
fnp-6382	234	28	)	)	PUNCT
fnp-6382	234	29	.	.	PUNCT
fnp-6382	235	1	consequently	consequently	ADV
fnp-6382	235	2	,	,	PUNCT
fnp-6382	235	3	future	future	ADJ
fnp-6382	235	4	investigations	investigation	NOUN
fnp-6382	235	5	may	may	AUX
fnp-6382	235	6	focus	focus	VERB
fnp-6382	235	7	on	on	ADP
fnp-6382	235	8	assessing	assess	VERB
fnp-6382	235	9	sensitivity	sensitivity	NOUN
fnp-6382	235	10	and	and	CCONJ
fnp-6382	235	11	specificity	specificity	NOUN
fnp-6382	235	12	of	of	ADP
fnp-6382	235	13	strem2	strem2	NOUN
fnp-6382	235	14	or	or	CCONJ
fnp-6382	235	15	other	other	ADJ
fnp-6382	235	16	potential	potential	ADJ
fnp-6382	235	17	microglial	microglial	ADJ
fnp-6382	235	18	markers	marker	NOUN
fnp-6382	235	19	in	in	ADP
fnp-6382	235	20	cte	cte	NOUN
fnp-6382	235	21	in	in	ADP
fnp-6382	235	22	comparison	comparison	NOUN
fnp-6382	235	23	to	to	ADP
fnp-6382	235	24	cases	case	NOUN
fnp-6382	235	25	of	of	ADP
fnp-6382	235	26	ad	ad	NOUN
fnp-6382	235	27	or	or	CCONJ
fnp-6382	235	28	other	other	ADJ
fnp-6382	235	29	tauopathies	tauopathie	NOUN
fnp-6382	235	30	.	.	PUNCT
fnp-6382	236	1	pro	pro	ADJ
fnp-6382	236	2	-	-	ADJ
fnp-6382	236	3	inflammatory	inflammatory	ADJ
fnp-6382	236	4	mediators	mediator	NOUN
fnp-6382	236	5	in	in	ADP
fnp-6382	236	6	addition	addition	NOUN
fnp-6382	236	7	to	to	ADP
fnp-6382	236	8	il-6	il-6	PRON
fnp-6382	236	9	,	,	PUNCT
fnp-6382	236	10	other	other	ADJ
fnp-6382	236	11	pro	pro	ADJ
fnp-6382	236	12	-	-	ADJ
fnp-6382	236	13	inflammatory	inflammatory	ADJ
fnp-6382	236	14	cytokines	cytokine	NOUN
fnp-6382	236	15	related	relate	VERB
fnp-6382	236	16	to	to	PART
fnp-6382	236	17	head	head	NOUN
fnp-6382	236	18	impact	impact	NOUN
fnp-6382	236	19	exposure	exposure	NOUN
fnp-6382	236	20	may	may	AUX
fnp-6382	236	21	serve	serve	VERB
fnp-6382	236	22	as	as	ADP
fnp-6382	236	23	potential	potential	ADJ
fnp-6382	236	24	markers	marker	NOUN
fnp-6382	236	25	of	of	ADP
fnp-6382	236	26	cte	cte	NOUN
fnp-6382	236	27	progression	progression	NOUN
fnp-6382	236	28	.	.	PUNCT
fnp-6382	237	1	gard	gard	NOUN
fnp-6382	237	2	et	et	PROPN
fnp-6382	237	3	al	al	PROPN
fnp-6382	237	4	.	.	PROPN
fnp-6382	237	5	found	find	VERB
fnp-6382	237	6	that	that	SCONJ
fnp-6382	237	7	among	among	ADP
fnp-6382	237	8	athletes	athlete	NOUN
fnp-6382	237	9	with	with	ADP
fnp-6382	237	10	prior	prior	ADJ
fnp-6382	237	11	exposure	exposure	NOUN
fnp-6382	237	12	to	to	ADP
fnp-6382	237	13	sports	sport	NOUN
fnp-6382	237	14	-	-	PUNCT
fnp-6382	237	15	related	relate	VERB
fnp-6382	237	16	concussions	concussion	NOUN
fnp-6382	237	17	,	,	PUNCT
fnp-6382	237	18	csf	csf	ADJ
fnp-6382	237	19	analysis	analysis	NOUN
fnp-6382	237	20	revealed	reveal	VERB
fnp-6382	237	21	a	a	DET
fnp-6382	237	22	significant	significant	ADJ
fnp-6382	237	23	increase	increase	NOUN
fnp-6382	237	24	in	in	ADP
fnp-6382	237	25	il-2	il-2	NUM
fnp-6382	237	26	,	,	PUNCT
fnp-6382	237	27	il-15	il-15	PRON
fnp-6382	237	28	,	,	PUNCT
fnp-6382	237	29	tnf	tnf	PROPN
fnp-6382	237	30	-	-	PUNCT
fnp-6382	237	31	α	α	PROPN
fnp-6382	237	32	,	,	PUNCT
fnp-6382	237	33	tnf	tnf	PROPN
fnp-6382	237	34	-	-	PUNCT
fnp-6382	237	35	β	β	PROPN
fnp-6382	237	36	,	,	PUNCT
fnp-6382	237	37	eotaxin	eotaxin	PROPN
fnp-6382	237	38	,	,	PUNCT
fnp-6382	237	39	and	and	CCONJ
fnp-6382	237	40	tarc	tarc	PROPN
fnp-6382	237	41	levels	level	NOUN
fnp-6382	237	42	compared	compare	VERB
fnp-6382	237	43	to	to	ADP
fnp-6382	237	44	those	those	PRON
fnp-6382	237	45	in	in	ADP
fnp-6382	237	46	control	control	NOUN
fnp-6382	237	47	athletes	athlete	NOUN
fnp-6382	237	48	.	.	PUNCT
fnp-6382	238	1	it	it	PRON
fnp-6382	238	2	is	be	AUX
fnp-6382	238	3	possible	possible	ADJ
fnp-6382	238	4	that	that	SCONJ
fnp-6382	238	5	these	these	DET
fnp-6382	238	6	protein	protein	NOUN
fnp-6382	238	7	levels	level	NOUN
fnp-6382	238	8	increase	increase	VERB
fnp-6382	238	9	with	with	ADP
fnp-6382	238	10	post	post	ADJ
fnp-6382	238	11	-	-	ADJ
fnp-6382	238	12	concussive	concussive	ADJ
fnp-6382	238	13	symptoms	symptom	NOUN
fnp-6382	238	14	,	,	PUNCT
fnp-6382	238	15	suggesting	suggest	VERB
fnp-6382	238	16	a	a	DET
fnp-6382	238	17	possible	possible	ADJ
fnp-6382	238	18	role	role	NOUN
fnp-6382	238	19	of	of	ADP
fnp-6382	238	20	these	these	DET
fnp-6382	238	21	cytokines	cytokine	NOUN
fnp-6382	238	22	in	in	ADP
fnp-6382	238	23	early	early	ADJ
fnp-6382	238	24	phases	phase	NOUN
fnp-6382	238	25	of	of	ADP
fnp-6382	238	26	injury	injury	NOUN
fnp-6382	238	27	-	-	PUNCT
fnp-6382	238	28	related	relate	VERB
fnp-6382	238	29	pathology	pathology	NOUN
fnp-6382	238	30	(	(	PUNCT
fnp-6382	238	31	104	104	NUM
fnp-6382	238	32	)	)	PUNCT
fnp-6382	238	33	.	.	PUNCT
fnp-6382	239	1	however	however	ADV
fnp-6382	239	2	,	,	PUNCT
fnp-6382	239	3	considering	consider	VERB
fnp-6382	239	4	that	that	SCONJ
fnp-6382	239	5	the	the	DET
fnp-6382	239	6	study	study	NOUN
fnp-6382	239	7	included	include	VERB
fnp-6382	239	8	healthy	healthy	ADJ
fnp-6382	239	9	controls	control	NOUN
fnp-6382	239	10	without	without	ADP
fnp-6382	239	11	ad	ad	NOUN
fnp-6382	239	12	for	for	ADP
fnp-6382	239	13	comparison	comparison	NOUN
fnp-6382	239	14	,	,	PUNCT
fnp-6382	239	15	it	it	PRON
fnp-6382	239	16	remains	remain	VERB
fnp-6382	239	17	unclear	unclear	ADJ
fnp-6382	239	18	whether	whether	SCONJ
fnp-6382	239	19	these	these	DET
fnp-6382	239	20	elevations	elevation	NOUN
fnp-6382	239	21	represent	represent	VERB
fnp-6382	239	22	acute	acute	ADJ
fnp-6382	239	23	or	or	CCONJ
fnp-6382	239	24	persistent	persistent	ADJ
fnp-6382	239	25	changes	change	NOUN
fnp-6382	239	26	.	.	PUNCT
fnp-6382	240	1	notably	notably	ADV
fnp-6382	240	2	,	,	PUNCT
fnp-6382	240	3	other	other	ADJ
fnp-6382	240	4	studies	study	NOUN
fnp-6382	240	5	have	have	AUX
fnp-6382	240	6	reported	report	VERB
fnp-6382	240	7	more	more	ADJ
fnp-6382	240	8	limited	limited	ADJ
fnp-6382	240	9	associations	association	NOUN
fnp-6382	240	10	between	between	ADP
fnp-6382	240	11	cytokines	cytokine	NOUN
fnp-6382	240	12	level	level	NOUN
fnp-6382	240	13	and	and	CCONJ
fnp-6382	240	14	rhi	rhi	PROPN
fnp-6382	240	15	exposure	exposure	NOUN
fnp-6382	240	16	.	.	PUNCT
fnp-6382	241	1	in	in	ADP
fnp-6382	241	2	one	one	NUM
fnp-6382	241	3	blood	blood	NOUN
fnp-6382	241	4	-	-	PUNCT
fnp-6382	241	5	sample	sample	NOUN
fnp-6382	241	6	analysis	analysis	NOUN
fnp-6382	241	7	of	of	ADP
fnp-6382	241	8	college	college	NOUN
fnp-6382	241	9	-	-	PUNCT
fnp-6382	241	10	level	level	NOUN
fnp-6382	241	11	athletes	athlete	NOUN
fnp-6382	241	12	,	,	PUNCT
fnp-6382	241	13	there	there	PRON
fnp-6382	241	14	was	be	VERB
fnp-6382	241	15	no	no	DET
fnp-6382	241	16	significant	significant	ADJ
fnp-6382	241	17	correlation	correlation	NOUN
fnp-6382	241	18	between	between	ADP
fnp-6382	241	19	participation	participation	NOUN
fnp-6382	241	20	in	in	ADP
fnp-6382	241	21	collision	collision	NOUN
fnp-6382	241	22	sports	sport	NOUN
fnp-6382	241	23	and	and	CCONJ
fnp-6382	241	24	levels	level	NOUN
fnp-6382	241	25	of	of	ADP
fnp-6382	241	26	il-8	il-8	NOUN
fnp-6382	241	27	,	,	PUNCT
fnp-6382	241	28	il-12	il-12	NOUN
fnp-6382	241	29	,	,	PUNCT
fnp-6382	241	30	il-15	il-15	X
fnp-6382	241	31	,	,	PUNCT
fnp-6382	241	32	or	or	CCONJ
fnp-6382	241	33	tnf	tnf	PROPN
fnp-6382	241	34	-	-	PUNCT
fnp-6382	241	35	α	α	PROPN
fnp-6382	241	36	.	.	PUNCT
fnp-6382	242	1	in	in	ADP
fnp-6382	242	2	fact	fact	NOUN
fnp-6382	242	3	,	,	PUNCT
fnp-6382	242	4	only	only	ADV
fnp-6382	242	5	peripheral	peripheral	ADJ
fnp-6382	242	6	levels	level	NOUN
fnp-6382	242	7	of	of	ADP
fnp-6382	242	8	tau	tau	PROPN
fnp-6382	242	9	were	be	AUX
fnp-6382	242	10	significantly	significantly	ADV
fnp-6382	242	11	associated	associate	VERB
fnp-6382	242	12	with	with	ADP
fnp-6382	242	13	participation	participation	NOUN
fnp-6382	242	14	in	in	ADP
fnp-6382	242	15	collision	collision	NOUN
fnp-6382	242	16	sports	sport	NOUN
fnp-6382	242	17	,	,	PUNCT
fnp-6382	242	18	suggesting	suggest	VERB
fnp-6382	242	19	that	that	SCONJ
fnp-6382	242	20	the	the	DET
fnp-6382	242	21	various	various	ADJ
fnp-6382	242	22	cytokines	cytokine	NOUN
fnp-6382	242	23	may	may	AUX
fnp-6382	242	24	not	not	PART
fnp-6382	242	25	show	show	VERB
fnp-6382	242	26	consistent	consistent	ADJ
fnp-6382	242	27	peripheral	peripheral	ADJ
fnp-6382	242	28	elevation	elevation	NOUN
fnp-6382	242	29	in	in	ADP
fnp-6382	242	30	response	response	NOUN
fnp-6382	242	31	to	to	ADP
fnp-6382	242	32	trauma	trauma	NOUN
fnp-6382	242	33	(	(	PUNCT
fnp-6382	242	34	42	42	NUM
fnp-6382	242	35	)	)	PUNCT
fnp-6382	242	36	.	.	PUNCT
fnp-6382	243	1	in	in	ADP
fnp-6382	243	2	addition	addition	NOUN
fnp-6382	243	3	,	,	PUNCT
fnp-6382	243	4	van	van	PROPN
fnp-6382	243	5	amerongen	amerongen	PROPN
fnp-6382	243	6	et	et	PROPN
fnp-6382	243	7	al	al	PROPN
fnp-6382	243	8	found	find	VERB
fnp-6382	243	9	no	no	DET
fnp-6382	243	10	significant	significant	ADJ
fnp-6382	243	11	association	association	NOUN
fnp-6382	243	12	between	between	ADP
fnp-6382	243	13	csf	csf	ADJ
fnp-6382	243	14	levels	level	NOUN
fnp-6382	243	15	of	of	ADP
fnp-6382	243	16	tnf	tnf	PROPN
fnp-6382	243	17	-	-	PUNCT
fnp-6382	243	18	α	α	PROPN
fnp-6382	243	19	and	and	CCONJ
fnp-6382	243	20	il-1β	il-1β	PROPN
fnp-6382	243	21	and	and	CCONJ
fnp-6382	243	22	nbd	nbd	PROPN
fnp-6382	243	23	scores	score	NOUN
fnp-6382	243	24	in	in	ADP
fnp-6382	243	25	retired	retire	VERB
fnp-6382	243	26	football	football	NOUN
fnp-6382	243	27	players	player	NOUN
fnp-6382	243	28	,	,	PUNCT
fnp-6382	243	29	suggesting	suggest	VERB
fnp-6382	243	30	that	that	SCONJ
fnp-6382	243	31	these	these	DET
fnp-6382	243	32	markers	marker	NOUN
fnp-6382	243	33	may	may	AUX
fnp-6382	243	34	not	not	PART
fnp-6382	243	35	be	be	AUX
fnp-6382	243	36	related	relate	VERB
fnp-6382	243	37	to	to	ADP
fnp-6382	243	38	clinical	clinical	ADJ
fnp-6382	243	39	symptom	symptom	NOUN
fnp-6382	243	40	expression	expression	NOUN
fnp-6382	243	41	(	(	PUNCT
fnp-6382	243	42	66	66	NUM
fnp-6382	243	43	)	)	PUNCT
fnp-6382	243	44	.	.	PUNCT
fnp-6382	244	1	plasma	plasma	NOUN
fnp-6382	244	2	levels	level	NOUN
fnp-6382	244	3	of	of	ADP
fnp-6382	244	4	ifn	ifn	PROPN
fnp-6382	244	5	-	-	PUNCT
fnp-6382	244	6	γ	γ	NOUN
fnp-6382	244	7	were	be	AUX
fnp-6382	244	8	also	also	ADV
fnp-6382	244	9	not	not	PART
fnp-6382	244	10	found	find	VERB
fnp-6382	244	11	to	to	PART
fnp-6382	244	12	be	be	AUX
fnp-6382	244	13	significantly	significantly	ADV
fnp-6382	244	14	increased	increase	VERB
fnp-6382	244	15	in	in	ADP
fnp-6382	244	16	living	living	NOUN
fnp-6382	244	17	subjects	subject	NOUN
fnp-6382	244	18	with	with	ADP
fnp-6382	244	19	rhi	rhi	PROPN
fnp-6382	244	20	/	/	SYM
fnp-6382	244	21	tes	tes	NOUN
fnp-6382	244	22	,	,	PUNCT
fnp-6382	244	23	when	when	SCONJ
fnp-6382	244	24	compared	compare	VERB
fnp-6382	244	25	to	to	ADP
fnp-6382	244	26	ad	ad	NOUN
fnp-6382	244	27	and	and	CCONJ
fnp-6382	244	28	controls	control	NOUN
fnp-6382	244	29	without	without	ADP
fnp-6382	244	30	rhi	rhi	PROPN
fnp-6382	244	31	exposure	exposure	NOUN
fnp-6382	244	32	(	(	PUNCT
fnp-6382	244	33	68	68	NUM
fnp-6382	244	34	)	)	PUNCT
fnp-6382	244	35	.	.	PUNCT
fnp-6382	245	1	while	while	SCONJ
fnp-6382	245	2	not	not	PART
fnp-6382	245	3	directly	directly	ADV
fnp-6382	245	4	applicable	applicable	ADJ
fnp-6382	245	5	to	to	PART
fnp-6382	245	6	cte	cte	VERB
fnp-6382	245	7	due	due	ADP
fnp-6382	245	8	to	to	ADP
fnp-6382	245	9	the	the	DET
fnp-6382	245	10	lack	lack	NOUN
fnp-6382	245	11	of	of	ADP
fnp-6382	245	12	validation	validation	NOUN
fnp-6382	245	13	of	of	ADP
fnp-6382	245	14	tes	tes	NOUN
fnp-6382	245	15	to	to	ADP
fnp-6382	245	16	pathology	pathology	NOUN
fnp-6382	245	17	,	,	PUNCT
fnp-6382	245	18	these	these	DET
fnp-6382	245	19	findings	finding	NOUN
fnp-6382	245	20	suggest	suggest	VERB
fnp-6382	245	21	that	that	SCONJ
fnp-6382	245	22	cytokine	cytokine	ADJ
fnp-6382	245	23	expression	expression	NOUN
fnp-6382	245	24	following	follow	VERB
fnp-6382	245	25	head	head	NOUN
fnp-6382	245	26	trauma	trauma	NOUN
fnp-6382	245	27	may	may	AUX
fnp-6382	245	28	be	be	AUX
fnp-6382	245	29	context	context	NOUN
fnp-6382	245	30	-	-	PUNCT
fnp-6382	245	31	dependent	dependent	ADJ
fnp-6382	245	32	,	,	PUNCT
fnp-6382	245	33	varying	vary	VERB
fnp-6382	245	34	by	by	ADP
fnp-6382	245	35	injury	injury	NOUN
fnp-6382	245	36	time	time	NOUN
fnp-6382	245	37	course	course	NOUN
fnp-6382	245	38	,	,	PUNCT
fnp-6382	245	39	sampling	sample	VERB
fnp-6382	245	40	method	method	NOUN
fnp-6382	245	41	,	,	PUNCT
fnp-6382	245	42	and	and	CCONJ
fnp-6382	245	43	clinical	clinical	ADJ
fnp-6382	245	44	phenotype	phenotype	NOUN
fnp-6382	245	45	.	.	PUNCT
fnp-6382	246	1	begum	begum	AUX
fnp-6382	246	2	et	et	AUX
fnp-6382	246	3	al	al	PROPN
fnp-6382	246	4	.	.	PROPN
fnp-6382	246	5	conducted	conduct	VERB
fnp-6382	246	6	a	a	DET
fnp-6382	246	7	serum	serum	NOUN
fnp-6382	246	8	-	-	PUNCT
fnp-6382	246	9	based	base	VERB
fnp-6382	246	10	comparison	comparison	NOUN
fnp-6382	246	11	of	of	ADP
fnp-6382	246	12	inflammatory	inflammatory	ADJ
fnp-6382	246	13	markers	marker	NOUN
fnp-6382	246	14	between	between	ADP
fnp-6382	246	15	athletes	athlete	NOUN
fnp-6382	246	16	after	after	ADP
fnp-6382	246	17	single	single	ADJ
fnp-6382	246	18	concussion	concussion	NOUN
fnp-6382	246	19	and	and	CCONJ
fnp-6382	246	20	athletes	athlete	NOUN
fnp-6382	246	21	who	who	PRON
fnp-6382	246	22	were	be	AUX
fnp-6382	246	23	repetitively	repetitively	ADV
fnp-6382	246	24	concussed	concuss	VERB
fnp-6382	246	25	.	.	PUNCT
fnp-6382	247	1	the	the	DET
fnp-6382	247	2	authors	author	NOUN
fnp-6382	247	3	found	find	VERB
fnp-6382	247	4	that	that	SCONJ
fnp-6382	247	5	serum	serum	NOUN
fnp-6382	247	6	levels	level	NOUN
fnp-6382	247	7	of	of	ADP
fnp-6382	247	8	tnfsf14	tnfsf14	NOUN
fnp-6382	247	9	,	,	PUNCT
fnp-6382	247	10	belonging	belong	VERB
fnp-6382	247	11	to	to	ADP
fnp-6382	247	12	the	the	DET
fnp-6382	247	13	tnf	tnf	PROPN
fnp-6382	247	14	superfamily	superfamily	NOUN
fnp-6382	247	15	,	,	PUNCT
fnp-6382	247	16	and	and	CCONJ
fnp-6382	247	17	il-7	il-7	PRON
fnp-6382	247	18	were	be	AUX
fnp-6382	247	19	significantly	significantly	ADV
fnp-6382	247	20	higher	high	ADJ
fnp-6382	247	21	in	in	ADP
fnp-6382	247	22	repetitively	repetitively	ADV
fnp-6382	247	23	concussed	concuss	VERB
fnp-6382	247	24	players	player	NOUN
fnp-6382	247	25	than	than	ADP
fnp-6382	247	26	in	in	ADP
fnp-6382	247	27	players	player	NOUN
fnp-6382	247	28	after	after	ADP
fnp-6382	247	29	single	single	ADJ
fnp-6382	247	30	concussion	concussion	NOUN
fnp-6382	247	31	,	,	PUNCT
fnp-6382	247	32	suggesting	suggest	VERB
fnp-6382	247	33	that	that	SCONJ
fnp-6382	247	34	the	the	DET
fnp-6382	247	35	two	two	NUM
fnp-6382	247	36	proteins	protein	NOUN
fnp-6382	247	37	may	may	AUX
fnp-6382	247	38	reflect	reflect	VERB
fnp-6382	247	39	inflammatory	inflammatory	ADJ
fnp-6382	247	40	responses	response	NOUN
fnp-6382	247	41	to	to	ADP
fnp-6382	247	42	repeated	repeat	VERB
fnp-6382	247	43	injury	injury	NOUN
fnp-6382	247	44	(	(	PUNCT
fnp-6382	247	45	43	43	NUM
fnp-6382	247	46	)	)	PUNCT
fnp-6382	247	47	.	.	PUNCT
fnp-6382	248	1	these	these	DET
fnp-6382	248	2	findings	finding	NOUN
fnp-6382	248	3	offer	offer	VERB
fnp-6382	248	4	preliminary	preliminary	ADJ
fnp-6382	248	5	support	support	NOUN
fnp-6382	248	6	to	to	PART
fnp-6382	248	7	use	use	VERB
fnp-6382	248	8	tnfsf14	tnfsf14	NOUN
fnp-6382	248	9	and	and	CCONJ
fnp-6382	248	10	il-7	il-7	VERB
fnp-6382	248	11	in	in	ADP
fnp-6382	248	12	order	order	NOUN
fnp-6382	248	13	to	to	PART
fnp-6382	248	14	distinguish	distinguish	VERB
fnp-6382	248	15	immune	immune	ADJ
fnp-6382	248	16	profiles	profile	NOUN
fnp-6382	248	17	between	between	ADP
fnp-6382	248	18	single	single	ADJ
fnp-6382	248	19	tbi	tbi	PROPN
fnp-6382	248	20	and	and	CCONJ
fnp-6382	248	21	rhi	rhi	PROPN
fnp-6382	248	22	.	.	PUNCT
fnp-6382	249	1	while	while	SCONJ
fnp-6382	249	2	the	the	DET
fnp-6382	249	3	study	study	NOUN
fnp-6382	249	4	defined	define	VERB
fnp-6382	249	5	“	"	PUNCT
fnp-6382	249	6	repetitively	repetitively	ADV
fnp-6382	249	7	concussed	concuss	VERB
fnp-6382	249	8	”	"	PUNCT
fnp-6382	249	9	as	as	ADP
fnp-6382	249	10	two	two	NUM
fnp-6382	249	11	concussions	concussion	NOUN
fnp-6382	249	12	within	within	ADP
fnp-6382	249	13	the	the	DET
fnp-6382	249	14	span	span	NOUN
fnp-6382	249	15	of	of	ADP
fnp-6382	249	16	three	three	NUM
fnp-6382	249	17	months	month	NOUN
fnp-6382	249	18	,	,	PUNCT
fnp-6382	249	19	which	which	PRON
fnp-6382	249	20	may	may	AUX
fnp-6382	249	21	not	not	PART
fnp-6382	249	22	fully	fully	ADV
fnp-6382	249	23	represent	represent	VERB
fnp-6382	249	24	the	the	DET
fnp-6382	249	25	accumulation	accumulation	NOUN
fnp-6382	249	26	of	of	ADP
fnp-6382	249	27	minor	minor	ADJ
fnp-6382	249	28	trauma	trauma	NOUN
fnp-6382	249	29	seen	see	VERB
fnp-6382	249	30	in	in	ADP
fnp-6382	249	31	rhi	rhi	PROPN
fnp-6382	249	32	,	,	PUNCT
fnp-6382	249	33	the	the	DET
fnp-6382	249	34	observed	observe	VERB
fnp-6382	249	35	differences	difference	NOUN
fnp-6382	249	36	still	still	ADV
fnp-6382	249	37	point	point	VERB
fnp-6382	249	38	toward	toward	ADP
fnp-6382	249	39	an	an	DET
fnp-6382	249	40	immunological	immunological	ADJ
fnp-6382	249	41	distinction	distinction	NOUN
fnp-6382	249	42	between	between	ADP
fnp-6382	249	43	acute	acute	ADJ
fnp-6382	249	44	and	and	CCONJ
fnp-6382	249	45	cumulative	cumulative	ADJ
fnp-6382	249	46	injury	injury	NOUN
fnp-6382	249	47	states	state	NOUN
fnp-6382	249	48	.	.	PUNCT
fnp-6382	250	1	as	as	SCONJ
fnp-6382	250	2	such	such	ADJ
fnp-6382	250	3	,	,	PUNCT
fnp-6382	250	4	future	future	ADJ
fnp-6382	250	5	studies	study	NOUN
fnp-6382	250	6	may	may	AUX
fnp-6382	250	7	benefit	benefit	VERB
fnp-6382	250	8	from	from	ADP
fnp-6382	250	9	determining	determine	VERB
fnp-6382	250	10	how	how	SCONJ
fnp-6382	250	11	tnfs14	tnfs14	ADJ
fnp-6382	250	12	and	and	CCONJ
fnp-6382	250	13	il-7	il-7	X
fnp-6382	250	14	might	might	AUX
fnp-6382	250	15	correlate	correlate	VERB
fnp-6382	250	16	with	with	ADP
fnp-6382	250	17	proxies	proxy	NOUN
fnp-6382	250	18	of	of	ADP
fnp-6382	250	19	rhi	rhi	PROPN
fnp-6382	250	20	.	.	PUNCT
fnp-6382	251	1	other	other	ADJ
fnp-6382	251	2	pro	pro	ADJ
fnp-6382	251	3	-	-	ADJ
fnp-6382	251	4	inflammatory	inflammatory	ADJ
fnp-6382	251	5	aspects	aspect	NOUN
fnp-6382	251	6	of	of	ADP
fnp-6382	251	7	the	the	DET
fnp-6382	251	8	cte	cte	NOUN
fnp-6382	251	9	immune	immune	ADJ
fnp-6382	251	10	signature	signature	NOUN
fnp-6382	251	11	that	that	PRON
fnp-6382	251	12	have	have	AUX
fnp-6382	251	13	not	not	PART
fnp-6382	251	14	yet	yet	ADV
fnp-6382	251	15	been	be	AUX
fnp-6382	251	16	explored	explore	VERB
fnp-6382	251	17	in	in	ADP
fnp-6382	251	18	cte	cte	NOUN
fnp-6382	251	19	include	include	VERB
fnp-6382	251	20	damps	damp	NOUN
fnp-6382	251	21	(	(	PUNCT
fnp-6382	251	22	damage	damage	NOUN
fnp-6382	251	23	-	-	PUNCT
fnp-6382	251	24	associated	associate	VERB
fnp-6382	251	25	molecular	molecular	ADJ
fnp-6382	251	26	pattern	pattern	NOUN
fnp-6382	251	27	)	)	PUNCT
fnp-6382	251	28	such	such	ADJ
fnp-6382	251	29	as	as	ADP
fnp-6382	251	30	high	high	ADJ
fnp-6382	251	31	mobility	mobility	NOUN
fnp-6382	251	32	group	group	NOUN
fnp-6382	251	33	box	box	NOUN
fnp-6382	251	34	protein	protein	NOUN
fnp-6382	251	35	1	1	NUM
fnp-6382	251	36	(	(	PUNCT
fnp-6382	251	37	hmgb1	hmgb1	PROPN
fnp-6382	251	38	)	)	PUNCT
fnp-6382	251	39	.	.	PUNCT
fnp-6382	252	1	hmgb1	hmgb1	PROPN
fnp-6382	252	2	is	be	AUX
fnp-6382	252	3	a	a	DET
fnp-6382	252	4	dna	dna	NOUN
fnp-6382	252	5	binding	bind	VERB
fnp-6382	252	6	protein	protein	NOUN
fnp-6382	252	7	that	that	PRON
fnp-6382	252	8	can	can	AUX
fnp-6382	252	9	be	be	AUX
fnp-6382	252	10	actively	actively	ADV
fnp-6382	252	11	secreted	secrete	VERB
fnp-6382	252	12	by	by	ADP
fnp-6382	252	13	leukocytes	leukocyte	NOUN
fnp-6382	252	14	in	in	ADP
fnp-6382	252	15	response	response	NOUN
fnp-6382	252	16	to	to	PART
fnp-6382	252	17	cytokine	cytokine	VERB
fnp-6382	252	18	activation	activation	NOUN
fnp-6382	252	19	,	,	PUNCT
fnp-6382	252	20	or	or	CCONJ
fnp-6382	252	21	it	it	PRON
fnp-6382	252	22	may	may	AUX
fnp-6382	252	23	be	be	AUX
fnp-6382	252	24	passively	passively	ADV
fnp-6382	252	25	released	release	VERB
fnp-6382	252	26	via	via	ADP
fnp-6382	252	27	neuronal	neuronal	ADJ
fnp-6382	252	28	death	death	NOUN
fnp-6382	252	29	(	(	PUNCT
fnp-6382	252	30	91,92	91,92	NUM
fnp-6382	252	31	)	)	PUNCT
fnp-6382	252	32	.	.	PUNCT
fnp-6382	253	1	in	in	ADP
fnp-6382	253	2	addition	addition	NOUN
fnp-6382	253	3	to	to	ADP
fnp-6382	253	4	being	be	AUX
fnp-6382	253	5	a	a	DET
fnp-6382	253	6	marker	marker	NOUN
fnp-6382	253	7	of	of	ADP
fnp-6382	253	8	neurodegeneration	neurodegeneration	NOUN
fnp-6382	253	9	,	,	PUNCT
fnp-6382	253	10	hmgb1	hmgb1	PROPN
fnp-6382	253	11	can	can	AUX
fnp-6382	253	12	act	act	VERB
fnp-6382	253	13	as	as	ADP
fnp-6382	253	14	a	a	DET
fnp-6382	253	15	damp	damp	ADJ
fnp-6382	253	16	and	and	CCONJ
fnp-6382	253	17	mediate	mediate	VERB
fnp-6382	253	18	further	further	ADJ
fnp-6382	253	19	inflammation	inflammation	NOUN
fnp-6382	253	20	(	(	PUNCT
fnp-6382	253	21	93	93	NUM
fnp-6382	253	22	)	)	PUNCT
fnp-6382	253	23	.	.	PUNCT
fnp-6382	254	1	while	while	SCONJ
fnp-6382	254	2	hmgb1	hmgb1	PROPN
fnp-6382	254	3	overexpression	overexpression	NOUN
fnp-6382	254	4	is	be	AUX
fnp-6382	254	5	also	also	ADV
fnp-6382	254	6	common	common	ADJ
fnp-6382	254	7	to	to	ADP
fnp-6382	254	8	conditions	condition	NOUN
fnp-6382	254	9	like	like	ADP
fnp-6382	254	10	epilepsy	epilepsy	NOUN
fnp-6382	254	11	or	or	CCONJ
fnp-6382	254	12	ad	ad	NOUN
fnp-6382	254	13	,	,	PUNCT
fnp-6382	254	14	an	an	DET
fnp-6382	254	15	analysis	analysis	NOUN
fnp-6382	254	16	of	of	ADP
fnp-6382	254	17	various	various	ADJ
fnp-6382	254	18	hmgb1	hmgb1	NOUN
fnp-6382	254	19	isoforms	isoform	NOUN
fnp-6382	254	20	and	and	CCONJ
fnp-6382	254	21	their	their	PRON
fnp-6382	254	22	potential	potential	ADJ
fnp-6382	254	23	specificity	specificity	NOUN
fnp-6382	254	24	for	for	ADP
fnp-6382	254	25	different	different	ADJ
fnp-6382	254	26	neurodegenerative	neurodegenerative	ADJ
fnp-6382	254	27	states	state	NOUN
fnp-6382	254	28	could	could	AUX
fnp-6382	254	29	help	help	AUX
fnp-6382	254	30	clarify	clarify	VERB
fnp-6382	254	31	the	the	DET
fnp-6382	254	32	immune	immune	ADJ
fnp-6382	254	33	signature	signature	NOUN
fnp-6382	254	34	for	for	ADP
fnp-6382	254	35	cte	cte	PROPN
fnp-6382	254	36	(	(	PUNCT
fnp-6382	254	37	94,95	94,95	NOUN
fnp-6382	254	38	)	)	PUNCT
fnp-6382	254	39	.	.	PUNCT
fnp-6382	255	1	likewise	likewise	ADV
fnp-6382	255	2	,	,	PUNCT
fnp-6382	255	3	heat	heat	NOUN
fnp-6382	255	4	shock	shock	NOUN
fnp-6382	255	5	proteins	protein	NOUN
fnp-6382	255	6	such	such	ADJ
fnp-6382	255	7	as	as	ADP
fnp-6382	255	8	hsp70	hsp70	NOUN
fnp-6382	255	9	or	or	CCONJ
fnp-6382	255	10	hsp90	hsp90	PROPN
fnp-6382	255	11	are	be	AUX
fnp-6382	255	12	other	other	ADJ
fnp-6382	255	13	proteins	protein	NOUN
fnp-6382	255	14	that	that	PRON
fnp-6382	255	15	are	be	AUX
fnp-6382	255	16	released	release	VERB
fnp-6382	255	17	during	during	ADP
fnp-6382	255	18	cell	cell	NOUN
fnp-6382	255	19	death	death	NOUN
fnp-6382	255	20	and	and	CCONJ
fnp-6382	255	21	may	may	AUX
fnp-6382	255	22	trigger	trigger	VERB
fnp-6382	255	23	more	more	ADJ
fnp-6382	255	24	inflammation	inflammation	NOUN
fnp-6382	255	25	by	by	ADP
fnp-6382	255	26	functioning	function	VERB
fnp-6382	255	27	as	as	ADP
fnp-6382	255	28	damps	damp	NOUN
fnp-6382	255	29	,	,	PUNCT
fnp-6382	255	30	thus	thus	ADV
fnp-6382	255	31	possibly	possibly	ADV
fnp-6382	255	32	serving	serve	VERB
fnp-6382	255	33	as	as	ADP
fnp-6382	255	34	a	a	DET
fnp-6382	255	35	measure	measure	NOUN
fnp-6382	255	36	of	of	ADP
fnp-6382	255	37	cellular	cellular	ADJ
fnp-6382	255	38	stress	stress	NOUN
fnp-6382	255	39	in	in	ADP
fnp-6382	255	40	response	response	NOUN
fnp-6382	255	41	to	to	ADP
fnp-6382	255	42	post	post	ADJ
fnp-6382	255	43	-	-	PROPN
fnp-6382	255	44	rhi	rhi	ADJ
fnp-6382	255	45	neuroinflammation	neuroinflammation	NOUN
fnp-6382	255	46	(	(	PUNCT
fnp-6382	255	47	96,97	96,97	NOUN
fnp-6382	255	48	)	)	PUNCT
fnp-6382	255	49	.	.	PUNCT
fnp-6382	256	1	although	although	SCONJ
fnp-6382	256	2	hmgb1	hmgb1	PROPN
fnp-6382	256	3	and	and	CCONJ
fnp-6382	256	4	heat	heat	NOUN
fnp-6382	256	5	shocks	shock	NOUN
fnp-6382	256	6	proteins	protein	NOUN
fnp-6382	256	7	have	have	VERB
fnp-6382	256	8	yet	yet	ADV
fnp-6382	256	9	to	to	PART
fnp-6382	256	10	be	be	AUX
fnp-6382	256	11	studied	study	VERB
fnp-6382	256	12	in	in	ADP
fnp-6382	256	13	either	either	CCONJ
fnp-6382	256	14	rhi	rhi	PROPN
fnp-6382	256	15	or	or	CCONJ
fnp-6382	256	16	cte	cte	NOUN
fnp-6382	256	17	,	,	PUNCT
fnp-6382	256	18	future	future	ADJ
fnp-6382	256	19	investigations	investigation	NOUN
fnp-6382	256	20	analyzing	analyze	VERB
fnp-6382	256	21	their	their	PRON
fnp-6382	256	22	precise	precise	ADJ
fnp-6382	256	23	role	role	NOUN
fnp-6382	256	24	in	in	ADP
fnp-6382	256	25	the	the	DET
fnp-6382	256	26	cte	cte	NOUN
fnp-6382	256	27	immune	immune	PROPN
fnp-6382	256	28	signature	signature	NOUN
fnp-6382	256	29	,	,	PUNCT
fnp-6382	256	30	such	such	ADJ
fnp-6382	256	31	as	as	ADP
fnp-6382	256	32	through	through	ADP
fnp-6382	256	33	immunoassay	immunoassay	NOUN
fnp-6382	256	34	or	or	CCONJ
fnp-6382	256	35	serum	serum	VERB
fnp-6382	256	36	analysis	analysis	NOUN
fnp-6382	256	37	,	,	PUNCT
fnp-6382	256	38	may	may	AUX
fnp-6382	256	39	help	help	VERB
fnp-6382	256	40	to	to	PART
fnp-6382	256	41	clarify	clarify	VERB
fnp-6382	256	42	their	their	PRON
fnp-6382	256	43	usefulness	usefulness	NOUN
fnp-6382	256	44	as	as	ADP
fnp-6382	256	45	markers	marker	NOUN
fnp-6382	256	46	.	.	PUNCT
fnp-6382	257	1	furthermore	furthermore	ADV
fnp-6382	257	2	,	,	PUNCT
fnp-6382	257	3	ykl-40	ykl-40	NOUN
fnp-6382	257	4	may	may	AUX
fnp-6382	257	5	be	be	AUX
fnp-6382	257	6	a	a	DET
fnp-6382	257	7	reliable	reliable	ADJ
fnp-6382	257	8	measure	measure	NOUN
fnp-6382	257	9	of	of	ADP
fnp-6382	257	10	astrocytic	astrocytic	ADJ
fnp-6382	257	11	-	-	PUNCT
fnp-6382	257	12	mediated	mediate	VERB
fnp-6382	257	13	inflammation	inflammation	NOUN
fnp-6382	257	14	in	in	ADP
fnp-6382	257	15	suspected	suspect	VERB
fnp-6382	257	16	cte	cte	NOUN
fnp-6382	257	17	,	,	PUNCT
fnp-6382	257	18	since	since	SCONJ
fnp-6382	257	19	it	it	PRON
fnp-6382	257	20	has	have	AUX
fnp-6382	257	21	been	be	AUX
fnp-6382	257	22	shown	show	VERB
fnp-6382	257	23	to	to	PART
fnp-6382	257	24	have	have	AUX
fnp-6382	257	25	upregulated	upregulate	VERB
fnp-6382	257	26	expression	expression	NOUN
fnp-6382	257	27	by	by	ADP
fnp-6382	257	28	astrocytes	astrocyte	NOUN
fnp-6382	257	29	and	and	CCONJ
fnp-6382	257	30	microglia	microglia	NOUN
fnp-6382	257	31	during	during	ADP
fnp-6382	257	32	trauma	trauma	NOUN
fnp-6382	257	33	,	,	PUNCT
fnp-6382	257	34	including	include	VERB
fnp-6382	257	35	in	in	ADP
fnp-6382	257	36	the	the	DET
fnp-6382	257	37	chronic	chronic	ADJ
fnp-6382	257	38	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	257	39	state	state	NOUN
fnp-6382	257	40	(	(	PUNCT
fnp-6382	257	41	98	98	NUM
fnp-6382	257	42	)	)	PUNCT
fnp-6382	257	43	.	.	PUNCT
fnp-6382	258	1	while	while	SCONJ
fnp-6382	258	2	asken	asken	VERB
fnp-6382	258	3	et	et	PROPN
fnp-6382	258	4	al	al	PROPN
fnp-6382	258	5	.	.	PROPN
fnp-6382	258	6	2023	2023	NUM
fnp-6382	258	7	did	do	AUX
fnp-6382	258	8	not	not	PART
fnp-6382	258	9	find	find	VERB
fnp-6382	258	10	a	a	DET
fnp-6382	258	11	significant	significant	ADJ
fnp-6382	258	12	elevation	elevation	NOUN
fnp-6382	258	13	of	of	ADP
fnp-6382	258	14	ykl-40	ykl-40	NOUN
fnp-6382	258	15	in	in	ADP
fnp-6382	258	16	living	live	VERB
fnp-6382	258	17	subjects	subject	NOUN
fnp-6382	258	18	with	with	ADP
fnp-6382	258	19	rhi	rhi	PROPN
fnp-6382	258	20	exposure	exposure	NOUN
fnp-6382	258	21	,	,	PUNCT
fnp-6382	258	22	it	it	PRON
fnp-6382	258	23	could	could	AUX
fnp-6382	258	24	be	be	AUX
fnp-6382	258	25	worth	worth	ADJ
fnp-6382	258	26	assessing	assess	VERB
fnp-6382	258	27	this	this	DET
fnp-6382	258	28	finding	finding	NOUN
fnp-6382	258	29	in	in	ADP
fnp-6382	258	30	the	the	DET
fnp-6382	258	31	post	post	ADJ
fnp-6382	258	32	-	-	ADJ
fnp-6382	258	33	mortem	mortem	ADJ
fnp-6382	258	34	setting	setting	NOUN
fnp-6382	258	35	(	(	PUNCT
fnp-6382	258	36	68	68	NUM
fnp-6382	258	37	)	)	PUNCT
fnp-6382	258	38	.	.	PUNCT
fnp-6382	259	1	notably	notably	ADV
fnp-6382	259	2	,	,	PUNCT
fnp-6382	259	3	csf	csf	ADJ
fnp-6382	259	4	levels	level	NOUN
fnp-6382	259	5	ykl-40	ykl-40	PROPN
fnp-6382	259	6	have	have	AUX
fnp-6382	259	7	also	also	ADV
fnp-6382	259	8	been	be	AUX
fnp-6382	259	9	shown	show	VERB
fnp-6382	259	10	to	to	PART
fnp-6382	259	11	be	be	AUX
fnp-6382	259	12	elevated	elevate	VERB
fnp-6382	259	13	in	in	ADP
fnp-6382	259	14	autopsy	autopsy	NOUN
fnp-6382	259	15	-	-	PUNCT
fnp-6382	259	16	confirmed	confirm	VERB
fnp-6382	259	17	ad	ad	NOUN
fnp-6382	259	18	,	,	PUNCT
fnp-6382	259	19	including	include	VERB
fnp-6382	259	20	some	some	DET
fnp-6382	259	21	correlation	correlation	NOUN
fnp-6382	259	22	with	with	ADP
fnp-6382	259	23	patterns	pattern	NOUN
fnp-6382	259	24	of	of	ADP
fnp-6382	259	25	aβ	aβ	NOUN
fnp-6382	259	26	deposition	deposition	NOUN
fnp-6382	259	27	(	(	PUNCT
fnp-6382	259	28	99	99	NUM
fnp-6382	259	29	)	)	PUNCT
fnp-6382	259	30	.	.	PUNCT
fnp-6382	260	1	thus	thus	ADV
fnp-6382	260	2	,	,	PUNCT
fnp-6382	260	3	it	it	PRON
fnp-6382	260	4	may	may	AUX
fnp-6382	260	5	be	be	AUX
fnp-6382	260	6	relevant	relevant	ADJ
fnp-6382	260	7	to	to	PART
fnp-6382	260	8	conduct	conduct	VERB
fnp-6382	260	9	a	a	DET
fnp-6382	260	10	comparison	comparison	NOUN
fnp-6382	260	11	between	between	ADP
fnp-6382	260	12	cte	cte	NOUN
fnp-6382	260	13	and	and	CCONJ
fnp-6382	260	14	ad	ad	NOUN
fnp-6382	260	15	tissue	tissue	NOUN
fnp-6382	260	16	,	,	PUNCT
fnp-6382	260	17	seeking	seek	VERB
fnp-6382	260	18	to	to	PART
fnp-6382	260	19	determine	determine	VERB
fnp-6382	260	20	whether	whether	SCONJ
fnp-6382	260	21	ykl-40	ykl-40	PRON
fnp-6382	260	22	can	can	AUX
fnp-6382	260	23	help	help	VERB
fnp-6382	260	24	discriminate	discriminate	VERB
fnp-6382	260	25	between	between	ADP
fnp-6382	260	26	those	those	DET
fnp-6382	260	27	two	two	NUM
fnp-6382	260	28	pathologies	pathology	NOUN
fnp-6382	260	29	.	.	PUNCT
fnp-6382	261	1	anti	anti	ADJ
fnp-6382	261	2	-	-	ADJ
fnp-6382	261	3	inflammatory	inflammatory	ADJ
fnp-6382	261	4	mediators	mediator	NOUN
fnp-6382	261	5	the	the	DET
fnp-6382	261	6	role	role	NOUN
fnp-6382	261	7	of	of	ADP
fnp-6382	261	8	anti	anti	ADJ
fnp-6382	261	9	-	-	ADJ
fnp-6382	261	10	inflammatory	inflammatory	ADJ
fnp-6382	261	11	proteins	protein	NOUN
fnp-6382	261	12	in	in	ADP
fnp-6382	261	13	post	post	ADJ
fnp-6382	261	14	-	-	ADJ
fnp-6382	261	15	rhi	rhi	ADJ
fnp-6382	261	16	immune	immune	ADJ
fnp-6382	261	17	processes	process	NOUN
fnp-6382	261	18	is	be	AUX
fnp-6382	261	19	even	even	ADV
fnp-6382	261	20	less	less	ADV
fnp-6382	261	21	understood	understand	VERB
fnp-6382	261	22	than	than	ADP
fnp-6382	261	23	that	that	PRON
fnp-6382	261	24	of	of	ADP
fnp-6382	261	25	pro	pro	ADJ
fnp-6382	261	26	-	-	ADJ
fnp-6382	261	27	inflammatory	inflammatory	ADJ
fnp-6382	261	28	cytokines	cytokine	NOUN
fnp-6382	261	29	.	.	PUNCT
fnp-6382	262	1	however	however	ADV
fnp-6382	262	2	,	,	PUNCT
fnp-6382	262	3	since	since	SCONJ
fnp-6382	262	4	anti	anti	ADJ
fnp-6382	262	5	-	-	ADJ
fnp-6382	262	6	inflammatory	inflammatory	ADJ
fnp-6382	262	7	proteins	protein	NOUN
fnp-6382	262	8	tend	tend	VERB
fnp-6382	262	9	to	to	PART
fnp-6382	262	10	resolve	resolve	VERB
fnp-6382	262	11	inflammation	inflammation	NOUN
fnp-6382	262	12	and	and	CCONJ
fnp-6382	262	13	to	to	PART
fnp-6382	262	14	promote	promote	VERB
fnp-6382	262	15	tissue	tissue	NOUN
fnp-6382	262	16	repair	repair	NOUN
fnp-6382	262	17	,	,	PUNCT
fnp-6382	262	18	related	relate	VERB
fnp-6382	262	19	investigations	investigation	NOUN
fnp-6382	262	20	may	may	AUX
fnp-6382	262	21	help	help	VERB
fnp-6382	262	22	to	to	PART
fnp-6382	262	23	elucidate	elucidate	VERB
fnp-6382	262	24	some	some	PRON
fnp-6382	262	25	of	of	ADP
fnp-6382	262	26	the	the	DET
fnp-6382	262	27	nuances	nuance	NOUN
fnp-6382	262	28	in	in	ADP
fnp-6382	262	29	cte	cte	NOUN
fnp-6382	262	30	progression	progression	NOUN
fnp-6382	262	31	,	,	PUNCT
fnp-6382	262	32	including	include	VERB
fnp-6382	262	33	any	any	DET
fnp-6382	262	34	immune	immune	NOUN
fnp-6382	262	35	-	-	PUNCT
fnp-6382	262	36	related	relate	VERB
fnp-6382	262	37	mechanisms	mechanism	NOUN
fnp-6382	262	38	in	in	ADP
fnp-6382	262	39	response	response	NOUN
fnp-6382	262	40	to	to	ADP
fnp-6382	262	41	secondary	secondary	ADJ
fnp-6382	262	42	injury	injury	NOUN
fnp-6382	262	43	from	from	ADP
fnp-6382	262	44	inflammation	inflammation	NOUN
fnp-6382	262	45	.	.	PUNCT
fnp-6382	263	1	while	while	SCONJ
fnp-6382	263	2	several	several	ADJ
fnp-6382	263	3	human	human	ADJ
fnp-6382	263	4	studies	study	NOUN
fnp-6382	263	5	have	have	AUX
fnp-6382	263	6	examined	examine	VERB
fnp-6382	263	7	anti	anti	ADJ
fnp-6382	263	8	-	-	ADJ
fnp-6382	263	9	inflammatory	inflammatory	ADJ
fnp-6382	263	10	factors	factor	NOUN
fnp-6382	263	11	like	like	ADP
fnp-6382	263	12	il-10	il-10	PRON
fnp-6382	263	13	,	,	PUNCT
fnp-6382	263	14	il-4	il-4	PRON
fnp-6382	263	15	,	,	PUNCT
fnp-6382	263	16	and	and	CCONJ
fnp-6382	263	17	il-13	il-13	CCONJ
fnp-6382	263	18	,	,	PUNCT
fnp-6382	263	19	few	few	ADJ
fnp-6382	263	20	correlations	correlation	NOUN
fnp-6382	263	21	could	could	AUX
fnp-6382	263	22	be	be	AUX
fnp-6382	263	23	identified	identify	VERB
fnp-6382	263	24	(	(	PUNCT
fnp-6382	263	25	54	54	NUM
fnp-6382	263	26	)	)	PUNCT
fnp-6382	263	27	(	(	PUNCT
fnp-6382	263	28	42	42	NUM
fnp-6382	263	29	)	)	PUNCT
fnp-6382	263	30	.	.	PUNCT
fnp-6382	264	1	however	however	ADV
fnp-6382	264	2	,	,	PUNCT
fnp-6382	264	3	there	there	PRON
fnp-6382	264	4	have	have	AUX
fnp-6382	264	5	been	be	AUX
fnp-6382	264	6	reports	report	NOUN
fnp-6382	264	7	in	in	ADP
fnp-6382	264	8	animal	animal	NOUN
fnp-6382	264	9	studies	study	NOUN
fnp-6382	264	10	that	that	PRON
fnp-6382	264	11	tgf	tgf	PROPN
fnp-6382	264	12	-	-	PUNCT
fnp-6382	264	13	β	β	PROPN
fnp-6382	264	14	could	could	AUX
fnp-6382	264	15	be	be	AUX
fnp-6382	264	16	elevated	elevate	VERB
fnp-6382	264	17	six	six	NUM
fnp-6382	264	18	months	month	NOUN
fnp-6382	264	19	after	after	ADP
fnp-6382	264	20	repetitive	repetitive	ADJ
fnp-6382	264	21	head	head	NOUN
fnp-6382	264	22	trauma	trauma	NOUN
fnp-6382	264	23	(	(	PUNCT
fnp-6382	264	24	100	100	NUM
fnp-6382	264	25	)	)	PUNCT
fnp-6382	264	26	.	.	PUNCT
fnp-6382	265	1	overall	overall	ADV
fnp-6382	265	2	,	,	PUNCT
fnp-6382	265	3	while	while	SCONJ
fnp-6382	265	4	there	there	PRON
fnp-6382	265	5	is	be	VERB
fnp-6382	265	6	less	less	ADJ
fnp-6382	265	7	support	support	NOUN
fnp-6382	265	8	for	for	ADP
fnp-6382	265	9	anti	anti	ADJ
fnp-6382	265	10	-	-	ADJ
fnp-6382	265	11	inflammatory	inflammatory	ADJ
fnp-6382	265	12	proteins	protein	NOUN
fnp-6382	265	13	as	as	ADP
fnp-6382	265	14	novel	novel	ADJ
fnp-6382	265	15	biomarkers	biomarker	NOUN
fnp-6382	265	16	for	for	ADP
fnp-6382	265	17	repetitive	repetitive	ADJ
fnp-6382	265	18	head	head	NOUN
fnp-6382	265	19	trauma	trauma	NOUN
fnp-6382	265	20	,	,	PUNCT
fnp-6382	265	21	more	more	ADJ
fnp-6382	265	22	work	work	NOUN
fnp-6382	265	23	is	be	AUX
fnp-6382	265	24	needed	need	VERB
fnp-6382	265	25	to	to	PART
fnp-6382	265	26	better	well	ADV
fnp-6382	265	27	clarify	clarify	VERB
fnp-6382	265	28	targets	target	NOUN
fnp-6382	265	29	.	.	PUNCT
fnp-6382	266	1	discussion	discussion	NOUN
fnp-6382	266	2	and	and	CCONJ
fnp-6382	266	3	future	future	ADJ
fnp-6382	266	4	directions	direction	NOUN
fnp-6382	266	5	emerging	emerge	VERB
fnp-6382	266	6	evidence	evidence	NOUN
fnp-6382	266	7	points	point	VERB
fnp-6382	266	8	to	to	ADP
fnp-6382	266	9	immune	immune	ADJ
fnp-6382	266	10	mediators	mediator	NOUN
fnp-6382	266	11	as	as	ADP
fnp-6382	266	12	more	more	ADV
fnp-6382	266	13	specific	specific	ADJ
fnp-6382	266	14	cte	cte	NOUN
fnp-6382	266	15	biomarkers	biomarker	NOUN
fnp-6382	266	16	.	.	PUNCT
fnp-6382	267	1	given	give	VERB
fnp-6382	267	2	that	that	DET
fnp-6382	267	3	inflammation	inflammation	NOUN
fnp-6382	267	4	contributes	contribute	VERB
fnp-6382	267	5	to	to	AUX
fnp-6382	267	6	cte	cte	VERB
fnp-6382	267	7	pathology	pathology	PROPN
fnp-6382	267	8	,	,	PUNCT
fnp-6382	267	9	immune	immune	ADJ
fnp-6382	267	10	mediators	mediator	NOUN
fnp-6382	267	11	that	that	PRON
fnp-6382	267	12	could	could	AUX
fnp-6382	267	13	be	be	AUX
fnp-6382	267	14	unique	unique	ADJ
fnp-6382	267	15	to	to	ADP
fnp-6382	267	16	cte	cte	VERB
fnp-6382	267	17	’s	’s	PART
fnp-6382	267	18	inflammatory	inflammatory	ADJ
fnp-6382	267	19	signature	signature	NOUN
fnp-6382	267	20	,	,	PUNCT
fnp-6382	267	21	such	such	ADJ
fnp-6382	267	22	as	as	ADP
fnp-6382	267	23	ccl11	ccl11	NOUN
fnp-6382	267	24	and	and	CCONJ
fnp-6382	267	25	ccl21	ccl21	PROPN
fnp-6382	267	26	,	,	PUNCT
fnp-6382	267	27	are	be	AUX
fnp-6382	267	28	worth	worth	ADJ
fnp-6382	267	29	further	further	ADJ
fnp-6382	267	30	exploration	exploration	NOUN
fnp-6382	267	31	(	(	PUNCT
fnp-6382	267	32	22,52	22,52	NUM
fnp-6382	267	33	)	)	PUNCT
fnp-6382	267	34	.	.	PUNCT
fnp-6382	268	1	however	however	ADV
fnp-6382	268	2	,	,	PUNCT
fnp-6382	268	3	a	a	DET
fnp-6382	268	4	definitive	definitive	ADJ
fnp-6382	268	5	answer	answer	NOUN
fnp-6382	268	6	on	on	ADP
fnp-6382	268	7	the	the	DET
fnp-6382	268	8	reliability	reliability	NOUN
fnp-6382	268	9	of	of	ADP
fnp-6382	268	10	immune	immune	ADJ
fnp-6382	268	11	mediators	mediator	NOUN
fnp-6382	268	12	depends	depend	VERB
fnp-6382	268	13	on	on	ADP
fnp-6382	268	14	a	a	DET
fnp-6382	268	15	few	few	ADJ
fnp-6382	268	16	challenges	challenge	NOUN
fnp-6382	268	17	and	and	CCONJ
fnp-6382	268	18	limitations	limitation	NOUN
fnp-6382	268	19	that	that	PRON
fnp-6382	268	20	will	will	AUX
fnp-6382	268	21	first	first	ADV
fnp-6382	268	22	need	need	VERB
fnp-6382	268	23	to	to	PART
fnp-6382	268	24	be	be	AUX
fnp-6382	268	25	addressed	address	VERB
fnp-6382	268	26	in	in	ADP
fnp-6382	268	27	future	future	ADJ
fnp-6382	268	28	studies	study	NOUN
fnp-6382	268	29	.	.	PUNCT
fnp-6382	269	1	one	one	NUM
fnp-6382	269	2	of	of	ADP
fnp-6382	269	3	the	the	DET
fnp-6382	269	4	challenges	challenge	NOUN
fnp-6382	269	5	is	be	AUX
fnp-6382	269	6	the	the	DET
fnp-6382	269	7	need	need	NOUN
fnp-6382	269	8	to	to	PART
fnp-6382	269	9	account	account	VERB
fnp-6382	269	10	for	for	ADP
fnp-6382	269	11	the	the	DET
fnp-6382	269	12	prolonged	prolonged	ADJ
fnp-6382	269	13	latent	latent	NOUN
fnp-6382	269	14	period	period	NOUN
fnp-6382	269	15	between	between	ADP
fnp-6382	269	16	rhi	rhi	PROPN
fnp-6382	269	17	exposure	exposure	NOUN
fnp-6382	269	18	and	and	CCONJ
fnp-6382	269	19	cte	cte	NOUN
fnp-6382	269	20	symptom	symptom	NOUN
fnp-6382	269	21	onset	onset	PROPN
fnp-6382	269	22	.	.	PUNCT
fnp-6382	270	1	the	the	DET
fnp-6382	270	2	progressive	progressive	ADJ
fnp-6382	270	3	nature	nature	NOUN
fnp-6382	270	4	of	of	ADP
fnp-6382	270	5	chronic	chronic	ADJ
fnp-6382	270	6	inflammation	inflammation	NOUN
fnp-6382	270	7	in	in	ADP
fnp-6382	270	8	cte	cte	PROPN
fnp-6382	270	9	complicates	complicate	VERB
fnp-6382	270	10	the	the	DET
fnp-6382	270	11	identification	identification	NOUN
fnp-6382	270	12	of	of	ADP
fnp-6382	270	13	immune	immune	ADJ
fnp-6382	270	14	markers	marker	NOUN
fnp-6382	270	15	that	that	PRON
fnp-6382	270	16	are	be	AUX
fnp-6382	270	17	involved	involve	VERB
fnp-6382	270	18	over	over	ADP
fnp-6382	270	19	the	the	DET
fnp-6382	270	20	course	course	NOUN
fnp-6382	270	21	of	of	ADP
fnp-6382	270	22	disease	disease	NOUN
fnp-6382	270	23	development	development	NOUN
fnp-6382	270	24	.	.	PUNCT
fnp-6382	271	1	additionally	additionally	ADV
fnp-6382	271	2	,	,	PUNCT
fnp-6382	271	3	promising	promise	VERB
fnp-6382	271	4	markers	marker	NOUN
fnp-6382	271	5	like	like	ADP
fnp-6382	271	6	ccl11	ccl11	NOUN
fnp-6382	271	7	and	and	CCONJ
fnp-6382	271	8	ccl21	ccl21	PROPN
fnp-6382	271	9	have	have	AUX
fnp-6382	271	10	been	be	AUX
fnp-6382	271	11	primarily	primarily	ADV
fnp-6382	271	12	assessed	assess	VERB
fnp-6382	271	13	post	post	ADJ
fnp-6382	271	14	-	-	ADJ
fnp-6382	271	15	mortem	mortem	ADJ
fnp-6382	271	16	,	,	PUNCT
fnp-6382	271	17	making	make	VERB
fnp-6382	271	18	it	it	PRON
fnp-6382	271	19	difficult	difficult	ADJ
fnp-6382	271	20	to	to	PART
fnp-6382	271	21	translate	translate	VERB
fnp-6382	271	22	these	these	DET
fnp-6382	271	23	findings	finding	NOUN
fnp-6382	271	24	to	to	ADP
fnp-6382	271	25	living	living	NOUN
fnp-6382	271	26	patients	patient	NOUN
fnp-6382	271	27	.	.	PUNCT
fnp-6382	272	1	an	an	DET
fnp-6382	272	2	overarching	overarching	ADJ
fnp-6382	272	3	challenge	challenge	NOUN
fnp-6382	272	4	with	with	ADP
fnp-6382	272	5	developing	develop	VERB
fnp-6382	272	6	ante	ante	NOUN
fnp-6382	272	7	-	-	PUNCT
fnp-6382	272	8	mortem	mortem	NOUN
fnp-6382	272	9	biomarkers	biomarker	NOUN
fnp-6382	272	10	from	from	ADP
fnp-6382	272	11	immune	immune	ADJ
fnp-6382	272	12	mediators	mediator	NOUN
fnp-6382	272	13	is	be	AUX
fnp-6382	272	14	that	that	SCONJ
fnp-6382	272	15	,	,	PUNCT
fnp-6382	272	16	currently	currently	ADV
fnp-6382	272	17	,	,	PUNCT
fnp-6382	272	18	cte	cte	PROPN
fnp-6382	272	19	can	can	AUX
fnp-6382	272	20	only	only	ADV
fnp-6382	272	21	be	be	AUX
fnp-6382	272	22	definitively	definitively	ADV
fnp-6382	272	23	diagnosed	diagnose	VERB
fnp-6382	272	24	post	post	ADJ
fnp-6382	272	25	-	-	ADJ
fnp-6382	272	26	mortem	mortem	ADJ
fnp-6382	272	27	,	,	PUNCT
fnp-6382	272	28	with	with	ADP
fnp-6382	272	29	the	the	DET
fnp-6382	272	30	2021	2021	NUM
fnp-6382	272	31	consensus	consensus	NOUN
fnp-6382	272	32	criteria	criterion	NOUN
fnp-6382	272	33	subject	subject	ADJ
fnp-6382	272	34	to	to	ADP
fnp-6382	272	35	future	future	ADJ
fnp-6382	272	36	refinement	refinement	NOUN
fnp-6382	272	37	(	(	PUNCT
fnp-6382	272	38	101	101	NUM
fnp-6382	272	39	)	)	PUNCT
fnp-6382	272	40	.	.	PUNCT
fnp-6382	273	1	as	as	ADP
fnp-6382	273	2	such	such	ADJ
fnp-6382	273	3	,	,	PUNCT
fnp-6382	273	4	many	many	ADJ
fnp-6382	273	5	of	of	ADP
fnp-6382	273	6	the	the	DET
fnp-6382	273	7	studies	study	NOUN
fnp-6382	273	8	on	on	ADP
fnp-6382	273	9	cte	cte	PROPN
fnp-6382	273	10	are	be	AUX
fnp-6382	273	11	essentially	essentially	ADV
fnp-6382	273	12	just	just	ADV
fnp-6382	273	13	a	a	DET
fnp-6382	273	14	snapshot	snapshot	NOUN
fnp-6382	273	15	in	in	ADP
fnp-6382	273	16	time	time	NOUN
fnp-6382	273	17	and	and	CCONJ
fnp-6382	273	18	are	be	AUX
fnp-6382	273	19	limited	limit	VERB
fnp-6382	273	20	in	in	ADP
fnp-6382	273	21	addressing	address	VERB
fnp-6382	273	22	full	full	ADJ
fnp-6382	273	23	“	"	PUNCT
fnp-6382	273	24	causation	causation	NOUN
fnp-6382	273	25	”	"	PUNCT
fnp-6382	273	26	of	of	ADP
fnp-6382	273	27	the	the	DET
fnp-6382	273	28	target	target	NOUN
fnp-6382	273	29	factor	factor	NOUN
fnp-6382	273	30	versus	versus	ADP
fnp-6382	273	31	apparent	apparent	ADJ
fnp-6382	273	32	correlation	correlation	NOUN
fnp-6382	273	33	.	.	PUNCT
fnp-6382	274	1	to	to	PART
fnp-6382	274	2	address	address	VERB
fnp-6382	274	3	this	this	PRON
fnp-6382	274	4	,	,	PUNCT
fnp-6382	274	5	future	future	ADJ
fnp-6382	274	6	studies	study	NOUN
fnp-6382	274	7	should	should	AUX
fnp-6382	274	8	track	track	VERB
fnp-6382	274	9	immune	immune	ADJ
fnp-6382	274	10	markers	marker	NOUN
fnp-6382	274	11	in	in	ADP
fnp-6382	274	12	living	live	VERB
fnp-6382	274	13	rhi	rhi	NOUN
fnp-6382	274	14	-	-	PUNCT
fnp-6382	274	15	exposed	expose	VERB
fnp-6382	274	16	individuals	individual	NOUN
fnp-6382	274	17	over	over	ADP
fnp-6382	274	18	time	time	NOUN
fnp-6382	274	19	,	,	PUNCT
fnp-6382	274	20	followed	follow	VERB
fnp-6382	274	21	by	by	ADP
fnp-6382	274	22	cte	cte	PROPN
fnp-6382	274	23	status	status	NOUN
fnp-6382	274	24	confirmation	confirmation	NOUN
fnp-6382	274	25	via	via	ADP
fnp-6382	274	26	autopsy	autopsy	ADJ
fnp-6382	274	27	.	.	PUNCT
fnp-6382	275	1	this	this	DET
fnp-6382	275	2	approach	approach	NOUN
fnp-6382	275	3	is	be	AUX
fnp-6382	275	4	essential	essential	ADJ
fnp-6382	275	5	not	not	PART
fnp-6382	275	6	only	only	ADV
fnp-6382	275	7	for	for	ADP
fnp-6382	275	8	offering	offer	VERB
fnp-6382	275	9	clearer	clear	ADJ
fnp-6382	275	10	insights	insight	NOUN
fnp-6382	275	11	into	into	ADP
fnp-6382	275	12	the	the	DET
fnp-6382	275	13	temporal	temporal	ADJ
fnp-6382	275	14	dynamics	dynamic	NOUN
fnp-6382	275	15	of	of	ADP
fnp-6382	275	16	the	the	DET
fnp-6382	275	17	cte	cte	NOUN
fnp-6382	275	18	inflammatory	inflammatory	ADJ
fnp-6382	275	19	profile	profile	NOUN
fnp-6382	275	20	but	but	CCONJ
fnp-6382	275	21	also	also	ADV
fnp-6382	275	22	for	for	ADP
fnp-6382	275	23	revealing	reveal	VERB
fnp-6382	275	24	additional	additional	ADJ
fnp-6382	275	25	novel	novel	ADJ
fnp-6382	275	26	biomarkers	biomarker	NOUN
fnp-6382	275	27	that	that	PRON
fnp-6382	275	28	distinguish	distinguish	VERB
fnp-6382	275	29	cte	cte	NOUN
fnp-6382	275	30	from	from	ADP
fnp-6382	275	31	other	other	ADJ
fnp-6382	275	32	diseases	disease	NOUN
fnp-6382	275	33	.	.	PUNCT
fnp-6382	276	1	prospective	prospective	ADJ
fnp-6382	276	2	studies	study	NOUN
fnp-6382	276	3	could	could	AUX
fnp-6382	276	4	measure	measure	VERB
fnp-6382	276	5	general	general	ADJ
fnp-6382	276	6	injury	injury	NOUN
fnp-6382	276	7	markers	marker	NOUN
fnp-6382	276	8	such	such	ADJ
fnp-6382	276	9	as	as	ADP
fnp-6382	276	10	nfl	nfl	PROPN
fnp-6382	276	11	or	or	CCONJ
fnp-6382	276	12	gfap	gfap	PROPN
fnp-6382	276	13	in	in	ADP
fnp-6382	276	14	rhi	rhi	NOUN
fnp-6382	276	15	-	-	PUNCT
fnp-6382	276	16	exposed	expose	VERB
fnp-6382	276	17	living	living	NOUN
fnp-6382	276	18	individuals	individual	NOUN
fnp-6382	276	19	to	to	PART
fnp-6382	276	20	find	find	VERB
fnp-6382	276	21	subjects	subject	NOUN
fnp-6382	276	22	in	in	ADP
fnp-6382	276	23	the	the	DET
fnp-6382	276	24	early	early	ADJ
fnp-6382	276	25	stages	stage	NOUN
fnp-6382	276	26	of	of	ADP
fnp-6382	276	27	neurodegeneration	neurodegeneration	NOUN
fnp-6382	276	28	who	who	PRON
fnp-6382	276	29	are	be	AUX
fnp-6382	276	30	not	not	PART
fnp-6382	276	31	yet	yet	ADV
fnp-6382	276	32	symptomatic	symptomatic	ADJ
fnp-6382	276	33	.	.	PUNCT
fnp-6382	277	1	subsequently	subsequently	ADV
fnp-6382	277	2	,	,	PUNCT
fnp-6382	277	3	there	there	PRON
fnp-6382	277	4	can	can	AUX
fnp-6382	277	5	be	be	AUX
fnp-6382	277	6	an	an	DET
fnp-6382	277	7	assessment	assessment	NOUN
fnp-6382	277	8	of	of	ADP
fnp-6382	277	9	immune	immune	ADJ
fnp-6382	277	10	profiles	profile	NOUN
fnp-6382	277	11	via	via	ADP
fnp-6382	277	12	csfor	csfor	PROPN
fnp-6382	277	13	serum	serum	NOUN
fnp-6382	277	14	-	-	PUNCT
fnp-6382	277	15	based	base	VERB
fnp-6382	277	16	analysis	analysis	NOUN
fnp-6382	277	17	during	during	ADP
fnp-6382	277	18	life	life	NOUN
fnp-6382	277	19	,	,	PUNCT
fnp-6382	277	20	followed	follow	VERB
fnp-6382	277	21	by	by	ADP
fnp-6382	277	22	pathological	pathological	ADJ
fnp-6382	277	23	confirmation	confirmation	NOUN
fnp-6382	277	24	.	.	PUNCT
fnp-6382	278	1	this	this	PRON
fnp-6382	278	2	would	would	AUX
fnp-6382	278	3	allow	allow	VERB
fnp-6382	278	4	researchers	researcher	NOUN
fnp-6382	278	5	to	to	PART
fnp-6382	278	6	assess	assess	VERB
fnp-6382	278	7	whether	whether	SCONJ
fnp-6382	278	8	fluid	fluid	NOUN
fnp-6382	278	9	-	-	PUNCT
fnp-6382	278	10	based	base	VERB
fnp-6382	278	11	detection	detection	NOUN
fnp-6382	278	12	of	of	ADP
fnp-6382	278	13	immune	immune	ADJ
fnp-6382	278	14	proteins	protein	NOUN
fnp-6382	278	15	corresponds	correspond	NOUN
fnp-6382	278	16	to	to	PART
fnp-6382	278	17	confirmed	confirm	VERB
fnp-6382	278	18	cte	cte	PROPN
fnp-6382	278	19	pathology	pathology	PROPN
fnp-6382	278	20	,	,	PUNCT
fnp-6382	278	21	helping	help	VERB
fnp-6382	278	22	bridge	bridge	NOUN
fnp-6382	278	23	fluid	fluid	ADJ
fnp-6382	278	24	markers	marker	NOUN
fnp-6382	278	25	to	to	PART
fnp-6382	278	26	tissue	tissue	NOUN
fnp-6382	278	27	-	-	PUNCT
fnp-6382	278	28	based	base	VERB
fnp-6382	278	29	diagnostic	diagnostic	ADJ
fnp-6382	278	30	criteria	criterion	NOUN
fnp-6382	278	31	.	.	PUNCT
fnp-6382	279	1	the	the	DET
fnp-6382	279	2	overlap	overlap	NOUN
fnp-6382	279	3	of	of	ADP
fnp-6382	279	4	some	some	DET
fnp-6382	279	5	immune	immune	ADJ
fnp-6382	279	6	mediators	mediator	NOUN
fnp-6382	279	7	between	between	ADP
fnp-6382	279	8	cte	cte	NOUN
fnp-6382	279	9	and	and	CCONJ
fnp-6382	279	10	other	other	ADJ
fnp-6382	279	11	neurologic	neurologic	ADJ
fnp-6382	279	12	conditions	condition	NOUN
fnp-6382	279	13	such	such	ADJ
fnp-6382	279	14	as	as	ADP
fnp-6382	279	15	aging	aging	NOUN
fnp-6382	279	16	or	or	CCONJ
fnp-6382	279	17	ad	ad	NOUN
fnp-6382	279	18	further	far	ADV
fnp-6382	279	19	complicates	complicate	VERB
fnp-6382	279	20	the	the	DET
fnp-6382	279	21	potential	potential	NOUN
fnp-6382	279	22	of	of	ADP
fnp-6382	279	23	immune	immune	ADJ
fnp-6382	279	24	mediators	mediator	NOUN
fnp-6382	279	25	as	as	ADP
fnp-6382	279	26	biomarkers	biomarker	NOUN
fnp-6382	279	27	for	for	ADP
fnp-6382	279	28	cte	cte	NOUN
fnp-6382	279	29	.	.	PUNCT
fnp-6382	280	1	for	for	ADP
fnp-6382	280	2	instance	instance	NOUN
fnp-6382	280	3	,	,	PUNCT
fnp-6382	280	4	cytokines	cytokine	VERB
fnp-6382	280	5	like	like	ADP
fnp-6382	280	6	ccl11	ccl11	NOUN
fnp-6382	280	7	and	and	CCONJ
fnp-6382	280	8	il-6	il-6	NOUN
fnp-6382	280	9	can	can	AUX
fnp-6382	280	10	be	be	AUX
fnp-6382	280	11	elevated	elevate	VERB
fnp-6382	280	12	in	in	ADP
fnp-6382	280	13	normal	normal	ADJ
fnp-6382	280	14	aging	aging	NOUN
fnp-6382	280	15	and	and	CCONJ
fnp-6382	280	16	in	in	ADP
fnp-6382	280	17	psychiatric	psychiatric	ADJ
fnp-6382	280	18	disorders	disorder	NOUN
fnp-6382	280	19	,	,	PUNCT
fnp-6382	280	20	respectively	respectively	ADV
fnp-6382	280	21	,	,	PUNCT
fnp-6382	280	22	limiting	limit	VERB
fnp-6382	280	23	specificity	specificity	NOUN
fnp-6382	280	24	to	to	ADP
fnp-6382	280	25	cte	cte	PROPN
fnp-6382	280	26	(	(	PUNCT
fnp-6382	280	27	58,69	58,69	PROPN
fnp-6382	280	28	)	)	PUNCT
fnp-6382	280	29	.	.	PUNCT
fnp-6382	281	1	however	however	ADV
fnp-6382	281	2	,	,	PUNCT
fnp-6382	281	3	despite	despite	SCONJ
fnp-6382	281	4	lack	lack	NOUN
fnp-6382	281	5	of	of	ADP
fnp-6382	281	6	specificity	specificity	NOUN
fnp-6382	281	7	for	for	ADP
fnp-6382	281	8	some	some	DET
fnp-6382	281	9	cytokines	cytokine	NOUN
fnp-6382	281	10	to	to	AUX
fnp-6382	281	11	cte	cte	VERB
fnp-6382	281	12	,	,	PUNCT
fnp-6382	281	13	implementing	implement	VERB
fnp-6382	281	14	this	this	DET
fnp-6382	281	15	approach	approach	NOUN
fnp-6382	281	16	may	may	AUX
fnp-6382	281	17	nevertheless	nevertheless	ADV
fnp-6382	281	18	allow	allow	VERB
fnp-6382	281	19	researchers	researcher	NOUN
fnp-6382	281	20	to	to	PART
fnp-6382	281	21	identify	identify	VERB
fnp-6382	281	22	changes	change	NOUN
fnp-6382	281	23	in	in	ADP
fnp-6382	281	24	immune	immune	ADJ
fnp-6382	281	25	mediators	mediator	NOUN
fnp-6382	281	26	across	across	ADP
fnp-6382	281	27	the	the	DET
fnp-6382	281	28	disease	disease	NOUN
fnp-6382	281	29	course	course	NOUN
fnp-6382	281	30	,	,	PUNCT
fnp-6382	281	31	including	include	VERB
fnp-6382	281	32	prior	prior	ADV
fnp-6382	281	33	to	to	ADP
fnp-6382	281	34	symptom	symptom	NOUN
fnp-6382	281	35	onset	onset	NOUN
fnp-6382	281	36	and	and	CCONJ
fnp-6382	281	37	early	early	ADJ
fnp-6382	281	38	and	and	CCONJ
fnp-6382	281	39	late	late	ADJ
fnp-6382	281	40	stage	stage	NOUN
fnp-6382	281	41	cte	cte	PROPN
fnp-6382	281	42	.	.	PUNCT
fnp-6382	282	1	inflammatory	inflammatory	ADJ
fnp-6382	282	2	markers	marker	NOUN
fnp-6382	282	3	should	should	AUX
fnp-6382	282	4	be	be	AUX
fnp-6382	282	5	viewed	view	VERB
fnp-6382	282	6	as	as	ADP
fnp-6382	282	7	central	central	ADJ
fnp-6382	282	8	though	though	SCONJ
fnp-6382	282	9	not	not	PART
fnp-6382	282	10	sole	sole	ADJ
fnp-6382	282	11	components	component	NOUN
fnp-6382	282	12	of	of	ADP
fnp-6382	282	13	a	a	DET
fnp-6382	282	14	comprehensive	comprehensive	ADJ
fnp-6382	282	15	cte	cte	NOUN
fnp-6382	282	16	biomarker	biomarker	NOUN
fnp-6382	282	17	profile	profile	NOUN
fnp-6382	282	18	.	.	PUNCT
fnp-6382	283	1	while	while	SCONJ
fnp-6382	283	2	they	they	PRON
fnp-6382	283	3	may	may	AUX
fnp-6382	283	4	not	not	PART
fnp-6382	283	5	provide	provide	VERB
fnp-6382	283	6	absolute	absolute	ADJ
fnp-6382	283	7	specificity	specificity	NOUN
fnp-6382	283	8	on	on	ADP
fnp-6382	283	9	their	their	PRON
fnp-6382	283	10	own	own	ADJ
fnp-6382	283	11	,	,	PUNCT
fnp-6382	283	12	immune	immune	ADJ
fnp-6382	283	13	mediators	mediator	NOUN
fnp-6382	283	14	may	may	AUX
fnp-6382	283	15	enhance	enhance	VERB
fnp-6382	283	16	the	the	DET
fnp-6382	283	17	disease	disease	NOUN
fnp-6382	283	18	-	-	PUNCT
fnp-6382	283	19	stage	stage	NOUN
fnp-6382	283	20	resolution	resolution	NOUN
fnp-6382	283	21	of	of	ADP
fnp-6382	283	22	diagnostic	diagnostic	ADJ
fnp-6382	283	23	panels	panel	NOUN
fnp-6382	283	24	when	when	SCONJ
fnp-6382	283	25	integrated	integrate	VERB
fnp-6382	283	26	with	with	ADP
fnp-6382	283	27	other	other	ADJ
fnp-6382	283	28	biomarkers	biomarker	NOUN
fnp-6382	283	29	such	such	ADJ
fnp-6382	283	30	as	as	ADP
fnp-6382	283	31	tau	tau	PROPN
fnp-6382	283	32	isoforms	isoform	NOUN
fnp-6382	283	33	or	or	CCONJ
fnp-6382	283	34	general	general	ADJ
fnp-6382	283	35	injury	injury	NOUN
fnp-6382	283	36	markers	marker	NOUN
fnp-6382	283	37	.	.	PUNCT
fnp-6382	284	1	for	for	ADP
fnp-6382	284	2	example	example	NOUN
fnp-6382	284	3	,	,	PUNCT
fnp-6382	284	4	while	while	SCONJ
fnp-6382	284	5	t	t	PROPN
fnp-6382	284	6	-	-	PUNCT
fnp-6382	284	7	tau	tau	PROPN
fnp-6382	284	8	may	may	AUX
fnp-6382	284	9	not	not	PART
fnp-6382	284	10	distinguish	distinguish	VERB
fnp-6382	284	11	cte	cte	NOUN
fnp-6382	284	12	from	from	ADP
fnp-6382	284	13	other	other	ADJ
fnp-6382	284	14	tauopathies	tauopathie	NOUN
fnp-6382	284	15	,	,	PUNCT
fnp-6382	284	16	specific	specific	ADJ
fnp-6382	284	17	tau	tau	PROPN
fnp-6382	284	18	epitopes	epitope	NOUN
fnp-6382	284	19	like	like	ADP
fnp-6382	284	20	p	p	NOUN
fnp-6382	284	21	-	-	PUNCT
fnp-6382	284	22	tau202	tau202	PROPN
fnp-6382	284	23	and	and	CCONJ
fnp-6382	284	24	p	p	PROPN
fnp-6382	284	25	-	-	PUNCT
fnp-6382	284	26	tau231	tau231	PROPN
fnp-6382	284	27	may	may	AUX
fnp-6382	284	28	be	be	AUX
fnp-6382	284	29	unique	unique	ADJ
fnp-6382	284	30	to	to	ADP
fnp-6382	284	31	cte	cte	VERB
fnp-6382	284	32	and	and	CCONJ
fnp-6382	284	33	warrant	warrant	VERB
fnp-6382	284	34	further	further	ADJ
fnp-6382	284	35	study	study	NOUN
fnp-6382	284	36	in	in	ADP
fnp-6382	284	37	both	both	DET
fnp-6382	284	38	living	live	VERB
fnp-6382	284	39	patients	patient	NOUN
fnp-6382	284	40	and	and	CCONJ
fnp-6382	284	41	in	in	ADP
fnp-6382	284	42	post	post	ADJ
fnp-6382	284	43	-	-	ADJ
fnp-6382	284	44	mortem	mortem	ADJ
fnp-6382	284	45	comparisons	comparison	NOUN
fnp-6382	284	46	with	with	ADP
fnp-6382	284	47	other	other	ADJ
fnp-6382	284	48	neurodegenerative	neurodegenerative	ADJ
fnp-6382	284	49	diseases	disease	NOUN
fnp-6382	284	50	(	(	PUNCT
fnp-6382	284	51	18,102	18,102	NUM
fnp-6382	284	52	)	)	PUNCT
fnp-6382	284	53	.	.	PUNCT
fnp-6382	285	1	overall	overall	ADV
fnp-6382	285	2	,	,	PUNCT
fnp-6382	285	3	continued	continued	ADJ
fnp-6382	285	4	validation	validation	NOUN
fnp-6382	285	5	of	of	ADP
fnp-6382	285	6	immune	immune	ADJ
fnp-6382	285	7	markers	marker	NOUN
fnp-6382	285	8	like	like	ADP
fnp-6382	285	9	ccl21	ccl21	NOUN
fnp-6382	285	10	and	and	CCONJ
fnp-6382	285	11	their	their	PRON
fnp-6382	285	12	potential	potential	ADJ
fnp-6382	285	13	role	role	NOUN
fnp-6382	285	14	in	in	ADP
fnp-6382	285	15	cte	cte	PROPN
fnp-6382	285	16	is	be	AUX
fnp-6382	285	17	needed	need	VERB
fnp-6382	285	18	through	through	ADP
fnp-6382	285	19	fluid	fluid	NOUN
fnp-6382	285	20	-	-	PUNCT
fnp-6382	285	21	based	base	VERB
fnp-6382	285	22	analyses	analysis	NOUN
fnp-6382	285	23	in	in	ADP
fnp-6382	285	24	both	both	CCONJ
fnp-6382	285	25	post	post	ADJ
fnp-6382	285	26	-	-	ADJ
fnp-6382	285	27	mortem	mortem	ADJ
fnp-6382	285	28	and	and	CCONJ
fnp-6382	285	29	ante	ante	NOUN
fnp-6382	285	30	-	-	PUNCT
fnp-6382	285	31	mortem	mortem	NOUN
fnp-6382	285	32	settings	setting	NOUN
fnp-6382	285	33	.	.	PUNCT
fnp-6382	286	1	in	in	ADP
fnp-6382	286	2	figure	figure	NOUN
fnp-6382	286	3	 	 	SPACE
fnp-6382	286	4	1	1	NUM
fnp-6382	286	5	,	,	PUNCT
fnp-6382	286	6	we	we	PRON
fnp-6382	286	7	provide	provide	VERB
fnp-6382	286	8	a	a	DET
fnp-6382	286	9	schematic	schematic	ADJ
fnp-6382	286	10	overview	overview	NOUN
fnp-6382	286	11	of	of	ADP
fnp-6382	286	12	the	the	DET
fnp-6382	286	13	inflammatory	inflammatory	ADJ
fnp-6382	286	14	pathways	pathway	NOUN
fnp-6382	286	15	comprising	comprise	VERB
fnp-6382	286	16	the	the	DET
fnp-6382	286	17	immune	immune	ADJ
fnp-6382	286	18	signature	signature	NOUN
fnp-6382	286	19	where	where	SCONJ
fnp-6382	286	20	prospective	prospective	ADJ
fnp-6382	286	21	cte	cte	NOUN
fnp-6382	286	22	biomarkers	biomarker	NOUN
fnp-6382	286	23	might	might	AUX
fnp-6382	286	24	fit	fit	VERB
fnp-6382	286	25	.	.	PROPN
fnp-6382	287	1	1	1	NUM
fnp-6382	287	2	)	)	PUNCT
fnp-6382	287	3	repeated	repeat	VERB
fnp-6382	287	4	head	head	NOUN
fnp-6382	287	5	trauma	trauma	NOUN
fnp-6382	287	6	damages	damage	NOUN
fnp-6382	287	7	vasculature	vasculature	VERB
fnp-6382	287	8	,	,	PUNCT
fnp-6382	287	9	leading	lead	VERB
fnp-6382	287	10	to	to	ADP
fnp-6382	287	11	increased	increase	VERB
fnp-6382	287	12	bbb	bbb	NOUN
fnp-6382	287	13	permeability	permeability	NOUN
fnp-6382	287	14	and	and	CCONJ
fnp-6382	287	15	infiltration	infiltration	NOUN
fnp-6382	287	16	of	of	ADP
fnp-6382	287	17	lymphocytes	lymphocyte	NOUN
fnp-6382	287	18	and	and	CCONJ
fnp-6382	287	19	pro	pro	ADJ
fnp-6382	287	20	-	-	ADJ
fnp-6382	287	21	inflammatory	inflammatory	ADJ
fnp-6382	287	22	cytokines	cytokine	NOUN
fnp-6382	287	23	like	like	ADP
fnp-6382	287	24	il-1β	il-1β	PROPN
fnp-6382	287	25	and	and	CCONJ
fnp-6382	287	26	ifn	ifn	PROPN
fnp-6382	287	27	-	-	PUNCT
fnp-6382	287	28	γ	γ	NOUN
fnp-6382	287	29	.	.	PUNCT
fnp-6382	288	1	at	at	ADP
fnp-6382	288	2	this	this	DET
fnp-6382	288	3	point	point	NOUN
fnp-6382	288	4	,	,	PUNCT
fnp-6382	288	5	ccl2	ccl2	NOUN
fnp-6382	288	6	and	and	CCONJ
fnp-6382	288	7	ccl21	ccl21	PROPN
fnp-6382	288	8	may	may	AUX
fnp-6382	288	9	be	be	AUX
fnp-6382	288	10	upregulated	upregulate	VERB
fnp-6382	288	11	by	by	ADP
fnp-6382	288	12	endothelial	endothelial	ADJ
fnp-6382	288	13	cells	cell	NOUN
fnp-6382	288	14	.	.	PUNCT
fnp-6382	289	1	2	2	X
fnp-6382	289	2	)	)	PUNCT
fnp-6382	289	3	microglia	microglia	NOUN
fnp-6382	289	4	are	be	AUX
fnp-6382	289	5	activated	activate	VERB
fnp-6382	289	6	by	by	ADP
fnp-6382	289	7	cytokines	cytokine	NOUN
fnp-6382	289	8	,	,	PUNCT
fnp-6382	289	9	proliferating	proliferate	VERB
fnp-6382	289	10	into	into	ADP
fnp-6382	289	11	phenotypes	phenotype	NOUN
fnp-6382	289	12	including	include	VERB
fnp-6382	289	13	satellite	satellite	NOUN
fnp-6382	289	14	,	,	PUNCT
fnp-6382	289	15	spp1	spp1	PROPN
fnp-6382	289	16	+	+	PROPN
fnp-6382	289	17	,	,	PUNCT
fnp-6382	289	18	and	and	CCONJ
fnp-6382	289	19	hifa+	hifa+	ADJ
fnp-6382	289	20	microglia	microglia	ADJ
fnp-6382	289	21	.	.	PUNCT
fnp-6382	290	1	microglia	microglia	NOUN
fnp-6382	290	2	then	then	ADV
fnp-6382	290	3	secrete	secrete	VERB
fnp-6382	290	4	factors	factor	NOUN
fnp-6382	290	5	such	such	ADJ
fnp-6382	290	6	as	as	ADP
fnp-6382	290	7	cx3cr1	cx3cr1	PROPN
fnp-6382	290	8	,	,	PUNCT
fnp-6382	290	9	tnf	tnf	PROPN
fnp-6382	290	10	-	-	PUNCT
fnp-6382	290	11	α	α	PROPN
fnp-6382	290	12	,	,	PUNCT
fnp-6382	290	13	and	and	CCONJ
fnp-6382	290	14	il-6	il-6	NOUN
fnp-6382	290	15	that	that	PRON
fnp-6382	290	16	propagate	propagate	VERB
fnp-6382	290	17	inflammation	inflammation	NOUN
fnp-6382	290	18	through	through	ADP
fnp-6382	290	19	stimulation	stimulation	NOUN
fnp-6382	290	20	of	of	ADP
fnp-6382	290	21	other	other	ADJ
fnp-6382	290	22	neural	neural	ADJ
fnp-6382	290	23	cell	cell	NOUN
fnp-6382	290	24	types	type	NOUN
fnp-6382	290	25	.	.	PUNCT
fnp-6382	291	1	microgliosis	microgliosis	NOUN
fnp-6382	291	2	may	may	AUX
fnp-6382	291	3	correlate	correlate	VERB
fnp-6382	291	4	with	with	ADP
fnp-6382	291	5	candidate	candidate	NOUN
fnp-6382	291	6	markers	marker	NOUN
fnp-6382	291	7	ccl2	ccl2	PROPN
fnp-6382	291	8	,	,	PUNCT
fnp-6382	291	9	ccl11	ccl11	NOUN
fnp-6382	291	10	,	,	PUNCT
fnp-6382	291	11	ccl21	ccl21	NOUN
fnp-6382	291	12	,	,	PUNCT
fnp-6382	291	13	and	and	CCONJ
fnp-6382	291	14	ykl-40	ykl-40	PROPN
fnp-6382	291	15	.	.	NOUN
fnp-6382	291	16	3	3	NUM
fnp-6382	291	17	)	)	PUNCT
fnp-6382	291	18	astrocytes	astrocyte	NOUN
fnp-6382	291	19	proliferate	proliferate	VERB
fnp-6382	291	20	and	and	CCONJ
fnp-6382	291	21	release	release	VERB
fnp-6382	291	22	inflammatory	inflammatory	ADJ
fnp-6382	291	23	cytokines	cytokine	NOUN
fnp-6382	292	1	e.g.	e.g.	ADV
fnp-6382	292	2	il-1β	il-1β	PROPN
fnp-6382	292	3	,	,	PUNCT
fnp-6382	292	4	il-2	il-2	NOUN
fnp-6382	292	5	,	,	PUNCT
fnp-6382	292	6	il-6	il-6	NUM
fnp-6382	292	7	,	,	PUNCT
fnp-6382	292	8	and	and	CCONJ
fnp-6382	292	9	il-15	il-15	X
fnp-6382	292	10	)	)	PUNCT
fnp-6382	292	11	that	that	PRON
fnp-6382	292	12	further	far	ADV
fnp-6382	292	13	activate	activate	VERB
fnp-6382	292	14	microglia	microglia	ADJ
fnp-6382	292	15	.	.	NOUN
fnp-6382	293	1	4	4	NUM
fnp-6382	293	2	)	)	PUNCT
fnp-6382	293	3	reactive	reactive	ADJ
fnp-6382	293	4	astrocytes	astrocyte	NOUN
fnp-6382	293	5	contribute	contribute	VERB
fnp-6382	293	6	to	to	ADP
fnp-6382	293	7	an	an	DET
fnp-6382	293	8	increased	increase	VERB
fnp-6382	293	9	bbb	bbb	NOUN
fnp-6382	293	10	permeability	permeability	NOUN
fnp-6382	293	11	,	,	PUNCT
fnp-6382	293	12	exacerbating	exacerbate	VERB
fnp-6382	293	13	inflammation	inflammation	NOUN
fnp-6382	293	14	.	.	PUNCT
fnp-6382	294	1	ykl-40	ykl-40	PROPN
fnp-6382	294	2	,	,	PUNCT
fnp-6382	294	3	ccl2	ccl2	PROPN
fnp-6382	294	4	,	,	PUNCT
fnp-6382	294	5	and	and	CCONJ
fnp-6382	294	6	ccl11	ccl11	NOUN
fnp-6382	294	7	may	may	AUX
fnp-6382	294	8	be	be	AUX
fnp-6382	294	9	released	release	VERB
fnp-6382	294	10	by	by	ADP
fnp-6382	294	11	activated	activate	VERB
fnp-6382	294	12	astrocytes	astrocyte	NOUN
fnp-6382	294	13	.	.	PUNCT
fnp-6382	295	1	5	5	X
fnp-6382	295	2	)	)	PUNCT
fnp-6382	295	3	the	the	DET
fnp-6382	295	4	neuron	neuron	NOUN
fnp-6382	295	5	-	-	PUNCT
fnp-6382	295	6	microglial	microglial	ADJ
fnp-6382	295	7	crosstalk	crosstalk	NOUN
fnp-6382	295	8	occurs	occur	NOUN
fnp-6382	295	9	,	,	PUNCT
fnp-6382	295	10	where	where	SCONJ
fnp-6382	295	11	microglia	microglia	ADJ
fnp-6382	295	12	damage	damage	NOUN
fnp-6382	295	13	neurons	neuron	NOUN
fnp-6382	295	14	through	through	ADP
fnp-6382	295	15	cytokine	cytokine	NOUN
fnp-6382	295	16	release	release	NOUN
fnp-6382	295	17	,	,	PUNCT
fnp-6382	295	18	and	and	CCONJ
fnp-6382	295	19	neurons	neuron	NOUN
fnp-6382	295	20	in	in	ADP
fnp-6382	295	21	turn	turn	NOUN
fnp-6382	295	22	secrete	secrete	NOUN
fnp-6382	295	23	mediators	mediator	NOUN
fnp-6382	295	24	including	include	VERB
fnp-6382	295	25	ros	ro	NOUN
fnp-6382	295	26	that	that	PRON
fnp-6382	295	27	promote	promote	VERB
fnp-6382	295	28	more	more	ADJ
fnp-6382	295	29	microgliosis	microgliosis	NOUN
fnp-6382	295	30	.	.	PUNCT
fnp-6382	296	1	markers	marker	NOUN
fnp-6382	296	2	associated	associate	VERB
fnp-6382	296	3	with	with	ADP
fnp-6382	296	4	this	this	DET
fnp-6382	296	5	event	event	NOUN
fnp-6382	296	6	could	could	AUX
fnp-6382	296	7	include	include	VERB
fnp-6382	296	8	ccl2	ccl2	PROPN
fnp-6382	296	9	,	,	PUNCT
fnp-6382	296	10	ccl11	ccl11	PROPN
fnp-6382	296	11	,	,	PUNCT
fnp-6382	296	12	hmgb1	hmgb1	PROPN
fnp-6382	296	13	,	,	PUNCT
fnp-6382	296	14	hsp	hsp	NOUN
fnp-6382	296	15	,	,	PUNCT
fnp-6382	296	16	and	and	CCONJ
fnp-6382	296	17	cx3cr1	cx3cr1	NOUN
fnp-6382	296	18	.	.	PROPN
fnp-6382	296	19	6	6	NUM
fnp-6382	296	20	)	)	PUNCT
fnp-6382	296	21	next	next	ADV
fnp-6382	296	22	,	,	PUNCT
fnp-6382	296	23	p	p	PROPN
fnp-6382	296	24	-	-	PUNCT
fnp-6382	296	25	tau	tau	PROPN
fnp-6382	296	26	is	be	AUX
fnp-6382	296	27	released	release	VERB
fnp-6382	296	28	from	from	ADP
fnp-6382	296	29	damaged	damage	VERB
fnp-6382	296	30	neurons	neuron	NOUN
fnp-6382	296	31	and	and	CCONJ
fnp-6382	296	32	accumulates	accumulate	VERB
fnp-6382	296	33	.	.	PUNCT
fnp-6382	297	1	7	7	X
fnp-6382	297	2	)	)	PUNCT
fnp-6382	297	3	tau	tau	PROPN
fnp-6382	297	4	deposition	deposition	NOUN
fnp-6382	297	5	is	be	AUX
fnp-6382	297	6	then	then	ADV
fnp-6382	297	7	sensed	sense	VERB
fnp-6382	297	8	by	by	ADP
fnp-6382	297	9	microglia	microglia	NOUN
fnp-6382	297	10	which	which	PRON
fnp-6382	297	11	are	be	AUX
fnp-6382	297	12	further	far	ADV
fnp-6382	297	13	activated	activate	VERB
fnp-6382	297	14	.	.	PUNCT
fnp-6382	298	1	8)	8)	NUM
fnp-6382	298	2	when	when	SCONJ
fnp-6382	298	3	damaged	damage	VERB
fnp-6382	298	4	,	,	PUNCT
fnp-6382	298	5	oligodendrocytes	oligodendrocyte	NOUN
fnp-6382	298	6	might	might	AUX
fnp-6382	298	7	cause	cause	VERB
fnp-6382	298	8	neuronal	neuronal	ADJ
fnp-6382	298	9	injury	injury	NOUN
fnp-6382	298	10	through	through	ADP
fnp-6382	298	11	secretion	secretion	NOUN
fnp-6382	298	12	of	of	ADP
fnp-6382	298	13	cytokines	cytokine	NOUN
fnp-6382	298	14	such	such	ADJ
fnp-6382	298	15	as	as	ADP
fnp-6382	298	16	il-1β	il-1β	PROPN
fnp-6382	298	17	,	,	PUNCT
fnp-6382	298	18	il-6	il-6	NUM
fnp-6382	298	19	,	,	PUNCT
fnp-6382	298	20	tnf	tnf	PROPN
fnp-6382	298	21	-	-	PUNCT
fnp-6382	298	22	α	α	PROPN
fnp-6382	298	23	,	,	PUNCT
fnp-6382	298	24	ccl2	ccl2	NOUN
fnp-6382	298	25	and	and	CCONJ
fnp-6382	298	26	also	also	ADV
fnp-6382	298	27	axonal	axonal	ADJ
fnp-6382	298	28	degeneration	degeneration	NOUN
fnp-6382	298	29	.	.	PUNCT
fnp-6382	299	1	while	while	SCONJ
fnp-6382	299	2	several	several	ADJ
fnp-6382	299	3	of	of	ADP
fnp-6382	299	4	these	these	DET
fnp-6382	299	5	processes	process	NOUN
fnp-6382	299	6	might	might	AUX
fnp-6382	299	7	also	also	ADV
fnp-6382	299	8	be	be	AUX
fnp-6382	299	9	involved	involve	VERB
fnp-6382	299	10	in	in	ADP
fnp-6382	299	11	other	other	ADJ
fnp-6382	299	12	diseases	disease	NOUN
fnp-6382	299	13	or	or	CCONJ
fnp-6382	299	14	even	even	ADV
fnp-6382	299	15	in	in	ADP
fnp-6382	299	16	single	single	ADJ
fnp-6382	299	17	tbi	tbi	PROPN
fnp-6382	299	18	,	,	PUNCT
fnp-6382	299	19	the	the	DET
fnp-6382	299	20	cellular	cellular	ADJ
fnp-6382	299	21	arrangement	arrangement	NOUN
fnp-6382	299	22	,	,	PUNCT
fnp-6382	299	23	brain	brain	NOUN
fnp-6382	299	24	region	region	NOUN
fnp-6382	299	25	affected	affect	VERB
fnp-6382	299	26	,	,	PUNCT
fnp-6382	299	27	regional	regional	ADJ
fnp-6382	299	28	spread	spread	NOUN
fnp-6382	299	29	,	,	PUNCT
fnp-6382	299	30	timing	timing	NOUN
fnp-6382	299	31	,	,	PUNCT
fnp-6382	299	32	and	and	CCONJ
fnp-6382	299	33	age	age	NOUN
fnp-6382	299	34	of	of	ADP
fnp-6382	299	35	onset	onset	NOUN
fnp-6382	299	36	can	can	AUX
fnp-6382	299	37	be	be	AUX
fnp-6382	299	38	distinct	distinct	ADJ
fnp-6382	299	39	in	in	ADP
fnp-6382	299	40	the	the	DET
fnp-6382	299	41	context	context	NOUN
fnp-6382	299	42	of	of	ADP
fnp-6382	299	43	cte	cte	PROPN
fnp-6382	299	44	.	.	PUNCT
fnp-6382	300	1	these	these	PRON
fnp-6382	300	2	are	be	AUX
fnp-6382	300	3	important	important	ADJ
fnp-6382	300	4	processes	process	NOUN
fnp-6382	300	5	to	to	PART
fnp-6382	300	6	consider	consider	VERB
fnp-6382	300	7	when	when	SCONJ
fnp-6382	300	8	utilizing	utilize	VERB
fnp-6382	300	9	biomarkers	biomarker	NOUN
fnp-6382	300	10	to	to	PART
fnp-6382	300	11	help	help	VERB
fnp-6382	300	12	discriminate	discriminate	VERB
fnp-6382	300	13	and	and	CCONJ
fnp-6382	300	14	identify	identify	VERB
fnp-6382	300	15	pathology	pathology	NOUN
fnp-6382	300	16	.	.	PUNCT
fnp-6382	301	1	for	for	ADP
fnp-6382	301	2	example	example	NOUN
fnp-6382	301	3	,	,	PUNCT
fnp-6382	301	4	although	although	SCONJ
fnp-6382	301	5	ccl2	ccl2	PROPN
fnp-6382	301	6	might	might	AUX
fnp-6382	301	7	also	also	ADV
fnp-6382	301	8	be	be	AUX
fnp-6382	301	9	implicated	implicate	VERB
fnp-6382	301	10	in	in	ADP
fnp-6382	301	11	ad	ad	NOUN
fnp-6382	301	12	,	,	PUNCT
fnp-6382	301	13	elevated	elevated	ADJ
fnp-6382	301	14	ccl2	ccl2	NOUN
fnp-6382	301	15	levels	level	NOUN
fnp-6382	301	16	found	find	VERB
fnp-6382	301	17	in	in	ADP
fnp-6382	301	18	individuals	individual	NOUN
fnp-6382	301	19	in	in	ADP
fnp-6382	301	20	their	their	PRON
fnp-6382	301	21	30s	30	NOUN
fnp-6382	301	22	may	may	AUX
fnp-6382	301	23	rather	rather	ADV
fnp-6382	301	24	point	point	VERB
fnp-6382	301	25	towards	towards	ADP
fnp-6382	301	26	cte	cte	NOUN
fnp-6382	301	27	,	,	PUNCT
fnp-6382	301	28	given	give	VERB
fnp-6382	301	29	that	that	SCONJ
fnp-6382	301	30	ad	ad	NOUN
fnp-6382	301	31	changes	change	NOUN
fnp-6382	301	32	typically	typically	ADV
fnp-6382	301	33	start	start	VERB
fnp-6382	301	34	around	around	ADP
fnp-6382	301	35	the	the	DET
fnp-6382	301	36	age	age	NOUN
fnp-6382	301	37	of	of	ADP
fnp-6382	301	38	60	60	NUM
fnp-6382	301	39	.	.	PUNCT
fnp-6382	302	1	figure	figure	NOUN
fnp-6382	302	2	1	1	NUM
fnp-6382	302	3	:	:	PUNCT
fnp-6382	302	4	schematic	schematic	ADJ
fnp-6382	302	5	overview	overview	NOUN
fnp-6382	302	6	of	of	ADP
fnp-6382	302	7	the	the	DET
fnp-6382	302	8	immune	immune	ADJ
fnp-6382	302	9	signature	signature	NOUN
fnp-6382	302	10	for	for	ADP
fnp-6382	302	11	cte	cte	PROPN
fnp-6382	302	12	inflammatory	inflammatory	ADJ
fnp-6382	302	13	pathways	pathway	NOUN
fnp-6382	302	14	contributing	contribute	VERB
fnp-6382	302	15	to	to	ADP
fnp-6382	302	16	the	the	DET
fnp-6382	302	17	immune	immune	ADJ
fnp-6382	302	18	signature	signature	NOUN
fnp-6382	302	19	for	for	ADP
fnp-6382	302	20	cte	cte	PROPN
fnp-6382	302	21	are	be	AUX
fnp-6382	302	22	highlighted	highlight	VERB
fnp-6382	302	23	,	,	PUNCT
fnp-6382	302	24	including	include	VERB
fnp-6382	302	25	key	key	ADJ
fnp-6382	302	26	cellular	cellular	ADJ
fnp-6382	302	27	interactions	interaction	NOUN
fnp-6382	302	28	and	and	CCONJ
fnp-6382	302	29	sources	source	NOUN
fnp-6382	302	30	of	of	ADP
fnp-6382	302	31	potential	potential	ADJ
fnp-6382	302	32	biomarkers	biomarker	NOUN
fnp-6382	302	33	.	.	PUNCT
fnp-6382	303	1	the	the	DET
fnp-6382	303	2	schematic	schematic	ADJ
fnp-6382	303	3	depicts	depict	VERB
fnp-6382	303	4	the	the	DET
fnp-6382	303	5	sequential	sequential	ADJ
fnp-6382	303	6	activation	activation	NOUN
fnp-6382	303	7	of	of	ADP
fnp-6382	303	8	endothelial	endothelial	ADJ
fnp-6382	303	9	cells	cell	NOUN
fnp-6382	303	10	,	,	PUNCT
fnp-6382	303	11	microglia	microglia	ADJ
fnp-6382	303	12	,	,	PUNCT
fnp-6382	303	13	astrocytes	astrocyte	NOUN
fnp-6382	303	14	,	,	PUNCT
fnp-6382	303	15	neurons	neuron	NOUN
fnp-6382	303	16	,	,	PUNCT
fnp-6382	303	17	and	and	CCONJ
fnp-6382	303	18	oligodendrocytes	oligodendrocyte	NOUN
fnp-6382	303	19	,	,	PUNCT
fnp-6382	303	20	through	through	ADP
fnp-6382	303	21	which	which	PRON
fnp-6382	303	22	chronic	chronic	ADJ
fnp-6382	303	23	inflammation	inflammation	NOUN
fnp-6382	303	24	and	and	CCONJ
fnp-6382	303	25	neurodegeneration	neurodegeneration	NOUN
fnp-6382	303	26	is	be	AUX
fnp-6382	303	27	maintained	maintain	VERB
fnp-6382	303	28	.	.	PUNCT
fnp-6382	304	1	created	create	VERB
fnp-6382	304	2	with	with	ADP
fnp-6382	304	3	biorender	biorender	NOUN
fnp-6382	304	4	.	.	PUNCT
fnp-6382	305	1	conclusion	conclusion	NOUN
fnp-6382	305	2	as	as	SCONJ
fnp-6382	305	3	it	it	PRON
fnp-6382	305	4	is	be	AUX
fnp-6382	305	5	the	the	DET
fnp-6382	305	6	case	case	NOUN
fnp-6382	305	7	in	in	ADP
fnp-6382	305	8	many	many	ADJ
fnp-6382	305	9	neurodegenerative	neurodegenerative	ADJ
fnp-6382	305	10	diseases	disease	NOUN
fnp-6382	305	11	,	,	PUNCT
fnp-6382	305	12	neuroinflammation	neuroinflammation	NOUN
fnp-6382	305	13	has	have	VERB
fnp-6382	305	14	a	a	DET
fnp-6382	305	15	critical	critical	ADJ
fnp-6382	305	16	role	role	NOUN
fnp-6382	305	17	in	in	ADP
fnp-6382	305	18	cte	cte	NOUN
fnp-6382	305	19	pathogenesis	pathogenesis	NOUN
fnp-6382	305	20	and	and	CCONJ
fnp-6382	305	21	disease	disease	NOUN
fnp-6382	305	22	trajectory	trajectory	NOUN
fnp-6382	305	23	.	.	PUNCT
fnp-6382	306	1	as	as	ADP
fnp-6382	306	2	such	such	ADJ
fnp-6382	306	3	,	,	PUNCT
fnp-6382	306	4	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	306	5	changes	change	NOUN
fnp-6382	306	6	might	might	AUX
fnp-6382	306	7	be	be	AUX
fnp-6382	306	8	useful	useful	ADJ
fnp-6382	306	9	to	to	PART
fnp-6382	306	10	foster	foster	VERB
fnp-6382	306	11	biomarker	biomarker	NOUN
fnp-6382	306	12	development	development	NOUN
fnp-6382	306	13	.	.	PUNCT
fnp-6382	307	1	in	in	ADP
fnp-6382	307	2	this	this	DET
fnp-6382	307	3	review	review	NOUN
fnp-6382	307	4	,	,	PUNCT
fnp-6382	307	5	we	we	PRON
fnp-6382	307	6	have	have	AUX
fnp-6382	307	7	highlighted	highlight	VERB
fnp-6382	307	8	several	several	ADJ
fnp-6382	307	9	prospective	prospective	ADJ
fnp-6382	307	10	fluidic	fluidic	ADJ
fnp-6382	307	11	neuroimmune	neuroimmune	NOUN
fnp-6382	307	12	biomarkers	biomarker	NOUN
fnp-6382	307	13	that	that	PRON
fnp-6382	307	14	might	might	AUX
fnp-6382	307	15	be	be	AUX
fnp-6382	307	16	useful	useful	ADJ
fnp-6382	307	17	to	to	PART
fnp-6382	307	18	identify	identify	VERB
fnp-6382	307	19	cte	cte	NOUN
fnp-6382	307	20	during	during	ADP
fnp-6382	307	21	life	life	NOUN
fnp-6382	307	22	.	.	PUNCT
fnp-6382	308	1	ccl21	ccl21	NOUN
fnp-6382	308	2	,	,	PUNCT
fnp-6382	308	3	ccl11	ccl11	PROPN
fnp-6382	308	4	,	,	PUNCT
fnp-6382	308	5	ccl2	ccl2	PROPN
fnp-6382	308	6	,	,	PUNCT
fnp-6382	308	7	il-6	il-6	NUM
fnp-6382	308	8	,	,	PUNCT
fnp-6382	308	9	and	and	CCONJ
fnp-6382	308	10	gfap	gfap	NOUN
fnp-6382	308	11	have	have	AUX
fnp-6382	308	12	all	all	PRON
fnp-6382	308	13	shown	show	VERB
fnp-6382	308	14	some	some	DET
fnp-6382	308	15	promise	promise	NOUN
fnp-6382	308	16	but	but	CCONJ
fnp-6382	308	17	have	have	VERB
fnp-6382	308	18	yet	yet	ADV
fnp-6382	308	19	to	to	PART
fnp-6382	308	20	be	be	AUX
fnp-6382	308	21	fully	fully	ADV
fnp-6382	308	22	validated	validate	VERB
fnp-6382	308	23	.	.	PUNCT
fnp-6382	309	1	however	however	ADV
fnp-6382	309	2	,	,	PUNCT
fnp-6382	309	3	several	several	ADJ
fnp-6382	309	4	limitations	limitation	NOUN
fnp-6382	309	5	surrounding	surround	VERB
fnp-6382	309	6	specificity	specificity	NOUN
fnp-6382	309	7	arise	arise	VERB
fnp-6382	309	8	as	as	SCONJ
fnp-6382	309	9	these	these	DET
fnp-6382	309	10	factors	factor	NOUN
fnp-6382	309	11	are	be	AUX
fnp-6382	309	12	also	also	ADV
fnp-6382	309	13	involved	involve	VERB
fnp-6382	309	14	in	in	ADP
fnp-6382	309	15	other	other	ADJ
fnp-6382	309	16	neuropathologies	neuropathologie	NOUN
fnp-6382	309	17	.	.	PUNCT
fnp-6382	310	1	therefore	therefore	ADV
fnp-6382	310	2	,	,	PUNCT
fnp-6382	310	3	it	it	PRON
fnp-6382	310	4	is	be	AUX
fnp-6382	310	5	not	not	PART
fnp-6382	310	6	likely	likely	ADJ
fnp-6382	310	7	that	that	SCONJ
fnp-6382	310	8	a	a	DET
fnp-6382	310	9	single	single	ADJ
fnp-6382	310	10	biomarker	biomarker	NOUN
fnp-6382	310	11	will	will	AUX
fnp-6382	310	12	be	be	AUX
fnp-6382	310	13	sufficient	sufficient	ADJ
fnp-6382	310	14	for	for	ADP
fnp-6382	310	15	accurate	accurate	ADJ
fnp-6382	310	16	cte	cte	NOUN
fnp-6382	310	17	detection	detection	NOUN
fnp-6382	310	18	.	.	PUNCT
fnp-6382	311	1	in	in	ADP
fnp-6382	311	2	genetics	genetic	NOUN
fnp-6382	311	3	,	,	PUNCT
fnp-6382	311	4	examining	examine	VERB
fnp-6382	311	5	multiple	multiple	ADJ
fnp-6382	311	6	genes	gene	NOUN
fnp-6382	311	7	together	together	ADV
fnp-6382	311	8	to	to	PART
fnp-6382	311	9	identify	identify	VERB
fnp-6382	311	10	“	"	PUNCT
fnp-6382	311	11	gene	gene	NOUN
fnp-6382	311	12	signatures	signature	NOUN
fnp-6382	311	13	”	"	PUNCT
fnp-6382	311	14	has	have	AUX
fnp-6382	311	15	shown	show	VERB
fnp-6382	311	16	to	to	PART
fnp-6382	311	17	be	be	AUX
fnp-6382	311	18	a	a	DET
fnp-6382	311	19	better	well	ADJ
fnp-6382	311	20	method	method	NOUN
fnp-6382	311	21	to	to	PART
fnp-6382	311	22	identify	identify	VERB
fnp-6382	311	23	complex	complex	ADJ
fnp-6382	311	24	changes	change	NOUN
fnp-6382	311	25	and	and	CCONJ
fnp-6382	311	26	disease	disease	NOUN
fnp-6382	311	27	-	-	PUNCT
fnp-6382	311	28	specific	specific	ADJ
fnp-6382	311	29	effects	effect	NOUN
fnp-6382	311	30	.	.	PUNCT
fnp-6382	312	1	in	in	ADP
fnp-6382	312	2	that	that	DET
fnp-6382	312	3	same	same	ADJ
fnp-6382	312	4	line	line	NOUN
fnp-6382	312	5	of	of	ADP
fnp-6382	312	6	ideas	idea	NOUN
fnp-6382	312	7	,	,	PUNCT
fnp-6382	312	8	it	it	PRON
fnp-6382	312	9	is	be	AUX
fnp-6382	312	10	likely	likely	ADJ
fnp-6382	312	11	that	that	SCONJ
fnp-6382	312	12	biomarker	biomarker	NOUN
fnp-6382	312	13	panels	panel	NOUN
fnp-6382	312	14	consisting	consist	VERB
fnp-6382	312	15	of	of	ADP
fnp-6382	312	16	several	several	ADJ
fnp-6382	312	17	neuroimmune	neuroimmune	NOUN
fnp-6382	312	18	proteins	protein	NOUN
fnp-6382	312	19	will	will	AUX
fnp-6382	312	20	be	be	AUX
fnp-6382	312	21	able	able	ADJ
fnp-6382	312	22	to	to	PART
fnp-6382	312	23	specifically	specifically	ADV
fnp-6382	312	24	identify	identify	VERB
fnp-6382	312	25	diseases	disease	NOUN
fnp-6382	312	26	more	more	ADV
fnp-6382	312	27	efficiently	efficiently	ADV
fnp-6382	312	28	as	as	SCONJ
fnp-6382	312	29	previously	previously	ADV
fnp-6382	312	30	suggested	suggest	VERB
fnp-6382	312	31	(	(	PUNCT
fnp-6382	312	32	103	103	NUM
fnp-6382	312	33	)	)	PUNCT
fnp-6382	312	34	.	.	PUNCT
fnp-6382	313	1	in	in	ADP
fnp-6382	313	2	addition	addition	NOUN
fnp-6382	313	3	,	,	PUNCT
fnp-6382	313	4	it	it	PRON
fnp-6382	313	5	will	will	AUX
fnp-6382	313	6	be	be	AUX
fnp-6382	313	7	useful	useful	ADJ
fnp-6382	313	8	to	to	PART
fnp-6382	313	9	also	also	ADV
fnp-6382	313	10	include	include	VERB
fnp-6382	313	11	other	other	ADJ
fnp-6382	313	12	variables	variable	NOUN
fnp-6382	313	13	such	such	ADJ
fnp-6382	313	14	as	as	ADP
fnp-6382	313	15	clinical	clinical	ADJ
fnp-6382	313	16	symptoms	symptom	NOUN
fnp-6382	313	17	,	,	PUNCT
fnp-6382	313	18	demographic	demographic	ADJ
fnp-6382	313	19	details	detail	NOUN
fnp-6382	313	20	,	,	PUNCT
fnp-6382	313	21	athletic	athletic	ADJ
fnp-6382	313	22	history	history	NOUN
fnp-6382	313	23	,	,	PUNCT
fnp-6382	313	24	and	and	CCONJ
fnp-6382	313	25	imaging	imaging	NOUN
fnp-6382	313	26	results	result	NOUN
fnp-6382	313	27	to	to	PART
fnp-6382	313	28	further	far	ADV
fnp-6382	313	29	help	help	VERB
fnp-6382	313	30	increase	increase	VERB
fnp-6382	313	31	the	the	DET
fnp-6382	313	32	specificity	specificity	NOUN
fnp-6382	313	33	of	of	ADP
fnp-6382	313	34	cte	cte	PROPN
fnp-6382	313	35	detection	detection	NOUN
fnp-6382	313	36	.	.	PUNCT
fnp-6382	314	1	these	these	DET
fnp-6382	314	2	types	type	NOUN
fnp-6382	314	3	of	of	ADP
fnp-6382	314	4	clinical	clinical	ADJ
fnp-6382	314	5	-	-	PUNCT
fnp-6382	314	6	pathologic	pathologic	ADJ
fnp-6382	314	7	correlation	correlation	NOUN
fnp-6382	314	8	studies	study	NOUN
fnp-6382	314	9	are	be	AUX
fnp-6382	314	10	currently	currently	ADV
fnp-6382	314	11	ongoing	ongoing	ADJ
fnp-6382	314	12	and	and	CCONJ
fnp-6382	314	13	hoped	hope	VERB
fnp-6382	314	14	to	to	PART
fnp-6382	314	15	bridge	bridge	VERB
fnp-6382	314	16	clinical	clinical	ADJ
fnp-6382	314	17	details	detail	NOUN
fnp-6382	314	18	with	with	ADP
fnp-6382	314	19	neuropathologically	neuropathologically	ADV
fnp-6382	314	20	confirmed	confirm	VERB
fnp-6382	314	21	disease	disease	NOUN
fnp-6382	314	22	status	status	NOUN
fnp-6382	314	23	and	and	CCONJ
fnp-6382	314	24	biomarker	biomarker	NOUN
fnp-6382	314	25	data	datum	NOUN
fnp-6382	314	26	.	.	PUNCT
fnp-6382	315	1	in	in	ADP
fnp-6382	315	2	conclusion	conclusion	NOUN
fnp-6382	315	3	,	,	PUNCT
fnp-6382	315	4	the	the	DET
fnp-6382	315	5	work	work	NOUN
fnp-6382	315	6	presented	present	VERB
fnp-6382	315	7	here	here	ADV
fnp-6382	315	8	highlights	highlight	NOUN
fnp-6382	315	9	that	that	SCONJ
fnp-6382	315	10	our	our	PRON
fnp-6382	315	11	continued	continue	VERB
fnp-6382	315	12	understanding	understanding	NOUN
fnp-6382	315	13	of	of	ADP
fnp-6382	315	14	neuroinflammation	neuroinflammation	NOUN
fnp-6382	315	15	offers	offer	VERB
fnp-6382	315	16	the	the	DET
fnp-6382	315	17	exiting	exit	VERB
fnp-6382	315	18	ability	ability	NOUN
fnp-6382	315	19	to	to	PART
fnp-6382	315	20	improve	improve	VERB
fnp-6382	315	21	existing	exist	VERB
fnp-6382	315	22	detecting	detect	VERB
fnp-6382	315	23	techniques	technique	NOUN
fnp-6382	315	24	and	and	CCONJ
fnp-6382	315	25	to	to	PART
fnp-6382	315	26	increase	increase	VERB
fnp-6382	315	27	our	our	PRON
fnp-6382	315	28	future	future	ADJ
fnp-6382	315	29	ability	ability	NOUN
fnp-6382	315	30	to	to	PART
fnp-6382	315	31	identify	identify	VERB
fnp-6382	315	32	cte	cte	NOUN
fnp-6382	315	33	during	during	ADP
fnp-6382	315	34	life	life	NOUN
fnp-6382	315	35	.	.	PUNCT
fnp-6382	316	1	authors	author	NOUN
fnp-6382	316	2	'	'	PART
fnp-6382	316	3	contributions	contribution	NOUN
fnp-6382	316	4	gsb	gsb	NOUN
fnp-6382	316	5	:	:	PUNCT
fnp-6382	316	6	conceptualization	conceptualization	NOUN
fnp-6382	316	7	,	,	PUNCT
fnp-6382	316	8	writing	writing	NOUN
fnp-6382	316	9	(	(	PUNCT
fnp-6382	316	10	original	original	ADJ
fnp-6382	316	11	draft	draft	NOUN
fnp-6382	316	12	)	)	PUNCT
fnp-6382	316	13	,	,	PUNCT
fnp-6382	316	14	writing	write	VERB
fnp-6382	316	15	(	(	PUNCT
fnp-6382	316	16	review	review	NOUN
fnp-6382	316	17	and	and	CCONJ
fnp-6382	316	18	editing	editing	NOUN
fnp-6382	316	19	)	)	PUNCT
fnp-6382	316	20	.	.	PUNCT
fnp-6382	317	1	sa	sa	PROPN
fnp-6382	317	2	:	:	PUNCT
fnp-6382	317	3	writing	write	VERB
fnp-6382	317	4	(	(	PUNCT
fnp-6382	317	5	original	original	ADJ
fnp-6382	317	6	draft	draft	NOUN
fnp-6382	317	7	)	)	PUNCT
fnp-6382	317	8	.	.	PUNCT
fnp-6382	318	1	js	js	PROPN
fnp-6382	318	2	:	:	PUNCT
fnp-6382	318	3	writing	writing	NOUN
fnp-6382	318	4	(	(	PUNCT
fnp-6382	318	5	original	original	ADJ
fnp-6382	318	6	draft	draft	NOUN
fnp-6382	318	7	)	)	PUNCT
fnp-6382	318	8	.	.	PUNCT
fnp-6382	319	1	fl	fl	PRON
fnp-6382	319	2	:	:	PUNCT
fnp-6382	319	3	conceptualization	conceptualization	NOUN
fnp-6382	319	4	.	.	PUNCT
fnp-6382	320	1	aeb	aeb	NOUN
fnp-6382	320	2	:	:	PUNCT
fnp-6382	320	3	writing	writing	NOUN
fnp-6382	320	4	(	(	PUNCT
fnp-6382	320	5	review	review	NOUN
fnp-6382	320	6	and	and	CCONJ
fnp-6382	320	7	editing	editing	NOUN
fnp-6382	320	8	)	)	PUNCT
fnp-6382	320	9	.	.	PUNCT
fnp-6382	321	1	kwt	kwt	NOUN
fnp-6382	321	2	:	:	PUNCT
fnp-6382	321	3	writing	writing	NOUN
fnp-6382	321	4	(	(	PUNCT
fnp-6382	321	5	review	review	NOUN
fnp-6382	321	6	and	and	CCONJ
fnp-6382	321	7	editing	editing	NOUN
fnp-6382	321	8	)	)	PUNCT
fnp-6382	321	9	.	.	PUNCT
fnp-6382	322	1	jdc	jdc	NOUN
fnp-6382	322	2	:	:	PUNCT
fnp-6382	322	3	conceptualization	conceptualization	NOUN
fnp-6382	322	4	,	,	PUNCT
fnp-6382	322	5	writing	writing	NOUN
fnp-6382	322	6	(	(	PUNCT
fnp-6382	322	7	original	original	ADJ
fnp-6382	322	8	draft	draft	NOUN
fnp-6382	322	9	)	)	PUNCT
fnp-6382	322	10	,	,	PUNCT
fnp-6382	322	11	writing	write	VERB
fnp-6382	322	12	(	(	PUNCT
fnp-6382	322	13	review	review	NOUN
fnp-6382	322	14	and	and	CCONJ
fnp-6382	322	15	editing	editing	NOUN
fnp-6382	322	16	)	)	PUNCT
fnp-6382	322	17	.	.	PUNCT
fnp-6382	323	1	all	all	DET
fnp-6382	323	2	authors	author	NOUN
fnp-6382	323	3	have	have	AUX
fnp-6382	323	4	read	read	VERB
fnp-6382	323	5	and	and	CCONJ
fnp-6382	323	6	approved	approve	VERB
fnp-6382	323	7	the	the	DET
fnp-6382	323	8	final	final	ADJ
fnp-6382	323	9	version	version	NOUN
fnp-6382	323	10	of	of	ADP
fnp-6382	323	11	the	the	DET
fnp-6382	323	12	manuscript	manuscript	NOUN
fnp-6382	323	13	.	.	PUNCT
fnp-6382	324	1	conflict	conflict	NOUN
fnp-6382	324	2	of	of	ADP
fnp-6382	324	3	interest	interest	NOUN
fnp-6382	324	4	statement	statement	NOUN
fnp-6382	324	5	the	the	DET
fnp-6382	324	6	authors	author	NOUN
fnp-6382	324	7	declare	declare	VERB
fnp-6382	324	8	no	no	DET
fnp-6382	324	9	competing	compete	VERB
fnp-6382	324	10	interests	interest	NOUN
fnp-6382	324	11	.	.	PUNCT
fnp-6382	325	1	funding	funding	NOUN
fnp-6382	325	2	statement	statement	NOUN
fnp-6382	325	3	this	this	DET
fnp-6382	325	4	work	work	NOUN
fnp-6382	325	5	was	be	AUX
fnp-6382	325	6	supported	support	VERB
fnp-6382	325	7	by	by	ADP
fnp-6382	325	8	grant	grant	NOUN
fnp-6382	325	9	funding	funding	NOUN
fnp-6382	325	10	from	from	ADP
fnp-6382	325	11	the	the	DET
fnp-6382	325	12	national	national	PROPN
fnp-6382	325	13	institute	institute	PROPN
fnp-6382	325	14	of	of	ADP
fnp-6382	325	15	aging	age	VERB
fnp-6382	325	16	boston	boston	PROPN
fnp-6382	325	17	university	university	PROPN
fnp-6382	325	18	ad	ad	NOUN
fnp-6382	325	19	center	center	NOUN
fnp-6382	325	20	(	(	PUNCT
fnp-6382	325	21	p30ag072978	p30ag072978	NOUN
fnp-6382	325	22	)	)	PUNCT
fnp-6382	325	23	and	and	CCONJ
fnp-6382	325	24	the	the	DET
fnp-6382	325	25	department	department	NOUN
fnp-6382	325	26	of	of	ADP
fnp-6382	325	27	veterans	veterans	PROPN
fnp-6382	325	28	affairs	affairs	PROPN
fnp-6382	325	29	career	career	NOUN
fnp-6382	325	30	development	development	NOUN
fnp-6382	325	31	awards	award	NOUN
fnp-6382	325	32	to	to	ADP
fnp-6382	325	33	jc	jc	PROPN
fnp-6382	325	34	(	(	PUNCT
fnp-6382	325	35	bx004349	bx004349	PROPN
fnp-6382	325	36	)	)	PUNCT
fnp-6382	325	37	and	and	CCONJ
fnp-6382	325	38	kt	kt	PROPN
fnp-6382	325	39	(	(	PUNCT
fnp-6382	325	40	ik2	ik2	PROPN
fnp-6382	325	41	cx002065	cx002065	PROPN
fnp-6382	325	42	)	)	PUNCT
fnp-6382	325	43	.	.	PUNCT
fnp-6382	326	1	references	reference	NOUN
fnp-6382	326	2	1	1	NUM
fnp-6382	326	3	.	.	PUNCT
fnp-6382	326	4	mckee	mckee	PROPN
fnp-6382	326	5	ac	ac	PROPN
fnp-6382	326	6	,	,	PUNCT
fnp-6382	326	7	stein	stein	PROPN
fnp-6382	326	8	td	td	PROPN
fnp-6382	326	9	,	,	PUNCT
fnp-6382	326	10	huber	huber	PROPN
fnp-6382	326	11	br	br	PROPN
fnp-6382	326	12	,	,	PUNCT
fnp-6382	326	13	crary	crary	PROPN
fnp-6382	326	14	jf	jf	PROPN
fnp-6382	326	15	,	,	PUNCT
fnp-6382	326	16	bieniek	bieniek	PROPN
fnp-6382	326	17	k	k	PROPN
fnp-6382	326	18	,	,	PUNCT
fnp-6382	326	19	dickson	dickson	PROPN
fnp-6382	326	20	d	d	PROPN
fnp-6382	326	21	,	,	PUNCT
fnp-6382	326	22	et	et	PROPN
fnp-6382	326	23	al	al	PROPN
fnp-6382	326	24	.	.	PROPN
fnp-6382	327	1	chronic	chronic	PROPN
fnp-6382	327	2	traumatic	traumatic	ADJ
fnp-6382	327	3	encephalopathy	encephalopathy	NOUN
fnp-6382	327	4	(	(	PUNCT
fnp-6382	327	5	cte	cte	NOUN
fnp-6382	327	6	):	):	PUNCT
fnp-6382	327	7	criteria	criterion	NOUN
fnp-6382	327	8	for	for	ADP
fnp-6382	327	9	neuropathological	neuropathological	ADJ
fnp-6382	327	10	diagnosis	diagnosis	NOUN
fnp-6382	327	11	and	and	CCONJ
fnp-6382	327	12	relationship	relationship	NOUN
fnp-6382	327	13	to	to	ADP
fnp-6382	327	14	repetitive	repetitive	ADJ
fnp-6382	327	15	head	head	NOUN
fnp-6382	327	16	impacts	impact	NOUN
fnp-6382	327	17	.	.	PUNCT
fnp-6382	328	1	acta	acta	PROPN
fnp-6382	328	2	neuropathol	neuropathol	PROPN
fnp-6382	328	3	(	(	PUNCT
fnp-6382	328	4	berl	berl	PROPN
fnp-6382	328	5	)	)	PUNCT
fnp-6382	328	6	.	.	PUNCT
fnp-6382	329	1	2023	2023	NUM
fnp-6382	329	2	apr;145(4):371	apr;145(4):371	NOUN
fnp-6382	329	3	-	-	PUNCT
fnp-6382	329	4	94	94	NUM
fnp-6382	329	5	.	.	PUNCT
fnp-6382	330	1	https://doi.org/10.1007/s00401-023-02540-w	https://doi.org/10.1007/s00401-023-02540-w	NOUN
fnp-6382	330	2	2	2	NUM
fnp-6382	330	3	.	.	PUNCT
fnp-6382	330	4	mckee	mckee	PROPN
fnp-6382	330	5	ac	ac	PROPN
fnp-6382	330	6	,	,	PUNCT
fnp-6382	330	7	alosco	alosco	PROPN
fnp-6382	330	8	ml	ml	PROPN
fnp-6382	330	9	,	,	PUNCT
fnp-6382	330	10	huber	huber	PROPN
fnp-6382	330	11	br	br	PROPN
fnp-6382	330	12	.	.	PUNCT
fnp-6382	331	1	repetitive	repetitive	ADJ
fnp-6382	331	2	head	head	NOUN
fnp-6382	331	3	impacts	impact	NOUN
fnp-6382	331	4	and	and	CCONJ
fnp-6382	331	5	chronic	chronic	ADJ
fnp-6382	331	6	traumatic	traumatic	ADJ
fnp-6382	331	7	encephalopathy	encephalopathy	NOUN
fnp-6382	331	8	.	.	PUNCT
fnp-6382	332	1	neurosurg	neurosurg	PROPN
fnp-6382	332	2	clin	clin	PROPN
fnp-6382	332	3	n	n	PRON
fnp-6382	332	4	am	be	AUX
fnp-6382	332	5	.	.	PUNCT
fnp-6382	333	1	2016	2016	NUM
fnp-6382	333	2	oct;27(4):529	oct;27(4):529	NUM
fnp-6382	333	3	-	-	SYM
fnp-6382	333	4	35	35	NUM
fnp-6382	333	5	.	.	PUNCT
fnp-6382	333	6	https://doi.org/10.1016/j.nec.2016.05.009	https://doi.org/10.1016/j.nec.2016.05.009	NOUN
fnp-6382	333	7	3	3	NUM
fnp-6382	333	8	.	.	PUNCT
fnp-6382	334	1	katz	katz	PROPN
fnp-6382	334	2	di	di	PROPN
fnp-6382	334	3	,	,	PUNCT
fnp-6382	334	4	bernick	bernick	PROPN
fnp-6382	334	5	c	c	PROPN
fnp-6382	334	6	,	,	PUNCT
fnp-6382	334	7	dodick	dodick	PROPN
fnp-6382	334	8	dw	dw	PROPN
fnp-6382	334	9	,	,	PUNCT
fnp-6382	334	10	mez	mez	PROPN
fnp-6382	334	11	j	j	PROPN
fnp-6382	334	12	,	,	PUNCT
fnp-6382	334	13	mariani	mariani	PROPN
fnp-6382	334	14	ml	ml	PROPN
fnp-6382	334	15	,	,	PUNCT
fnp-6382	334	16	adler	adler	PROPN
fnp-6382	334	17	ch	ch	PROPN
fnp-6382	334	18	,	,	PUNCT
fnp-6382	334	19	et	et	PROPN
fnp-6382	334	20	al	al	PROPN
fnp-6382	334	21	.	.	PROPN
fnp-6382	334	22	national	national	PROPN
fnp-6382	334	23	institute	institute	PROPN
fnp-6382	334	24	of	of	ADP
fnp-6382	334	25	neurological	neurological	ADJ
fnp-6382	334	26	disorders	disorder	NOUN
fnp-6382	334	27	and	and	CCONJ
fnp-6382	334	28	stroke	stroke	NOUN
fnp-6382	334	29	consensus	consensus	NOUN
fnp-6382	334	30	diagnostic	diagnostic	ADJ
fnp-6382	334	31	criteria	criterion	NOUN
fnp-6382	334	32	for	for	ADP
fnp-6382	334	33	traumatic	traumatic	ADJ
fnp-6382	334	34	encephalopathy	encephalopathy	ADJ
fnp-6382	334	35	syndrome	syndrome	NOUN
fnp-6382	334	36	.	.	PUNCT
fnp-6382	335	1	neurology	neurology	NOUN
fnp-6382	335	2	.	.	PUNCT
fnp-6382	336	1	2021	2021	NUM
fnp-6382	336	2	may	may	PROPN
fnp-6382	336	3	4;96(18):848	4;96(18):848	NUM
fnp-6382	336	4	-	-	PUNCT
fnp-6382	336	5	63	63	NUM
fnp-6382	336	6	.	.	PUNCT
fnp-6382	337	1	https://doi.org/10.1212/wnl.0000000000011850	https://doi.org/10.1212/wnl.0000000000011850	NOUN
fnp-6382	337	2	4	4	NUM
fnp-6382	337	3	.	.	PUNCT
fnp-6382	337	4	mez	mez	PROPN
fnp-6382	337	5	j	j	PROPN
fnp-6382	337	6	,	,	PUNCT
fnp-6382	337	7	daneshvar	daneshvar	PROPN
fnp-6382	337	8	dh	dh	NOUN
fnp-6382	337	9	,	,	PUNCT
fnp-6382	337	10	abdolmohammadi	abdolmohammadi	PROPN
fnp-6382	337	11	b	b	PROPN
fnp-6382	337	12	,	,	PUNCT
fnp-6382	337	13	chua	chua	PROPN
fnp-6382	337	14	as	as	ADP
fnp-6382	337	15	,	,	PUNCT
fnp-6382	337	16	alosco	alosco	PROPN
fnp-6382	337	17	ml	ml	PROPN
fnp-6382	337	18	,	,	PUNCT
fnp-6382	337	19	kiernan	kiernan	PROPN
fnp-6382	337	20	pt	pt	PROPN
fnp-6382	337	21	,	,	PUNCT
fnp-6382	337	22	et	et	PROPN
fnp-6382	337	23	al	al	PROPN
fnp-6382	337	24	.	.	PUNCT
fnp-6382	337	25	duration	duration	NOUN
fnp-6382	337	26	of	of	ADP
fnp-6382	337	27	american	american	ADJ
fnp-6382	337	28	football	football	NOUN
fnp-6382	337	29	play	play	NOUN
fnp-6382	337	30	and	and	CCONJ
fnp-6382	337	31	chronic	chronic	ADJ
fnp-6382	337	32	traumatic	traumatic	ADJ
fnp-6382	337	33	encephalopathy	encephalopathy	NOUN
fnp-6382	337	34	.	.	PUNCT
fnp-6382	338	1	ann	ann	PROPN
fnp-6382	338	2	neurol	neurol	PROPN
fnp-6382	338	3	.	.	PUNCT
fnp-6382	339	1	2020	2020	NUM
fnp-6382	340	1	jan;87(1):116	jan;87(1):116	ADP
fnp-6382	340	2	-	-	PUNCT
fnp-6382	340	3	31	31	NUM
fnp-6382	340	4	.	.	PUNCT
fnp-6382	341	1	https://doi.org/10.1002/ana.25611	https://doi.org/10.1002/ana.25611	NOUN
fnp-6382	341	2	5	5	NUM
fnp-6382	341	3	.	.	PUNCT
fnp-6382	342	1	priemer	priemer	PROPN
fnp-6382	342	2	ds	ds	PROPN
fnp-6382	342	3	,	,	PUNCT
fnp-6382	342	4	iacono	iacono	ADJ
fnp-6382	342	5	d	d	PROPN
fnp-6382	342	6	,	,	PUNCT
fnp-6382	342	7	rhodes	rhodes	PROPN
fnp-6382	342	8	ch	ch	PROPN
fnp-6382	342	9	,	,	PUNCT
fnp-6382	342	10	olsen	olsen	PROPN
fnp-6382	342	11	ch	ch	PROPN
fnp-6382	342	12	,	,	PUNCT
fnp-6382	342	13	perl	perl	NOUN
fnp-6382	342	14	dp	dp	PROPN
fnp-6382	342	15	.	.	PUNCT
fnp-6382	342	16	chronic	chronic	ADJ
fnp-6382	342	17	traumatic	traumatic	ADJ
fnp-6382	342	18	encephalopathy	encephalopathy	NOUN
fnp-6382	342	19	in	in	ADP
fnp-6382	342	20	the	the	DET
fnp-6382	342	21	brains	brain	NOUN
fnp-6382	342	22	of	of	ADP
fnp-6382	342	23	military	military	ADJ
fnp-6382	342	24	personnel	personnel	NOUN
fnp-6382	342	25	.	.	PUNCT
fnp-6382	343	1	n	n	PROPN
fnp-6382	343	2	engl	engl	PROPN
fnp-6382	343	3	j	j	PROPN
fnp-6382	343	4	med	med	PROPN
fnp-6382	343	5	.	.	PUNCT
fnp-6382	344	1	2022	2022	NUM
fnp-6382	344	2	jun	jun	PROPN
fnp-6382	344	3	9;386(23):2169	9;386(23):2169	PROPN
fnp-6382	344	4	-	-	SYM
fnp-6382	344	5	77	77	NUM
fnp-6382	344	6	.	.	PUNCT
fnp-6382	344	7	https://doi.org/10.1056/nejmoa2203199	https://doi.org/10.1056/nejmoa2203199	PROPN
fnp-6382	344	8	6	6	NUM
fnp-6382	344	9	.	.	PUNCT
fnp-6382	345	1	walt	walt	PROPN
fnp-6382	345	2	gs	gs	PROPN
fnp-6382	345	3	,	,	PUNCT
fnp-6382	345	4	burris	burris	PROPN
fnp-6382	345	5	hm	hm	PROPN
fnp-6382	345	6	,	,	PUNCT
fnp-6382	345	7	brady	brady	PROPN
fnp-6382	345	8	cb	cb	PROPN
fnp-6382	345	9	,	,	PUNCT
fnp-6382	345	10	spencer	spencer	PROPN
fnp-6382	345	11	kr	kr	PROPN
fnp-6382	345	12	,	,	PUNCT
fnp-6382	345	13	alvarez	alvarez	PROPN
fnp-6382	345	14	ve	ve	PROPN
fnp-6382	345	15	,	,	PUNCT
fnp-6382	345	16	huber	huber	PROPN
fnp-6382	345	17	br	br	PROPN
fnp-6382	345	18	,	,	PUNCT
fnp-6382	345	19	et	et	PROPN
fnp-6382	345	20	al	al	PROPN
fnp-6382	345	21	.	.	PROPN
fnp-6382	345	22	chronic	chronic	PROPN
fnp-6382	345	23	traumatic	traumatic	ADJ
fnp-6382	345	24	encephalopathy	encephalopathy	NOUN
fnp-6382	345	25	within	within	ADP
fnp-6382	345	26	an	an	DET
fnp-6382	345	27	amyotrophic	amyotrophic	ADJ
fnp-6382	345	28	lateral	lateral	ADJ
fnp-6382	345	29	sclerosis	sclerosis	NOUN
fnp-6382	345	30	brain	brain	PROPN
fnp-6382	345	31	bank	bank	PROPN
fnp-6382	345	32	cohort	cohort	NOUN
fnp-6382	345	33	.	.	PUNCT
fnp-6382	346	1	j	j	PROPN
fnp-6382	346	2	neuropathol	neuropathol	PROPN
fnp-6382	346	3	exp	exp	PROPN
fnp-6382	346	4	neurol	neurol	NOUN
fnp-6382	346	5	.	.	PUNCT
fnp-6382	347	1	2018	2018	NUM
fnp-6382	347	2	dec	dec	PROPN
fnp-6382	347	3	1;77(12):1091	1;77(12):1091	NUM
fnp-6382	347	4	-	-	SYM
fnp-6382	347	5	100	100	NUM
fnp-6382	347	6	.	.	PUNCT
fnp-6382	348	1	https://doi.org/10.1093/jnen/nly092	https://doi.org/10.1093/jnen/nly092	X
fnp-6382	348	2	7	7	X
fnp-6382	348	3	.	.	X
fnp-6382	348	4	mckee	mckee	PROPN
fnp-6382	348	5	ac	ac	PROPN
fnp-6382	348	6	,	,	PUNCT
fnp-6382	348	7	stein	stein	PROPN
fnp-6382	348	8	td	td	PROPN
fnp-6382	348	9	,	,	PUNCT
fnp-6382	348	10	nowinski	nowinski	ADJ
fnp-6382	348	11	cj	cj	PROPN
fnp-6382	348	12	,	,	PUNCT
fnp-6382	348	13	stern	stern	PROPN
fnp-6382	348	14	ra	ra	PROPN
fnp-6382	348	15	,	,	PUNCT
fnp-6382	348	16	daneshvar	daneshvar	PROPN
fnp-6382	348	17	dh	dh	PROPN
fnp-6382	348	18	,	,	PUNCT
fnp-6382	348	19	alvarez	alvarez	PROPN
fnp-6382	348	20	ve	ve	PROPN
fnp-6382	348	21	,	,	PUNCT
fnp-6382	348	22	et	et	PROPN
fnp-6382	348	23	al	al	PROPN
fnp-6382	348	24	.	.	PUNCT
fnp-6382	349	1	the	the	DET
fnp-6382	349	2	spectrum	spectrum	NOUN
fnp-6382	349	3	of	of	ADP
fnp-6382	349	4	disease	disease	NOUN
fnp-6382	349	5	in	in	ADP
fnp-6382	349	6	chronic	chronic	ADJ
fnp-6382	349	7	traumatic	traumatic	ADJ
fnp-6382	349	8	encephalopathy	encephalopathy	NOUN
fnp-6382	349	9	.	.	PUNCT
fnp-6382	350	1	brain	brain	NOUN
fnp-6382	350	2	.	.	PUNCT
fnp-6382	351	1	2013	2013	NUM
fnp-6382	351	2	jan;136(1):43	jan;136(1):43	PROPN
fnp-6382	351	3	-	-	PUNCT
fnp-6382	351	4	64	64	NUM
fnp-6382	351	5	.	.	PUNCT
fnp-6382	352	1	https://doi.org/10.1093/brain/aws307	https://doi.org/10.1093/brain/aws307	ADJ
fnp-6382	352	2	8	8	X
fnp-6382	352	3	.	.	PUNCT
fnp-6382	352	4	mckee	mckee	PROPN
fnp-6382	352	5	ac	ac	PROPN
fnp-6382	352	6	,	,	PUNCT
fnp-6382	352	7	robinson	robinson	PROPN
fnp-6382	352	8	me	i	PRON
fnp-6382	352	9	.	.	PUNCT
fnp-6382	353	1	military‐related	military‐relate	VERB
fnp-6382	353	2	traumatic	traumatic	ADJ
fnp-6382	353	3	brain	brain	NOUN
fnp-6382	353	4	injury	injury	NOUN
fnp-6382	353	5	and	and	CCONJ
fnp-6382	353	6	neurodegeneration	neurodegeneration	NOUN
fnp-6382	353	7	.	.	PUNCT
fnp-6382	354	1	alzheimers	alzheimers	PROPN
fnp-6382	354	2	dement	dement	PROPN
fnp-6382	355	1	[	[	X
fnp-6382	355	2	internet	internet	NOUN
fnp-6382	355	3	]	]	PUNCT
fnp-6382	355	4	.	.	PUNCT
fnp-6382	356	1	2014	2014	NUM
fnp-6382	356	2	jun	jun	PROPN
fnp-6382	357	1	[	[	X
fnp-6382	357	2	cited	cite	VERB
fnp-6382	357	3	2025	2025	NUM
fnp-6382	357	4	may	may	AUX
fnp-6382	357	5	10];10(3s	10];10(3s	NUM
fnp-6382	357	6	)	)	PUNCT
fnp-6382	357	7	.	.	PUNCT
fnp-6382	358	1	available	available	ADJ
fnp-6382	358	2	from	from	ADP
fnp-6382	358	3	:	:	PUNCT
fnp-6382	358	4	https://doi.org/10.1016/j.jalz.2014.04.003	https://doi.org/10.1016/j.jalz.2014.04.003	PROPN
fnp-6382	358	5	9	9	NUM
fnp-6382	358	6	.	.	PUNCT
fnp-6382	358	7	goldstein	goldstein	PROPN
fnp-6382	358	8	le	le	PROPN
fnp-6382	358	9	,	,	PUNCT
fnp-6382	358	10	fisher	fisher	PROPN
fnp-6382	358	11	am	be	AUX
fnp-6382	358	12	,	,	PUNCT
fnp-6382	358	13	tagge	tagge	NOUN
fnp-6382	358	14	ca	ca	PROPN
fnp-6382	358	15	,	,	PUNCT
fnp-6382	358	16	zhang	zhang	PROPN
fnp-6382	358	17	xl	xl	PROPN
fnp-6382	358	18	,	,	PUNCT
fnp-6382	358	19	velisek	velisek	PROPN
fnp-6382	358	20	l	l	NOUN
fnp-6382	358	21	,	,	PUNCT
fnp-6382	358	22	sullivan	sullivan	PROPN
fnp-6382	358	23	ja	ja	PROPN
fnp-6382	358	24	,	,	PUNCT
fnp-6382	358	25	et	et	PROPN
fnp-6382	358	26	al	al	PROPN
fnp-6382	358	27	.	.	PROPN
fnp-6382	359	1	chronic	chronic	PROPN
fnp-6382	359	2	traumatic	traumatic	ADJ
fnp-6382	359	3	encephalopathy	encephalopathy	NOUN
fnp-6382	359	4	in	in	ADP
fnp-6382	359	5	blast	blast	NOUN
fnp-6382	359	6	-	-	PUNCT
fnp-6382	359	7	exposed	expose	VERB
fnp-6382	359	8	military	military	ADJ
fnp-6382	359	9	veterans	veteran	NOUN
fnp-6382	359	10	and	and	CCONJ
fnp-6382	359	11	a	a	DET
fnp-6382	359	12	blast	blast	NOUN
fnp-6382	359	13	neurotrauma	neurotrauma	PROPN
fnp-6382	359	14	mouse	mouse	NOUN
fnp-6382	359	15	model	model	NOUN
fnp-6382	359	16	.	.	PUNCT
fnp-6382	360	1	sci	sci	PROPN
fnp-6382	360	2	transl	transl	PROPN
fnp-6382	360	3	med	med	PROPN
fnp-6382	361	1	[	[	X
fnp-6382	361	2	internet	internet	NOUN
fnp-6382	361	3	]	]	PUNCT
fnp-6382	361	4	.	.	PUNCT
fnp-6382	362	1	2012	2012	NUM
fnp-6382	362	2	may	may	AUX
fnp-6382	362	3	16	16	NUM
fnp-6382	362	4	[	[	X
fnp-6382	362	5	cited	cite	VERB
fnp-6382	362	6	2024	2024	NUM
fnp-6382	362	7	sep	sep	PROPN
fnp-6382	362	8	6];4(134	6];4(134	NUM
fnp-6382	362	9	)	)	PUNCT
fnp-6382	362	10	.	.	PUNCT
fnp-6382	363	1	available	available	ADJ
fnp-6382	363	2	from	from	ADP
fnp-6382	363	3	:	:	PUNCT
fnp-6382	363	4	https://doi.org/10.1126/scitranslmed.3004862	https://doi.org/10.1126/scitranslmed.3004862	NUM
fnp-6382	363	5	10	10	NUM
fnp-6382	363	6	.	.	PUNCT
fnp-6382	364	1	dams	dam	NOUN
fnp-6382	364	2	-	-	PUNCT
fnp-6382	364	3	o'connor	o'connor	PROPN
fnp-6382	364	4	k	k	PROPN
fnp-6382	364	5	,	,	PUNCT
fnp-6382	364	6	seifert	seifert	PROPN
fnp-6382	364	7	ac	ac	PROPN
fnp-6382	364	8	,	,	PUNCT
fnp-6382	364	9	crary	crary	PROPN
fnp-6382	364	10	jf	jf	PROPN
fnp-6382	364	11	,	,	PUNCT
fnp-6382	364	12	delman	delman	PROPN
fnp-6382	364	13	bn	bn	PROPN
fnp-6382	364	14	,	,	PUNCT
fnp-6382	364	15	del	del	PROPN
fnp-6382	364	16	bigio	bigio	NOUN
fnp-6382	364	17	mr	mr	PROPN
fnp-6382	364	18	,	,	PUNCT
fnp-6382	364	19	kovacs	kovacs	PROPN
fnp-6382	364	20	gg	gg	PROPN
fnp-6382	364	21	,	,	PUNCT
fnp-6382	364	22	et	et	PROPN
fnp-6382	364	23	al	al	PROPN
fnp-6382	364	24	.	.	PUNCT
fnp-6382	365	1	the	the	DET
fnp-6382	365	2	neuropathology	neuropathology	NOUN
fnp-6382	365	3	of	of	ADP
fnp-6382	365	4	intimate	intimate	ADJ
fnp-6382	365	5	partner	partner	NOUN
fnp-6382	365	6	violence	violence	NOUN
fnp-6382	365	7	.	.	PUNCT
fnp-6382	366	1	acta	acta	PROPN
fnp-6382	366	2	neuropathol	neuropathol	PROPN
fnp-6382	366	3	(	(	PUNCT
fnp-6382	366	4	berl	berl	PROPN
fnp-6382	366	5	)	)	PUNCT
fnp-6382	366	6	.	.	PUNCT
fnp-6382	367	1	2023	2023	NUM
fnp-6382	367	2	dec;146(6):803	dec;146(6):803	NOUN
fnp-6382	367	3	-	-	PUNCT
fnp-6382	367	4	15	15	NUM
fnp-6382	367	5	.	.	PUNCT
fnp-6382	367	6	https://doi.org/10.1007/s00401-023-02646-1	https://doi.org/10.1007/s00401-023-02646-1	NUM
fnp-6382	367	7	11	11	NUM
fnp-6382	367	8	.	.	PUNCT
fnp-6382	368	1	danielsen	danielsen	PROPN
fnp-6382	368	2	t	t	PROPN
fnp-6382	368	3	,	,	PUNCT
fnp-6382	368	4	hauch	hauch	ADJ
fnp-6382	368	5	c	c	NOUN
fnp-6382	368	6	,	,	PUNCT
fnp-6382	368	7	kelly	kelly	PROPN
fnp-6382	368	8	l	l	PROPN
fnp-6382	368	9	,	,	PUNCT
fnp-6382	368	10	white	white	ADJ
fnp-6382	368	11	cl	cl	NOUN
fnp-6382	368	12	.	.	PUNCT
fnp-6382	369	1	chronic	chronic	ADJ
fnp-6382	369	2	traumatic	traumatic	ADJ
fnp-6382	369	3	encephalopathy	encephalopathy	NOUN
fnp-6382	369	4	(	(	PUNCT
fnp-6382	369	5	cte)-type	cte)-type	VERB
fnp-6382	369	6	neuropathology	neuropathology	NOUN
fnp-6382	369	7	in	in	ADP
fnp-6382	369	8	a	a	DET
fnp-6382	369	9	young	young	ADJ
fnp-6382	369	10	victim	victim	NOUN
fnp-6382	369	11	of	of	ADP
fnp-6382	369	12	domestic	domestic	ADJ
fnp-6382	369	13	abuse	abuse	NOUN
fnp-6382	369	14	.	.	PUNCT
fnp-6382	370	1	j	j	PROPN
fnp-6382	370	2	neuropathol	neuropathol	PROPN
fnp-6382	370	3	exp	exp	PROPN
fnp-6382	370	4	neurol	neurol	NOUN
fnp-6382	370	5	.	.	PUNCT
fnp-6382	371	1	2021	2021	NUM
fnp-6382	371	2	jun	jun	PROPN
fnp-6382	371	3	4;80(6):624	4;80(6):624	PROPN
fnp-6382	371	4	-	-	PUNCT
fnp-6382	371	5	7	7	NUM
fnp-6382	371	6	.	.	PUNCT
fnp-6382	371	7	https://doi.org/10.1093/jnen/nlab015	https://doi.org/10.1093/jnen/nlab015	PROPN
fnp-6382	372	1	12	12	NUM
fnp-6382	372	2	.	.	PUNCT
fnp-6382	372	3	tiemensma	tiemensma	PROPN
fnp-6382	372	4	m	m	PROPN
fnp-6382	372	5	,	,	PUNCT
fnp-6382	372	6	byard	byard	ADV
fnp-6382	372	7	rw	rw	NOUN
fnp-6382	372	8	,	,	PUNCT
fnp-6382	372	9	vink	vink	PROPN
fnp-6382	372	10	r	r	PROPN
fnp-6382	372	11	,	,	PUNCT
fnp-6382	372	12	affleck	affleck	PROPN
fnp-6382	372	13	aj	aj	PROPN
fnp-6382	372	14	,	,	PUNCT
fnp-6382	372	15	blumbergs	blumbergs	PROPN
fnp-6382	372	16	p	p	X
fnp-6382	372	17	,	,	PUNCT
fnp-6382	372	18	buckland	buckland	PROPN
fnp-6382	372	19	me	i	PRON
fnp-6382	372	20	.	.	PUNCT
fnp-6382	373	1	chronic	chronic	ADJ
fnp-6382	373	2	traumatic	traumatic	ADJ
fnp-6382	373	3	encephalopathy	encephalopathy	NOUN
fnp-6382	373	4	(	(	PUNCT
fnp-6382	373	5	cte	cte	NOUN
fnp-6382	373	6	)	)	PUNCT
fnp-6382	373	7	in	in	ADP
fnp-6382	373	8	the	the	DET
fnp-6382	373	9	context	context	NOUN
fnp-6382	373	10	of	of	ADP
fnp-6382	373	11	longstanding	longstande	VERB
fnp-6382	373	12	intimate	intimate	ADJ
fnp-6382	373	13	partner	partner	NOUN
fnp-6382	373	14	violence	violence	NOUN
fnp-6382	373	15	.	.	PUNCT
fnp-6382	374	1	acta	acta	PROPN
fnp-6382	374	2	neuropathol	neuropathol	PROPN
fnp-6382	374	3	(	(	PUNCT
fnp-6382	374	4	berl	berl	PROPN
fnp-6382	374	5	)	)	PUNCT
fnp-6382	374	6	.	.	PUNCT
fnp-6382	375	1	2024	2024	NUM
fnp-6382	375	2	jul	jul	PROPN
fnp-6382	375	3	8;148(1):1	8;148(1):1	NUM
fnp-6382	375	4	.	.	PUNCT
fnp-6382	375	5	https://doi.org/10.1007/s00401-024-02757-3	https://doi.org/10.1007/s00401-024-02757-3	PROPN
fnp-6382	375	6	13	13	NUM
fnp-6382	375	7	.	.	PUNCT
fnp-6382	376	1	del	del	PROPN
fnp-6382	376	2	bigio	bigio	NOUN
fnp-6382	376	3	mr	mr	PROPN
fnp-6382	376	4	,	,	PUNCT
fnp-6382	376	5	krawitz	krawitz	PROPN
fnp-6382	376	6	s	s	PROPN
fnp-6382	376	7	,	,	PUNCT
fnp-6382	376	8	sinha	sinha	PROPN
fnp-6382	376	9	n.	n.	PROPN
fnp-6382	376	10	chronic	chronic	PROPN
fnp-6382	376	11	traumatic	traumatic	ADJ
fnp-6382	376	12	encephalopathy	encephalopathy	ADJ
fnp-6382	376	13	-	-	PUNCT
fnp-6382	376	14	neuropathologic	neuropathologic	NOUN
fnp-6382	376	15	change	change	NOUN
fnp-6382	376	16	in	in	ADP
fnp-6382	376	17	a	a	DET
fnp-6382	376	18	routine	routine	ADJ
fnp-6382	376	19	neuropathology	neuropathology	NOUN
fnp-6382	376	20	service	service	NOUN
fnp-6382	376	21	:	:	PUNCT
fnp-6382	376	22	7	7	NUM
fnp-6382	376	23	-	-	PUNCT
fnp-6382	376	24	year	year	NOUN
fnp-6382	376	25	follow	follow	NOUN
fnp-6382	376	26	-	-	PUNCT
fnp-6382	376	27	up	up	NOUN
fnp-6382	376	28	.	.	PUNCT
fnp-6382	377	1	j	j	PROPN
fnp-6382	377	2	neuropathol	neuropathol	PROPN
fnp-6382	377	3	exp	exp	PROPN
fnp-6382	377	4	neurol	neurol	NOUN
fnp-6382	377	5	.	.	PUNCT
fnp-6382	378	1	2023	2023	NUM
fnp-6382	378	2	oct	oct	NOUN
fnp-6382	378	3	20;82(11):948	20;82(11):948	NUM
fnp-6382	378	4	-	-	SYM
fnp-6382	378	5	57	57	NUM
fnp-6382	378	6	.	.	PUNCT
fnp-6382	379	1	https://doi.org/10.1093/jnen/nlad079	https://doi.org/10.1093/jnen/nlad079	X
fnp-6382	380	1	14	14	NUM
fnp-6382	380	2	.	.	PUNCT
fnp-6382	381	1	hazrati	hazrati	PROPN
fnp-6382	381	2	ln	ln	PROPN
fnp-6382	381	3	,	,	PUNCT
fnp-6382	381	4	tartaglia	tartaglia	PROPN
fnp-6382	381	5	mc	mc	PROPN
fnp-6382	381	6	,	,	PUNCT
fnp-6382	381	7	diamandis	diamandis	PROPN
fnp-6382	381	8	p	p	PROPN
fnp-6382	381	9	,	,	PUNCT
fnp-6382	381	10	davis	davis	PROPN
fnp-6382	381	11	kd	kd	PROPN
fnp-6382	381	12	,	,	PUNCT
fnp-6382	381	13	green	green	PROPN
fnp-6382	381	14	re	re	PROPN
fnp-6382	381	15	,	,	PUNCT
fnp-6382	381	16	wennberg	wennberg	PROPN
fnp-6382	381	17	r	r	PROPN
fnp-6382	381	18	,	,	PUNCT
fnp-6382	381	19	et	et	PROPN
fnp-6382	381	20	al	al	PROPN
fnp-6382	381	21	.	.	PROPN
fnp-6382	382	1	absence	absence	NOUN
fnp-6382	382	2	of	of	ADP
fnp-6382	382	3	chronic	chronic	ADJ
fnp-6382	382	4	traumatic	traumatic	ADJ
fnp-6382	382	5	encephalopathy	encephalopathy	NOUN
fnp-6382	382	6	in	in	ADP
fnp-6382	382	7	retired	retire	VERB
fnp-6382	382	8	football	football	NOUN
fnp-6382	382	9	players	player	NOUN
fnp-6382	382	10	with	with	ADP
fnp-6382	382	11	multiple	multiple	ADJ
fnp-6382	382	12	concussions	concussion	NOUN
fnp-6382	382	13	and	and	CCONJ
fnp-6382	382	14	neurological	neurological	ADJ
fnp-6382	382	15	symptomatology	symptomatology	NOUN
fnp-6382	382	16	.	.	PUNCT
fnp-6382	383	1	front	front	ADJ
fnp-6382	383	2	hum	hum	PROPN
fnp-6382	383	3	neurosci	neurosci	PROPN
fnp-6382	384	1	[	[	X
fnp-6382	384	2	internet	internet	NOUN
fnp-6382	384	3	]	]	X
fnp-6382	384	4	.	.	PUNCT
fnp-6382	385	1	2013	2013	NUM
fnp-6382	386	1	[	[	X
fnp-6382	386	2	cited	cite	VERB
fnp-6382	386	3	2025	2025	NUM
fnp-6382	386	4	apr	apr	NOUN
fnp-6382	386	5	29];7	29];7	NUM
fnp-6382	386	6	.	.	PUNCT
fnp-6382	387	1	available	available	ADJ
fnp-6382	387	2	from	from	ADP
fnp-6382	387	3	:	:	PUNCT
fnp-6382	387	4	https://doi.org/10.3389/fnhum.2013.00222	https://doi.org/10.3389/fnhum.2013.00222	PROPN
fnp-6382	387	5	15	15	NUM
fnp-6382	387	6	.	.	PUNCT
fnp-6382	388	1	alosco	alosco	PROPN
fnp-6382	388	2	ml	ml	PROPN
fnp-6382	388	3	,	,	PUNCT
fnp-6382	388	4	tripodis	tripodis	PROPN
fnp-6382	388	5	y	y	PROPN
fnp-6382	388	6	,	,	PUNCT
fnp-6382	388	7	fritts	fritts	PROPN
fnp-6382	388	8	ng	ng	PROPN
fnp-6382	388	9	,	,	PUNCT
fnp-6382	388	10	heslegrave	heslegrave	X
fnp-6382	388	11	a	a	PRON
fnp-6382	388	12	,	,	PUNCT
fnp-6382	388	13	baugh	baugh	PROPN
fnp-6382	388	14	cm	cm	PROPN
fnp-6382	388	15	,	,	PUNCT
fnp-6382	388	16	conneely	conneely	ADV
fnp-6382	388	17	s	s	PART
fnp-6382	388	18	,	,	PUNCT
fnp-6382	388	19	et	et	PROPN
fnp-6382	388	20	al	al	PROPN
fnp-6382	388	21	.	.	PUNCT
fnp-6382	388	22	cerebrospinal	cerebrospinal	ADJ
fnp-6382	388	23	fluid	fluid	NOUN
fnp-6382	388	24	tau	tau	NOUN
fnp-6382	388	25	,	,	PUNCT
fnp-6382	388	26	aβ	aβ	NOUN
fnp-6382	388	27	,	,	PUNCT
fnp-6382	388	28	and	and	CCONJ
fnp-6382	388	29	strem2	strem2	NOUN
fnp-6382	388	30	in	in	ADP
fnp-6382	388	31	former	former	ADJ
fnp-6382	388	32	national	national	PROPN
fnp-6382	388	33	football	football	PROPN
fnp-6382	388	34	league	league	PROPN
fnp-6382	388	35	players	player	NOUN
fnp-6382	388	36	:	:	PUNCT
fnp-6382	388	37	modeling	model	VERB
fnp-6382	388	38	the	the	DET
fnp-6382	388	39	relationship	relationship	NOUN
fnp-6382	388	40	between	between	ADP
fnp-6382	388	41	repetitive	repetitive	ADJ
fnp-6382	388	42	head	head	NOUN
fnp-6382	388	43	impacts	impact	NOUN
fnp-6382	388	44	,	,	PUNCT
fnp-6382	388	45	microglial	microglial	ADJ
fnp-6382	388	46	activation	activation	NOUN
fnp-6382	388	47	,	,	PUNCT
fnp-6382	388	48	and	and	CCONJ
fnp-6382	388	49	neurodegeneration	neurodegeneration	NOUN
fnp-6382	388	50	.	.	PUNCT
fnp-6382	389	1	alzheimers	alzheimers	PROPN
fnp-6382	389	2	dement	dement	PROPN
fnp-6382	389	3	.	.	PUNCT
fnp-6382	390	1	2018	2018	NUM
fnp-6382	390	2	sep;14(9):1159	sep;14(9):1159	PROPN
fnp-6382	390	3	-	-	PUNCT
fnp-6382	390	4	70	70	PROPN
fnp-6382	390	5	.	.	PUNCT
fnp-6382	391	1	https://doi.org/10.1016/j.jalz.2018.05.004	https://doi.org/10.1016/j.jalz.2018.05.004	VERB
fnp-6382	391	2	16	16	NUM
fnp-6382	391	3	.	.	PUNCT
fnp-6382	392	1	babcock	babcock	PROPN
fnp-6382	392	2	kj	kj	PROPN
fnp-6382	392	3	,	,	PUNCT
fnp-6382	392	4	abdolmohammadi	abdolmohammadi	PROPN
fnp-6382	392	5	b	b	PROPN
fnp-6382	392	6	,	,	PUNCT
fnp-6382	392	7	kiernan	kiernan	PROPN
fnp-6382	392	8	pt	pt	PROPN
fnp-6382	392	9	,	,	PUNCT
fnp-6382	392	10	mahar	mahar	PROPN
fnp-6382	392	11	i	i	PROPN
fnp-6382	392	12	,	,	PUNCT
fnp-6382	392	13	cherry	cherry	PROPN
fnp-6382	392	14	jd	jd	PROPN
fnp-6382	392	15	,	,	PUNCT
fnp-6382	392	16	alvarez	alvarez	PROPN
fnp-6382	392	17	ve	ve	PROPN
fnp-6382	392	18	,	,	PUNCT
fnp-6382	392	19	et	et	PROPN
fnp-6382	392	20	al	al	PROPN
fnp-6382	392	21	.	.	PROPN
fnp-6382	392	22	interface	interface	NOUN
fnp-6382	392	23	astrogliosis	astrogliosis	NOUN
fnp-6382	392	24	in	in	ADP
fnp-6382	392	25	contact	contact	NOUN
fnp-6382	392	26	sport	sport	NOUN
fnp-6382	392	27	head	head	NOUN
fnp-6382	392	28	impacts	impact	NOUN
fnp-6382	392	29	and	and	CCONJ
fnp-6382	392	30	military	military	ADJ
fnp-6382	392	31	blast	blast	NOUN
fnp-6382	392	32	exposure	exposure	NOUN
fnp-6382	392	33	.	.	PUNCT
fnp-6382	393	1	acta	acta	PROPN
fnp-6382	393	2	neuropathol	neuropathol	PROPN
fnp-6382	393	3	commun	commun	PROPN
fnp-6382	393	4	.	.	PUNCT
fnp-6382	394	1	2022	2022	NUM
fnp-6382	394	2	dec;10(1):52	dec;10(1):52	PROPN
fnp-6382	394	3	.	.	PUNCT
fnp-6382	395	1	https://doi.org/10.1186/s40478-022-01358-z	https://doi.org/10.1186/s40478-022-01358-z	PROPN
fnp-6382	395	2	17	17	NUM
fnp-6382	395	3	.	.	PUNCT
fnp-6382	396	1	dickstein	dickstein	PROPN
fnp-6382	396	2	dl	dl	PROPN
fnp-6382	396	3	,	,	PUNCT
fnp-6382	396	4	de	de	X
fnp-6382	396	5	gasperi	gasperi	PROPN
fnp-6382	396	6	r	r	PROPN
fnp-6382	396	7	,	,	PUNCT
fnp-6382	396	8	gama	gama	PROPN
fnp-6382	396	9	sosa	sosa	PROPN
fnp-6382	396	10	ma	ma	PROPN
fnp-6382	396	11	,	,	PUNCT
fnp-6382	396	12	perez	perez	PROPN
fnp-6382	396	13	-	-	PUNCT
fnp-6382	396	14	garcia	garcia	PROPN
fnp-6382	396	15	g	g	PROPN
fnp-6382	396	16	,	,	PUNCT
fnp-6382	396	17	short	short	PROPN
fnp-6382	396	18	ja	ja	PROPN
fnp-6382	396	19	,	,	PUNCT
fnp-6382	396	20	sosa	sosa	PROPN
fnp-6382	396	21	h	h	PROPN
fnp-6382	396	22	,	,	PUNCT
fnp-6382	396	23	et	et	PROPN
fnp-6382	396	24	al	al	PROPN
fnp-6382	396	25	.	.	PROPN
fnp-6382	396	26	brain	brain	PROPN
fnp-6382	396	27	and	and	CCONJ
fnp-6382	396	28	blood	blood	NOUN
fnp-6382	396	29	biomarkers	biomarker	NOUN
fnp-6382	396	30	of	of	ADP
fnp-6382	396	31	tauopathy	tauopathy	NOUN
fnp-6382	396	32	and	and	CCONJ
fnp-6382	396	33	neuronal	neuronal	ADJ
fnp-6382	396	34	injury	injury	NOUN
fnp-6382	396	35	in	in	ADP
fnp-6382	396	36	humans	human	NOUN
fnp-6382	396	37	and	and	CCONJ
fnp-6382	396	38	rats	rat	NOUN
fnp-6382	396	39	with	with	ADP
fnp-6382	396	40	neurobehavioral	neurobehavioral	ADJ
fnp-6382	396	41	syndromes	syndrome	NOUN
fnp-6382	396	42	following	follow	VERB
fnp-6382	396	43	blast	blast	NOUN
fnp-6382	396	44	exposure	exposure	NOUN
fnp-6382	396	45	.	.	PUNCT
fnp-6382	397	1	mol	mol	ADP
fnp-6382	397	2	psychiatry	psychiatry	NOUN
fnp-6382	397	3	.	.	PUNCT
fnp-6382	398	1	2021	2021	NUM
fnp-6382	398	2	oct;26(10):5940	oct;26(10):5940	NOUN
fnp-6382	398	3	-	-	SYM
fnp-6382	398	4	54	54	NUM
fnp-6382	398	5	.	.	PUNCT
fnp-6382	399	1	https://doi.org/10.1038/s41380-020-0674-z	https://doi.org/10.1038/s41380-020-0674-z	PROPN
fnp-6382	399	2	18	18	NUM
fnp-6382	399	3	.	.	PUNCT
fnp-6382	400	1	turk	turk	PROPN
fnp-6382	400	2	kw	kw	PROPN
fnp-6382	400	3	,	,	PUNCT
fnp-6382	400	4	geada	geada	PROPN
fnp-6382	400	5	a	a	PROPN
fnp-6382	400	6	,	,	PUNCT
fnp-6382	400	7	alvarez	alvarez	PROPN
fnp-6382	400	8	ve	ve	PROPN
fnp-6382	400	9	,	,	PUNCT
fnp-6382	400	10	xia	xia	PROPN
fnp-6382	400	11	w	w	PROPN
fnp-6382	400	12	,	,	PUNCT
fnp-6382	400	13	cherry	cherry	PROPN
fnp-6382	400	14	jd	jd	PROPN
fnp-6382	400	15	,	,	PUNCT
fnp-6382	400	16	nicks	nicks	PROPN
fnp-6382	400	17	r	r	NOUN
fnp-6382	400	18	,	,	PUNCT
fnp-6382	400	19	et	et	PROPN
fnp-6382	400	20	al	al	PROPN
fnp-6382	400	21	.	.	PUNCT
fnp-6382	401	1	a	a	DET
fnp-6382	401	2	comparison	comparison	NOUN
fnp-6382	401	3	between	between	ADP
fnp-6382	401	4	tau	tau	PROPN
fnp-6382	401	5	and	and	CCONJ
fnp-6382	401	6	amyloid	amyloid	NOUN
fnp-6382	401	7	-	-	PUNCT
fnp-6382	401	8	β	β	X
fnp-6382	401	9	cerebrospinal	cerebrospinal	ADJ
fnp-6382	401	10	fluid	fluid	NOUN
fnp-6382	401	11	biomarkers	biomarker	NOUN
fnp-6382	401	12	in	in	ADP
fnp-6382	401	13	chronic	chronic	ADJ
fnp-6382	401	14	traumatic	traumatic	ADJ
fnp-6382	401	15	encephalopathy	encephalopathy	NOUN
fnp-6382	401	16	and	and	CCONJ
fnp-6382	401	17	alzheimer	alzheimer	PROPN
fnp-6382	401	18	disease	disease	NOUN
fnp-6382	401	19	.	.	PUNCT
fnp-6382	402	1	alzheimers	alzheimer	NOUN
fnp-6382	402	2	res	re	VERB
fnp-6382	402	3	ther	ther	ADV
fnp-6382	402	4	.	.	PUNCT
fnp-6382	403	1	2022	2022	NUM
fnp-6382	403	2	feb	feb	PROPN
fnp-6382	403	3	9;14(1):28	9;14(1):28	PROPN
fnp-6382	403	4	.	.	PUNCT
fnp-6382	404	1	https://doi.org/10.1186/s13195-022-00976-y	https://doi.org/10.1186/s13195-022-00976-y	PROPN
fnp-6382	404	2	19	19	NUM
fnp-6382	404	3	.	.	PUNCT
fnp-6382	404	4	ferrari	ferrari	PROPN
fnp-6382	405	1	f	f	PROPN
fnp-6382	405	2	,	,	PUNCT
fnp-6382	405	3	rossi	rossi	PROPN
fnp-6382	405	4	d	d	NOUN
fnp-6382	405	5	,	,	PUNCT
fnp-6382	405	6	ricciardi	ricciardi	PROPN
fnp-6382	405	7	a	a	PRON
fnp-6382	405	8	,	,	PUNCT
fnp-6382	405	9	morasso	morasso	NOUN
fnp-6382	405	10	c	c	NOUN
fnp-6382	405	11	,	,	PUNCT
fnp-6382	405	12	brambilla	brambilla	PROPN
fnp-6382	405	13	l	l	PROPN
fnp-6382	405	14	,	,	PUNCT
fnp-6382	405	15	albasini	albasini	PROPN
fnp-6382	405	16	s	s	PROPN
fnp-6382	405	17	,	,	PUNCT
fnp-6382	405	18	et	et	PROPN
fnp-6382	405	19	al	al	PROPN
fnp-6382	405	20	.	.	PUNCT
fnp-6382	406	1	quantification	quantification	NOUN
fnp-6382	406	2	and	and	CCONJ
fnp-6382	406	3	prospective	prospective	ADJ
fnp-6382	406	4	evaluation	evaluation	NOUN
fnp-6382	406	5	of	of	ADP
fnp-6382	406	6	serum	serum	PROPN
fnp-6382	406	7	nfl	nfl	PROPN
fnp-6382	406	8	and	and	CCONJ
fnp-6382	406	9	gfap	gfap	ADJ
fnp-6382	406	10	as	as	ADP
fnp-6382	406	11	blood	blood	NOUN
fnp-6382	406	12	-	-	PUNCT
fnp-6382	406	13	derived	derive	VERB
fnp-6382	406	14	biomarkers	biomarker	NOUN
fnp-6382	406	15	of	of	ADP
fnp-6382	406	16	outcome	outcome	NOUN
fnp-6382	406	17	in	in	ADP
fnp-6382	406	18	acute	acute	ADJ
fnp-6382	406	19	ischemic	ischemic	ADJ
fnp-6382	406	20	stroke	stroke	NOUN
fnp-6382	406	21	patients	patient	NOUN
fnp-6382	406	22	.	.	PUNCT
fnp-6382	407	1	j	j	PROPN
fnp-6382	407	2	cereb	cereb	PROPN
fnp-6382	407	3	blood	blood	NOUN
fnp-6382	407	4	flow	flow	NOUN
fnp-6382	407	5	metab	metab	NOUN
fnp-6382	407	6	.	.	PUNCT
fnp-6382	408	1	2023	2023	NUM
fnp-6382	408	2	sep;43(9):1601	sep;43(9):1601	PROPN
fnp-6382	408	3	-	-	PUNCT
fnp-6382	408	4	11	11	NUM
fnp-6382	408	5	.	.	PUNCT
fnp-6382	409	1	https://doi.org/10.1177/0271678x231172520	https://doi.org/10.1177/0271678x231172520	NUM
fnp-6382	409	2	20	20	NUM
fnp-6382	409	3	.	.	PUNCT
fnp-6382	410	1	shahim	shahim	PROPN
fnp-6382	410	2	p	p	PROPN
fnp-6382	410	3	,	,	PUNCT
fnp-6382	410	4	politis	politis	PROPN
fnp-6382	410	5	a	a	X
fnp-6382	410	6	,	,	PUNCT
fnp-6382	410	7	van	van	PROPN
fnp-6382	410	8	der	der	PROPN
fnp-6382	410	9	merwe	merwe	PROPN
fnp-6382	410	10	a	a	PROPN
fnp-6382	410	11	,	,	PUNCT
fnp-6382	410	12	moore	moore	PROPN
fnp-6382	410	13	b	b	PROPN
fnp-6382	410	14	,	,	PUNCT
fnp-6382	410	15	chou	chou	PROPN
fnp-6382	410	16	yy	yy	PROPN
fnp-6382	410	17	,	,	PUNCT
fnp-6382	410	18	pham	pham	PROPN
fnp-6382	410	19	dl	dl	PROPN
fnp-6382	410	20	,	,	PUNCT
fnp-6382	410	21	et	et	PROPN
fnp-6382	410	22	al	al	PROPN
fnp-6382	410	23	.	.	PROPN
fnp-6382	410	24	neurofilament	neurofilament	PROPN
fnp-6382	410	25	light	light	NOUN
fnp-6382	410	26	as	as	ADP
fnp-6382	410	27	a	a	DET
fnp-6382	410	28	biomarker	biomarker	NOUN
fnp-6382	410	29	in	in	ADP
fnp-6382	410	30	traumatic	traumatic	ADJ
fnp-6382	410	31	brain	brain	NOUN
fnp-6382	410	32	injury	injury	NOUN
fnp-6382	410	33	.	.	PUNCT
fnp-6382	411	1	neurology	neurology	NOUN
fnp-6382	412	1	[	[	X
fnp-6382	412	2	internet	internet	NOUN
fnp-6382	412	3	]	]	PUNCT
fnp-6382	412	4	.	.	PUNCT
fnp-6382	413	1	2020	2020	NUM
fnp-6382	413	2	aug	aug	PROPN
fnp-6382	413	3	11	11	NUM
fnp-6382	413	4	[	[	X
fnp-6382	413	5	cited	cite	VERB
fnp-6382	413	6	2024	2024	NUM
fnp-6382	413	7	sep	sep	NOUN
fnp-6382	413	8	6];95(6	6];95(6	NUM
fnp-6382	413	9	)	)	PUNCT
fnp-6382	413	10	.	.	PUNCT
fnp-6382	414	1	available	available	ADJ
fnp-6382	414	2	from	from	ADP
fnp-6382	414	3	:	:	PUNCT
fnp-6382	414	4	https://doi.org/10.1212/wnl.0000000000009983	https://doi.org/10.1212/wnl.0000000000009983	PROPN
fnp-6382	414	5	21	21	NUM
fnp-6382	414	6	.	.	PUNCT
fnp-6382	415	1	arena	arena	PROPN
fnp-6382	415	2	jd	jd	PROPN
fnp-6382	415	3	,	,	PUNCT
fnp-6382	415	4	smith	smith	PROPN
fnp-6382	415	5	dh	dh	PROPN
fnp-6382	415	6	,	,	PUNCT
fnp-6382	415	7	lee	lee	PROPN
fnp-6382	415	8	eb	eb	PROPN
fnp-6382	415	9	,	,	PUNCT
fnp-6382	415	10	gibbons	gibbons	PROPN
fnp-6382	415	11	gs	gs	PROPN
fnp-6382	415	12	,	,	PUNCT
fnp-6382	415	13	irwin	irwin	PROPN
fnp-6382	415	14	dj	dj	PROPN
fnp-6382	415	15	,	,	PUNCT
fnp-6382	415	16	robinson	robinson	PROPN
fnp-6382	415	17	jl	jl	PROPN
fnp-6382	415	18	,	,	PUNCT
fnp-6382	415	19	et	et	PROPN
fnp-6382	415	20	al	al	PROPN
fnp-6382	415	21	.	.	PUNCT
fnp-6382	416	1	tau	tau	PROPN
fnp-6382	416	2	immunophenotypes	immunophenotype	NOUN
fnp-6382	416	3	in	in	ADP
fnp-6382	416	4	chronic	chronic	ADJ
fnp-6382	416	5	traumatic	traumatic	ADJ
fnp-6382	416	6	encephalopathy	encephalopathy	NOUN
fnp-6382	416	7	recapitulate	recapitulate	VERB
fnp-6382	416	8	those	those	PRON
fnp-6382	416	9	of	of	ADP
fnp-6382	416	10	ageing	age	VERB
fnp-6382	416	11	and	and	CCONJ
fnp-6382	416	12	alzheimer	alzheimer	NOUN
fnp-6382	416	13	's	's	PART
fnp-6382	416	14	disease	disease	NOUN
fnp-6382	416	15	.	.	PUNCT
fnp-6382	417	1	brain	brain	NOUN
fnp-6382	417	2	.	.	PUNCT
fnp-6382	418	1	2020	2020	NUM
fnp-6382	418	2	may	may	AUX
fnp-6382	418	3	1;143(5):1572	1;143(5):1572	ADV
fnp-6382	418	4	-	-	PUNCT
fnp-6382	418	5	87	87	NUM
fnp-6382	418	6	.	.	PUNCT
fnp-6382	419	1	https://doi.org/10.1093/brain/awaa071	https://doi.org/10.1093/brain/awaa071	PROPN
fnp-6382	419	2	22	22	NUM
fnp-6382	419	3	.	.	PUNCT
fnp-6382	420	1	cherry	cherry	PROPN
fnp-6382	420	2	jd	jd	PROPN
fnp-6382	420	3	,	,	PUNCT
fnp-6382	420	4	baucom	baucom	PROPN
fnp-6382	420	5	zh	zh	PROPN
fnp-6382	420	6	,	,	PUNCT
fnp-6382	420	7	eppich	eppich	NOUN
fnp-6382	420	8	kg	kg	PROPN
fnp-6382	420	9	,	,	PUNCT
fnp-6382	420	10	kirsch	kirsch	PROPN
fnp-6382	420	11	d	d	PROPN
fnp-6382	420	12	,	,	PUNCT
fnp-6382	420	13	dixon	dixon	PROPN
fnp-6382	420	14	er	er	INTJ
fnp-6382	420	15	,	,	PUNCT
fnp-6382	420	16	tripodis	tripodis	PROPN
fnp-6382	420	17	y	y	PROPN
fnp-6382	420	18	,	,	PUNCT
fnp-6382	420	19	et	et	PROPN
fnp-6382	420	20	al	al	PROPN
fnp-6382	420	21	.	.	PROPN
fnp-6382	420	22	neuroimmune	neuroimmune	PROPN
fnp-6382	420	23	proteins	protein	NOUN
fnp-6382	420	24	can	can	AUX
fnp-6382	420	25	differentiate	differentiate	VERB
fnp-6382	420	26	between	between	ADP
fnp-6382	420	27	tauopathies	tauopathie	NOUN
fnp-6382	420	28	.	.	PUNCT
fnp-6382	421	1	j	j	PROPN
fnp-6382	421	2	neuroinflammation	neuroinflammation	PROPN
fnp-6382	421	3	.	.	PUNCT
fnp-6382	422	1	2022	2022	NUM
fnp-6382	422	2	nov	nov	NOUN
fnp-6382	422	3	19;19(1):278	19;19(1):278	NUM
fnp-6382	422	4	.	.	PUNCT
fnp-6382	423	1	https://doi.org/10.1186/s12974-022-02640-6	https://doi.org/10.1186/s12974-022-02640-6	PROPN
fnp-6382	423	2	23	23	NUM
fnp-6382	423	3	.	.	PUNCT
fnp-6382	424	1	guerreiro	guerreiro	PROPN
fnp-6382	424	2	r	r	PROPN
fnp-6382	424	3	,	,	PUNCT
fnp-6382	424	4	wojtas	wojta	NOUN
fnp-6382	424	5	a	a	PRON
fnp-6382	424	6	,	,	PUNCT
fnp-6382	424	7	bras	bras	PROPN
fnp-6382	424	8	j	j	PROPN
fnp-6382	424	9	,	,	PUNCT
fnp-6382	424	10	carrasquillo	carrasquillo	PROPN
fnp-6382	424	11	m	m	PROPN
fnp-6382	424	12	,	,	PUNCT
fnp-6382	424	13	rogaeva	rogaeva	NOUN
fnp-6382	424	14	e	e	NOUN
fnp-6382	424	15	,	,	PUNCT
fnp-6382	424	16	majounie	majounie	NOUN
fnp-6382	424	17	e	e	NOUN
fnp-6382	424	18	,	,	PUNCT
fnp-6382	424	19	et	et	PROPN
fnp-6382	424	20	al	al	PROPN
fnp-6382	424	21	.	.	PUNCT
fnp-6382	425	1	trem2	trem2	PROPN
fnp-6382	425	2	variants	variant	NOUN
fnp-6382	425	3	in	in	ADP
fnp-6382	425	4	alzheimer	alzheimer	PROPN
fnp-6382	425	5	's	's	PART
fnp-6382	425	6	disease	disease	NOUN
fnp-6382	425	7	.	.	PUNCT
fnp-6382	426	1	n	n	PROPN
fnp-6382	426	2	engl	engl	PROPN
fnp-6382	426	3	j	j	PROPN
fnp-6382	426	4	med	med	PROPN
fnp-6382	426	5	.	.	PUNCT
fnp-6382	427	1	2013	2013	NUM
fnp-6382	427	2	jan	jan	PROPN
fnp-6382	427	3	10;368(2):117	10;368(2):117	NUM
fnp-6382	427	4	-	-	SYM
fnp-6382	427	5	27	27	NUM
fnp-6382	427	6	.	.	PUNCT
fnp-6382	428	1	https://doi.org/10.1056/nejmoa1211851	https://doi.org/10.1056/nejmoa1211851	NOUN
fnp-6382	428	2	24	24	NUM
fnp-6382	428	3	.	.	PUNCT
fnp-6382	428	4	aruk	aruk	PROPN
fnp-6382	428	5	consortium	consortium	PROPN
fnp-6382	428	6	,	,	PUNCT
fnp-6382	428	7	gerad	gerad	NOUN
fnp-6382	428	8	/	/	SYM
fnp-6382	428	9	perades	perade	NOUN
fnp-6382	428	10	,	,	PUNCT
fnp-6382	428	11	charge	charge	NOUN
fnp-6382	428	12	,	,	PUNCT
fnp-6382	428	13	adgc	adgc	NOUN
fnp-6382	428	14	,	,	PUNCT
fnp-6382	428	15	eadi	eadi	NOUN
fnp-6382	428	16	,	,	PUNCT
fnp-6382	428	17	sims	sim	NOUN
fnp-6382	428	18	r	r	NOUN
fnp-6382	428	19	,	,	PUNCT
fnp-6382	428	20	van	van	PROPN
fnp-6382	428	21	der	der	NOUN
fnp-6382	428	22	lee	lee	PROPN
fnp-6382	428	23	sj	sj	PROPN
fnp-6382	428	24	,	,	PUNCT
fnp-6382	428	25	naj	naj	PROPN
fnp-6382	428	26	ac	ac	PROPN
fnp-6382	428	27	,	,	PUNCT
fnp-6382	428	28	bellenguez	bellenguez	PROPN
fnp-6382	428	29	c	c	AUX
fnp-6382	428	30	,	,	PUNCT
fnp-6382	428	31	et	et	PROPN
fnp-6382	428	32	al	al	PROPN
fnp-6382	428	33	.	.	PROPN
fnp-6382	429	1	rare	rare	ADJ
fnp-6382	429	2	coding	code	VERB
fnp-6382	429	3	variants	variant	NOUN
fnp-6382	429	4	in	in	ADP
fnp-6382	429	5	plcg2	plcg2	NOUN
fnp-6382	429	6	,	,	PUNCT
fnp-6382	429	7	abi3	abi3	NOUN
fnp-6382	429	8	,	,	PUNCT
fnp-6382	429	9	and	and	CCONJ
fnp-6382	429	10	trem2	trem2	NOUN
fnp-6382	429	11	implicate	implicate	VERB
fnp-6382	429	12	microglial	microglial	ADJ
fnp-6382	429	13	-	-	PUNCT
fnp-6382	429	14	mediated	mediate	VERB
fnp-6382	429	15	innate	innate	ADJ
fnp-6382	429	16	immunity	immunity	NOUN
fnp-6382	429	17	in	in	ADP
fnp-6382	429	18	alzheimer	alzheimer	PROPN
fnp-6382	429	19	's	's	PART
fnp-6382	429	20	disease	disease	NOUN
fnp-6382	429	21	.	.	PUNCT
fnp-6382	430	1	nat	nat	PROPN
fnp-6382	430	2	genet	genet	PROPN
fnp-6382	430	3	.	.	PUNCT
fnp-6382	431	1	2017	2017	NUM
fnp-6382	431	2	sep;49(9):1373	sep;49(9):1373	PROPN
fnp-6382	431	3	-	-	PUNCT
fnp-6382	431	4	84	84	NUM
fnp-6382	431	5	.	.	PUNCT
fnp-6382	432	1	https://10.1038	https://10.1038	PUNCT
fnp-6382	432	2	/	/	SYM
fnp-6382	432	3	ng.3916	ng.3916	NUM
fnp-6382	432	4	25	25	NUM
fnp-6382	432	5	.	.	PUNCT
fnp-6382	432	6	lui	lui	NOUN
fnp-6382	432	7	h	h	PROPN
fnp-6382	432	8	,	,	PUNCT
fnp-6382	432	9	zhang	zhang	PROPN
fnp-6382	432	10	j	j	PROPN
fnp-6382	432	11	,	,	PUNCT
fnp-6382	432	12	makinson	makinson	PROPN
fnp-6382	432	13	sr	sr	PROPN
fnp-6382	432	14	,	,	PUNCT
fnp-6382	432	15	cahill	cahill	PROPN
fnp-6382	432	16	mk	mk	PROPN
fnp-6382	432	17	,	,	PUNCT
fnp-6382	432	18	kelley	kelley	PROPN
fnp-6382	432	19	kw	kw	PROPN
fnp-6382	432	20	,	,	PUNCT
fnp-6382	432	21	huang	huang	PROPN
fnp-6382	432	22	hy	hy	PROPN
fnp-6382	432	23	,	,	PUNCT
fnp-6382	432	24	et	et	PROPN
fnp-6382	432	25	al	al	PROPN
fnp-6382	432	26	.	.	PROPN
fnp-6382	433	1	progranulin	progranulin	PROPN
fnp-6382	433	2	deficiency	deficiency	NOUN
fnp-6382	433	3	promotes	promote	VERB
fnp-6382	433	4	circuit	circuit	NOUN
fnp-6382	433	5	-	-	PUNCT
fnp-6382	433	6	specific	specific	ADJ
fnp-6382	433	7	synaptic	synaptic	ADJ
fnp-6382	433	8	pruning	pruning	NOUN
fnp-6382	433	9	by	by	ADP
fnp-6382	433	10	microglia	microglia	NOUN
fnp-6382	433	11	via	via	ADP
fnp-6382	433	12	complement	complement	NOUN
fnp-6382	433	13	activation	activation	NOUN
fnp-6382	433	14	.	.	PUNCT
fnp-6382	434	1	cell	cell	NOUN
fnp-6382	434	2	.	.	PUNCT
fnp-6382	435	1	2016	2016	NUM
fnp-6382	435	2	may;165(4):921	may;165(4):921	NOUN
fnp-6382	435	3	-	-	PROPN
fnp-6382	435	4	35	35	NUM
fnp-6382	435	5	.	.	PUNCT
fnp-6382	436	1	https://doi.org/10.1016/j.cell.2016.04.001	https://doi.org/10.1016/j.cell.2016.04.001	NOUN
fnp-6382	436	2	26	26	NUM
fnp-6382	436	3	.	.	PUNCT
fnp-6382	437	1	klein	klein	PROPN
fnp-6382	437	2	za	za	PROPN
fnp-6382	437	3	,	,	PUNCT
fnp-6382	437	4	takahashi	takahashi	PROPN
fnp-6382	437	5	h	h	PROPN
fnp-6382	437	6	,	,	PUNCT
fnp-6382	437	7	ma	ma	PROPN
fnp-6382	437	8	m	m	PROPN
fnp-6382	437	9	,	,	PUNCT
fnp-6382	437	10	stagi	stagi	PROPN
fnp-6382	437	11	m	m	PROPN
fnp-6382	437	12	,	,	PUNCT
fnp-6382	437	13	zhou	zhou	PROPN
fnp-6382	437	14	m	m	PROPN
fnp-6382	437	15	,	,	PUNCT
fnp-6382	437	16	lam	lam	PROPN
fnp-6382	437	17	tt	tt	PROPN
fnp-6382	437	18	,	,	PUNCT
fnp-6382	437	19	et	et	PROPN
fnp-6382	437	20	al	al	PROPN
fnp-6382	437	21	.	.	PUNCT
fnp-6382	437	22	loss	loss	NOUN
fnp-6382	437	23	of	of	ADP
fnp-6382	437	24	tmem106b	tmem106b	ADJ
fnp-6382	437	25	ameliorates	ameliorate	NOUN
fnp-6382	437	26	lysosomal	lysosomal	ADJ
fnp-6382	437	27	and	and	CCONJ
fnp-6382	437	28	frontotemporal	frontotemporal	ADJ
fnp-6382	437	29	dementia	dementia	NOUN
fnp-6382	437	30	-	-	PUNCT
fnp-6382	437	31	related	relate	VERB
fnp-6382	437	32	phenotypes	phenotype	NOUN
fnp-6382	437	33	in	in	ADP
fnp-6382	437	34	progranulin	progranulin	ADJ
fnp-6382	437	35	-	-	PUNCT
fnp-6382	437	36	deficient	deficient	ADJ
fnp-6382	437	37	mice	mouse	NOUN
fnp-6382	437	38	.	.	PUNCT
fnp-6382	438	1	neuron	neuron	PROPN
fnp-6382	438	2	.	.	PUNCT
fnp-6382	439	1	2017	2017	NUM
fnp-6382	439	2	jul;95(2):281	jul;95(2):281	NOUN
fnp-6382	439	3	-	-	PUNCT
fnp-6382	439	4	296.e6	296.e6	NUM
fnp-6382	439	5	.	.	PUNCT
fnp-6382	440	1	https://doi.org/10.1016/j.neuron.2017.06.026	https://doi.org/10.1016/j.neuron.2017.06.026	PROPN
fnp-6382	440	2	27	27	NUM
fnp-6382	440	3	.	.	PUNCT
fnp-6382	441	1	gao	gao	PROPN
fnp-6382	441	2	hm	hm	PROPN
fnp-6382	441	3	,	,	PUNCT
fnp-6382	441	4	zhou	zhou	PROPN
fnp-6382	441	5	h	h	PROPN
fnp-6382	441	6	,	,	PUNCT
fnp-6382	441	7	zhang	zhang	PROPN
fnp-6382	441	8	f	f	PROPN
fnp-6382	441	9	,	,	PUNCT
fnp-6382	441	10	wilson	wilson	PROPN
fnp-6382	441	11	bc	bc	PROPN
fnp-6382	441	12	,	,	PUNCT
fnp-6382	441	13	kam	kam	PROPN
fnp-6382	441	14	w	w	PROPN
fnp-6382	441	15	,	,	PUNCT
fnp-6382	441	16	hong	hong	PROPN
fnp-6382	441	17	js	js	PROPN
fnp-6382	441	18	.	.	PUNCT
fnp-6382	442	1	hmgb1	hmgb1	PROPN
fnp-6382	442	2	acts	act	NOUN
fnp-6382	442	3	on	on	ADP
fnp-6382	442	4	microglia	microglia	ADJ
fnp-6382	442	5	mac1	mac1	NOUN
fnp-6382	442	6	to	to	PART
fnp-6382	442	7	mediate	mediate	VERB
fnp-6382	442	8	chronic	chronic	ADJ
fnp-6382	442	9	neuroinflammation	neuroinflammation	NOUN
fnp-6382	442	10	that	that	PRON
fnp-6382	442	11	drives	drive	VERB
fnp-6382	442	12	progressive	progressive	ADJ
fnp-6382	442	13	neurodegeneration	neurodegeneration	NOUN
fnp-6382	442	14	.	.	PUNCT
fnp-6382	443	1	j	j	PROPN
fnp-6382	443	2	neurosci	neurosci	PROPN
fnp-6382	443	3	.	.	PUNCT
fnp-6382	444	1	2011	2011	NUM
fnp-6382	444	2	jan	jan	PROPN
fnp-6382	444	3	19;31(3):1081	19;31(3):1081	NUM
fnp-6382	444	4	-	-	SYM
fnp-6382	444	5	92	92	NUM
fnp-6382	444	6	.	.	PUNCT
fnp-6382	445	1	https://doi.org/10.1523/jneurosci.3732-10.2011	https://doi.org/10.1523/jneurosci.3732-10.2011	PROPN
fnp-6382	445	2	28	28	NUM
fnp-6382	445	3	.	.	PUNCT
fnp-6382	446	1	russo	russo	PROPN
fnp-6382	446	2	i	i	PRON
fnp-6382	446	3	,	,	PUNCT
fnp-6382	446	4	berti	berti	PROPN
fnp-6382	446	5	g	g	PROPN
fnp-6382	446	6	,	,	PUNCT
fnp-6382	446	7	plotegher	plotegher	NOUN
fnp-6382	446	8	n	n	NOUN
fnp-6382	446	9	,	,	PUNCT
fnp-6382	446	10	bernardo	bernardo	NOUN
fnp-6382	446	11	g	g	NOUN
fnp-6382	446	12	,	,	PUNCT
fnp-6382	446	13	filograna	filograna	NOUN
fnp-6382	446	14	r	r	NOUN
fnp-6382	446	15	,	,	PUNCT
fnp-6382	446	16	bubacco	bubacco	PROPN
fnp-6382	446	17	l	l	NOUN
fnp-6382	446	18	,	,	PUNCT
fnp-6382	446	19	et	et	PROPN
fnp-6382	446	20	al	al	PROPN
fnp-6382	446	21	.	.	PROPN
fnp-6382	446	22	leucine	leucine	PROPN
fnp-6382	446	23	-	-	PUNCT
fnp-6382	446	24	rich	rich	ADJ
fnp-6382	446	25	repeat	repeat	NOUN
fnp-6382	446	26	kinase	kinase	NOUN
fnp-6382	446	27	2	2	NUM
fnp-6382	446	28	positively	positively	ADV
fnp-6382	446	29	regulates	regulate	VERB
fnp-6382	446	30	inflammation	inflammation	NOUN
fnp-6382	446	31	and	and	CCONJ
fnp-6382	446	32	down	down	ADV
fnp-6382	446	33	-	-	PUNCT
fnp-6382	446	34	regulates	regulate	VERB
fnp-6382	446	35	nf	nf	ADJ
fnp-6382	446	36	-	-	PUNCT
fnp-6382	446	37	κb	κb	NOUN
fnp-6382	446	38	p50	p50	NOUN
fnp-6382	446	39	signaling	signal	VERB
fnp-6382	446	40	in	in	ADP
fnp-6382	446	41	cultured	cultured	ADJ
fnp-6382	446	42	microglia	microglia	ADJ
fnp-6382	446	43	cells	cell	NOUN
fnp-6382	446	44	.	.	PUNCT
fnp-6382	447	1	j	j	PROPN
fnp-6382	447	2	neuroinflammation	neuroinflammation	PROPN
fnp-6382	447	3	.	.	PUNCT
fnp-6382	448	1	2015	2015	NUM
fnp-6382	448	2	dec;12(1):230	dec;12(1):230	NOUN
fnp-6382	448	3	.	.	PROPN
fnp-6382	449	1	https://doi.org/10.1186/s12974-015-0449-7	https://doi.org/10.1186/s12974-015-0449-7	NUM
fnp-6382	449	2	29	29	NUM
fnp-6382	449	3	.	.	PUNCT
fnp-6382	450	1	chakrabarty	chakrabarty	PROPN
fnp-6382	450	2	p	p	NOUN
fnp-6382	450	3	,	,	PUNCT
fnp-6382	450	4	tianbai	tianbai	PROPN
fnp-6382	450	5	l	l	NOUN
fnp-6382	450	6	,	,	PUNCT
fnp-6382	450	7	herring	herre	VERB
fnp-6382	450	8	a	a	DET
fnp-6382	450	9	,	,	PUNCT
fnp-6382	450	10	ceballos	ceballos	PROPN
fnp-6382	450	11	-	-	PUNCT
fnp-6382	450	12	diaz	diaz	PROPN
fnp-6382	450	13	c	c	PROPN
fnp-6382	450	14	,	,	PUNCT
fnp-6382	450	15	das	das	PROPN
fnp-6382	450	16	p	p	X
fnp-6382	450	17	,	,	PUNCT
fnp-6382	450	18	golde	golde	PROPN
fnp-6382	450	19	te	te	PROPN
fnp-6382	450	20	.	.	PROPN
fnp-6382	450	21	hippocampal	hippocampal	ADJ
fnp-6382	450	22	expression	expression	NOUN
fnp-6382	450	23	of	of	ADP
fnp-6382	450	24	murine	murine	ADJ
fnp-6382	450	25	il-4	il-4	PART
fnp-6382	450	26	results	result	NOUN
fnp-6382	450	27	in	in	ADP
fnp-6382	450	28	exacerbation	exacerbation	NOUN
fnp-6382	450	29	of	of	ADP
fnp-6382	450	30	amyloid	amyloid	NOUN
fnp-6382	450	31	deposition	deposition	NOUN
fnp-6382	450	32	.	.	PUNCT
fnp-6382	451	1	mol	mol	ADP
fnp-6382	451	2	neurodegener	neurodegener	NOUN
fnp-6382	451	3	.	.	PUNCT
fnp-6382	452	1	2012	2012	NUM
fnp-6382	452	2	dec;7(1):36	dec;7(1):36	NOUN
fnp-6382	452	3	.	.	PUNCT
fnp-6382	453	1	https://doi.org/10.1186/1750-1326-7-36	https://doi.org/10.1186/1750-1326-7-36	X
fnp-6382	453	2	30	30	NUM
fnp-6382	453	3	.	.	PUNCT
fnp-6382	454	1	li	li	PROPN
fnp-6382	454	2	y	y	PROPN
fnp-6382	454	3	,	,	PUNCT
fnp-6382	454	4	liu	liu	PROPN
fnp-6382	454	5	l	l	PROPN
fnp-6382	454	6	,	,	PUNCT
fnp-6382	454	7	barger	barger	PROPN
fnp-6382	454	8	sw	sw	PROPN
fnp-6382	454	9	,	,	PUNCT
fnp-6382	454	10	griffin	griffin	PROPN
fnp-6382	454	11	wst	wst	PROPN
fnp-6382	454	12	.	.	PUNCT
fnp-6382	455	1	interleukin-1	interleukin-1	NOUN
fnp-6382	455	2	mediates	mediate	NOUN
fnp-6382	455	3	pathological	pathological	ADJ
fnp-6382	455	4	effects	effect	NOUN
fnp-6382	455	5	of	of	ADP
fnp-6382	455	6	microglia	microglia	NOUN
fnp-6382	455	7	on	on	ADP
fnp-6382	455	8	tau	tau	PROPN
fnp-6382	455	9	phosphorylation	phosphorylation	NOUN
fnp-6382	455	10	and	and	CCONJ
fnp-6382	455	11	on	on	ADP
fnp-6382	455	12	synaptophysin	synaptophysin	NOUN
fnp-6382	455	13	synthesis	synthesis	NOUN
fnp-6382	455	14	in	in	ADP
fnp-6382	455	15	cortical	cortical	ADJ
fnp-6382	455	16	neurons	neuron	NOUN
fnp-6382	455	17	through	through	ADP
fnp-6382	455	18	a	a	DET
fnp-6382	455	19	p38	p38	NOUN
fnp-6382	455	20	-	-	PUNCT
fnp-6382	455	21	mapk	mapk	NOUN
fnp-6382	455	22	pathway	pathway	NOUN
fnp-6382	455	23	.	.	PUNCT
fnp-6382	456	1	j	j	PROPN
fnp-6382	456	2	neurosci	neurosci	PROPN
fnp-6382	456	3	.	.	PUNCT
fnp-6382	457	1	2003	2003	NUM
fnp-6382	457	2	mar	mar	PROPN
fnp-6382	457	3	1;23(5):1605	1;23(5):1605	NUM
fnp-6382	457	4	-	-	SYM
fnp-6382	457	5	11	11	NUM
fnp-6382	457	6	.	.	PUNCT
fnp-6382	458	1	https://doi.org/10.1523/jneurosci.23-05-01605.2003	https://doi.org/10.1523/jneurosci.23-05-01605.2003	NOUN
fnp-6382	458	2	31	31	NUM
fnp-6382	458	3	.	.	PUNCT
fnp-6382	459	1	kitazawa	kitazawa	PROPN
fnp-6382	459	2	m	m	PROPN
fnp-6382	459	3	,	,	PUNCT
fnp-6382	459	4	yamasaki	yamasaki	PROPN
fnp-6382	459	5	tr	tr	VERB
fnp-6382	459	6	,	,	PUNCT
fnp-6382	459	7	laferla	laferla	PROPN
fnp-6382	459	8	fm	fm	PROPN
fnp-6382	459	9	.	.	PROPN
fnp-6382	459	10	microglia	microglia	PROPN
fnp-6382	459	11	as	as	ADP
fnp-6382	459	12	a	a	DET
fnp-6382	459	13	potential	potential	ADJ
fnp-6382	459	14	bridge	bridge	NOUN
fnp-6382	459	15	between	between	ADP
fnp-6382	459	16	the	the	DET
fnp-6382	459	17	amyloid	amyloid	NOUN
fnp-6382	459	18	β‐peptide	β‐peptide	PUNCT
fnp-6382	459	19	and	and	CCONJ
fnp-6382	459	20	tau	tau	PROPN
fnp-6382	459	21	.	.	PUNCT
fnp-6382	460	1	ann	ann	PROPN
fnp-6382	460	2	n	n	PROPN
fnp-6382	460	3	y	y	PROPN
fnp-6382	460	4	acad	acad	PROPN
fnp-6382	460	5	sci	sci	PROPN
fnp-6382	460	6	.	.	PROPN
fnp-6382	460	7	2004	2004	NUM
fnp-6382	460	8	dec;1035(1):85	dec;1035(1):85	PROPN
fnp-6382	460	9	-	-	PUNCT
fnp-6382	460	10	103	103	NUM
fnp-6382	460	11	.	.	PUNCT
fnp-6382	461	1	https://doi.org/10.1196/annals.1332.006	https://doi.org/10.1196/annals.1332.006	ADJ
fnp-6382	461	2	32	32	NUM
fnp-6382	461	3	.	.	PUNCT
fnp-6382	462	1	labadorf	labadorf	PROPN
fnp-6382	462	2	a	a	PROPN
fnp-6382	462	3	,	,	PUNCT
fnp-6382	462	4	agus	agus	PROPN
fnp-6382	462	5	f	f	PROPN
fnp-6382	462	6	,	,	PUNCT
fnp-6382	462	7	aytan	aytan	PROPN
fnp-6382	462	8	n	n	CCONJ
fnp-6382	462	9	,	,	PUNCT
fnp-6382	462	10	cherry	cherry	PROPN
fnp-6382	462	11	j	j	PROPN
fnp-6382	462	12	,	,	PUNCT
fnp-6382	462	13	mez	mez	PROPN
fnp-6382	462	14	j	j	PROPN
fnp-6382	462	15	,	,	PUNCT
fnp-6382	462	16	mckee	mckee	PROPN
fnp-6382	462	17	a	a	PROPN
fnp-6382	462	18	,	,	PUNCT
fnp-6382	462	19	et	et	PROPN
fnp-6382	462	20	al	al	PROPN
fnp-6382	462	21	.	.	PROPN
fnp-6382	462	22	inflammation	inflammation	NOUN
fnp-6382	462	23	and	and	CCONJ
fnp-6382	462	24	neuronal	neuronal	ADJ
fnp-6382	462	25	gene	gene	NOUN
fnp-6382	462	26	expression	expression	NOUN
fnp-6382	462	27	changes	change	NOUN
fnp-6382	462	28	differ	differ	VERB
fnp-6382	462	29	in	in	ADP
fnp-6382	462	30	early	early	ADJ
fnp-6382	462	31	versus	versus	ADP
fnp-6382	462	32	late	late	ADJ
fnp-6382	462	33	chronic	chronic	ADJ
fnp-6382	462	34	traumatic	traumatic	ADJ
fnp-6382	462	35	encephalopathy	encephalopathy	ADJ
fnp-6382	462	36	brain	brain	NOUN
fnp-6382	462	37	.	.	PUNCT
fnp-6382	463	1	bmc	bmc	ADJ
fnp-6382	463	2	med	med	ADJ
fnp-6382	463	3	genomics	genomic	NOUN
fnp-6382	463	4	.	.	PUNCT
fnp-6382	464	1	2023	2023	NUM
fnp-6382	464	2	mar	mar	PROPN
fnp-6382	464	3	9;16(1):49	9;16(1):49	NUM
fnp-6382	464	4	.	.	PUNCT
fnp-6382	465	1	https://doi.org/10.1186/s12920-023-01471-5	https://doi.org/10.1186/s12920-023-01471-5	NUM
fnp-6382	465	2	33	33	NUM
fnp-6382	465	3	.	.	PUNCT
fnp-6382	466	1	cherry	cherry	PROPN
fnp-6382	466	2	jd	jd	PROPN
fnp-6382	466	3	,	,	PUNCT
fnp-6382	466	4	agus	agus	PROPN
fnp-6382	466	5	f	f	PROPN
fnp-6382	466	6	,	,	PUNCT
fnp-6382	466	7	dixon	dixon	PROPN
fnp-6382	466	8	e	e	PROPN
fnp-6382	466	9	,	,	PUNCT
fnp-6382	466	10	huber	huber	PROPN
fnp-6382	466	11	b	b	PROPN
fnp-6382	466	12	,	,	PUNCT
fnp-6382	466	13	alvarez	alvarez	PROPN
fnp-6382	466	14	ve	ve	PROPN
fnp-6382	466	15	,	,	PUNCT
fnp-6382	466	16	mez	mez	PROPN
fnp-6382	466	17	j	j	PROPN
fnp-6382	466	18	,	,	PUNCT
fnp-6382	466	19	et	et	PROPN
fnp-6382	466	20	al	al	PROPN
fnp-6382	466	21	.	.	PROPN
fnp-6382	466	22	differential	differential	ADJ
fnp-6382	466	23	gene	gene	NOUN
fnp-6382	466	24	expression	expression	NOUN
fnp-6382	466	25	in	in	ADP
fnp-6382	466	26	the	the	DET
fnp-6382	466	27	cortical	cortical	ADJ
fnp-6382	466	28	sulcus	sulcus	NOUN
fnp-6382	466	29	compared	compare	VERB
fnp-6382	466	30	to	to	ADP
fnp-6382	466	31	the	the	DET
fnp-6382	466	32	gyral	gyral	ADJ
fnp-6382	466	33	crest	crest	NOUN
fnp-6382	466	34	within	within	ADP
fnp-6382	466	35	the	the	DET
fnp-6382	466	36	early	early	ADJ
fnp-6382	466	37	stages	stage	NOUN
fnp-6382	466	38	of	of	ADP
fnp-6382	466	39	chronic	chronic	ADJ
fnp-6382	466	40	traumatic	traumatic	ADJ
fnp-6382	466	41	encephalopathy	encephalopathy	NOUN
fnp-6382	466	42	.	.	PUNCT
fnp-6382	467	1	free	free	ADJ
fnp-6382	467	2	neuropathol	neuropathol	NOUN
fnp-6382	467	3	.	.	PUNCT
fnp-6382	468	1	2021	2021	NUM
fnp-6382	468	2	aug	aug	PROPN
fnp-6382	468	3	17;21	17;21	NUM
fnp-6382	468	4	seiten	seiten	NOUN
fnp-6382	468	5	.	.	PUNCT
fnp-6382	469	1	https://10.17879	https://10.17879	PUNCT
fnp-6382	469	2	/	/	SYM
fnp-6382	469	3	freeneuropathology-2021	freeneuropathology-2021	NOUN
fnp-6382	469	4	-	-	PUNCT
fnp-6382	469	5	3453	3453	NUM
fnp-6382	469	6	34	34	NUM
fnp-6382	469	7	.	.	PUNCT
fnp-6382	470	1	butler	butler	PROPN
fnp-6382	470	2	mlmd	mlmd	PROPN
fnp-6382	470	3	,	,	PUNCT
fnp-6382	470	4	pervaiz	pervaiz	NOUN
fnp-6382	470	5	n	n	CCONJ
fnp-6382	470	6	,	,	PUNCT
fnp-6382	470	7	ypsilantis	ypsilantis	NOUN
fnp-6382	470	8	p	p	NOUN
fnp-6382	470	9	,	,	PUNCT
fnp-6382	470	10	wang	wang	PROPN
fnp-6382	470	11	y	y	PROPN
fnp-6382	470	12	,	,	PUNCT
fnp-6382	470	13	breda	breda	PROPN
fnp-6382	470	14	jc	jc	PROPN
fnp-6382	470	15	,	,	PUNCT
fnp-6382	470	16	mazzilli	mazzilli	PROPN
fnp-6382	470	17	s	s	PROPN
fnp-6382	470	18	,	,	PUNCT
fnp-6382	470	19	et	et	PROPN
fnp-6382	470	20	al	al	PROPN
fnp-6382	470	21	.	.	PROPN
fnp-6382	471	1	repetitive	repetitive	ADJ
fnp-6382	471	2	head	head	NOUN
fnp-6382	471	3	impacts	impact	NOUN
fnp-6382	471	4	induce	induce	VERB
fnp-6382	471	5	neuronal	neuronal	ADJ
fnp-6382	471	6	loss	loss	NOUN
fnp-6382	471	7	and	and	CCONJ
fnp-6382	471	8	neuroinflammation	neuroinflammation	NOUN
fnp-6382	471	9	in	in	ADP
fnp-6382	471	10	young	young	ADJ
fnp-6382	471	11	athletes	athlete	NOUN
fnp-6382	471	12	[	[	X
fnp-6382	471	13	internet	internet	NOUN
fnp-6382	471	14	]	]	PUNCT
fnp-6382	471	15	.	.	PUNCT
fnp-6382	472	1	2024	2024	NUM
fnp-6382	473	1	[	[	X
fnp-6382	473	2	cited	cite	VERB
fnp-6382	473	3	2024	2024	NUM
fnp-6382	473	4	sep	sep	NOUN
fnp-6382	473	5	6	6	NUM
fnp-6382	473	6	]	]	PUNCT
fnp-6382	473	7	.	.	PUNCT
fnp-6382	474	1	available	available	ADJ
fnp-6382	474	2	from	from	ADP
fnp-6382	474	3	:	:	PUNCT
fnp-6382	474	4	https://doi.org/10.1101/2024.03.26.586815	https://doi.org/10.1101/2024.03.26.586815	NOUN
fnp-6382	474	5	35	35	NUM
fnp-6382	474	6	.	.	PUNCT
fnp-6382	475	1	coughlin	coughlin	PROPN
fnp-6382	475	2	jm	jm	PROPN
fnp-6382	475	3	,	,	PUNCT
fnp-6382	475	4	wang	wang	PROPN
fnp-6382	475	5	y	y	PROPN
fnp-6382	475	6	,	,	PUNCT
fnp-6382	475	7	munro	munro	PROPN
fnp-6382	475	8	ca	ca	PROPN
fnp-6382	475	9	,	,	PUNCT
fnp-6382	475	10	ma	ma	PROPN
fnp-6382	475	11	s	s	PROPN
fnp-6382	475	12	,	,	PUNCT
fnp-6382	475	13	yue	yue	PROPN
fnp-6382	475	14	c	c	PROPN
fnp-6382	475	15	,	,	PUNCT
fnp-6382	475	16	chen	chen	PROPN
fnp-6382	475	17	s	s	PROPN
fnp-6382	475	18	,	,	PUNCT
fnp-6382	475	19	et	et	PROPN
fnp-6382	475	20	al	al	PROPN
fnp-6382	475	21	.	.	PUNCT
fnp-6382	475	22	neuroinflammation	neuroinflammation	NOUN
fnp-6382	475	23	and	and	CCONJ
fnp-6382	475	24	brain	brain	NOUN
fnp-6382	475	25	atrophy	atrophy	NOUN
fnp-6382	475	26	in	in	ADP
fnp-6382	475	27	former	former	ADJ
fnp-6382	475	28	nfl	nfl	PROPN
fnp-6382	475	29	players	player	NOUN
fnp-6382	475	30	:	:	PUNCT
fnp-6382	475	31	an	an	DET
fnp-6382	475	32	in	in	ADP
fnp-6382	475	33	vivo	vivo	ADJ
fnp-6382	475	34	multimodal	multimodal	NOUN
fnp-6382	475	35	imaging	imaging	NOUN
fnp-6382	475	36	pilot	pilot	NOUN
fnp-6382	475	37	study	study	NOUN
fnp-6382	475	38	.	.	PUNCT
fnp-6382	476	1	neurobiol	neurobiol	PROPN
fnp-6382	476	2	dis	dis	PROPN
fnp-6382	476	3	.	.	PUNCT
fnp-6382	477	1	2015	2015	NUM
fnp-6382	477	2	feb;74:58	feb;74:58	PROPN
fnp-6382	477	3	-	-	PUNCT
fnp-6382	477	4	65	65	NUM
fnp-6382	477	5	.	.	PUNCT
fnp-6382	478	1	https://doi.org/10.1016/j.nbd.2014.10.019	https://doi.org/10.1016/j.nbd.2014.10.019	PROPN
fnp-6382	478	2	36	36	NUM
fnp-6382	478	3	.	.	PUNCT
fnp-6382	479	1	coughlin	coughlin	PROPN
fnp-6382	479	2	jm	jm	PROPN
fnp-6382	479	3	,	,	PUNCT
fnp-6382	479	4	wang	wang	PROPN
fnp-6382	479	5	y	y	PROPN
fnp-6382	479	6	,	,	PUNCT
fnp-6382	479	7	minn	minn	PROPN
fnp-6382	479	8	i	i	PROPN
fnp-6382	479	9	,	,	PUNCT
fnp-6382	479	10	bienko	bienko	ADJ
fnp-6382	479	11	n	n	CCONJ
fnp-6382	479	12	,	,	PUNCT
fnp-6382	479	13	ambinder	ambinder	PROPN
fnp-6382	479	14	eb	eb	PROPN
fnp-6382	479	15	,	,	PUNCT
fnp-6382	479	16	xu	xu	PROPN
fnp-6382	480	1	x	x	PROPN
fnp-6382	480	2	,	,	PUNCT
fnp-6382	480	3	et	et	PROPN
fnp-6382	480	4	al	al	PROPN
fnp-6382	480	5	.	.	PUNCT
fnp-6382	480	6	imaging	imaging	NOUN
fnp-6382	480	7	of	of	ADP
fnp-6382	480	8	glial	glial	ADJ
fnp-6382	480	9	cell	cell	NOUN
fnp-6382	480	10	activation	activation	NOUN
fnp-6382	480	11	and	and	CCONJ
fnp-6382	480	12	white	white	ADJ
fnp-6382	480	13	matter	matter	NOUN
fnp-6382	480	14	integrity	integrity	NOUN
fnp-6382	480	15	in	in	ADP
fnp-6382	480	16	brains	brain	NOUN
fnp-6382	480	17	of	of	ADP
fnp-6382	480	18	active	active	ADJ
fnp-6382	480	19	and	and	CCONJ
fnp-6382	480	20	recently	recently	ADV
fnp-6382	480	21	retired	retire	VERB
fnp-6382	480	22	national	national	PROPN
fnp-6382	480	23	football	football	PROPN
fnp-6382	480	24	league	league	PROPN
fnp-6382	480	25	players	player	NOUN
fnp-6382	480	26	.	.	PUNCT
fnp-6382	481	1	jama	jama	PROPN
fnp-6382	481	2	neurol	neurol	PROPN
fnp-6382	481	3	.	.	PUNCT
fnp-6382	482	1	2017	2017	NUM
fnp-6382	482	2	jan	jan	NOUN
fnp-6382	482	3	1;74(1):67	1;74(1):67	NUM
fnp-6382	482	4	.	.	PUNCT
fnp-6382	483	1	https://doi.org/10.1001/jamaneurol.2016.3764	https://doi.org/10.1001/jamaneurol.2016.3764	PROPN
fnp-6382	483	2	37	37	NUM
fnp-6382	483	3	.	.	PUNCT
fnp-6382	484	1	varlow	varlow	PROPN
fnp-6382	484	2	c	c	PROPN
fnp-6382	484	3	,	,	PUNCT
fnp-6382	484	4	knight	knight	PROPN
fnp-6382	484	5	ac	ac	PROPN
fnp-6382	484	6	,	,	PUNCT
fnp-6382	484	7	mcquade	mcquade	PROPN
fnp-6382	484	8	p	p	PROPN
fnp-6382	484	9	,	,	PUNCT
fnp-6382	484	10	vasdev	vasdev	NOUN
fnp-6382	484	11	n.	n.	NOUN
fnp-6382	484	12	characterization	characterization	NOUN
fnp-6382	484	13	of	of	ADP
fnp-6382	484	14	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	484	15	positron	positron	NOUN
fnp-6382	484	16	emission	emission	NOUN
fnp-6382	484	17	tomography	tomography	NOUN
fnp-6382	484	18	biomarkers	biomarker	NOUN
fnp-6382	484	19	in	in	ADP
fnp-6382	484	20	chronic	chronic	ADJ
fnp-6382	484	21	traumatic	traumatic	ADJ
fnp-6382	484	22	encephalopathy	encephalopathy	NOUN
fnp-6382	484	23	.	.	PUNCT
fnp-6382	485	1	brain	brain	NOUN
fnp-6382	485	2	commun	commun	PROPN
fnp-6382	485	3	.	.	PUNCT
fnp-6382	486	1	2022	2022	NUM
fnp-6382	486	2	jan	jan	PROPN
fnp-6382	486	3	4;4(1):fcac019	4;4(1):fcac019	NUM
fnp-6382	486	4	.	.	PUNCT
fnp-6382	487	1	https://doi.org/10.1093/braincomms/fcac019	https://doi.org/10.1093/braincomms/fcac019	X
fnp-6382	487	2	38	38	NUM
fnp-6382	487	3	.	.	PUNCT
fnp-6382	488	1	somebang	somebang	PROPN
fnp-6382	488	2	k	k	PROPN
fnp-6382	488	3	,	,	PUNCT
fnp-6382	488	4	rudolph	rudolph	PROPN
fnp-6382	488	5	j	j	PROPN
fnp-6382	488	6	,	,	PUNCT
fnp-6382	488	7	imhof	imhof	PROPN
fnp-6382	488	8	i	i	PRON
fnp-6382	488	9	,	,	PUNCT
fnp-6382	488	10	li	li	PROPN
fnp-6382	488	11	l	l	PROPN
fnp-6382	488	12	,	,	PUNCT
fnp-6382	488	13	niemi	niemi	PROPN
fnp-6382	488	14	ec	ec	PROPN
fnp-6382	488	15	,	,	PUNCT
fnp-6382	488	16	shigenaga	shigenaga	PROPN
fnp-6382	488	17	j	j	PROPN
fnp-6382	488	18	,	,	PUNCT
fnp-6382	488	19	et	et	PROPN
fnp-6382	488	20	al	al	PROPN
fnp-6382	488	21	.	.	PUNCT
fnp-6382	489	1	ccr2	ccr2	NOUN
fnp-6382	489	2	deficiency	deficiency	NOUN
fnp-6382	489	3	alters	alter	VERB
fnp-6382	489	4	activation	activation	NOUN
fnp-6382	489	5	of	of	ADP
fnp-6382	489	6	microglia	microglia	ADJ
fnp-6382	489	7	subsets	subset	NOUN
fnp-6382	489	8	in	in	ADP
fnp-6382	489	9	traumatic	traumatic	ADJ
fnp-6382	489	10	brain	brain	NOUN
fnp-6382	489	11	injury	injury	NOUN
fnp-6382	489	12	.	.	PUNCT
fnp-6382	490	1	cell	cell	NOUN
fnp-6382	490	2	rep	rep	PROPN
fnp-6382	490	3	.	.	PROPN
fnp-6382	490	4	2021	2021	NUM
fnp-6382	490	5	sep;36(12):109727	sep;36(12):109727	PUNCT
fnp-6382	490	6	.	.	PUNCT
fnp-6382	491	1	https://doi.org/10.1016/j.celrep.2021.109727	https://doi.org/10.1016/j.celrep.2021.109727	PROPN
fnp-6382	491	2	39	39	NUM
fnp-6382	491	3	.	.	PUNCT
fnp-6382	492	1	hsieh	hsieh	PROPN
fnp-6382	492	2	cl	cl	PROPN
fnp-6382	492	3	,	,	PUNCT
fnp-6382	492	4	niemi	niemi	PROPN
fnp-6382	492	5	ec	ec	PROPN
fnp-6382	492	6	,	,	PUNCT
fnp-6382	492	7	wang	wang	PROPN
fnp-6382	492	8	sh	sh	PROPN
fnp-6382	492	9	,	,	PUNCT
fnp-6382	492	10	lee	lee	PROPN
fnp-6382	492	11	cc	cc	PROPN
fnp-6382	492	12	,	,	PUNCT
fnp-6382	492	13	bingham	bingham	PROPN
fnp-6382	492	14	d	d	PROPN
fnp-6382	492	15	,	,	PUNCT
fnp-6382	492	16	zhang	zhang	PROPN
fnp-6382	492	17	j	j	PROPN
fnp-6382	492	18	,	,	PUNCT
fnp-6382	492	19	et	et	PROPN
fnp-6382	492	20	al	al	PROPN
fnp-6382	492	21	.	.	PUNCT
fnp-6382	493	1	ccr2	ccr2	PROPN
fnp-6382	493	2	deficiency	deficiency	NOUN
fnp-6382	493	3	impairs	impair	VERB
fnp-6382	493	4	macrophage	macrophage	ADJ
fnp-6382	493	5	infiltration	infiltration	NOUN
fnp-6382	493	6	and	and	CCONJ
fnp-6382	493	7	improves	improve	VERB
fnp-6382	493	8	cognitive	cognitive	ADJ
fnp-6382	493	9	function	function	NOUN
fnp-6382	493	10	after	after	ADP
fnp-6382	493	11	traumatic	traumatic	ADJ
fnp-6382	493	12	brain	brain	NOUN
fnp-6382	493	13	injury	injury	NOUN
fnp-6382	493	14	.	.	PUNCT
fnp-6382	494	1	j	j	PROPN
fnp-6382	494	2	neurotrauma	neurotrauma	PROPN
fnp-6382	494	3	.	.	PUNCT
fnp-6382	495	1	2014	2014	NUM
fnp-6382	495	2	oct	oct	NOUN
fnp-6382	495	3	15;31(20):1677	15;31(20):1677	NUM
fnp-6382	495	4	-	-	SYM
fnp-6382	495	5	88	88	NUM
fnp-6382	495	6	.	.	PUNCT
fnp-6382	495	7	https://doi.org/10.1089/neu.2013.3252	https://doi.org/10.1089/neu.2013.3252	VERB
fnp-6382	495	8	40	40	NUM
fnp-6382	495	9	.	.	PUNCT
fnp-6382	496	1	morganti	morganti	PROPN
fnp-6382	496	2	jm	jm	PROPN
fnp-6382	496	3	,	,	PUNCT
fnp-6382	496	4	jopson	jopson	NOUN
fnp-6382	496	5	td	td	PROPN
fnp-6382	496	6	,	,	PUNCT
fnp-6382	496	7	liu	liu	PROPN
fnp-6382	496	8	s	s	PROPN
fnp-6382	496	9	,	,	PUNCT
fnp-6382	496	10	riparip	riparip	NOUN
fnp-6382	496	11	lk	lk	NOUN
fnp-6382	496	12	,	,	PUNCT
fnp-6382	496	13	guandique	guandique	NOUN
fnp-6382	496	14	ck	ck	PROPN
fnp-6382	496	15	,	,	PUNCT
fnp-6382	496	16	gupta	gupta	PROPN
fnp-6382	496	17	n	n	CCONJ
fnp-6382	496	18	,	,	PUNCT
fnp-6382	496	19	et	et	PROPN
fnp-6382	496	20	al	al	PROPN
fnp-6382	496	21	.	.	PUNCT
fnp-6382	497	1	ccr2	ccr2	PROPN
fnp-6382	497	2	antagonism	antagonism	NOUN
fnp-6382	497	3	alters	alter	VERB
fnp-6382	497	4	brain	brain	NOUN
fnp-6382	497	5	macrophage	macrophage	ADJ
fnp-6382	497	6	polarization	polarization	NOUN
fnp-6382	497	7	and	and	CCONJ
fnp-6382	497	8	ameliorates	ameliorate	VERB
fnp-6382	497	9	cognitive	cognitive	ADJ
fnp-6382	497	10	dysfunction	dysfunction	NOUN
fnp-6382	497	11	induced	induce	VERB
fnp-6382	497	12	by	by	ADP
fnp-6382	497	13	traumatic	traumatic	ADJ
fnp-6382	497	14	brain	brain	NOUN
fnp-6382	497	15	injury	injury	NOUN
fnp-6382	497	16	.	.	PUNCT
fnp-6382	498	1	j	j	PROPN
fnp-6382	498	2	neurosci	neurosci	PROPN
fnp-6382	498	3	.	.	PUNCT
fnp-6382	499	1	2015	2015	NUM
fnp-6382	499	2	jan	jan	PROPN
fnp-6382	499	3	14;35(2):748	14;35(2):748	NUM
fnp-6382	499	4	-	-	SYM
fnp-6382	499	5	60	60	NUM
fnp-6382	499	6	.	.	PUNCT
fnp-6382	500	1	https://doi.org/10.1523/jneurosci.2405-14.2015	https://doi.org/10.1523/jneurosci.2405-14.2015	PROPN
fnp-6382	500	2	41	41	NUM
fnp-6382	500	3	.	.	PUNCT
fnp-6382	501	1	cherry	cherry	PROPN
fnp-6382	501	2	jd	jd	PROPN
fnp-6382	501	3	,	,	PUNCT
fnp-6382	501	4	meng	meng	PROPN
fnp-6382	501	5	g	g	PROPN
fnp-6382	501	6	,	,	PUNCT
fnp-6382	501	7	daley	daley	PROPN
fnp-6382	501	8	s	s	PROPN
fnp-6382	501	9	,	,	PUNCT
fnp-6382	501	10	xia	xia	PROPN
fnp-6382	501	11	w	w	PROPN
fnp-6382	501	12	,	,	PUNCT
fnp-6382	501	13	svirsky	svirsky	PROPN
fnp-6382	501	14	s	s	NOUN
fnp-6382	501	15	,	,	PUNCT
fnp-6382	501	16	alvarez	alvarez	PROPN
fnp-6382	501	17	ve	ve	PROPN
fnp-6382	501	18	,	,	PUNCT
fnp-6382	501	19	et	et	PROPN
fnp-6382	501	20	al	al	PROPN
fnp-6382	501	21	.	.	PUNCT
fnp-6382	502	1	ccl2	ccl2	PROPN
fnp-6382	502	2	is	be	AUX
fnp-6382	502	3	associated	associate	VERB
fnp-6382	502	4	with	with	ADP
fnp-6382	502	5	microglia	microglia	ADJ
fnp-6382	502	6	and	and	CCONJ
fnp-6382	502	7	macrophage	macrophage	ADJ
fnp-6382	502	8	recruitment	recruitment	NOUN
fnp-6382	502	9	in	in	ADP
fnp-6382	502	10	chronic	chronic	ADJ
fnp-6382	502	11	traumatic	traumatic	ADJ
fnp-6382	502	12	encephalopathy	encephalopathy	NOUN
fnp-6382	502	13	.	.	PUNCT
fnp-6382	503	1	j	j	PROPN
fnp-6382	503	2	neuroinflammation	neuroinflammation	PROPN
fnp-6382	503	3	.	.	PUNCT
fnp-6382	504	1	2020	2020	NUM
fnp-6382	505	1	dec;17(1):370	dec;17(1):370	NUM
fnp-6382	505	2	.	.	PUNCT
fnp-6382	506	1	https://doi.org/10.1186/s12974-020-02036-4	https://doi.org/10.1186/s12974-020-02036-4	NUM
fnp-6382	506	2	42	42	NUM
fnp-6382	506	3	.	.	PUNCT
fnp-6382	507	1	di	di	PROPN
fnp-6382	507	2	battista	battista	PROPN
fnp-6382	507	3	ap	ap	PROPN
fnp-6382	507	4	,	,	PUNCT
fnp-6382	507	5	rhind	rhind	NOUN
fnp-6382	507	6	sg	sg	PROPN
fnp-6382	507	7	,	,	PUNCT
fnp-6382	507	8	richards	richards	PROPN
fnp-6382	507	9	d	d	PROPN
fnp-6382	507	10	,	,	PUNCT
fnp-6382	507	11	churchill	churchill	PROPN
fnp-6382	507	12	n	n	PROPN
fnp-6382	507	13	,	,	PUNCT
fnp-6382	507	14	baker	baker	PROPN
fnp-6382	507	15	aj	aj	PROPN
fnp-6382	507	16	,	,	PUNCT
fnp-6382	507	17	hutchison	hutchison	PROPN
fnp-6382	507	18	mg	mg	PROPN
fnp-6382	507	19	.	.	PUNCT
fnp-6382	507	20	altered	alter	VERB
fnp-6382	507	21	blood	blood	NOUN
fnp-6382	507	22	biomarker	biomarker	NOUN
fnp-6382	507	23	profiles	profile	NOUN
fnp-6382	507	24	in	in	ADP
fnp-6382	507	25	athletes	athlete	NOUN
fnp-6382	507	26	with	with	ADP
fnp-6382	507	27	a	a	DET
fnp-6382	507	28	history	history	NOUN
fnp-6382	507	29	of	of	ADP
fnp-6382	507	30	repetitive	repetitive	ADJ
fnp-6382	507	31	head	head	NOUN
fnp-6382	507	32	impacts	impact	NOUN
fnp-6382	507	33	.	.	PUNCT
fnp-6382	508	1	christie	christie	PROPN
fnp-6382	508	2	b	b	PROPN
fnp-6382	508	3	,	,	PUNCT
fnp-6382	508	4	editor	editor	NOUN
fnp-6382	508	5	.	.	PUNCT
fnp-6382	509	1	plos	plos	PROPN
fnp-6382	509	2	one	one	NUM
fnp-6382	509	3	.	.	PUNCT
fnp-6382	510	1	2016	2016	NUM
fnp-6382	510	2	jul	jul	PROPN
fnp-6382	510	3	26;11(7):e0159929	26;11(7):e0159929	NUM
fnp-6382	510	4	.	.	PUNCT
fnp-6382	511	1	https://doi.org/10.1371/journal.pone.0159929	https://doi.org/10.1371/journal.pone.0159929	NOUN
fnp-6382	511	2	43	43	NUM
fnp-6382	511	3	.	.	PUNCT
fnp-6382	512	1	begum	begum	VERB
fnp-6382	512	2	g	g	PROPN
fnp-6382	512	3	,	,	PUNCT
fnp-6382	512	4	reddy	reddy	PROPN
fnp-6382	512	5	r	r	PROPN
fnp-6382	512	6	,	,	PUNCT
fnp-6382	512	7	yakoub	yakoub	PROPN
fnp-6382	512	8	km	km	PROPN
fnp-6382	512	9	,	,	PUNCT
fnp-6382	512	10	belli	belli	PROPN
fnp-6382	512	11	a	a	X
fnp-6382	512	12	,	,	PUNCT
fnp-6382	512	13	davies	davy	NOUN
fnp-6382	512	14	dj	dj	PROPN
fnp-6382	512	15	,	,	PUNCT
fnp-6382	512	16	di	di	NOUN
fnp-6382	512	17	pietro	pietro	NOUN
fnp-6382	512	18	v.	v.	ADP
fnp-6382	512	19	differential	differential	ADJ
fnp-6382	512	20	expression	expression	NOUN
fnp-6382	512	21	of	of	ADP
fnp-6382	512	22	circulating	circulate	VERB
fnp-6382	512	23	inflammatory	inflammatory	ADJ
fnp-6382	512	24	proteins	protein	NOUN
fnp-6382	512	25	following	follow	VERB
fnp-6382	512	26	sport	sport	NOUN
fnp-6382	512	27	-	-	PUNCT
fnp-6382	512	28	related	relate	VERB
fnp-6382	512	29	traumatic	traumatic	ADJ
fnp-6382	512	30	brain	brain	NOUN
fnp-6382	512	31	injury	injury	NOUN
fnp-6382	512	32	.	.	PUNCT
fnp-6382	513	1	int	int	PROPN
fnp-6382	513	2	j	j	PROPN
fnp-6382	513	3	mol	mol	ADP
fnp-6382	513	4	sci	sci	PROPN
fnp-6382	513	5	.	.	PROPN
fnp-6382	513	6	2020	2020	NUM
fnp-6382	513	7	feb	feb	PROPN
fnp-6382	513	8	12;21(4):1216	12;21(4):1216	NUM
fnp-6382	513	9	.	.	PUNCT
fnp-6382	513	10	https://doi.org/10.3390/ijms21041216	https://doi.org/10.3390/ijms21041216	VERB
fnp-6382	513	11	44	44	NUM
fnp-6382	513	12	.	.	PUNCT
fnp-6382	514	1	arfaei	arfaei	PROPN
fnp-6382	514	2	r	r	NOUN
fnp-6382	514	3	,	,	PUNCT
fnp-6382	514	4	mikaeili	mikaeili	NOUN
fnp-6382	514	5	n	n	CCONJ
fnp-6382	514	6	,	,	PUNCT
fnp-6382	514	7	daj	daj	PROPN
fnp-6382	514	8	f	f	AUX
fnp-6382	514	9	,	,	PUNCT
fnp-6382	514	10	boroumand	boroumand	VERB
fnp-6382	514	11	a	a	PRON
fnp-6382	514	12	,	,	PUNCT
fnp-6382	514	13	kheyri	kheyri	NOUN
fnp-6382	514	14	a	a	X
fnp-6382	514	15	,	,	PUNCT
fnp-6382	514	16	yaraghi	yaraghi	PROPN
fnp-6382	514	17	p	p	X
fnp-6382	514	18	,	,	PUNCT
fnp-6382	514	19	et	et	PROPN
fnp-6382	514	20	al	al	PROPN
fnp-6382	514	21	.	.	PUNCT
fnp-6382	515	1	decoding	decode	VERB
fnp-6382	515	2	the	the	DET
fnp-6382	515	3	role	role	NOUN
fnp-6382	515	4	of	of	ADP
fnp-6382	515	5	the	the	DET
fnp-6382	515	6	ccl2	ccl2	PROPN
fnp-6382	515	7	/	/	SYM
fnp-6382	515	8	ccr2	ccr2	PROPN
fnp-6382	515	9	axis	axis	NOUN
fnp-6382	515	10	in	in	ADP
fnp-6382	515	11	alzheimer	alzheimer	PROPN
fnp-6382	515	12	's	's	PART
fnp-6382	515	13	disease	disease	NOUN
fnp-6382	515	14	and	and	CCONJ
fnp-6382	515	15	innovating	innovate	VERB
fnp-6382	515	16	therapeutic	therapeutic	ADJ
fnp-6382	515	17	approaches	approach	NOUN
fnp-6382	515	18	:	:	PUNCT
fnp-6382	515	19	keeping	keep	VERB
fnp-6382	515	20	all	all	DET
fnp-6382	515	21	options	option	NOUN
fnp-6382	515	22	open	open	ADJ
fnp-6382	515	23	.	.	PUNCT
fnp-6382	516	1	int	int	NOUN
fnp-6382	516	2	immunopharmacol	immunopharmacol	PROPN
fnp-6382	516	3	.	.	PUNCT
fnp-6382	517	1	2024	2024	NUM
fnp-6382	517	2	jun;135:112328	jun;135:112328	PROPN
fnp-6382	517	3	.	.	PUNCT
fnp-6382	518	1	https://doi.org/10.1016/j.intimp.2024.112328	https://doi.org/10.1016/j.intimp.2024.112328	PROPN
fnp-6382	518	2	45	45	NUM
fnp-6382	518	3	.	.	PUNCT
fnp-6382	518	4	kiyota	kiyota	PROPN
fnp-6382	518	5	t	t	PROPN
fnp-6382	518	6	,	,	PUNCT
fnp-6382	518	7	gendelman	gendelman	NOUN
fnp-6382	518	8	he	he	PRON
fnp-6382	518	9	,	,	PUNCT
fnp-6382	518	10	weir	weir	PROPN
fnp-6382	518	11	ra	ra	PROPN
fnp-6382	518	12	,	,	PUNCT
fnp-6382	518	13	higgins	higgins	PROPN
fnp-6382	518	14	ee	ee	PROPN
fnp-6382	518	15	,	,	PUNCT
fnp-6382	518	16	zhang	zhang	PROPN
fnp-6382	518	17	g	g	PROPN
fnp-6382	518	18	,	,	PUNCT
fnp-6382	518	19	jain	jain	PROPN
fnp-6382	518	20	m.	m.	PROPN
fnp-6382	518	21	ccl2	ccl2	PROPN
fnp-6382	518	22	affects	affect	VERB
fnp-6382	518	23	β	β	NOUN
fnp-6382	518	24	-	-	NOUN
fnp-6382	518	25	amyloidosis	amyloidosis	NOUN
fnp-6382	518	26	and	and	CCONJ
fnp-6382	518	27	progressive	progressive	ADJ
fnp-6382	518	28	neurocognitive	neurocognitive	ADJ
fnp-6382	518	29	dysfunction	dysfunction	NOUN
fnp-6382	518	30	in	in	ADP
fnp-6382	518	31	a	a	DET
fnp-6382	518	32	mouse	mouse	NOUN
fnp-6382	518	33	model	model	NOUN
fnp-6382	518	34	of	of	ADP
fnp-6382	518	35	alzheimer	alzheimer	PROPN
fnp-6382	518	36	's	's	PART
fnp-6382	518	37	disease	disease	NOUN
fnp-6382	518	38	.	.	PUNCT
fnp-6382	519	1	neurobiol	neurobiol	PROPN
fnp-6382	519	2	aging	aging	NOUN
fnp-6382	519	3	.	.	PUNCT
fnp-6382	520	1	2013	2013	NUM
fnp-6382	520	2	apr;34(4):1060	apr;34(4):1060	NOUN
fnp-6382	520	3	-	-	PUNCT
fnp-6382	520	4	8	8	NUM
fnp-6382	520	5	.	.	PUNCT
fnp-6382	521	1	https://doi.org/10.1016/j.neurobiolaging.2012.08.009	https://doi.org/10.1016/j.neurobiolaging.2012.08.009	PROPN
fnp-6382	521	2	46	46	NUM
fnp-6382	521	3	.	.	PUNCT
fnp-6382	522	1	westin	westin	PROPN
fnp-6382	522	2	k	k	PROPN
fnp-6382	522	3	,	,	PUNCT
fnp-6382	522	4	buchhave	buchhave	VERB
fnp-6382	522	5	p	p	X
fnp-6382	522	6	,	,	PUNCT
fnp-6382	522	7	nielsen	nielsen	PROPN
fnp-6382	522	8	h	h	PROPN
fnp-6382	522	9	,	,	PUNCT
fnp-6382	522	10	minthon	minthon	ADV
fnp-6382	522	11	l	l	NOUN
fnp-6382	522	12	,	,	PUNCT
fnp-6382	522	13	janciauskiene	janciauskiene	PROPN
fnp-6382	522	14	s	s	PROPN
fnp-6382	522	15	,	,	PUNCT
fnp-6382	522	16	hansson	hansson	PROPN
fnp-6382	522	17	o.	o.	PROPN
fnp-6382	522	18	ccl2	ccl2	PROPN
fnp-6382	522	19	is	be	AUX
fnp-6382	522	20	associated	associate	VERB
fnp-6382	522	21	with	with	ADP
fnp-6382	522	22	a	a	DET
fnp-6382	522	23	faster	fast	ADJ
fnp-6382	522	24	rate	rate	NOUN
fnp-6382	522	25	of	of	ADP
fnp-6382	522	26	cognitive	cognitive	ADJ
fnp-6382	522	27	decline	decline	NOUN
fnp-6382	522	28	during	during	ADP
fnp-6382	522	29	early	early	ADJ
fnp-6382	522	30	stages	stage	NOUN
fnp-6382	522	31	of	of	ADP
fnp-6382	522	32	alzheimer	alzheimer	PROPN
fnp-6382	522	33	's	's	PART
fnp-6382	522	34	disease	disease	NOUN
fnp-6382	522	35	.	.	PUNCT
fnp-6382	523	1	ginsberg	ginsberg	PROPN
fnp-6382	523	2	sd	sd	PROPN
fnp-6382	523	3	,	,	PUNCT
fnp-6382	523	4	editor	editor	NOUN
fnp-6382	523	5	.	.	PUNCT
fnp-6382	524	1	plos	plos	PROPN
fnp-6382	524	2	one	one	NUM
fnp-6382	524	3	.	.	PUNCT
fnp-6382	525	1	2012	2012	NUM
fnp-6382	525	2	jan	jan	PROPN
fnp-6382	525	3	30;7(1):e30525	30;7(1):e30525	NUM
fnp-6382	525	4	.	.	PUNCT
fnp-6382	526	1	https://doi.org/10.1371/journal.pone.0030525	https://doi.org/10.1371/journal.pone.0030525	X
fnp-6382	527	1	47	47	NUM
fnp-6382	527	2	.	.	PUNCT
fnp-6382	528	1	mcmanus	mcmanus	PROPN
fnp-6382	528	2	c	c	PROPN
fnp-6382	528	3	,	,	PUNCT
fnp-6382	528	4	berman	berman	PROPN
fnp-6382	528	5	jw	jw	PROPN
fnp-6382	528	6	,	,	PUNCT
fnp-6382	528	7	brett	brett	PROPN
fnp-6382	528	8	fm	fm	PROPN
fnp-6382	528	9	,	,	PUNCT
fnp-6382	528	10	staunton	staunton	PROPN
fnp-6382	528	11	h	h	PROPN
fnp-6382	528	12	,	,	PUNCT
fnp-6382	528	13	farrell	farrell	PROPN
fnp-6382	528	14	m	m	PROPN
fnp-6382	528	15	,	,	PUNCT
fnp-6382	528	16	brosnan	brosnan	PROPN
fnp-6382	528	17	cf	cf	PROPN
fnp-6382	528	18	.	.	PUNCT
fnp-6382	529	1	mcp-1	mcp-1	NOUN
fnp-6382	529	2	,	,	PUNCT
fnp-6382	529	3	mcp-2	mcp-2	PUNCT
fnp-6382	529	4	and	and	CCONJ
fnp-6382	529	5	mcp-3	mcp-3	NUM
fnp-6382	529	6	expression	expression	NOUN
fnp-6382	529	7	in	in	ADP
fnp-6382	529	8	multiple	multiple	ADJ
fnp-6382	529	9	sclerosis	sclerosis	NOUN
fnp-6382	529	10	lesions	lesion	NOUN
fnp-6382	529	11	:	:	PUNCT
fnp-6382	529	12	an	an	DET
fnp-6382	529	13	immunohistochemical	immunohistochemical	ADJ
fnp-6382	529	14	and	and	CCONJ
fnp-6382	529	15	in	in	ADP
fnp-6382	529	16	situ	situ	ADJ
fnp-6382	529	17	hybridization	hybridization	NOUN
fnp-6382	529	18	study	study	NOUN
fnp-6382	529	19	.	.	PUNCT
fnp-6382	530	1	j	j	PROPN
fnp-6382	530	2	neuroimmunol	neuroimmunol	PROPN
fnp-6382	530	3	.	.	PUNCT
fnp-6382	531	1	1998	1998	NUM
fnp-6382	531	2	jun;86(1):20	jun;86(1):20	NOUN
fnp-6382	531	3	-	-	PUNCT
fnp-6382	531	4	9	9	NUM
fnp-6382	531	5	.	.	PUNCT
fnp-6382	532	1	https://doi.org/10.1016/s0165-5728	https://doi.org/10.1016/s0165-5728	NOUN
fnp-6382	532	2	48	48	NUM
fnp-6382	532	3	.	.	PUNCT
fnp-6382	533	1	hughes	hughes	PROPN
fnp-6382	533	2	pm	pm	PROPN
fnp-6382	533	3	,	,	PUNCT
fnp-6382	533	4	allegrini	allegrini	ADJ
fnp-6382	533	5	pr	pr	NOUN
fnp-6382	533	6	,	,	PUNCT
fnp-6382	533	7	rudin	rudin	PROPN
fnp-6382	533	8	m	m	PROPN
fnp-6382	533	9	,	,	PUNCT
fnp-6382	533	10	perry	perry	PROPN
fnp-6382	533	11	vh	vh	PROPN
fnp-6382	533	12	,	,	PUNCT
fnp-6382	533	13	mir	mir	PROPN
fnp-6382	533	14	ak	ak	PROPN
fnp-6382	533	15	,	,	PUNCT
fnp-6382	533	16	wiessner	wiessner	PROPN
fnp-6382	533	17	c.	c.	PROPN
fnp-6382	533	18	monocyte	monocyte	PROPN
fnp-6382	533	19	chemoattractant	chemoattractant	PROPN
fnp-6382	533	20	protein-1	protein-1	NUM
fnp-6382	533	21	deficiency	deficiency	NOUN
fnp-6382	533	22	is	be	AUX
fnp-6382	533	23	protective	protective	ADJ
fnp-6382	533	24	in	in	ADP
fnp-6382	533	25	a	a	DET
fnp-6382	533	26	murine	murine	ADJ
fnp-6382	533	27	stroke	stroke	NOUN
fnp-6382	533	28	model	model	NOUN
fnp-6382	533	29	.	.	PUNCT
fnp-6382	534	1	j	j	PROPN
fnp-6382	534	2	cereb	cereb	PROPN
fnp-6382	534	3	blood	blood	NOUN
fnp-6382	534	4	flow	flow	NOUN
fnp-6382	534	5	metab	metab	NOUN
fnp-6382	534	6	.	.	PUNCT
fnp-6382	535	1	2002	2002	NUM
fnp-6382	535	2	mar;22(3):308	mar;22(3):308	PROPN
fnp-6382	535	3	-	-	PUNCT
fnp-6382	535	4	17	17	NUM
fnp-6382	535	5	.	.	PUNCT
fnp-6382	536	1	https://doi.org/10.1097/00004647-200203000-00008	https://doi.org/10.1097/00004647-200203000-00008	NOUN
fnp-6382	536	2	49	49	NUM
fnp-6382	536	3	.	.	PUNCT
fnp-6382	537	1	chen	chen	PROPN
fnp-6382	537	2	d	d	PROPN
fnp-6382	537	3	,	,	PUNCT
fnp-6382	537	4	ding	ding	NOUN
fnp-6382	537	5	y	y	PROPN
fnp-6382	537	6	,	,	PUNCT
fnp-6382	537	7	schröppel	schröppel	PROPN
fnp-6382	537	8	b	b	PROPN
fnp-6382	537	9	,	,	PUNCT
fnp-6382	537	10	zhang	zhang	PROPN
fnp-6382	537	11	n	n	CCONJ
fnp-6382	537	12	,	,	PUNCT
fnp-6382	537	13	fu	fu	PROPN
fnp-6382	537	14	s	s	PROPN
fnp-6382	537	15	,	,	PUNCT
fnp-6382	537	16	chen	chen	PROPN
fnp-6382	537	17	d	d	PROPN
fnp-6382	537	18	,	,	PUNCT
fnp-6382	537	19	et	et	PROPN
fnp-6382	537	20	al	al	PROPN
fnp-6382	537	21	.	.	PROPN
fnp-6382	537	22	differential	differential	PROPN
fnp-6382	537	23	chemokine	chemokine	ADJ
fnp-6382	537	24	and	and	CCONJ
fnp-6382	537	25	chemokine	chemokine	ADJ
fnp-6382	537	26	receptor	receptor	NOUN
fnp-6382	537	27	gene	gene	NOUN
fnp-6382	537	28	induction	induction	NOUN
fnp-6382	537	29	by	by	ADP
fnp-6382	537	30	ischemia	ischemia	NOUN
fnp-6382	537	31	,	,	PUNCT
fnp-6382	537	32	alloantigen	alloantigen	NOUN
fnp-6382	537	33	,	,	PUNCT
fnp-6382	537	34	and	and	CCONJ
fnp-6382	537	35	gene	gene	NOUN
fnp-6382	537	36	transfer	transfer	NOUN
fnp-6382	537	37	in	in	ADP
fnp-6382	537	38	cardiac	cardiac	ADJ
fnp-6382	537	39	grafts	graft	NOUN
fnp-6382	537	40	.	.	PUNCT
fnp-6382	538	1	am	be	AUX
fnp-6382	538	2	j	j	PROPN
fnp-6382	538	3	transplant	transplant	NOUN
fnp-6382	538	4	.	.	PUNCT
fnp-6382	539	1	2003	2003	NUM
fnp-6382	539	2	oct;3(10):1216	oct;3(10):1216	NOUN
fnp-6382	539	3	-	-	SYM
fnp-6382	539	4	29	29	NUM
fnp-6382	539	5	.	.	PUNCT
fnp-6382	540	1	https://doi.org/10.1046/j.1600-6143.2003.00207.x	https://doi.org/10.1046/j.1600-6143.2003.00207.x	NOUN
fnp-6382	540	2	50	50	NUM
fnp-6382	540	3	.	.	PUNCT
fnp-6382	541	1	garcia	garcia	PROPN
fnp-6382	541	2	-	-	PUNCT
fnp-6382	541	3	zepeda	zepeda	PROPN
fnp-6382	541	4	ea	ea	PROPN
fnp-6382	541	5	,	,	PUNCT
fnp-6382	541	6	rothenberg	rothenberg	PROPN
fnp-6382	541	7	me	i	PRON
fnp-6382	541	8	,	,	PUNCT
fnp-6382	541	9	ownbey	ownbey	PROPN
fnp-6382	541	10	rt	rt	PROPN
fnp-6382	541	11	,	,	PUNCT
fnp-6382	541	12	celestin	celestin	PROPN
fnp-6382	541	13	j	j	PROPN
fnp-6382	541	14	,	,	PUNCT
fnp-6382	541	15	leder	leder	NOUN
fnp-6382	541	16	p	p	NOUN
fnp-6382	541	17	,	,	PUNCT
fnp-6382	541	18	luster	luster	NOUN
fnp-6382	541	19	ad	ad	NOUN
fnp-6382	541	20	.	.	PUNCT
fnp-6382	542	1	human	human	ADJ
fnp-6382	542	2	eotaxin	eotaxin	PROPN
fnp-6382	542	3	is	be	AUX
fnp-6382	542	4	a	a	DET
fnp-6382	542	5	specific	specific	ADJ
fnp-6382	542	6	chemoattractant	chemoattractant	NOUN
fnp-6382	542	7	for	for	ADP
fnp-6382	542	8	eosinophil	eosinophil	ADJ
fnp-6382	542	9	cells	cell	NOUN
fnp-6382	542	10	and	and	CCONJ
fnp-6382	542	11	provides	provide	VERB
fnp-6382	542	12	a	a	DET
fnp-6382	542	13	new	new	ADJ
fnp-6382	542	14	mechanism	mechanism	NOUN
fnp-6382	542	15	to	to	PART
fnp-6382	542	16	explain	explain	VERB
fnp-6382	542	17	tissue	tissue	NOUN
fnp-6382	542	18	eosinophilia	eosinophilia	NOUN
fnp-6382	542	19	.	.	PUNCT
fnp-6382	543	1	nat	nat	PROPN
fnp-6382	543	2	med	med	PROPN
fnp-6382	543	3	.	.	PUNCT
fnp-6382	543	4	1996	1996	NUM
fnp-6382	543	5	apr;2(4):449	apr;2(4):449	PROPN
fnp-6382	543	6	-	-	PUNCT
fnp-6382	543	7	56	56	PROPN
fnp-6382	543	8	.	.	PUNCT
fnp-6382	544	1	https://doi.org/10.1038/nm0496-449	https://doi.org/10.1038/nm0496-449	PROPN
fnp-6382	545	1	51	51	NUM
fnp-6382	545	2	.	.	PUNCT
fnp-6382	546	1	huber	huber	PROPN
fnp-6382	546	2	ak	ak	PROPN
fnp-6382	546	3	,	,	PUNCT
fnp-6382	546	4	giles	giles	PROPN
fnp-6382	546	5	da	da	PROPN
fnp-6382	546	6	,	,	PUNCT
fnp-6382	546	7	segal	segal	PROPN
fnp-6382	546	8	bm	bm	PROPN
fnp-6382	546	9	,	,	PUNCT
fnp-6382	546	10	irani	irani	PROPN
fnp-6382	546	11	dn	dn	PROPN
fnp-6382	546	12	.	.	PUNCT
fnp-6382	547	1	an	an	DET
fnp-6382	547	2	emerging	emerge	VERB
fnp-6382	547	3	role	role	NOUN
fnp-6382	547	4	for	for	ADP
fnp-6382	547	5	eotaxins	eotaxin	NOUN
fnp-6382	547	6	in	in	ADP
fnp-6382	547	7	neurodegenerative	neurodegenerative	ADJ
fnp-6382	547	8	disease	disease	NOUN
fnp-6382	547	9	.	.	PUNCT
fnp-6382	548	1	clin	clin	PROPN
fnp-6382	548	2	immunol	immunol	NOUN
fnp-6382	548	3	.	.	PUNCT
fnp-6382	549	1	2018	2018	NUM
fnp-6382	549	2	apr;189:29	apr;189:29	PROPN
fnp-6382	549	3	-	-	PUNCT
fnp-6382	549	4	33	33	NUM
fnp-6382	549	5	.	.	PUNCT
fnp-6382	550	1	https://doi.org/10.1016/j.clim.2016.09.010	https://doi.org/10.1016/j.clim.2016.09.010	NOUN
fnp-6382	550	2	52	52	NUM
fnp-6382	550	3	.	.	PUNCT
fnp-6382	551	1	cherry	cherry	PROPN
fnp-6382	551	2	jd	jd	PROPN
fnp-6382	551	3	,	,	PUNCT
fnp-6382	551	4	stein	stein	PROPN
fnp-6382	551	5	td	td	PROPN
fnp-6382	551	6	,	,	PUNCT
fnp-6382	551	7	tripodis	tripodis	PROPN
fnp-6382	551	8	y	y	PROPN
fnp-6382	551	9	,	,	PUNCT
fnp-6382	551	10	alvarez	alvarez	PROPN
fnp-6382	551	11	ve	ve	PROPN
fnp-6382	551	12	,	,	PUNCT
fnp-6382	551	13	huber	huber	PROPN
fnp-6382	551	14	br	br	PROPN
fnp-6382	551	15	,	,	PUNCT
fnp-6382	551	16	au	au	ADJ
fnp-6382	551	17	r	r	NOUN
fnp-6382	551	18	,	,	PUNCT
fnp-6382	551	19	et	et	PROPN
fnp-6382	551	20	al	al	PROPN
fnp-6382	551	21	.	.	PUNCT
fnp-6382	552	1	ccl11	ccl11	PROPN
fnp-6382	552	2	is	be	AUX
fnp-6382	552	3	increased	increase	VERB
fnp-6382	552	4	in	in	ADP
fnp-6382	552	5	the	the	DET
fnp-6382	552	6	cns	cns	NOUN
fnp-6382	552	7	in	in	ADP
fnp-6382	552	8	chronic	chronic	ADJ
fnp-6382	552	9	traumatic	traumatic	ADJ
fnp-6382	552	10	encephalopathy	encephalopathy	NOUN
fnp-6382	552	11	but	but	CCONJ
fnp-6382	552	12	not	not	PART
fnp-6382	552	13	in	in	ADP
fnp-6382	552	14	alzheimer	alzheimer	PROPN
fnp-6382	552	15	's	's	PART
fnp-6382	552	16	disease	disease	NOUN
fnp-6382	552	17	.	.	PUNCT
fnp-6382	553	1	ginsberg	ginsberg	PROPN
fnp-6382	553	2	sd	sd	PROPN
fnp-6382	553	3	,	,	PUNCT
fnp-6382	553	4	editor	editor	NOUN
fnp-6382	553	5	.	.	PUNCT
fnp-6382	554	1	plos	plos	PROPN
fnp-6382	554	2	one	one	NUM
fnp-6382	554	3	.	.	PUNCT
fnp-6382	554	4	2017	2017	NUM
fnp-6382	554	5	sep	sep	PROPN
fnp-6382	554	6	26;12(9):e0185541	26;12(9):e0185541	NUM
fnp-6382	554	7	.	.	PUNCT
fnp-6382	555	1	https://doi.org/10.1371/journal.pone.0185541	https://doi.org/10.1371/journal.pone.0185541	NOUN
fnp-6382	555	2	53	53	NUM
fnp-6382	555	3	.	.	PUNCT
fnp-6382	556	1	leung	leung	PROPN
fnp-6382	556	2	r	r	PROPN
fnp-6382	556	3	,	,	PUNCT
fnp-6382	556	4	proitsi	proitsi	NOUN
fnp-6382	556	5	p	p	NOUN
fnp-6382	556	6	,	,	PUNCT
fnp-6382	556	7	simmons	simmon	NOUN
fnp-6382	556	8	a	a	PRON
fnp-6382	556	9	,	,	PUNCT
fnp-6382	556	10	lunnon	lunnon	PROPN
fnp-6382	556	11	k	k	NOUN
fnp-6382	556	12	,	,	PUNCT
fnp-6382	556	13	güntert	güntert	VERB
fnp-6382	556	14	a	a	PRON
fnp-6382	556	15	,	,	PUNCT
fnp-6382	556	16	kronenberg	kronenberg	PROPN
fnp-6382	556	17	d	d	PROPN
fnp-6382	556	18	,	,	PUNCT
fnp-6382	556	19	et	et	PROPN
fnp-6382	556	20	al	al	PROPN
fnp-6382	556	21	.	.	PUNCT
fnp-6382	557	1	inflammatory	inflammatory	ADJ
fnp-6382	557	2	proteins	protein	NOUN
fnp-6382	557	3	in	in	ADP
fnp-6382	557	4	plasma	plasma	NOUN
fnp-6382	557	5	are	be	AUX
fnp-6382	557	6	associated	associate	VERB
fnp-6382	557	7	with	with	ADP
fnp-6382	557	8	severity	severity	NOUN
fnp-6382	557	9	of	of	ADP
fnp-6382	557	10	alzheimer	alzheimer	PROPN
fnp-6382	557	11	's	's	PART
fnp-6382	557	12	disease	disease	NOUN
fnp-6382	557	13	.	.	PUNCT
fnp-6382	558	1	bush	bush	PROPN
fnp-6382	558	2	ai	ai	VERB
fnp-6382	558	3	,	,	PUNCT
fnp-6382	558	4	editor	editor	NOUN
fnp-6382	558	5	.	.	PUNCT
fnp-6382	559	1	plos	plos	PROPN
fnp-6382	559	2	one	one	NUM
fnp-6382	559	3	.	.	PUNCT
fnp-6382	560	1	2013	2013	NUM
fnp-6382	560	2	jun	jun	PROPN
fnp-6382	560	3	10;8(6):e64971	10;8(6):e64971	NUM
fnp-6382	560	4	.	.	PUNCT
fnp-6382	561	1	https://doi.org/10.1371/journal.pone.0064971	https://doi.org/10.1371/journal.pone.0064971	NOUN
fnp-6382	561	2	54	54	NUM
fnp-6382	561	3	.	.	PUNCT
fnp-6382	562	1	huibregtse	huibregtse	VERB
fnp-6382	562	2	me	i	PRON
fnp-6382	562	3	,	,	PUNCT
fnp-6382	562	4	ejima	ejima	PROPN
fnp-6382	562	5	k	k	PROPN
fnp-6382	562	6	,	,	PUNCT
fnp-6382	563	1	chen	chen	PROPN
fnp-6382	563	2	z	z	PROPN
fnp-6382	563	3	,	,	PUNCT
fnp-6382	563	4	kalbfell	kalbfell	PROPN
fnp-6382	563	5	rm	rm	PROPN
fnp-6382	563	6	,	,	PUNCT
fnp-6382	563	7	koppineni	koppineni	PROPN
fnp-6382	563	8	a	a	PRON
fnp-6382	563	9	,	,	PUNCT
fnp-6382	563	10	kawata	kawata	PROPN
fnp-6382	563	11	k.	k.	PROPN
fnp-6382	563	12	acute	acute	PROPN
fnp-6382	563	13	time	time	NOUN
fnp-6382	563	14	-	-	PUNCT
fnp-6382	563	15	course	course	NOUN
fnp-6382	563	16	changes	change	NOUN
fnp-6382	563	17	in	in	ADP
fnp-6382	563	18	ccl11	ccl11	PROPN
fnp-6382	563	19	,	,	PUNCT
fnp-6382	563	20	ccl2	ccl2	PROPN
fnp-6382	563	21	,	,	PUNCT
fnp-6382	563	22	and	and	CCONJ
fnp-6382	563	23	il-10	il-10	NOUN
fnp-6382	563	24	levels	level	NOUN
fnp-6382	563	25	after	after	ADP
fnp-6382	563	26	controlled	control	VERB
fnp-6382	563	27	subconcussive	subconcussive	ADJ
fnp-6382	563	28	head	head	NOUN
fnp-6382	563	29	impacts	impact	NOUN
fnp-6382	563	30	:	:	PUNCT
fnp-6382	563	31	a	a	DET
fnp-6382	563	32	pilot	pilot	NOUN
fnp-6382	563	33	randomized	randomize	VERB
fnp-6382	563	34	clinical	clinical	ADJ
fnp-6382	563	35	trial	trial	NOUN
fnp-6382	563	36	.	.	PUNCT
fnp-6382	564	1	j	j	PROPN
fnp-6382	564	2	head	head	NOUN
fnp-6382	564	3	trauma	trauma	NOUN
fnp-6382	564	4	rehabil	rehabil	NOUN
fnp-6382	564	5	.	.	PUNCT
fnp-6382	565	1	2020	2020	NUM
fnp-6382	565	2	sep;35(5):308	sep;35(5):308	NOUN
fnp-6382	565	3	-	-	SYM
fnp-6382	565	4	16	16	NUM
fnp-6382	565	5	.	.	PUNCT
fnp-6382	566	1	https://doi.org/10.1097/htr.0000000000000597	https://doi.org/10.1097/htr.0000000000000597	PROPN
fnp-6382	566	2	55	55	NUM
fnp-6382	566	3	.	.	PUNCT
fnp-6382	567	1	roy	roy	PROPN
fnp-6382	567	2	-	-	PUNCT
fnp-6382	567	3	o'reilly	o'reilly	NOUN
fnp-6382	567	4	m	m	PROPN
fnp-6382	567	5	,	,	PUNCT
fnp-6382	567	6	ritzel	ritzel	PROPN
fnp-6382	567	7	rm	rm	PROPN
fnp-6382	567	8	,	,	PUNCT
fnp-6382	567	9	conway	conway	PROPN
fnp-6382	567	10	se	se	PROPN
fnp-6382	567	11	,	,	PUNCT
fnp-6382	567	12	staff	staff	NOUN
fnp-6382	567	13	i	i	PRON
fnp-6382	567	14	,	,	PUNCT
fnp-6382	567	15	fortunato	fortunato	PROPN
fnp-6382	567	16	g	g	PROPN
fnp-6382	567	17	,	,	PUNCT
fnp-6382	567	18	mccullough	mccullough	PROPN
fnp-6382	567	19	ld	ld	PROPN
fnp-6382	567	20	.	.	PUNCT
fnp-6382	568	1	ccl11	ccl11	PROPN
fnp-6382	568	2	(	(	PUNCT
fnp-6382	568	3	eotaxin-1	eotaxin-1	PROPN
fnp-6382	568	4	)	)	PUNCT
fnp-6382	568	5	levels	level	NOUN
fnp-6382	568	6	predict	predict	VERB
fnp-6382	568	7	long	long	ADJ
fnp-6382	568	8	-	-	PUNCT
fnp-6382	568	9	term	term	NOUN
fnp-6382	568	10	functional	functional	ADJ
fnp-6382	568	11	outcomes	outcome	NOUN
fnp-6382	568	12	in	in	ADP
fnp-6382	568	13	patients	patient	NOUN
fnp-6382	568	14	following	follow	VERB
fnp-6382	568	15	ischemic	ischemic	ADJ
fnp-6382	568	16	stroke	stroke	NOUN
fnp-6382	568	17	.	.	PUNCT
fnp-6382	569	1	transl	transl	PROPN
fnp-6382	569	2	stroke	stroke	PROPN
fnp-6382	569	3	res	re	NOUN
fnp-6382	569	4	.	.	PUNCT
fnp-6382	569	5	2017	2017	NUM
fnp-6382	569	6	dec;8(6):578	dec;8(6):578	NOUN
fnp-6382	569	7	-	-	SYM
fnp-6382	569	8	84	84	NUM
fnp-6382	569	9	.	.	PUNCT
fnp-6382	570	1	https://doi.org/10.1007/s12975-017-0545-3	https://doi.org/10.1007/s12975-017-0545-3	PROPN
fnp-6382	570	2	56	56	NUM
fnp-6382	570	3	.	.	PUNCT
fnp-6382	571	1	leung	leung	PROPN
fnp-6382	571	2	r	r	PROPN
fnp-6382	571	3	,	,	PUNCT
fnp-6382	571	4	proitsi	proitsi	NOUN
fnp-6382	571	5	p	p	NOUN
fnp-6382	571	6	,	,	PUNCT
fnp-6382	571	7	simmons	simmon	NOUN
fnp-6382	571	8	a	a	PRON
fnp-6382	571	9	,	,	PUNCT
fnp-6382	571	10	lunnon	lunnon	PROPN
fnp-6382	571	11	k	k	NOUN
fnp-6382	571	12	,	,	PUNCT
fnp-6382	571	13	güntert	güntert	VERB
fnp-6382	571	14	a	a	PRON
fnp-6382	571	15	,	,	PUNCT
fnp-6382	571	16	kronenberg	kronenberg	PROPN
fnp-6382	571	17	d	d	PROPN
fnp-6382	571	18	,	,	PUNCT
fnp-6382	571	19	et	et	PROPN
fnp-6382	571	20	al	al	PROPN
fnp-6382	571	21	.	.	PUNCT
fnp-6382	572	1	inflammatory	inflammatory	ADJ
fnp-6382	572	2	proteins	protein	NOUN
fnp-6382	572	3	in	in	ADP
fnp-6382	572	4	plasma	plasma	NOUN
fnp-6382	572	5	are	be	AUX
fnp-6382	572	6	associated	associate	VERB
fnp-6382	572	7	with	with	ADP
fnp-6382	572	8	severity	severity	NOUN
fnp-6382	572	9	of	of	ADP
fnp-6382	572	10	alzheimer	alzheimer	PROPN
fnp-6382	572	11	's	's	PART
fnp-6382	572	12	disease	disease	NOUN
fnp-6382	572	13	.	.	PUNCT
fnp-6382	573	1	bush	bush	PROPN
fnp-6382	573	2	ai	ai	VERB
fnp-6382	573	3	,	,	PUNCT
fnp-6382	573	4	editor	editor	NOUN
fnp-6382	573	5	.	.	PUNCT
fnp-6382	574	1	plos	plos	PROPN
fnp-6382	574	2	one	one	NUM
fnp-6382	574	3	.	.	PUNCT
fnp-6382	575	1	2013	2013	NUM
fnp-6382	575	2	jun	jun	PROPN
fnp-6382	575	3	10;8(6):e64971	10;8(6):e64971	NUM
fnp-6382	575	4	.	.	PUNCT
fnp-6382	576	1	https://doi.org/10.1371/journal.pone.0064971	https://doi.org/10.1371/journal.pone.0064971	PROPN
fnp-6382	576	2	57	57	NUM
fnp-6382	576	3	.	.	PUNCT
fnp-6382	577	1	wild	wild	PROPN
fnp-6382	577	2	e	e	PROPN
fnp-6382	577	3	,	,	PUNCT
fnp-6382	577	4	magnusson	magnusson	PROPN
fnp-6382	577	5	a	a	PROPN
fnp-6382	577	6	,	,	PUNCT
fnp-6382	577	7	lahiri	lahiri	PROPN
fnp-6382	577	8	n	n	CCONJ
fnp-6382	577	9	,	,	PUNCT
fnp-6382	577	10	krus	krus	PROPN
fnp-6382	577	11	u	u	PROPN
fnp-6382	577	12	,	,	PUNCT
fnp-6382	577	13	orth	orth	PROPN
fnp-6382	577	14	m	m	PROPN
fnp-6382	577	15	,	,	PUNCT
fnp-6382	577	16	tabrizi	tabrizi	NOUN
fnp-6382	577	17	sj	sj	NOUN
fnp-6382	577	18	,	,	PUNCT
fnp-6382	577	19	et	et	PROPN
fnp-6382	577	20	al	al	PROPN
fnp-6382	577	21	.	.	PROPN
fnp-6382	577	22	abnormal	abnormal	ADJ
fnp-6382	577	23	peripheral	peripheral	ADJ
fnp-6382	577	24	chemokine	chemokine	ADJ
fnp-6382	577	25	profile	profile	NOUN
fnp-6382	577	26	in	in	ADP
fnp-6382	577	27	huntington	huntington	PROPN
fnp-6382	577	28	's	's	PART
fnp-6382	577	29	disease	disease	NOUN
fnp-6382	577	30	.	.	PUNCT
fnp-6382	578	1	plos	plos	PROPN
fnp-6382	578	2	curr	curr	PROPN
fnp-6382	578	3	.	.	PROPN
fnp-6382	579	1	2011	2011	NUM
fnp-6382	579	2	apr	apr	NOUN
fnp-6382	579	3	13;3	13;3	NUM
fnp-6382	579	4	:	:	PUNCT
fnp-6382	579	5	rrn1231	rrn1231	ADJ
fnp-6382	579	6	.	.	PUNCT
fnp-6382	580	1	https://doi.org/10.1371/currents.rrn1231	https://doi.org/10.1371/currents.rrn1231	PROPN
fnp-6382	580	2	58	58	NUM
fnp-6382	580	3	.	.	PUNCT
fnp-6382	581	1	villeda	villeda	PROPN
fnp-6382	581	2	sa	sa	PROPN
fnp-6382	581	3	,	,	PUNCT
fnp-6382	581	4	luo	luo	PROPN
fnp-6382	581	5	j	j	PROPN
fnp-6382	581	6	,	,	PUNCT
fnp-6382	581	7	mosher	mosher	PROPN
fnp-6382	581	8	ki	ki	PROPN
fnp-6382	581	9	,	,	PUNCT
fnp-6382	581	10	zou	zou	PROPN
fnp-6382	581	11	b	b	PROPN
fnp-6382	581	12	,	,	PUNCT
fnp-6382	581	13	britschgi	britschgi	PROPN
fnp-6382	581	14	m	m	PROPN
fnp-6382	581	15	,	,	PUNCT
fnp-6382	581	16	bieri	bieri	ADJ
fnp-6382	581	17	g	g	PROPN
fnp-6382	581	18	,	,	PUNCT
fnp-6382	581	19	et	et	PROPN
fnp-6382	581	20	al	al	PROPN
fnp-6382	581	21	.	.	PUNCT
fnp-6382	582	1	the	the	DET
fnp-6382	582	2	ageing	age	VERB
fnp-6382	582	3	systemic	systemic	ADJ
fnp-6382	582	4	milieu	milieu	NOUN
fnp-6382	582	5	negatively	negatively	ADV
fnp-6382	582	6	regulates	regulate	VERB
fnp-6382	582	7	neurogenesis	neurogenesis	NOUN
fnp-6382	582	8	and	and	CCONJ
fnp-6382	582	9	cognitive	cognitive	ADJ
fnp-6382	582	10	function	function	NOUN
fnp-6382	582	11	.	.	PUNCT
fnp-6382	583	1	nature	nature	NOUN
fnp-6382	583	2	.	.	PUNCT
fnp-6382	584	1	2011	2011	NUM
fnp-6382	584	2	sep;477(7362):90	sep;477(7362):90	NOUN
fnp-6382	584	3	-	-	PUNCT
fnp-6382	584	4	4	4	NUM
fnp-6382	584	5	.	.	PUNCT
fnp-6382	584	6	https://doi.org/10.1038/nature10357	https://doi.org/10.1038/nature10357	PROPN
fnp-6382	584	7	59	59	NUM
fnp-6382	584	8	.	.	PUNCT
fnp-6382	584	9	vig	vig	PROPN
fnp-6382	584	10	v	v	PROPN
fnp-6382	584	11	,	,	PUNCT
fnp-6382	584	12	garg	garg	PROPN
fnp-6382	584	13	i	i	PRON
fnp-6382	584	14	,	,	PUNCT
fnp-6382	584	15	tuz	tuz	PROPN
fnp-6382	584	16	-	-	PUNCT
fnp-6382	584	17	zahra	zahra	PROPN
fnp-6382	584	18	f	f	PROPN
fnp-6382	584	19	,	,	PUNCT
fnp-6382	584	20	xu	xu	PROPN
fnp-6382	584	21	j	j	PROPN
fnp-6382	584	22	,	,	PUNCT
fnp-6382	584	23	tripodis	tripodis	VERB
fnp-6382	584	24	y	y	PROPN
fnp-6382	584	25	,	,	PUNCT
fnp-6382	584	26	nicks	nicks	PROPN
fnp-6382	584	27	r	r	NOUN
fnp-6382	584	28	,	,	PUNCT
fnp-6382	584	29	et	et	PROPN
fnp-6382	584	30	al	al	PROPN
fnp-6382	584	31	.	.	PROPN
fnp-6382	585	1	vitreous	vitreous	ADJ
fnp-6382	585	2	humor	humor	NOUN
fnp-6382	585	3	biomarkers	biomarker	NOUN
fnp-6382	585	4	reflect	reflect	VERB
fnp-6382	585	5	pathological	pathological	ADJ
fnp-6382	585	6	changes	change	NOUN
fnp-6382	585	7	in	in	ADP
fnp-6382	585	8	the	the	DET
fnp-6382	585	9	brain	brain	NOUN
fnp-6382	585	10	for	for	ADP
fnp-6382	585	11	alzheimer	alzheimer	PROPN
fnp-6382	585	12	's	's	PART
fnp-6382	585	13	disease	disease	NOUN
fnp-6382	585	14	and	and	CCONJ
fnp-6382	585	15	chronic	chronic	ADJ
fnp-6382	585	16	traumatic	traumatic	ADJ
fnp-6382	585	17	encephalopathy	encephalopathy	NOUN
fnp-6382	585	18	.	.	PUNCT
fnp-6382	586	1	j	j	PROPN
fnp-6382	586	2	alzheimers	alzheimers	PROPN
fnp-6382	586	3	dis	dis	PROPN
fnp-6382	586	4	.	.	PUNCT
fnp-6382	587	1	2023	2023	NUM
fnp-6382	587	2	may	may	AUX
fnp-6382	587	3	30;93(3):1181	30;93(3):1181	NUM
fnp-6382	587	4	-	-	SYM
fnp-6382	587	5	93	93	NUM
fnp-6382	587	6	.	.	PUNCT
fnp-6382	588	1	https://doi.org/10.3233/jad-230167	https://doi.org/10.3233/jad-230167	PROPN
fnp-6382	589	1	60	60	NUM
fnp-6382	589	2	.	.	PUNCT
fnp-6382	590	1	li	li	PROPN
fnp-6382	590	2	y	y	PROPN
fnp-6382	590	3	,	,	PUNCT
fnp-6382	590	4	cao	cao	PROPN
fnp-6382	590	5	t	t	PROPN
fnp-6382	590	6	,	,	PUNCT
fnp-6382	590	7	ritzel	ritzel	PROPN
fnp-6382	590	8	rm	rm	PROPN
fnp-6382	590	9	,	,	PUNCT
fnp-6382	590	10	he	he	PRON
fnp-6382	590	11	j	j	PROPN
fnp-6382	590	12	,	,	PUNCT
fnp-6382	590	13	faden	faden	PROPN
fnp-6382	590	14	ai	ai	VERB
fnp-6382	590	15	,	,	PUNCT
fnp-6382	590	16	wu	wu	PROPN
fnp-6382	590	17	j.	j.	PROPN
fnp-6382	590	18	dementia	dementia	PROPN
fnp-6382	590	19	,	,	PUNCT
fnp-6382	590	20	depression	depression	NOUN
fnp-6382	590	21	,	,	PUNCT
fnp-6382	590	22	and	and	CCONJ
fnp-6382	590	23	associated	associated	ADJ
fnp-6382	590	24	brain	brain	NOUN
fnp-6382	590	25	inflammatory	inflammatory	ADJ
fnp-6382	590	26	mechanisms	mechanism	NOUN
fnp-6382	590	27	after	after	ADP
fnp-6382	590	28	spinal	spinal	PROPN
fnp-6382	590	29	cord	cord	NOUN
fnp-6382	590	30	injury	injury	NOUN
fnp-6382	590	31	.	.	PUNCT
fnp-6382	591	1	cells	cell	NOUN
fnp-6382	591	2	.	.	PUNCT
fnp-6382	592	1	2020	2020	NUM
fnp-6382	592	2	jun	jun	PROPN
fnp-6382	592	3	8;9(6):1420	8;9(6):1420	NUM
fnp-6382	592	4	.	.	PUNCT
fnp-6382	593	1	https://doi.org/10.3390/cells9061420	https://doi.org/10.3390/cells9061420	PROPN
fnp-6382	593	2	61	61	NUM
fnp-6382	593	3	.	.	PUNCT
fnp-6382	594	1	zhao	zhao	PROPN
fnp-6382	594	2	p	p	PROPN
fnp-6382	594	3	,	,	PUNCT
fnp-6382	594	4	waxman	waxman	PROPN
fnp-6382	594	5	sg	sg	PROPN
fnp-6382	594	6	,	,	PUNCT
fnp-6382	594	7	hains	hain	NOUN
fnp-6382	594	8	bc	bc	PROPN
fnp-6382	594	9	.	.	PROPN
fnp-6382	594	10	modulation	modulation	NOUN
fnp-6382	594	11	of	of	ADP
fnp-6382	594	12	thalamic	thalamic	ADJ
fnp-6382	594	13	nociceptive	nociceptive	ADJ
fnp-6382	594	14	processing	processing	NOUN
fnp-6382	594	15	after	after	ADP
fnp-6382	594	16	spinal	spinal	PROPN
fnp-6382	594	17	cord	cord	NOUN
fnp-6382	594	18	injury	injury	NOUN
fnp-6382	594	19	through	through	ADP
fnp-6382	594	20	remote	remote	ADJ
fnp-6382	594	21	activation	activation	NOUN
fnp-6382	594	22	of	of	ADP
fnp-6382	594	23	thalamic	thalamic	ADJ
fnp-6382	594	24	microglia	microglia	NOUN
fnp-6382	594	25	by	by	ADP
fnp-6382	594	26	cysteine	cysteine	NOUN
fnp-6382	594	27	-	-	PUNCT
fnp-6382	594	28	cysteine	cysteine	NOUN
fnp-6382	594	29	chemokine	chemokine	ADJ
fnp-6382	594	30	ligand	ligand	NOUN
fnp-6382	594	31	21	21	NUM
fnp-6382	594	32	.	.	PUNCT
fnp-6382	595	1	j	j	PROPN
fnp-6382	595	2	neurosci	neurosci	PROPN
fnp-6382	595	3	.	.	PUNCT
fnp-6382	596	1	2007	2007	NUM
fnp-6382	596	2	aug	aug	PROPN
fnp-6382	596	3	15;27(33):8893	15;27(33):8893	NUM
fnp-6382	596	4	-	-	SYM
fnp-6382	596	5	902	902	NUM
fnp-6382	596	6	.	.	PUNCT
fnp-6382	597	1	https://doi.org/10.1523/jneurosci.2209-07.2007	https://doi.org/10.1523/jneurosci.2209-07.2007	VERB
fnp-6382	597	2	62	62	NUM
fnp-6382	597	3	.	.	PUNCT
fnp-6382	598	1	wu	wu	PROPN
fnp-6382	598	2	j	j	PROPN
fnp-6382	598	3	,	,	PUNCT
fnp-6382	598	4	zhao	zhao	PROPN
fnp-6382	598	5	z	z	PROPN
fnp-6382	598	6	,	,	PUNCT
fnp-6382	598	7	sabirzhanov	sabirzhanov	NOUN
fnp-6382	598	8	b	b	NUM
fnp-6382	598	9	,	,	PUNCT
fnp-6382	598	10	stoica	stoica	PROPN
fnp-6382	598	11	ba	ba	PROPN
fnp-6382	598	12	,	,	PUNCT
fnp-6382	598	13	kumar	kumar	PROPN
fnp-6382	598	14	a	a	PROPN
fnp-6382	598	15	,	,	PUNCT
fnp-6382	598	16	luo	luo	PROPN
fnp-6382	598	17	t	t	PROPN
fnp-6382	598	18	,	,	PUNCT
fnp-6382	598	19	et	et	PROPN
fnp-6382	598	20	al	al	PROPN
fnp-6382	598	21	.	.	PUNCT
fnp-6382	599	1	spinal	spinal	PROPN
fnp-6382	599	2	cord	cord	NOUN
fnp-6382	599	3	injury	injury	NOUN
fnp-6382	599	4	causes	cause	VERB
fnp-6382	599	5	brain	brain	NOUN
fnp-6382	599	6	inflammation	inflammation	NOUN
fnp-6382	599	7	associated	associate	VERB
fnp-6382	599	8	with	with	ADP
fnp-6382	599	9	cognitive	cognitive	ADJ
fnp-6382	599	10	and	and	CCONJ
fnp-6382	599	11	affective	affective	ADJ
fnp-6382	599	12	changes	change	NOUN
fnp-6382	599	13	:	:	PUNCT
fnp-6382	599	14	role	role	NOUN
fnp-6382	599	15	of	of	ADP
fnp-6382	599	16	cell	cell	NOUN
fnp-6382	599	17	cycle	cycle	NOUN
fnp-6382	599	18	pathways	pathway	NOUN
fnp-6382	599	19	.	.	PUNCT
fnp-6382	600	1	j	j	PROPN
fnp-6382	600	2	neurosci	neurosci	PROPN
fnp-6382	600	3	.	.	PUNCT
fnp-6382	601	1	2014	2014	NUM
fnp-6382	601	2	aug	aug	PROPN
fnp-6382	601	3	13;34(33):10989	13;34(33):10989	NUM
fnp-6382	601	4	-	-	SYM
fnp-6382	601	5	1006	1006	NUM
fnp-6382	601	6	.	.	PUNCT
fnp-6382	602	1	https://doi.org/10.1523/jneurosci.5110-13.2014	https://doi.org/10.1523/jneurosci.5110-13.2014	PROPN
fnp-6382	602	2	63	63	NUM
fnp-6382	602	3	.	.	PUNCT
fnp-6382	603	1	chen	chen	PROPN
fnp-6382	603	2	y	y	PROPN
fnp-6382	603	3	,	,	PUNCT
fnp-6382	603	4	liang	liang	PROPN
fnp-6382	603	5	l	l	PROPN
fnp-6382	603	6	,	,	PUNCT
fnp-6382	603	7	cao	cao	PROPN
fnp-6382	603	8	s	s	PROPN
fnp-6382	603	9	,	,	PUNCT
fnp-6382	603	10	hou	hou	PROPN
fnp-6382	603	11	g	g	PROPN
fnp-6382	603	12	,	,	PUNCT
fnp-6382	603	13	zhang	zhang	PROPN
fnp-6382	603	14	q	q	PROPN
fnp-6382	603	15	,	,	PUNCT
fnp-6382	603	16	ma	ma	PROPN
fnp-6382	603	17	h	h	PROPN
fnp-6382	603	18	,	,	PUNCT
fnp-6382	603	19	et	et	PROPN
fnp-6382	603	20	al	al	PROPN
fnp-6382	603	21	.	.	PROPN
fnp-6382	603	22	serum	serum	PROPN
fnp-6382	603	23	ccl21	ccl21	PROPN
fnp-6382	603	24	as	as	ADP
fnp-6382	603	25	a	a	DET
fnp-6382	603	26	potential	potential	ADJ
fnp-6382	603	27	biomarker	biomarker	NOUN
fnp-6382	603	28	for	for	ADP
fnp-6382	603	29	cognitive	cognitive	ADJ
fnp-6382	603	30	impairment	impairment	NOUN
fnp-6382	603	31	in	in	ADP
fnp-6382	603	32	spinal	spinal	ADJ
fnp-6382	603	33	cord	cord	NOUN
fnp-6382	603	34	injury	injury	NOUN
fnp-6382	603	35	.	.	PUNCT
fnp-6382	604	1	xu	xu	PROPN
fnp-6382	605	1	y	y	PROPN
fnp-6382	605	2	,	,	PUNCT
fnp-6382	605	3	editor	editor	NOUN
fnp-6382	605	4	.	.	PUNCT
fnp-6382	605	5	biomed	biome	VERB
fnp-6382	605	6	res	re	NOUN
fnp-6382	605	7	int	int	NOUN
fnp-6382	605	8	.	.	PUNCT
fnp-6382	606	1	2020	2020	NUM
fnp-6382	606	2	jan;2020(1):6692802	jan;2020(1):6692802	PROPN
fnp-6382	606	3	.	.	PUNCT
fnp-6382	607	1	https://doi.org/10.1155/2020/6692802	https://doi.org/10.1155/2020/6692802	ADJ
fnp-6382	607	2	64	64	NUM
fnp-6382	607	3	.	.	PUNCT
fnp-6382	608	1	uciechowski	uciechowski	PROPN
fnp-6382	608	2	p	p	X
fnp-6382	608	3	,	,	PUNCT
fnp-6382	608	4	dempke	dempke	ADJ
fnp-6382	608	5	wcm	wcm	NOUN
fnp-6382	608	6	.	.	PUNCT
fnp-6382	609	1	interleukin-6	interleukin-6	NOUN
fnp-6382	609	2	:	:	PUNCT
fnp-6382	609	3	a	a	DET
fnp-6382	609	4	masterplayer	masterplayer	NOUN
fnp-6382	609	5	in	in	ADP
fnp-6382	609	6	the	the	DET
fnp-6382	609	7	cytokine	cytokine	NOUN
fnp-6382	609	8	network	network	NOUN
fnp-6382	609	9	.	.	PUNCT
fnp-6382	610	1	oncology	oncology	NOUN
fnp-6382	610	2	.	.	PUNCT
fnp-6382	611	1	2020;98(3):131	2020;98(3):131	NUM
fnp-6382	611	2	-	-	SYM
fnp-6382	611	3	7	7	NUM
fnp-6382	611	4	.	.	PUNCT
fnp-6382	611	5	https://doi.org/10.1159/000505099	https://doi.org/10.1159/000505099	NOUN
fnp-6382	611	6	65	65	NUM
fnp-6382	611	7	.	.	PUNCT
fnp-6382	612	1	yang	yang	PROPN
fnp-6382	612	2	sh	sh	PROPN
fnp-6382	612	3	,	,	PUNCT
fnp-6382	612	4	gangidine	gangidine	PROPN
fnp-6382	612	5	m	m	PROPN
fnp-6382	612	6	,	,	PUNCT
fnp-6382	612	7	pritts	pritts	PROPN
fnp-6382	612	8	ta	ta	PROPN
fnp-6382	612	9	,	,	PUNCT
fnp-6382	612	10	goodman	goodman	PROPN
fnp-6382	612	11	md	md	PROPN
fnp-6382	612	12	,	,	PUNCT
fnp-6382	612	13	lentsch	lentsch	PROPN
fnp-6382	612	14	ab	ab	PROPN
fnp-6382	612	15	.	.	PUNCT
fnp-6382	613	1	interleukin	interleukin	NOUN
fnp-6382	613	2	6	6	NUM
fnp-6382	613	3	mediates	mediate	NOUN
fnp-6382	613	4	neuroinflammation	neuroinflammation	NOUN
fnp-6382	613	5	and	and	CCONJ
fnp-6382	613	6	motor	motor	NOUN
fnp-6382	613	7	coordination	coordination	NOUN
fnp-6382	613	8	deficits	deficit	NOUN
fnp-6382	613	9	after	after	ADP
fnp-6382	613	10	mild	mild	ADJ
fnp-6382	613	11	traumatic	traumatic	ADJ
fnp-6382	613	12	brain	brain	NOUN
fnp-6382	613	13	injury	injury	NOUN
fnp-6382	613	14	and	and	CCONJ
fnp-6382	613	15	brief	brief	ADJ
fnp-6382	613	16	hypoxia	hypoxia	NOUN
fnp-6382	613	17	in	in	ADP
fnp-6382	613	18	mice	mouse	NOUN
fnp-6382	613	19	.	.	PUNCT
fnp-6382	614	1	shock	shock	NOUN
fnp-6382	614	2	.	.	PUNCT
fnp-6382	615	1	2013	2013	NUM
fnp-6382	615	2	dec;40(6):471	dec;40(6):471	NOUN
fnp-6382	615	3	-	-	SYM
fnp-6382	615	4	5	5	NUM
fnp-6382	615	5	.	.	PUNCT
fnp-6382	615	6	https://doi.org/10.1097/shk.0000000000000037	https://doi.org/10.1097/shk.0000000000000037	PROPN
fnp-6382	615	7	66	66	NUM
fnp-6382	615	8	.	.	PUNCT
fnp-6382	616	1	van	van	PROPN
fnp-6382	616	2	amerongen	amerongen	PROPN
fnp-6382	616	3	s	s	PART
fnp-6382	616	4	,	,	PUNCT
fnp-6382	616	5	pulukuri	pulukuri	PROPN
fnp-6382	616	6	sv	sv	PROPN
fnp-6382	616	7	,	,	PUNCT
fnp-6382	616	8	tuz	tuz	PROPN
fnp-6382	616	9	-	-	PUNCT
fnp-6382	616	10	zahra	zahra	PROPN
fnp-6382	616	11	f	f	PROPN
fnp-6382	616	12	,	,	PUNCT
fnp-6382	616	13	tripodis	tripodis	PROPN
fnp-6382	616	14	y	y	PROPN
fnp-6382	616	15	,	,	PUNCT
fnp-6382	616	16	cherry	cherry	PROPN
fnp-6382	616	17	jd	jd	PROPN
fnp-6382	616	18	,	,	PUNCT
fnp-6382	616	19	bernick	bernick	PROPN
fnp-6382	616	20	c	c	PROPN
fnp-6382	616	21	,	,	PUNCT
fnp-6382	616	22	et	et	PROPN
fnp-6382	616	23	al	al	PROPN
fnp-6382	616	24	.	.	PUNCT
fnp-6382	616	25	inflammatory	inflammatory	ADJ
fnp-6382	616	26	biomarkers	biomarker	NOUN
fnp-6382	616	27	for	for	ADP
fnp-6382	616	28	neurobehavioral	neurobehavioral	ADJ
fnp-6382	616	29	dysregulation	dysregulation	NOUN
fnp-6382	616	30	in	in	ADP
fnp-6382	616	31	former	former	ADJ
fnp-6382	616	32	american	american	ADJ
fnp-6382	616	33	football	football	NOUN
fnp-6382	616	34	players	player	NOUN
fnp-6382	616	35	:	:	PUNCT
fnp-6382	616	36	findings	finding	NOUN
fnp-6382	616	37	from	from	ADP
fnp-6382	616	38	the	the	DET
fnp-6382	616	39	diagnose	diagnose	NOUN
fnp-6382	616	40	cte	cte	NOUN
fnp-6382	616	41	research	research	NOUN
fnp-6382	616	42	project	project	NOUN
fnp-6382	616	43	.	.	PUNCT
fnp-6382	617	1	j	j	PROPN
fnp-6382	617	2	neuroinflammation	neuroinflammation	PROPN
fnp-6382	617	3	.	.	PUNCT
fnp-6382	618	1	2024	2024	NUM
fnp-6382	618	2	feb	feb	X
fnp-6382	618	3	9;21(1):46	9;21(1):46	NUM
fnp-6382	618	4	.	.	PUNCT
fnp-6382	619	1	https://doi.org/10.1186/s12974-024-03034-6	https://doi.org/10.1186/s12974-024-03034-6	NOUN
fnp-6382	620	1	67	67	NUM
fnp-6382	620	2	.	.	PUNCT
fnp-6382	621	1	nitta	nitta	PROPN
fnp-6382	621	2	me	i	PRON
fnp-6382	621	3	,	,	PUNCT
fnp-6382	621	4	savitz	savitz	PROPN
fnp-6382	621	5	j	j	PROPN
fnp-6382	621	6	,	,	PUNCT
fnp-6382	621	7	nelson	nelson	PROPN
fnp-6382	621	8	ld	ld	PROPN
fnp-6382	621	9	,	,	PUNCT
fnp-6382	621	10	teague	teague	PROPN
fnp-6382	621	11	tk	tk	PROPN
fnp-6382	621	12	,	,	PUNCT
fnp-6382	621	13	hoelzle	hoelzle	PROPN
fnp-6382	621	14	jb	jb	PROPN
fnp-6382	621	15	,	,	PUNCT
fnp-6382	621	16	mccrea	mccrea	PROPN
fnp-6382	621	17	ma	ma	PROPN
fnp-6382	621	18	,	,	PUNCT
fnp-6382	621	19	et	et	PROPN
fnp-6382	621	20	al	al	PROPN
fnp-6382	621	21	.	.	PROPN
fnp-6382	621	22	acute	acute	PROPN
fnp-6382	621	23	elevation	elevation	NOUN
fnp-6382	621	24	of	of	ADP
fnp-6382	621	25	serum	serum	NOUN
fnp-6382	621	26	inflammatory	inflammatory	ADJ
fnp-6382	621	27	markers	marker	NOUN
fnp-6382	621	28	predicts	predict	VERB
fnp-6382	621	29	symptom	symptom	NOUN
fnp-6382	621	30	recovery	recovery	NOUN
fnp-6382	621	31	after	after	ADP
fnp-6382	621	32	concussion	concussion	NOUN
fnp-6382	621	33	.	.	PUNCT
fnp-6382	622	1	neurology	neurology	NOUN
fnp-6382	623	1	[	[	X
fnp-6382	623	2	internet	internet	NOUN
fnp-6382	623	3	]	]	PUNCT
fnp-6382	623	4	.	.	PUNCT
fnp-6382	624	1	2019	2019	NUM
fnp-6382	624	2	jul	jul	NOUN
fnp-6382	624	3	30	30	NUM
fnp-6382	624	4	[	[	X
fnp-6382	624	5	cited	cite	VERB
fnp-6382	624	6	2025	2025	NUM
fnp-6382	624	7	may	may	PROPN
fnp-6382	624	8	9];93(5	9];93(5	NUM
fnp-6382	624	9	)	)	PUNCT
fnp-6382	624	10	.	.	PUNCT
fnp-6382	625	1	available	available	ADJ
fnp-6382	625	2	from	from	ADP
fnp-6382	625	3	:	:	PUNCT
fnp-6382	625	4	https://doi.org/10.1212/wnl.0000000000007864	https://doi.org/10.1212/wnl.0000000000007864	PROPN
fnp-6382	625	5	68	68	NUM
fnp-6382	625	6	.	.	PUNCT
fnp-6382	626	1	asken	asken	VERB
fnp-6382	626	2	bm	bm	PROPN
fnp-6382	626	3	,	,	PUNCT
fnp-6382	626	4	tanner	tanner	PROPN
fnp-6382	626	5	ja	ja	PROPN
fnp-6382	626	6	,	,	PUNCT
fnp-6382	626	7	gaynor	gaynor	PROPN
fnp-6382	626	8	ls	ls	PROPN
fnp-6382	626	9	,	,	PUNCT
fnp-6382	626	10	vandevrede	vandevrede	PROPN
fnp-6382	626	11	l	l	NOUN
fnp-6382	626	12	,	,	PUNCT
fnp-6382	626	13	mantyh	mantyh	VERB
fnp-6382	626	14	wg	wg	PROPN
fnp-6382	626	15	,	,	PUNCT
fnp-6382	626	16	casaletto	casaletto	PROPN
fnp-6382	626	17	kb	kb	PROPN
fnp-6382	626	18	,	,	PUNCT
fnp-6382	626	19	et	et	PROPN
fnp-6382	626	20	al	al	PROPN
fnp-6382	626	21	.	.	PROPN
fnp-6382	626	22	alzheimer	alzheimer	PROPN
fnp-6382	626	23	's	's	PART
fnp-6382	626	24	pathology	pathology	NOUN
fnp-6382	626	25	is	be	AUX
fnp-6382	626	26	associated	associate	VERB
fnp-6382	626	27	with	with	ADP
fnp-6382	626	28	altered	altered	ADJ
fnp-6382	626	29	cognition	cognition	NOUN
fnp-6382	626	30	,	,	PUNCT
fnp-6382	626	31	brain	brain	NOUN
fnp-6382	626	32	volume	volume	NOUN
fnp-6382	626	33	,	,	PUNCT
fnp-6382	626	34	and	and	CCONJ
fnp-6382	626	35	plasma	plasma	NOUN
fnp-6382	626	36	biomarker	biomarker	NOUN
fnp-6382	626	37	patterns	pattern	NOUN
fnp-6382	626	38	in	in	ADP
fnp-6382	626	39	traumatic	traumatic	ADJ
fnp-6382	626	40	encephalopathy	encephalopathy	ADJ
fnp-6382	626	41	syndrome	syndrome	NOUN
fnp-6382	626	42	.	.	PUNCT
fnp-6382	627	1	alzheimers	alzheimer	NOUN
fnp-6382	627	2	res	re	VERB
fnp-6382	627	3	ther	ther	ADV
fnp-6382	627	4	.	.	PUNCT
fnp-6382	628	1	2023	2023	NUM
fnp-6382	628	2	jul	jul	PROPN
fnp-6382	628	3	21;15(1):126	21;15(1):126	NUM
fnp-6382	628	4	.	.	PUNCT
fnp-6382	629	1	https://doi.org/10.1186/s13195-023-01275-w	https://doi.org/10.1186/s13195-023-01275-w	NOUN
fnp-6382	629	2	69	69	NUM
fnp-6382	629	3	.	.	PUNCT
fnp-6382	630	1	chu	chu	PROPN
fnp-6382	630	2	m	m	PROPN
fnp-6382	630	3	,	,	PUNCT
fnp-6382	630	4	wen	wen	PROPN
fnp-6382	630	5	l	l	PROPN
fnp-6382	630	6	,	,	PUNCT
fnp-6382	630	7	jiang	jiang	PROPN
fnp-6382	630	8	d	d	PROPN
fnp-6382	630	9	,	,	PUNCT
fnp-6382	630	10	liu	liu	PROPN
fnp-6382	630	11	l	l	PROPN
fnp-6382	630	12	,	,	PUNCT
fnp-6382	630	13	nan	nan	PROPN
fnp-6382	630	14	h	h	PROPN
fnp-6382	630	15	,	,	PUNCT
fnp-6382	630	16	yue	yue	PROPN
fnp-6382	630	17	a	a	X
fnp-6382	630	18	,	,	PUNCT
fnp-6382	630	19	et	et	PROPN
fnp-6382	630	20	al	al	PROPN
fnp-6382	630	21	.	.	PROPN
fnp-6382	630	22	peripheral	peripheral	ADJ
fnp-6382	630	23	inflammation	inflammation	NOUN
fnp-6382	630	24	in	in	ADP
fnp-6382	630	25	behavioural	behavioural	ADJ
fnp-6382	630	26	variant	variant	ADJ
fnp-6382	630	27	frontotemporal	frontotemporal	ADJ
fnp-6382	630	28	dementia	dementia	NOUN
fnp-6382	630	29	:	:	PUNCT
fnp-6382	630	30	associations	association	NOUN
fnp-6382	630	31	with	with	ADP
fnp-6382	630	32	central	central	ADJ
fnp-6382	630	33	degeneration	degeneration	NOUN
fnp-6382	630	34	and	and	CCONJ
fnp-6382	630	35	clinical	clinical	ADJ
fnp-6382	630	36	measures	measure	NOUN
fnp-6382	630	37	.	.	PUNCT
fnp-6382	631	1	j	j	PROPN
fnp-6382	631	2	neuroinflammation	neuroinflammation	PROPN
fnp-6382	631	3	.	.	PUNCT
fnp-6382	632	1	2023	2023	NUM
fnp-6382	632	2	mar	mar	PROPN
fnp-6382	632	3	8;20(1):65	8;20(1):65	NUM
fnp-6382	632	4	.	.	PUNCT
fnp-6382	633	1	https://doi.org/10.1186/s12974-023-02746-5	https://doi.org/10.1186/s12974-023-02746-5	PROPN
fnp-6382	633	2	70	70	NUM
fnp-6382	633	3	.	.	PUNCT
fnp-6382	634	1	holmes	holmes	PROPN
fnp-6382	634	2	c	c	PROPN
fnp-6382	634	3	,	,	PUNCT
fnp-6382	634	4	cunningham	cunningham	PROPN
fnp-6382	634	5	c	c	PROPN
fnp-6382	634	6	,	,	PUNCT
fnp-6382	634	7	zotova	zotova	X
fnp-6382	634	8	e	e	X
fnp-6382	634	9	,	,	PUNCT
fnp-6382	634	10	culliford	culliford	PROPN
fnp-6382	634	11	d	d	PROPN
fnp-6382	634	12	,	,	PUNCT
fnp-6382	634	13	perry	perry	PROPN
fnp-6382	634	14	vh	vh	PROPN
fnp-6382	634	15	.	.	PUNCT
fnp-6382	634	16	proinflammatory	proinflammatory	ADJ
fnp-6382	634	17	cytokines	cytokine	NOUN
fnp-6382	634	18	,	,	PUNCT
fnp-6382	634	19	sickness	sickness	NOUN
fnp-6382	634	20	behavior	behavior	NOUN
fnp-6382	634	21	,	,	PUNCT
fnp-6382	634	22	and	and	CCONJ
fnp-6382	634	23	alzheimer	alzheimer	PROPN
fnp-6382	634	24	disease	disease	NOUN
fnp-6382	634	25	.	.	PUNCT
fnp-6382	635	1	neurology	neurology	NOUN
fnp-6382	635	2	.	.	PUNCT
fnp-6382	636	1	2011	2011	NUM
fnp-6382	636	2	jul	jul	PROPN
fnp-6382	636	3	19;77(3):212	19;77(3):212	NUM
fnp-6382	636	4	-	-	SYM
fnp-6382	636	5	8	8	NUM
fnp-6382	636	6	.	.	PUNCT
fnp-6382	637	1	https://doi.org/10.1212/wnl.0b013e318225ae07	https://doi.org/10.1212/wnl.0b013e318225ae07	NOUN
fnp-6382	638	1	71	71	NUM
fnp-6382	638	2	.	.	PUNCT
fnp-6382	639	1	teixeira	teixeira	PROPN
fnp-6382	639	2	al	al	PROPN
fnp-6382	639	3	,	,	PUNCT
fnp-6382	639	4	salem	salem	PROPN
fnp-6382	639	5	h	h	PROPN
fnp-6382	639	6	,	,	PUNCT
fnp-6382	639	7	martins	martin	VERB
fnp-6382	639	8	lb	lb	NUM
fnp-6382	639	9	,	,	PUNCT
fnp-6382	639	10	gonzales	gonzales	PROPN
fnp-6382	639	11	mm	mm	PROPN
fnp-6382	639	12	,	,	PUNCT
fnp-6382	639	13	seshadri	seshadri	PROPN
fnp-6382	639	14	s	s	PART
fnp-6382	639	15	,	,	PUNCT
fnp-6382	639	16	suchting	suchte	VERB
fnp-6382	639	17	r.	r.	NOUN
fnp-6382	639	18	factors	factor	NOUN
fnp-6382	639	19	associated	associate	VERB
fnp-6382	639	20	with	with	ADP
fnp-6382	639	21	apathy	apathy	NOUN
fnp-6382	639	22	in	in	ADP
fnp-6382	639	23	alzheimer	alzheimer	PROPN
fnp-6382	639	24	's	's	PART
fnp-6382	639	25	disease	disease	NOUN
fnp-6382	639	26	:	:	PUNCT
fnp-6382	639	27	a	a	DET
fnp-6382	639	28	cross	cross	ADJ
fnp-6382	639	29	-	-	ADJ
fnp-6382	639	30	sectional	sectional	ADJ
fnp-6382	639	31	analysis	analysis	NOUN
fnp-6382	639	32	of	of	ADP
fnp-6382	639	33	the	the	DET
fnp-6382	639	34	texas	texas	PROPN
fnp-6382	639	35	alzheimer	alzheimer	PROPN
fnp-6382	639	36	's	's	PART
fnp-6382	639	37	research	research	NOUN
fnp-6382	639	38	and	and	CCONJ
fnp-6382	639	39	care	care	NOUN
fnp-6382	639	40	consortium	consortium	NOUN
fnp-6382	639	41	(	(	PUNCT
fnp-6382	639	42	tarcc	tarcc	NOUN
fnp-6382	639	43	)	)	PUNCT
fnp-6382	639	44	study	study	NOUN
fnp-6382	639	45	.	.	PUNCT
fnp-6382	640	1	j	j	PROPN
fnp-6382	640	2	alzheimers	alzheimers	PROPN
fnp-6382	640	3	dis	dis	PROPN
fnp-6382	640	4	.	.	PUNCT
fnp-6382	641	1	2022	2022	NUM
fnp-6382	641	2	mar	mar	PROPN
fnp-6382	641	3	8;86(1):403	8;86(1):403	NOUN
fnp-6382	641	4	-	-	SYM
fnp-6382	641	5	11	11	NUM
fnp-6382	641	6	.	.	PUNCT
fnp-6382	642	1	https://doi.org/10.3233/jad-215314	https://doi.org/10.3233/jad-215314	NUM
fnp-6382	642	2	72	72	NUM
fnp-6382	642	3	.	.	PUNCT
fnp-6382	643	1	goldsmith	goldsmith	PROPN
fnp-6382	643	2	dr	dr	PROPN
fnp-6382	643	3	,	,	PUNCT
fnp-6382	643	4	rapaport	rapaport	PROPN
fnp-6382	643	5	mh	mh	PROPN
fnp-6382	643	6	,	,	PUNCT
fnp-6382	643	7	miller	miller	PROPN
fnp-6382	643	8	bj	bj	PROPN
fnp-6382	643	9	.	.	PUNCT
fnp-6382	644	1	a	a	DET
fnp-6382	644	2	meta	meta	ADJ
fnp-6382	644	3	-	-	PUNCT
fnp-6382	644	4	analysis	analysis	NOUN
fnp-6382	644	5	of	of	ADP
fnp-6382	644	6	blood	blood	NOUN
fnp-6382	644	7	cytokine	cytokine	NOUN
fnp-6382	644	8	network	network	NOUN
fnp-6382	644	9	alterations	alteration	NOUN
fnp-6382	644	10	in	in	ADP
fnp-6382	644	11	psychiatric	psychiatric	ADJ
fnp-6382	644	12	patients	patient	NOUN
fnp-6382	644	13	:	:	PUNCT
fnp-6382	644	14	comparisons	comparison	NOUN
fnp-6382	644	15	between	between	ADP
fnp-6382	644	16	schizophrenia	schizophrenia	NOUN
fnp-6382	644	17	,	,	PUNCT
fnp-6382	644	18	bipolar	bipolar	ADJ
fnp-6382	644	19	disorder	disorder	NOUN
fnp-6382	644	20	and	and	CCONJ
fnp-6382	644	21	depression	depression	NOUN
fnp-6382	644	22	.	.	PUNCT
fnp-6382	645	1	mol	mol	ADP
fnp-6382	645	2	psychiatry	psychiatry	NOUN
fnp-6382	645	3	.	.	PUNCT
fnp-6382	646	1	2016	2016	NUM
fnp-6382	646	2	dec;21(12):1696	dec;21(12):1696	NOUN
fnp-6382	646	3	-	-	PUNCT
fnp-6382	646	4	709	709	NUM
fnp-6382	646	5	.	.	PUNCT
fnp-6382	647	1	https://doi.org/10.1038/mp.2016.3	https://doi.org/10.1038/mp.2016.3	PROPN
fnp-6382	647	2	73	73	NUM
fnp-6382	647	3	.	.	PUNCT
fnp-6382	648	1	parkin	parkin	PROPN
fnp-6382	648	2	gm	gm	PROPN
fnp-6382	648	3	,	,	PUNCT
fnp-6382	648	4	clarke	clarke	PROPN
fnp-6382	648	5	c	c	PROPN
fnp-6382	648	6	,	,	PUNCT
fnp-6382	648	7	takagi	takagi	PROPN
fnp-6382	648	8	m	m	PROPN
fnp-6382	648	9	,	,	PUNCT
fnp-6382	648	10	hearps	hearps	PROPN
fnp-6382	648	11	s	s	NOUN
fnp-6382	648	12	,	,	PUNCT
fnp-6382	648	13	babl	babl	PROPN
fnp-6382	648	14	fe	fe	PROPN
fnp-6382	648	15	,	,	PUNCT
fnp-6382	648	16	davis	davis	PROPN
fnp-6382	648	17	ga	ga	PROPN
fnp-6382	648	18	,	,	PUNCT
fnp-6382	648	19	et	et	PROPN
fnp-6382	648	20	al	al	PROPN
fnp-6382	648	21	.	.	PUNCT
fnp-6382	648	22	plasma	plasma	PROPN
fnp-6382	648	23	tumor	tumor	NOUN
fnp-6382	648	24	necrosis	necrosis	NOUN
fnp-6382	648	25	factor	factor	NOUN
fnp-6382	648	26	alpha	alpha	NOUN
fnp-6382	648	27	is	be	AUX
fnp-6382	648	28	a	a	DET
fnp-6382	648	29	predictor	predictor	NOUN
fnp-6382	648	30	of	of	ADP
fnp-6382	648	31	persisting	persist	VERB
fnp-6382	648	32	symptoms	symptom	NOUN
fnp-6382	648	33	post	post	NOUN
fnp-6382	648	34	-	-	NOUN
fnp-6382	648	35	concussion	concussion	NOUN
fnp-6382	648	36	in	in	ADP
fnp-6382	648	37	children	child	NOUN
fnp-6382	648	38	.	.	PUNCT
fnp-6382	649	1	j	j	PROPN
fnp-6382	649	2	neurotrauma	neurotrauma	PROPN
fnp-6382	649	3	.	.	PUNCT
fnp-6382	650	1	2019	2019	NUM
fnp-6382	650	2	jun;36(11):1768	jun;36(11):1768	NOUN
fnp-6382	650	3	-	-	PUNCT
fnp-6382	650	4	75	75	NUM
fnp-6382	650	5	.	.	PUNCT
fnp-6382	651	1	https://doi.org/10.1089/neu.2018.6042	https://doi.org/10.1089/neu.2018.6042	VERB
fnp-6382	651	2	74	74	NUM
fnp-6382	651	3	.	.	PUNCT
fnp-6382	652	1	miner	miner	PROPN
fnp-6382	652	2	ae	ae	PROPN
fnp-6382	652	3	,	,	PUNCT
fnp-6382	652	4	groh	groh	PROPN
fnp-6382	652	5	jr	jr	PROPN
fnp-6382	652	6	,	,	PUNCT
fnp-6382	652	7	tripodis	tripodis	PROPN
fnp-6382	652	8	y	y	PROPN
fnp-6382	652	9	,	,	PUNCT
fnp-6382	652	10	adler	adler	PROPN
fnp-6382	652	11	ch	ch	PROPN
fnp-6382	652	12	,	,	PUNCT
fnp-6382	652	13	balcer	balcer	PROPN
fnp-6382	652	14	lj	lj	PROPN
fnp-6382	652	15	,	,	PUNCT
fnp-6382	652	16	bernick	bernick	PROPN
fnp-6382	652	17	c	c	PROPN
fnp-6382	652	18	,	,	PUNCT
fnp-6382	652	19	et	et	PROPN
fnp-6382	652	20	al	al	PROPN
fnp-6382	652	21	.	.	PROPN
fnp-6382	652	22	examination	examination	NOUN
fnp-6382	652	23	of	of	ADP
fnp-6382	652	24	plasma	plasma	NOUN
fnp-6382	652	25	biomarkers	biomarker	NOUN
fnp-6382	652	26	of	of	ADP
fnp-6382	652	27	amyloid	amyloid	NOUN
fnp-6382	652	28	,	,	PUNCT
fnp-6382	652	29	tau	tau	NOUN
fnp-6382	652	30	,	,	PUNCT
fnp-6382	652	31	neurodegeneration	neurodegeneration	NOUN
fnp-6382	652	32	,	,	PUNCT
fnp-6382	652	33	and	and	CCONJ
fnp-6382	652	34	neuroinflammation	neuroinflammation	NOUN
fnp-6382	652	35	in	in	ADP
fnp-6382	652	36	former	former	ADJ
fnp-6382	652	37	elite	elite	ADJ
fnp-6382	652	38	american	american	ADJ
fnp-6382	652	39	football	football	NOUN
fnp-6382	652	40	players	player	NOUN
fnp-6382	652	41	.	.	PUNCT
fnp-6382	653	1	alzheimers	alzheimers	PROPN
fnp-6382	653	2	dement	dement	PROPN
fnp-6382	653	3	.	.	PUNCT
fnp-6382	654	1	2024	2024	NUM
fnp-6382	654	2	nov;20(11):7529	nov;20(11):7529	PROPN
fnp-6382	654	3	-	-	SYM
fnp-6382	654	4	46	46	NUM
fnp-6382	654	5	.	.	PUNCT
fnp-6382	655	1	https://doi.org/10.1002/alz.14231	https://doi.org/10.1002/alz.14231	NOUN
fnp-6382	655	2	75	75	NUM
fnp-6382	655	3	.	.	PUNCT
fnp-6382	656	1	hol	hol	VERB
fnp-6382	656	2	em	em	PRON
fnp-6382	656	3	,	,	PUNCT
fnp-6382	656	4	pekny	pekny	ADJ
fnp-6382	656	5	m.	m.	NOUN
fnp-6382	656	6	glial	glial	ADJ
fnp-6382	656	7	fibrillary	fibrillary	ADJ
fnp-6382	656	8	acidic	acidic	ADJ
fnp-6382	656	9	protein	protein	NOUN
fnp-6382	656	10	(	(	PUNCT
fnp-6382	656	11	gfap	gfap	ADJ
fnp-6382	656	12	)	)	PUNCT
fnp-6382	656	13	and	and	CCONJ
fnp-6382	656	14	the	the	DET
fnp-6382	656	15	astrocyte	astrocyte	NOUN
fnp-6382	656	16	intermediate	intermediate	ADJ
fnp-6382	656	17	filament	filament	NOUN
fnp-6382	656	18	system	system	NOUN
fnp-6382	656	19	in	in	ADP
fnp-6382	656	20	diseases	disease	NOUN
fnp-6382	656	21	of	of	ADP
fnp-6382	656	22	the	the	DET
fnp-6382	656	23	central	central	ADJ
fnp-6382	656	24	nervous	nervous	ADJ
fnp-6382	656	25	system	system	NOUN
fnp-6382	656	26	.	.	PUNCT
fnp-6382	657	1	curr	curr	PROPN
fnp-6382	657	2	opin	opin	NOUN
fnp-6382	657	3	cell	cell	NOUN
fnp-6382	657	4	biol	biol	NOUN
fnp-6382	657	5	.	.	PUNCT
fnp-6382	658	1	2015	2015	NUM
fnp-6382	658	2	feb;32:121	feb;32:121	NOUN
fnp-6382	658	3	-	-	SYM
fnp-6382	658	4	30	30	NUM
fnp-6382	658	5	.	.	PUNCT
fnp-6382	659	1	https://doi.org/10.1016/j.ceb.2015.02.004	https://doi.org/10.1016/j.ceb.2015.02.004	NOUN
fnp-6382	659	2	76	76	NUM
fnp-6382	659	3	.	.	PUNCT
fnp-6382	660	1	abdelhak	abdelhak	VERB
fnp-6382	660	2	a	a	PRON
fnp-6382	660	3	,	,	PUNCT
fnp-6382	660	4	foschi	foschi	NOUN
fnp-6382	660	5	m	m	PROPN
fnp-6382	660	6	,	,	PUNCT
fnp-6382	660	7	abu	abu	PROPN
fnp-6382	660	8	-	-	PUNCT
fnp-6382	660	9	rumeileh	rumeileh	PROPN
fnp-6382	660	10	s	s	PROPN
fnp-6382	660	11	,	,	PUNCT
fnp-6382	660	12	yue	yue	PROPN
fnp-6382	660	13	jk	jk	PROPN
fnp-6382	660	14	,	,	PUNCT
fnp-6382	660	15	d'anna	d'anna	PROPN
fnp-6382	660	16	l	l	PROPN
fnp-6382	660	17	,	,	PUNCT
fnp-6382	660	18	huss	huss	PROPN
fnp-6382	660	19	a	a	PROPN
fnp-6382	660	20	,	,	PUNCT
fnp-6382	660	21	et	et	PROPN
fnp-6382	660	22	al	al	PROPN
fnp-6382	660	23	.	.	PUNCT
fnp-6382	660	24	blood	blood	NOUN
fnp-6382	660	25	gfap	gfap	NOUN
fnp-6382	660	26	as	as	ADP
fnp-6382	660	27	an	an	DET
fnp-6382	660	28	emerging	emerge	VERB
fnp-6382	660	29	biomarker	biomarker	NOUN
fnp-6382	660	30	in	in	ADP
fnp-6382	660	31	brain	brain	NOUN
fnp-6382	660	32	and	and	CCONJ
fnp-6382	660	33	spinal	spinal	ADJ
fnp-6382	660	34	cord	cord	NOUN
fnp-6382	660	35	disorders	disorder	NOUN
fnp-6382	660	36	.	.	PUNCT
fnp-6382	661	1	nat	nat	PROPN
fnp-6382	661	2	rev	rev	VERB
fnp-6382	661	3	neurol	neurol	PROPN
fnp-6382	661	4	.	.	PUNCT
fnp-6382	662	1	2022	2022	NUM
fnp-6382	662	2	mar;18(3):158	mar;18(3):158	PROPN
fnp-6382	662	3	-	-	SYM
fnp-6382	662	4	72	72	NUM
fnp-6382	662	5	.	.	PUNCT
fnp-6382	662	6	https://doi.org/10.1038/s41582-021-00616-3	https://doi.org/10.1038/s41582-021-00616-3	NUM
fnp-6382	662	7	77	77	NUM
fnp-6382	662	8	.	.	PUNCT
fnp-6382	663	1	nakamura	nakamura	PROPN
fnp-6382	663	2	y	y	PROPN
fnp-6382	663	3	,	,	PUNCT
fnp-6382	663	4	kitamura	kitamura	PROPN
fnp-6382	663	5	t	t	PROPN
fnp-6382	663	6	,	,	PUNCT
fnp-6382	663	7	kawano	kawano	PROPN
fnp-6382	663	8	y	y	PROPN
fnp-6382	663	9	,	,	PUNCT
fnp-6382	663	10	hoshino	hoshino	PROPN
fnp-6382	663	11	k	k	PROPN
fnp-6382	663	12	,	,	PUNCT
fnp-6382	663	13	irie	irie	PROPN
fnp-6382	663	14	y	y	PROPN
fnp-6382	663	15	,	,	PUNCT
fnp-6382	663	16	muranishi	muranishi	PROPN
fnp-6382	663	17	k	k	PROPN
fnp-6382	663	18	,	,	PUNCT
fnp-6382	663	19	et	et	PROPN
fnp-6382	663	20	al	al	PROPN
fnp-6382	663	21	.	.	PUNCT
fnp-6382	664	1	glial	glial	ADJ
fnp-6382	664	2	fibrillary	fibrillary	ADJ
fnp-6382	664	3	acidic	acidic	ADJ
fnp-6382	664	4	protein	protein	NOUN
fnp-6382	664	5	level	level	NOUN
fnp-6382	664	6	on	on	ADP
fnp-6382	664	7	admission	admission	NOUN
fnp-6382	664	8	can	can	AUX
fnp-6382	664	9	predict	predict	VERB
fnp-6382	664	10	severe	severe	ADJ
fnp-6382	664	11	traumatic	traumatic	ADJ
fnp-6382	664	12	brain	brain	NOUN
fnp-6382	664	13	injury	injury	NOUN
fnp-6382	664	14	in	in	ADP
fnp-6382	664	15	patients	patient	NOUN
fnp-6382	664	16	with	with	ADP
fnp-6382	664	17	severe	severe	ADJ
fnp-6382	664	18	multiple	multiple	ADJ
fnp-6382	664	19	trauma	trauma	NOUN
fnp-6382	664	20	:	:	PUNCT
fnp-6382	664	21	a	a	DET
fnp-6382	664	22	single	single	ADJ
fnp-6382	664	23	-	-	PUNCT
fnp-6382	664	24	center	center	NOUN
fnp-6382	664	25	retrospective	retrospective	ADJ
fnp-6382	664	26	observational	observational	ADJ
fnp-6382	664	27	study	study	NOUN
fnp-6382	664	28	.	.	PUNCT
fnp-6382	665	1	curr	curr	PROPN
fnp-6382	665	2	res	re	NOUN
fnp-6382	665	3	neurobiol	neurobiol	PROPN
fnp-6382	665	4	.	.	PUNCT
fnp-6382	666	1	2022;3:100047	2022;3:100047	NOUN
fnp-6382	666	2	.	.	PUNCT
fnp-6382	667	1	https://doi.org/10.1016/j.crneur.2022.100047	https://doi.org/10.1016/j.crneur.2022.100047	PROPN
fnp-6382	667	2	78	78	NUM
fnp-6382	667	3	.	.	PUNCT
fnp-6382	668	1	papa	papa	PROPN
fnp-6382	668	2	l	l	PROPN
fnp-6382	668	3	,	,	PUNCT
fnp-6382	668	4	zonfrillo	zonfrillo	PROPN
fnp-6382	668	5	mr	mr	PROPN
fnp-6382	668	6	,	,	PUNCT
fnp-6382	668	7	welch	welch	PROPN
fnp-6382	668	8	rd	rd	PROPN
fnp-6382	668	9	,	,	PUNCT
fnp-6382	668	10	lewis	lewis	PROPN
fnp-6382	668	11	lm	lm	PROPN
fnp-6382	668	12	,	,	PUNCT
fnp-6382	668	13	braga	braga	NOUN
fnp-6382	668	14	cf	cf	PROPN
fnp-6382	668	15	,	,	PUNCT
fnp-6382	668	16	tan	tan	PROPN
fnp-6382	668	17	cn	cn	PROPN
fnp-6382	668	18	,	,	PUNCT
fnp-6382	668	19	et	et	PROPN
fnp-6382	668	20	al	al	PROPN
fnp-6382	668	21	.	.	PUNCT
fnp-6382	669	1	evaluating	evaluate	VERB
fnp-6382	669	2	glial	glial	ADJ
fnp-6382	669	3	and	and	CCONJ
fnp-6382	669	4	neuronal	neuronal	ADJ
fnp-6382	669	5	blood	blood	NOUN
fnp-6382	669	6	biomarkers	biomarker	NOUN
fnp-6382	669	7	gfap	gfap	ADJ
fnp-6382	669	8	and	and	CCONJ
fnp-6382	669	9	uch	uch	ADJ
fnp-6382	669	10	-	-	PUNCT
fnp-6382	669	11	l1	l1	NOUN
fnp-6382	669	12	as	as	ADP
fnp-6382	669	13	gradients	gradient	NOUN
fnp-6382	669	14	of	of	ADP
fnp-6382	669	15	brain	brain	NOUN
fnp-6382	669	16	injury	injury	NOUN
fnp-6382	669	17	in	in	ADP
fnp-6382	669	18	concussive	concussive	NOUN
fnp-6382	669	19	,	,	PUNCT
fnp-6382	669	20	subconcussive	subconcussive	ADJ
fnp-6382	669	21	and	and	CCONJ
fnp-6382	669	22	non	non	ADJ
fnp-6382	669	23	-	-	ADJ
fnp-6382	669	24	concussive	concussive	ADJ
fnp-6382	669	25	trauma	trauma	NOUN
fnp-6382	669	26	:	:	PUNCT
fnp-6382	669	27	a	a	DET
fnp-6382	669	28	prospective	prospective	ADJ
fnp-6382	669	29	cohort	cohort	NOUN
fnp-6382	669	30	study	study	NOUN
fnp-6382	669	31	.	.	PUNCT
fnp-6382	670	1	bmj	bmj	VERB
fnp-6382	670	2	paediatr	paediatr	ADV
fnp-6382	670	3	open	open	ADJ
fnp-6382	670	4	.	.	PUNCT
fnp-6382	671	1	2019	2019	NUM
fnp-6382	671	2	aug;3(1):e000473	aug;3(1):e000473	NOUN
fnp-6382	671	3	.	.	PUNCT
fnp-6382	671	4	https://doi.org/10.1136/bmjpo-2019-000473	https://doi.org/10.1136/bmjpo-2019-000473	PROPN
fnp-6382	671	5	79	79	NUM
fnp-6382	671	6	.	.	PUNCT
fnp-6382	671	7	hsu	hsu	PROPN
fnp-6382	671	8	et	et	PROPN
fnp-6382	671	9	,	,	PUNCT
fnp-6382	671	10	gangolli	gangolli	PROPN
fnp-6382	671	11	m	m	PROPN
fnp-6382	671	12	,	,	PUNCT
fnp-6382	671	13	su	su	PROPN
fnp-6382	671	14	s	s	PROPN
fnp-6382	671	15	,	,	PUNCT
fnp-6382	671	16	holleran	holleran	ADJ
fnp-6382	671	17	l	l	PROPN
fnp-6382	671	18	,	,	PUNCT
fnp-6382	671	19	stein	stein	PROPN
fnp-6382	671	20	td	td	PROPN
fnp-6382	671	21	,	,	PUNCT
fnp-6382	671	22	alvarez	alvarez	PROPN
fnp-6382	671	23	ve	ve	PROPN
fnp-6382	671	24	,	,	PUNCT
fnp-6382	671	25	et	et	PROPN
fnp-6382	671	26	al	al	PROPN
fnp-6382	671	27	.	.	PROPN
fnp-6382	671	28	astrocytic	astrocytic	ADJ
fnp-6382	671	29	degeneration	degeneration	NOUN
fnp-6382	671	30	in	in	ADP
fnp-6382	671	31	chronic	chronic	ADJ
fnp-6382	671	32	traumatic	traumatic	ADJ
fnp-6382	671	33	encephalopathy	encephalopathy	NOUN
fnp-6382	671	34	.	.	PUNCT
fnp-6382	672	1	acta	acta	PROPN
fnp-6382	672	2	neuropathol	neuropathol	PROPN
fnp-6382	672	3	(	(	PUNCT
fnp-6382	672	4	berl	berl	PROPN
fnp-6382	672	5	)	)	PUNCT
fnp-6382	672	6	.	.	PUNCT
fnp-6382	673	1	2018	2018	NUM
fnp-6382	673	2	dec;136(6):955	dec;136(6):955	NOUN
fnp-6382	673	3	-	-	PUNCT
fnp-6382	673	4	72	72	NUM
fnp-6382	673	5	.	.	PUNCT
fnp-6382	673	6	https://doi.org/10.1007/s00401-018-1902-3	https://doi.org/10.1007/s00401-018-1902-3	NUM
fnp-6382	673	7	80	80	NUM
fnp-6382	673	8	.	.	PUNCT
fnp-6382	674	1	bernick	bernick	PROPN
fnp-6382	674	2	c	c	PROPN
fnp-6382	674	3	,	,	PUNCT
fnp-6382	674	4	shan	shan	ADJ
fnp-6382	674	5	g	g	PROPN
fnp-6382	674	6	,	,	PUNCT
fnp-6382	674	7	ritter	ritter	PROPN
fnp-6382	674	8	a	a	PROPN
fnp-6382	674	9	,	,	PUNCT
fnp-6382	674	10	ashton	ashton	PROPN
fnp-6382	674	11	nj	nj	PROPN
fnp-6382	674	12	,	,	PUNCT
fnp-6382	674	13	blennow	blennow	ADV
fnp-6382	674	14	k	k	NOUN
fnp-6382	674	15	,	,	PUNCT
fnp-6382	674	16	lantero	lantero	PROPN
fnp-6382	674	17	-	-	PUNCT
fnp-6382	674	18	rodriguez	rodriguez	PROPN
fnp-6382	674	19	j	j	PROPN
fnp-6382	674	20	,	,	PUNCT
fnp-6382	674	21	et	et	PROPN
fnp-6382	674	22	al	al	PROPN
fnp-6382	674	23	.	.	PUNCT
fnp-6382	674	24	blood	blood	NOUN
fnp-6382	674	25	biomarkers	biomarker	NOUN
fnp-6382	674	26	and	and	CCONJ
fnp-6382	674	27	neurodegeneration	neurodegeneration	NOUN
fnp-6382	674	28	in	in	ADP
fnp-6382	674	29	individuals	individual	NOUN
fnp-6382	674	30	exposed	expose	VERB
fnp-6382	674	31	to	to	ADP
fnp-6382	674	32	repetitive	repetitive	ADJ
fnp-6382	674	33	head	head	NOUN
fnp-6382	674	34	impacts	impact	NOUN
fnp-6382	674	35	.	.	PUNCT
fnp-6382	675	1	alzheimers	alzheimer	NOUN
fnp-6382	675	2	res	re	VERB
fnp-6382	675	3	ther	ther	ADV
fnp-6382	675	4	.	.	PUNCT
fnp-6382	676	1	2023	2023	NUM
fnp-6382	676	2	oct	oct	PROPN
fnp-6382	676	3	12;15(1):173	12;15(1):173	PROPN
fnp-6382	676	4	.	.	PUNCT
fnp-6382	677	1	https://doi.org/10.1186/s13195-023-01310-w	https://doi.org/10.1186/s13195-023-01310-w	PROPN
fnp-6382	677	2	81	81	NUM
fnp-6382	677	3	.	.	PUNCT
fnp-6382	678	1	bazarian	bazarian	PROPN
fnp-6382	678	2	jj	jj	PROPN
fnp-6382	678	3	,	,	PUNCT
fnp-6382	678	4	abar	abar	PROPN
fnp-6382	678	5	b	b	NOUN
fnp-6382	678	6	,	,	PUNCT
fnp-6382	678	7	merchant	merchant	NOUN
fnp-6382	678	8	-	-	PUNCT
fnp-6382	678	9	borna	borna	NOUN
fnp-6382	678	10	k	k	PROPN
fnp-6382	678	11	,	,	PUNCT
fnp-6382	678	12	pham	pham	PROPN
fnp-6382	678	13	dl	dl	PROPN
fnp-6382	678	14	,	,	PUNCT
fnp-6382	678	15	rozen	rozen	PROPN
fnp-6382	678	16	e	e	PROPN
fnp-6382	678	17	,	,	PUNCT
fnp-6382	678	18	mannix	mannix	PROPN
fnp-6382	678	19	r	r	PROPN
fnp-6382	678	20	,	,	PUNCT
fnp-6382	678	21	et	et	PROPN
fnp-6382	678	22	al	al	PROPN
fnp-6382	678	23	.	.	PUNCT
fnp-6382	679	1	a	a	DET
fnp-6382	679	2	pilot	pilot	NOUN
fnp-6382	679	3	study	study	NOUN
fnp-6382	679	4	investigating	investigate	VERB
fnp-6382	679	5	the	the	DET
fnp-6382	679	6	use	use	NOUN
fnp-6382	679	7	of	of	ADP
fnp-6382	679	8	serum	serum	NOUN
fnp-6382	679	9	glial	glial	ADJ
fnp-6382	679	10	fibrillary	fibrillary	ADJ
fnp-6382	679	11	acidic	acidic	ADJ
fnp-6382	679	12	protein	protein	NOUN
fnp-6382	679	13	to	to	PART
fnp-6382	679	14	monitor	monitor	VERB
fnp-6382	679	15	changes	change	NOUN
fnp-6382	679	16	in	in	ADP
fnp-6382	679	17	brain	brain	NOUN
fnp-6382	679	18	white	white	ADJ
fnp-6382	679	19	matter	matter	PROPN
fnp-6382	679	20	integrity	integrity	NOUN
fnp-6382	679	21	after	after	SCONJ
fnp-6382	679	22	repetitive	repetitive	ADJ
fnp-6382	679	23	head	head	NOUN
fnp-6382	679	24	hits	hit	VERB
fnp-6382	679	25	during	during	ADP
fnp-6382	679	26	a	a	DET
fnp-6382	679	27	single	single	ADJ
fnp-6382	679	28	collegiate	collegiate	ADJ
fnp-6382	679	29	football	football	NOUN
fnp-6382	679	30	game	game	NOUN
fnp-6382	679	31	.	.	PUNCT
fnp-6382	680	1	j	j	PROPN
fnp-6382	680	2	neurotrauma	neurotrauma	PROPN
fnp-6382	680	3	.	.	PUNCT
fnp-6382	681	1	2024	2024	NUM
fnp-6382	681	2	jul	jul	PROPN
fnp-6382	681	3	1;41	1;41	NUM
fnp-6382	681	4	(	(	PUNCT
fnp-6382	681	5	13	13	NUM
fnp-6382	681	6	-	-	SYM
fnp-6382	681	7	14	14	NUM
fnp-6382	681	8	):	):	SYM
fnp-6382	681	9	1597	1597	NUM
fnp-6382	681	10	-	-	SYM
fnp-6382	681	11	608	608	NUM
fnp-6382	681	12	.	.	PUNCT
fnp-6382	682	1	https://doi.org/10.1089/neu.2023.0307	https://doi.org/10.1089/neu.2023.0307	NOUN
fnp-6382	682	2	82	82	NUM
fnp-6382	682	3	.	.	PUNCT
fnp-6382	683	1	huibregtse	huibregtse	VERB
fnp-6382	683	2	me	i	PRON
fnp-6382	683	3	,	,	PUNCT
fnp-6382	683	4	sweeney	sweeney	PROPN
fnp-6382	683	5	sh	sh	PROPN
fnp-6382	683	6	,	,	PUNCT
fnp-6382	683	7	stephens	stephens	PROPN
fnp-6382	683	8	mr	mr	PROPN
fnp-6382	683	9	,	,	PUNCT
fnp-6382	683	10	cheng	cheng	PROPN
fnp-6382	683	11	h	h	PROPN
fnp-6382	683	12	,	,	PUNCT
fnp-6382	683	13	chen	chen	PROPN
fnp-6382	683	14	z	z	PROPN
fnp-6382	683	15	,	,	PUNCT
fnp-6382	683	16	block	block	PROPN
fnp-6382	683	17	hj	hj	PROPN
fnp-6382	683	18	,	,	PUNCT
fnp-6382	683	19	et	et	PROPN
fnp-6382	683	20	al	al	PROPN
fnp-6382	683	21	.	.	PROPN
fnp-6382	683	22	association	association	PROPN
fnp-6382	683	23	between	between	ADP
fnp-6382	683	24	serum	serum	NOUN
fnp-6382	683	25	neurofilament	neurofilament	NOUN
fnp-6382	683	26	light	light	NOUN
fnp-6382	683	27	and	and	CCONJ
fnp-6382	683	28	glial	glial	ADJ
fnp-6382	683	29	fibrillary	fibrillary	ADJ
fnp-6382	683	30	acidic	acidic	ADJ
fnp-6382	683	31	protein	protein	NOUN
fnp-6382	683	32	levels	level	NOUN
fnp-6382	683	33	and	and	CCONJ
fnp-6382	683	34	head	head	NOUN
fnp-6382	683	35	impact	impact	NOUN
fnp-6382	683	36	burden	burden	NOUN
fnp-6382	683	37	in	in	ADP
fnp-6382	683	38	women	woman	NOUN
fnp-6382	683	39	's	's	PART
fnp-6382	683	40	collegiate	collegiate	ADJ
fnp-6382	683	41	water	water	NOUN
fnp-6382	683	42	polo	polo	NOUN
fnp-6382	683	43	.	.	PUNCT
fnp-6382	684	1	j	j	PROPN
fnp-6382	684	2	neurotrauma	neurotrauma	PROPN
fnp-6382	684	3	.	.	PUNCT
fnp-6382	685	1	2023	2023	NUM
fnp-6382	685	2	jun	jun	PROPN
fnp-6382	685	3	1;40	1;40	NUM
fnp-6382	685	4	(	(	PUNCT
fnp-6382	685	5	11	11	NUM
fnp-6382	685	6	-	-	SYM
fnp-6382	685	7	12	12	NUM
fnp-6382	685	8	):	):	SYM
fnp-6382	685	9	1130	1130	NUM
fnp-6382	685	10	-	-	SYM
fnp-6382	685	11	43	43	NUM
fnp-6382	685	12	.	.	PUNCT
fnp-6382	686	1	https://doi.org/10.1089/neu.2022.0300	https://doi.org/10.1089/neu.2022.0300	PROPN
fnp-6382	686	2	83	83	NUM
fnp-6382	686	3	.	.	PUNCT
fnp-6382	687	1	shahim	shahim	PROPN
fnp-6382	687	2	p	p	X
fnp-6382	687	3	,	,	PUNCT
fnp-6382	687	4	zetterberg	zetterberg	PROPN
fnp-6382	687	5	h	h	PROPN
fnp-6382	687	6	,	,	PUNCT
fnp-6382	687	7	simrén	simrén	PROPN
fnp-6382	687	8	j	j	PROPN
fnp-6382	687	9	,	,	PUNCT
fnp-6382	687	10	ashton	ashton	PROPN
fnp-6382	687	11	nj	nj	PROPN
fnp-6382	687	12	,	,	PUNCT
fnp-6382	687	13	norato	norato	PROPN
fnp-6382	687	14	g	g	NOUN
fnp-6382	687	15	,	,	PUNCT
fnp-6382	687	16	schöll	schöll	PROPN
fnp-6382	687	17	m	m	PROPN
fnp-6382	687	18	,	,	PUNCT
fnp-6382	687	19	et	et	PROPN
fnp-6382	687	20	al	al	PROPN
fnp-6382	687	21	.	.	PROPN
fnp-6382	687	22	association	association	PROPN
fnp-6382	687	23	of	of	ADP
fnp-6382	687	24	plasma	plasma	NOUN
fnp-6382	687	25	biomarker	biomarker	NOUN
fnp-6382	687	26	levels	level	NOUN
fnp-6382	687	27	with	with	ADP
fnp-6382	687	28	their	their	PRON
fnp-6382	687	29	csf	csf	ADJ
fnp-6382	687	30	concentration	concentration	NOUN
fnp-6382	687	31	and	and	CCONJ
fnp-6382	687	32	the	the	DET
fnp-6382	687	33	number	number	NOUN
fnp-6382	687	34	and	and	CCONJ
fnp-6382	687	35	severity	severity	NOUN
fnp-6382	687	36	of	of	ADP
fnp-6382	687	37	concussions	concussion	NOUN
fnp-6382	687	38	in	in	ADP
fnp-6382	687	39	professional	professional	ADJ
fnp-6382	687	40	athletes	athlete	NOUN
fnp-6382	687	41	.	.	PUNCT
fnp-6382	688	1	neurology	neurology	NOUN
fnp-6382	689	1	[	[	X
fnp-6382	689	2	internet	internet	NOUN
fnp-6382	689	3	]	]	X
fnp-6382	689	4	.	.	PUNCT
fnp-6382	690	1	2022	2022	NUM
fnp-6382	690	2	jul	jul	NOUN
fnp-6382	690	3	26	26	NUM
fnp-6382	690	4	[	[	X
fnp-6382	690	5	cited	cite	VERB
fnp-6382	690	6	2025	2025	NUM
fnp-6382	690	7	jun	jun	PROPN
fnp-6382	690	8	10];99(4	10];99(4	NUM
fnp-6382	690	9	)	)	PUNCT
fnp-6382	690	10	.	.	PUNCT
fnp-6382	691	1	available	available	ADJ
fnp-6382	691	2	from	from	ADP
fnp-6382	691	3	:	:	PUNCT
fnp-6382	691	4	https://doi.org/10.1212/wnl.0000000000200615	https://doi.org/10.1212/wnl.0000000000200615	NOUN
fnp-6382	691	5	84	84	NUM
fnp-6382	691	6	.	.	PUNCT
fnp-6382	692	1	asken	asken	VERB
fnp-6382	692	2	bm	bm	PROPN
fnp-6382	692	3	,	,	PUNCT
fnp-6382	692	4	tanner	tanner	PROPN
fnp-6382	692	5	ja	ja	PROPN
fnp-6382	692	6	,	,	PUNCT
fnp-6382	692	7	vandevrede	vandevrede	PROPN
fnp-6382	692	8	l	l	NOUN
fnp-6382	692	9	,	,	PUNCT
fnp-6382	692	10	casaletto	casaletto	PROPN
fnp-6382	692	11	kb	kb	PROPN
fnp-6382	692	12	,	,	PUNCT
fnp-6382	692	13	staffaroni	staffaroni	PROPN
fnp-6382	692	14	am	be	AUX
fnp-6382	692	15	,	,	PUNCT
fnp-6382	692	16	mundada	mundada	PROPN
fnp-6382	692	17	n	n	CCONJ
fnp-6382	692	18	,	,	PUNCT
fnp-6382	692	19	et	et	PROPN
fnp-6382	692	20	al	al	PROPN
fnp-6382	692	21	.	.	PUNCT
fnp-6382	693	1	multi	multi	ADJ
fnp-6382	693	2	-	-	ADJ
fnp-6382	693	3	modal	modal	ADJ
fnp-6382	693	4	biomarkers	biomarker	NOUN
fnp-6382	693	5	of	of	ADP
fnp-6382	693	6	repetitive	repetitive	ADJ
fnp-6382	693	7	head	head	NOUN
fnp-6382	693	8	impacts	impact	NOUN
fnp-6382	693	9	and	and	CCONJ
fnp-6382	693	10	traumatic	traumatic	ADJ
fnp-6382	693	11	encephalopathy	encephalopathy	ADJ
fnp-6382	693	12	syndrome	syndrome	NOUN
fnp-6382	693	13	:	:	PUNCT
fnp-6382	693	14	a	a	DET
fnp-6382	693	15	clinicopathological	clinicopathological	ADJ
fnp-6382	693	16	case	case	NOUN
fnp-6382	693	17	series	series	NOUN
fnp-6382	693	18	.	.	PUNCT
fnp-6382	694	1	j	j	PROPN
fnp-6382	694	2	neurotrauma	neurotrauma	PROPN
fnp-6382	694	3	.	.	PUNCT
fnp-6382	695	1	2022	2022	NUM
fnp-6382	695	2	sep	sep	NOUN
fnp-6382	695	3	1;39	1;39	NUM
fnp-6382	695	4	(	(	PUNCT
fnp-6382	695	5	17	17	NUM
fnp-6382	695	6	-	-	SYM
fnp-6382	695	7	18	18	NUM
fnp-6382	695	8	):	):	SYM
fnp-6382	695	9	1195	1195	NUM
fnp-6382	695	10	-	-	SYM
fnp-6382	695	11	213	213	NUM
fnp-6382	695	12	.	.	PUNCT
fnp-6382	696	1	https://doi.org/10.1089/neu.2022.0060	https://doi.org/10.1089/neu.2022.0060	NOUN
fnp-6382	696	2	85	85	NUM
fnp-6382	696	3	.	.	PUNCT
fnp-6382	697	1	tagge	tagge	NOUN
fnp-6382	697	2	ca	ca	PROPN
fnp-6382	697	3	,	,	PUNCT
fnp-6382	697	4	fisher	fisher	PROPN
fnp-6382	697	5	am	be	AUX
fnp-6382	697	6	,	,	PUNCT
fnp-6382	697	7	minaeva	minaeva	VERB
fnp-6382	697	8	ov	ov	PROPN
fnp-6382	697	9	,	,	PUNCT
fnp-6382	697	10	gaudreau	gaudreau	PROPN
fnp-6382	697	11	-	-	PUNCT
fnp-6382	697	12	balderrama	balderrama	PROPN
fnp-6382	697	13	a	a	NOUN
fnp-6382	697	14	,	,	PUNCT
fnp-6382	697	15	moncaster	moncaster	NOUN
fnp-6382	697	16	ja	ja	PROPN
fnp-6382	697	17	,	,	PUNCT
fnp-6382	697	18	zhang	zhang	PROPN
fnp-6382	697	19	xl	xl	PROPN
fnp-6382	697	20	,	,	PUNCT
fnp-6382	697	21	et	et	PROPN
fnp-6382	697	22	al	al	PROPN
fnp-6382	697	23	.	.	PROPN
fnp-6382	697	24	concussion	concussion	NOUN
fnp-6382	697	25	,	,	PUNCT
fnp-6382	697	26	microvascular	microvascular	ADJ
fnp-6382	697	27	injury	injury	NOUN
fnp-6382	697	28	,	,	PUNCT
fnp-6382	697	29	and	and	CCONJ
fnp-6382	697	30	early	early	ADJ
fnp-6382	697	31	tauopathy	tauopathy	NOUN
fnp-6382	697	32	in	in	ADP
fnp-6382	697	33	young	young	ADJ
fnp-6382	697	34	athletes	athlete	NOUN
fnp-6382	697	35	after	after	ADP
fnp-6382	697	36	impact	impact	NOUN
fnp-6382	697	37	head	head	NOUN
fnp-6382	697	38	injury	injury	NOUN
fnp-6382	697	39	and	and	CCONJ
fnp-6382	697	40	an	an	DET
fnp-6382	697	41	impact	impact	NOUN
fnp-6382	697	42	concussion	concussion	NOUN
fnp-6382	697	43	mouse	mouse	NOUN
fnp-6382	697	44	model	model	NOUN
fnp-6382	697	45	.	.	PUNCT
fnp-6382	698	1	brain	brain	NOUN
fnp-6382	698	2	.	.	PUNCT
fnp-6382	699	1	2018	2018	NUM
fnp-6382	699	2	feb	feb	PROPN
fnp-6382	699	3	1;141(2):422	1;141(2):422	NUM
fnp-6382	699	4	-	-	SYM
fnp-6382	699	5	58	58	NUM
fnp-6382	699	6	.	.	PUNCT
fnp-6382	699	7	https://10.1093	https://10.1093	ADV
fnp-6382	699	8	/	/	SYM
fnp-6382	699	9	brain	brain	NOUN
fnp-6382	699	10	/	/	SYM
fnp-6382	699	11	awx350	awx350	PROPN
fnp-6382	699	12	86	86	NUM
fnp-6382	699	13	.	.	PUNCT
fnp-6382	699	14	li	li	PROPN
fnp-6382	700	1	q	q	PROPN
fnp-6382	700	2	,	,	PUNCT
fnp-6382	700	3	cheng	cheng	PROPN
fnp-6382	700	4	z	z	PROPN
fnp-6382	700	5	,	,	PUNCT
fnp-6382	701	1	zhou	zhou	PROPN
fnp-6382	701	2	l	l	PROPN
fnp-6382	701	3	,	,	PUNCT
fnp-6382	701	4	darmanis	darmanis	PROPN
fnp-6382	701	5	s	s	PROPN
fnp-6382	701	6	,	,	PUNCT
fnp-6382	701	7	neff	neff	PROPN
fnp-6382	701	8	nf	nf	PROPN
fnp-6382	701	9	,	,	PUNCT
fnp-6382	701	10	okamoto	okamoto	PROPN
fnp-6382	701	11	j	j	PROPN
fnp-6382	701	12	,	,	PUNCT
fnp-6382	701	13	et	et	PROPN
fnp-6382	701	14	al	al	PROPN
fnp-6382	701	15	.	.	PUNCT
fnp-6382	702	1	developmental	developmental	ADJ
fnp-6382	702	2	heterogeneity	heterogeneity	NOUN
fnp-6382	702	3	of	of	ADP
fnp-6382	702	4	microglia	microglia	ADJ
fnp-6382	702	5	and	and	CCONJ
fnp-6382	702	6	brain	brain	NOUN
fnp-6382	702	7	myeloid	myeloid	NOUN
fnp-6382	702	8	cells	cell	NOUN
fnp-6382	702	9	revealed	reveal	VERB
fnp-6382	702	10	by	by	ADP
fnp-6382	702	11	deep	deep	ADJ
fnp-6382	702	12	single	single	ADJ
fnp-6382	702	13	-	-	PUNCT
fnp-6382	702	14	cell	cell	NOUN
fnp-6382	702	15	rna	rna	NOUN
fnp-6382	702	16	sequencing	sequencing	NOUN
fnp-6382	702	17	.	.	PUNCT
fnp-6382	703	1	neuron	neuron	PROPN
fnp-6382	703	2	.	.	PUNCT
fnp-6382	704	1	2019	2019	NUM
fnp-6382	704	2	jan;101(2):207	jan;101(2):207	NOUN
fnp-6382	704	3	-	-	PUNCT
fnp-6382	704	4	223.e10	223.e10	PROPN
fnp-6382	704	5	.	.	PUNCT
fnp-6382	705	1	https://doi.org/10.1016/j.neuron.2018.12.006	https://doi.org/10.1016/j.neuron.2018.12.006	ADJ
fnp-6382	705	2	87	87	NUM
fnp-6382	705	3	.	.	PUNCT
fnp-6382	706	1	zhong	zhong	PROPN
fnp-6382	706	2	l	l	PROPN
fnp-6382	706	3	,	,	PUNCT
fnp-6382	706	4	chen	chen	PROPN
fnp-6382	706	5	xf	xf	PROPN
fnp-6382	706	6	,	,	PUNCT
fnp-6382	706	7	wang	wang	PROPN
fnp-6382	706	8	t	t	PROPN
fnp-6382	706	9	,	,	PUNCT
fnp-6382	706	10	wang	wang	PROPN
fnp-6382	706	11	z	z	PROPN
fnp-6382	706	12	,	,	PUNCT
fnp-6382	706	13	liao	liao	PROPN
fnp-6382	706	14	c	c	PROPN
fnp-6382	706	15	,	,	PUNCT
fnp-6382	706	16	wang	wang	PROPN
fnp-6382	706	17	z	z	PROPN
fnp-6382	706	18	,	,	PUNCT
fnp-6382	706	19	et	et	PROPN
fnp-6382	706	20	al	al	PROPN
fnp-6382	706	21	.	.	PROPN
fnp-6382	706	22	soluble	soluble	ADJ
fnp-6382	706	23	trem2	trem2	NOUN
fnp-6382	706	24	induces	induce	VERB
fnp-6382	706	25	inflammatory	inflammatory	ADJ
fnp-6382	706	26	responses	response	NOUN
fnp-6382	706	27	and	and	CCONJ
fnp-6382	706	28	enhances	enhance	VERB
fnp-6382	706	29	microglial	microglial	ADJ
fnp-6382	706	30	survival	survival	NOUN
fnp-6382	706	31	.	.	PUNCT
fnp-6382	707	1	j	j	PROPN
fnp-6382	707	2	exp	exp	NOUN
fnp-6382	707	3	med	med	PROPN
fnp-6382	707	4	.	.	PROPN
fnp-6382	708	1	2017	2017	NUM
fnp-6382	708	2	mar	mar	PROPN
fnp-6382	708	3	6;214(3):597	6;214(3):597	PROPN
fnp-6382	708	4	-	-	PUNCT
fnp-6382	708	5	607	607	NUM
fnp-6382	708	6	.	.	PUNCT
fnp-6382	709	1	https://doi.org/10.1084/jem.20160844	https://doi.org/10.1084/jem.20160844	NOUN
fnp-6382	709	2	88	88	NUM
fnp-6382	709	3	.	.	PUNCT
fnp-6382	710	1	heslegrave	heslegrave	PROPN
fnp-6382	710	2	a	a	PRON
fnp-6382	710	3	,	,	PUNCT
fnp-6382	710	4	heywood	heywood	PROPN
fnp-6382	710	5	w	w	PROPN
fnp-6382	710	6	,	,	PUNCT
fnp-6382	710	7	paterson	paterson	PROPN
fnp-6382	710	8	r	r	PROPN
fnp-6382	710	9	,	,	PUNCT
fnp-6382	710	10	magdalinou	magdalinou	NOUN
fnp-6382	710	11	n	n	CCONJ
fnp-6382	710	12	,	,	PUNCT
fnp-6382	710	13	svensson	svensson	PROPN
fnp-6382	710	14	j	j	PROPN
fnp-6382	710	15	,	,	PUNCT
fnp-6382	710	16	johansson	johansson	PROPN
fnp-6382	710	17	p	p	PROPN
fnp-6382	710	18	,	,	PUNCT
fnp-6382	710	19	et	et	PROPN
fnp-6382	710	20	al	al	PROPN
fnp-6382	710	21	.	.	PROPN
fnp-6382	710	22	increased	increase	VERB
fnp-6382	710	23	cerebrospinal	cerebrospinal	ADJ
fnp-6382	710	24	fluid	fluid	ADJ
fnp-6382	710	25	soluble	soluble	ADJ
fnp-6382	710	26	trem2	trem2	NOUN
fnp-6382	710	27	concentration	concentration	NOUN
fnp-6382	710	28	in	in	ADP
fnp-6382	710	29	alzheimer	alzheimer	PROPN
fnp-6382	710	30	's	's	PART
fnp-6382	710	31	disease	disease	NOUN
fnp-6382	710	32	.	.	PUNCT
fnp-6382	711	1	mol	mol	ADP
fnp-6382	711	2	neurodegener	neurodegener	NOUN
fnp-6382	711	3	.	.	PUNCT
fnp-6382	712	1	2016	2016	NUM
fnp-6382	712	2	dec;11(1):3	dec;11(1):3	NOUN
fnp-6382	712	3	.	.	PUNCT
fnp-6382	713	1	https://doi.org/10.1186/s13024-016-0071-x	https://doi.org/10.1186/s13024-016-0071-x	PROPN
fnp-6382	713	2	89	89	NUM
fnp-6382	713	3	.	.	PUNCT
fnp-6382	714	1	rauchmann	rauchmann	PROPN
fnp-6382	714	2	bs	bs	PROPN
fnp-6382	714	3	,	,	PUNCT
fnp-6382	714	4	schneider	schneider	NOUN
fnp-6382	714	5	-	-	PUNCT
fnp-6382	714	6	axmann	axmann	PROPN
fnp-6382	714	7	t	t	PROPN
fnp-6382	714	8	,	,	PUNCT
fnp-6382	714	9	alexopoulos	alexopoulos	PROPN
fnp-6382	714	10	p	p	PROPN
fnp-6382	714	11	,	,	PUNCT
fnp-6382	714	12	perneczky	perneczky	ADJ
fnp-6382	714	13	r.	r.	X
fnp-6382	714	14	csf	csf	X
fnp-6382	714	15	soluble	soluble	ADJ
fnp-6382	714	16	trem2	trem2	NOUN
fnp-6382	714	17	as	as	ADP
fnp-6382	714	18	a	a	DET
fnp-6382	714	19	measure	measure	NOUN
fnp-6382	714	20	of	of	ADP
fnp-6382	714	21	immune	immune	ADJ
fnp-6382	714	22	response	response	NOUN
fnp-6382	714	23	along	along	ADP
fnp-6382	714	24	the	the	DET
fnp-6382	714	25	alzheimer	alzheimer	PROPN
fnp-6382	714	26	's	's	PART
fnp-6382	714	27	disease	disease	NOUN
fnp-6382	714	28	continuum	continuum	ADJ
fnp-6382	714	29	.	.	PUNCT
fnp-6382	715	1	neurobiol	neurobiol	PROPN
fnp-6382	715	2	aging	aging	NOUN
fnp-6382	715	3	.	.	PUNCT
fnp-6382	716	1	2019	2019	NUM
fnp-6382	716	2	feb;74:182	feb;74:182	NOUN
fnp-6382	716	3	-	-	SYM
fnp-6382	716	4	90	90	NUM
fnp-6382	716	5	.	.	PUNCT
fnp-6382	717	1	https://doi.org/10.1016/j.neurobiolaging.2018.10.022	https://doi.org/10.1016/j.neurobiolaging.2018.10.022	PROPN
fnp-6382	717	2	90	90	NUM
fnp-6382	717	3	.	.	PUNCT
fnp-6382	718	1	zhao	zhao	PROPN
fnp-6382	718	2	a	a	PROPN
fnp-6382	718	3	,	,	PUNCT
fnp-6382	718	4	jiao	jiao	PROPN
fnp-6382	718	5	y	y	PROPN
fnp-6382	718	6	,	,	PUNCT
fnp-6382	718	7	ye	ye	PRON
fnp-6382	718	8	g	g	NOUN
fnp-6382	718	9	,	,	PUNCT
fnp-6382	718	10	kang	kang	PROPN
fnp-6382	718	11	w	w	PROPN
fnp-6382	718	12	,	,	PUNCT
fnp-6382	718	13	tan	tan	PROPN
fnp-6382	718	14	l	l	NOUN
fnp-6382	718	15	,	,	PUNCT
fnp-6382	718	16	li	li	PROPN
fnp-6382	718	17	y	y	PROPN
fnp-6382	718	18	,	,	PUNCT
fnp-6382	718	19	et	et	PROPN
fnp-6382	718	20	al	al	PROPN
fnp-6382	718	21	.	.	PROPN
fnp-6382	719	1	soluble	soluble	ADJ
fnp-6382	719	2	trem2	trem2	NOUN
fnp-6382	719	3	levels	level	NOUN
fnp-6382	719	4	associate	associate	VERB
fnp-6382	719	5	with	with	ADP
fnp-6382	719	6	conversion	conversion	NOUN
fnp-6382	719	7	from	from	ADP
fnp-6382	719	8	mild	mild	ADJ
fnp-6382	719	9	cognitive	cognitive	ADJ
fnp-6382	719	10	impairment	impairment	NOUN
fnp-6382	719	11	to	to	ADP
fnp-6382	719	12	alzheimer	alzheimer	PROPN
fnp-6382	719	13	's	's	PART
fnp-6382	719	14	disease	disease	NOUN
fnp-6382	719	15	.	.	PUNCT
fnp-6382	720	1	j	j	PROPN
fnp-6382	720	2	clin	clin	PROPN
fnp-6382	720	3	invest	invest	PROPN
fnp-6382	720	4	.	.	PUNCT
fnp-6382	721	1	2022	2022	NUM
fnp-6382	721	2	dec	dec	PROPN
fnp-6382	721	3	15;132(24):e158708	15;132(24):e158708	NUM
fnp-6382	721	4	.	.	PUNCT
fnp-6382	721	5	https://doi.org/10.1172/jci158708	https://doi.org/10.1172/jci158708	PROPN
fnp-6382	721	6	91	91	NUM
fnp-6382	721	7	.	.	PUNCT
fnp-6382	722	1	wang	wang	PROPN
fnp-6382	722	2	ky	ky	PROPN
fnp-6382	722	3	,	,	PUNCT
fnp-6382	722	4	yu	yu	PROPN
fnp-6382	722	5	gf	gf	PROPN
fnp-6382	722	6	,	,	PUNCT
fnp-6382	722	7	zhang	zhang	PROPN
fnp-6382	722	8	zy	zy	PROPN
fnp-6382	722	9	,	,	PUNCT
fnp-6382	722	10	huang	huang	PROPN
fnp-6382	722	11	q	q	PROPN
fnp-6382	722	12	,	,	PUNCT
fnp-6382	722	13	dong	dong	PROPN
fnp-6382	722	14	xq	xq	PROPN
fnp-6382	722	15	.	.	PUNCT
fnp-6382	722	16	plasma	plasma	VERB
fnp-6382	722	17	high	high	ADJ
fnp-6382	722	18	-	-	PUNCT
fnp-6382	722	19	mobility	mobility	NOUN
fnp-6382	722	20	group	group	NOUN
fnp-6382	722	21	box	box	PROPN
fnp-6382	722	22	1	1	NUM
fnp-6382	722	23	levels	level	NOUN
fnp-6382	722	24	and	and	CCONJ
fnp-6382	722	25	prediction	prediction	NOUN
fnp-6382	722	26	of	of	ADP
fnp-6382	722	27	outcome	outcome	NOUN
fnp-6382	722	28	in	in	ADP
fnp-6382	722	29	patients	patient	NOUN
fnp-6382	722	30	with	with	ADP
fnp-6382	722	31	traumatic	traumatic	ADJ
fnp-6382	722	32	brain	brain	NOUN
fnp-6382	722	33	injury	injury	NOUN
fnp-6382	722	34	.	.	PUNCT
fnp-6382	723	1	clin	clin	PROPN
fnp-6382	723	2	chim	chim	PROPN
fnp-6382	723	3	acta	acta	PROPN
fnp-6382	723	4	.	.	PUNCT
fnp-6382	724	1	2012	2012	NUM
fnp-6382	724	2	nov;413	nov;413	PROPN
fnp-6382	724	3	(	(	PUNCT
fnp-6382	724	4	21	21	NUM
fnp-6382	724	5	-	-	SYM
fnp-6382	724	6	22	22	NUM
fnp-6382	724	7	):	):	SYM
fnp-6382	724	8	1737	1737	NUM
fnp-6382	724	9	-	-	SYM
fnp-6382	724	10	41	41	NUM
fnp-6382	724	11	.	.	PUNCT
fnp-6382	725	1	https://doi.org/10.1016/j.cca.2012.07.002	https://doi.org/10.1016/j.cca.2012.07.002	PROPN
fnp-6382	725	2	92	92	NUM
fnp-6382	725	3	.	.	PUNCT
fnp-6382	726	1	yang	yang	PROPN
fnp-6382	726	2	h	h	PROPN
fnp-6382	726	3	,	,	PUNCT
fnp-6382	726	4	antoine	antoine	PROPN
fnp-6382	726	5	dj	dj	PROPN
fnp-6382	726	6	,	,	PUNCT
fnp-6382	726	7	andersson	andersson	PROPN
fnp-6382	726	8	u	u	PROPN
fnp-6382	726	9	,	,	PUNCT
fnp-6382	726	10	tracey	tracey	PROPN
fnp-6382	726	11	kj	kj	PROPN
fnp-6382	726	12	.	.	PUNCT
fnp-6382	727	1	the	the	DET
fnp-6382	727	2	many	many	ADJ
fnp-6382	727	3	faces	face	NOUN
fnp-6382	727	4	of	of	ADP
fnp-6382	727	5	hmgb1	hmgb1	NOUN
fnp-6382	727	6	:	:	PUNCT
fnp-6382	727	7	molecular	molecular	ADJ
fnp-6382	727	8	structure	structure	NOUN
fnp-6382	727	9	-	-	PUNCT
fnp-6382	727	10	functional	functional	ADJ
fnp-6382	727	11	activity	activity	NOUN
fnp-6382	727	12	in	in	ADP
fnp-6382	727	13	inflammation	inflammation	NOUN
fnp-6382	727	14	,	,	PUNCT
fnp-6382	727	15	apoptosis	apoptosis	NOUN
fnp-6382	727	16	,	,	PUNCT
fnp-6382	727	17	and	and	CCONJ
fnp-6382	727	18	chemotaxis	chemotaxis	ADJ
fnp-6382	727	19	.	.	PUNCT
fnp-6382	728	1	j	j	PROPN
fnp-6382	728	2	leukoc	leukoc	VERB
fnp-6382	728	3	biol	biol	PROPN
fnp-6382	728	4	.	.	PUNCT
fnp-6382	729	1	2013	2013	NUM
fnp-6382	729	2	feb	feb	NOUN
fnp-6382	729	3	27;93(6):865	27;93(6):865	NUM
fnp-6382	729	4	-	-	SYM
fnp-6382	729	5	73	73	NUM
fnp-6382	729	6	.	.	PUNCT
fnp-6382	730	1	https://doi.org/10.1189/jlb.1212662	https://doi.org/10.1189/jlb.1212662	PROPN
fnp-6382	730	2	93	93	NUM
fnp-6382	730	3	.	.	PUNCT
fnp-6382	731	1	paudel	paudel	PROPN
fnp-6382	731	2	yn	yn	PROPN
fnp-6382	731	3	,	,	PUNCT
fnp-6382	731	4	shaikh	shaikh	PROPN
fnp-6382	731	5	mohdf	mohdf	PROPN
fnp-6382	731	6	,	,	PUNCT
fnp-6382	731	7	chakraborti	chakraborti	NOUN
fnp-6382	731	8	a	a	NOUN
fnp-6382	731	9	,	,	PUNCT
fnp-6382	731	10	kumari	kumari	PROPN
fnp-6382	731	11	y	y	PROPN
fnp-6382	731	12	,	,	PUNCT
fnp-6382	731	13	aledo	aledo	PROPN
fnp-6382	731	14	-	-	PUNCT
fnp-6382	731	15	serrano	serrano	NOUN
fnp-6382	731	16	á	á	NOUN
fnp-6382	731	17	,	,	PUNCT
fnp-6382	731	18	aleksovska	aleksovska	ADJ
fnp-6382	731	19	k	k	NOUN
fnp-6382	731	20	,	,	PUNCT
fnp-6382	731	21	et	et	PROPN
fnp-6382	731	22	al	al	PROPN
fnp-6382	731	23	.	.	PUNCT
fnp-6382	732	1	hmgb1	hmgb1	PROPN
fnp-6382	732	2	:	:	PUNCT
fnp-6382	732	3	a	a	DET
fnp-6382	732	4	common	common	ADJ
fnp-6382	732	5	biomarker	biomarker	NOUN
fnp-6382	732	6	and	and	CCONJ
fnp-6382	732	7	potential	potential	ADJ
fnp-6382	732	8	target	target	NOUN
fnp-6382	732	9	for	for	ADP
fnp-6382	732	10	tbi	tbi	PROPN
fnp-6382	732	11	,	,	PUNCT
fnp-6382	732	12	neuroinflammation	neuroinflammation	NOUN
fnp-6382	732	13	,	,	PUNCT
fnp-6382	732	14	epilepsy	epilepsy	NOUN
fnp-6382	732	15	,	,	PUNCT
fnp-6382	732	16	and	and	CCONJ
fnp-6382	732	17	cognitive	cognitive	ADJ
fnp-6382	732	18	dysfunction	dysfunction	NOUN
fnp-6382	732	19	.	.	PUNCT
fnp-6382	733	1	front	front	ADJ
fnp-6382	733	2	neurosci	neurosci	PROPN
fnp-6382	733	3	.	.	PUNCT
fnp-6382	734	1	2018	2018	NUM
fnp-6382	734	2	sep	sep	NOUN
fnp-6382	734	3	11;12:628	11;12:628	NUM
fnp-6382	734	4	.	.	PUNCT
fnp-6382	735	1	https://doi.org/10.3389/fnins.2018.00628	https://doi.org/10.3389/fnins.2018.00628	PROPN
fnp-6382	735	2	94	94	NUM
fnp-6382	735	3	.	.	PUNCT
fnp-6382	736	1	maroso	maroso	PROPN
fnp-6382	736	2	m	m	PROPN
fnp-6382	736	3	,	,	PUNCT
fnp-6382	736	4	balosso	balosso	PROPN
fnp-6382	736	5	s	s	PART
fnp-6382	736	6	,	,	PUNCT
fnp-6382	736	7	ravizza	ravizza	PROPN
fnp-6382	736	8	t	t	PROPN
fnp-6382	736	9	,	,	PUNCT
fnp-6382	736	10	liu	liu	PROPN
fnp-6382	736	11	j	j	PROPN
fnp-6382	736	12	,	,	PUNCT
fnp-6382	736	13	aronica	aronica	PROPN
fnp-6382	736	14	e	e	NOUN
fnp-6382	736	15	,	,	PUNCT
fnp-6382	736	16	iyer	iyer	PROPN
fnp-6382	736	17	am	am	PROPN
fnp-6382	736	18	,	,	PUNCT
fnp-6382	736	19	et	et	PROPN
fnp-6382	736	20	al	al	PROPN
fnp-6382	736	21	.	.	PUNCT
fnp-6382	737	1	toll	toll	NOUN
fnp-6382	737	2	-	-	PUNCT
fnp-6382	737	3	like	like	ADJ
fnp-6382	737	4	receptor	receptor	NOUN
fnp-6382	737	5	4	4	NUM
fnp-6382	737	6	and	and	CCONJ
fnp-6382	737	7	high	high	ADJ
fnp-6382	737	8	-	-	PUNCT
fnp-6382	737	9	mobility	mobility	NOUN
fnp-6382	737	10	group	group	NOUN
fnp-6382	737	11	box-1	box-1	PRON
fnp-6382	737	12	are	be	AUX
fnp-6382	737	13	involved	involve	VERB
fnp-6382	737	14	in	in	ADP
fnp-6382	737	15	ictogenesis	ictogenesis	NOUN
fnp-6382	737	16	and	and	CCONJ
fnp-6382	737	17	can	can	AUX
fnp-6382	737	18	be	be	AUX
fnp-6382	737	19	targeted	target	VERB
fnp-6382	737	20	to	to	PART
fnp-6382	737	21	reduce	reduce	VERB
fnp-6382	737	22	seizures	seizure	NOUN
fnp-6382	737	23	.	.	PUNCT
fnp-6382	738	1	nat	nat	PROPN
fnp-6382	738	2	med	med	PROPN
fnp-6382	738	3	.	.	PUNCT
fnp-6382	739	1	2010	2010	NUM
fnp-6382	739	2	apr;16(4):413	apr;16(4):413	NOUN
fnp-6382	739	3	-	-	SYM
fnp-6382	739	4	9	9	NUM
fnp-6382	739	5	.	.	PUNCT
fnp-6382	740	1	https://doi.org/10.1038/nm.2127	https://doi.org/10.1038/nm.2127	PROPN
fnp-6382	740	2	95	95	NUM
fnp-6382	740	3	.	.	PUNCT
fnp-6382	741	1	meneghini	meneghini	ADJ
fnp-6382	741	2	v	v	NOUN
fnp-6382	741	3	,	,	PUNCT
fnp-6382	741	4	bortolotto	bortolotto	ADJ
fnp-6382	741	5	v	v	NOUN
fnp-6382	741	6	,	,	PUNCT
fnp-6382	741	7	francese	francese	PROPN
fnp-6382	741	8	mt	mt	PROPN
fnp-6382	741	9	,	,	PUNCT
fnp-6382	741	10	dellarole	dellarole	VERB
fnp-6382	741	11	a	a	PRON
fnp-6382	741	12	,	,	PUNCT
fnp-6382	741	13	carraro	carraro	NOUN
fnp-6382	741	14	l	l	PROPN
fnp-6382	741	15	,	,	PUNCT
fnp-6382	741	16	terzieva	terzieva	PROPN
fnp-6382	741	17	s	s	PROPN
fnp-6382	741	18	,	,	PUNCT
fnp-6382	741	19	et	et	PROPN
fnp-6382	741	20	al	al	PROPN
fnp-6382	741	21	.	.	PROPN
fnp-6382	741	22	high	high	ADJ
fnp-6382	741	23	-	-	PUNCT
fnp-6382	741	24	mobility	mobility	NOUN
fnp-6382	741	25	group	group	NOUN
fnp-6382	741	26	box-1	box-1	NOUN
fnp-6382	741	27	protein	protein	NOUN
fnp-6382	741	28	and	and	CCONJ
fnp-6382	741	29	β	β	NOUN
fnp-6382	741	30	-	-	ADJ
fnp-6382	741	31	amyloid	amyloid	ADJ
fnp-6382	741	32	oligomers	oligomer	NOUN
fnp-6382	741	33	promote	promote	VERB
fnp-6382	741	34	neuronal	neuronal	ADJ
fnp-6382	741	35	differentiation	differentiation	NOUN
fnp-6382	741	36	of	of	ADP
fnp-6382	741	37	adult	adult	NOUN
fnp-6382	741	38	hippocampal	hippocampal	ADJ
fnp-6382	741	39	neural	neural	ADJ
fnp-6382	741	40	progenitors	progenitor	NOUN
fnp-6382	741	41	via	via	ADP
fnp-6382	741	42	receptor	receptor	NOUN
fnp-6382	741	43	for	for	ADP
fnp-6382	741	44	advanced	advanced	ADJ
fnp-6382	741	45	glycation	glycation	NOUN
fnp-6382	741	46	end	end	NOUN
fnp-6382	741	47	products	product	NOUN
fnp-6382	741	48	/	/	SYM
fnp-6382	741	49	nuclear	nuclear	ADJ
fnp-6382	741	50	factor	factor	NOUN
fnp-6382	741	51	-	-	PUNCT
fnp-6382	741	52	κb	κb	NOUN
fnp-6382	741	53	axis	axis	NOUN
fnp-6382	741	54	:	:	PUNCT
fnp-6382	741	55	relevance	relevance	NOUN
fnp-6382	741	56	for	for	ADP
fnp-6382	741	57	alzheimer	alzheimer	PROPN
fnp-6382	741	58	's	's	PART
fnp-6382	741	59	disease	disease	NOUN
fnp-6382	741	60	.	.	PUNCT
fnp-6382	742	1	j	j	PROPN
fnp-6382	742	2	neurosci	neurosci	PROPN
fnp-6382	742	3	.	.	PUNCT
fnp-6382	743	1	2013	2013	NUM
fnp-6382	743	2	apr	apr	NOUN
fnp-6382	743	3	3;33(14):6047	3;33(14):6047	VERB
fnp-6382	743	4	-	-	SYM
fnp-6382	743	5	59	59	NUM
fnp-6382	743	6	.	.	PUNCT
fnp-6382	744	1	https://doi.org/10.1523/jneurosci.2052-12.2013	https://doi.org/10.1523/jneurosci.2052-12.2013	PROPN
fnp-6382	744	2	96	96	NUM
fnp-6382	744	3	.	.	PUNCT
fnp-6382	745	1	dukay	dukay	PROPN
fnp-6382	745	2	b	b	NOUN
fnp-6382	745	3	,	,	PUNCT
fnp-6382	745	4	csoboz	csoboz	ADJ
fnp-6382	745	5	b	b	PROPN
fnp-6382	745	6	,	,	PUNCT
fnp-6382	745	7	tóth	tóth	NOUN
fnp-6382	745	8	me	i	PRON
fnp-6382	745	9	.	.	PUNCT
fnp-6382	746	1	heat	heat	NOUN
fnp-6382	746	2	-	-	PUNCT
fnp-6382	746	3	shock	shock	NOUN
fnp-6382	746	4	proteins	protein	NOUN
fnp-6382	746	5	in	in	ADP
fnp-6382	746	6	neuroinflammation	neuroinflammation	NOUN
fnp-6382	746	7	.	.	PUNCT
fnp-6382	747	1	front	front	ADJ
fnp-6382	747	2	pharmacol	pharmacol	PROPN
fnp-6382	747	3	.	.	PUNCT
fnp-6382	748	1	2019	2019	NUM
fnp-6382	748	2	aug	aug	PROPN
fnp-6382	748	3	27;10:920	27;10:920	NUM
fnp-6382	748	4	.	.	PUNCT
fnp-6382	749	1	https://doi.org/10.3389/fphar.2019.00920	https://doi.org/10.3389/fphar.2019.00920	PROPN
fnp-6382	749	2	97	97	NUM
fnp-6382	749	3	.	.	PUNCT
fnp-6382	749	4	hu	hu	PROPN
fnp-6382	750	1	c	c	PROPN
fnp-6382	750	2	,	,	PUNCT
fnp-6382	750	3	yang	yang	PROPN
fnp-6382	750	4	j	j	PROPN
fnp-6382	750	5	,	,	PUNCT
fnp-6382	750	6	qi	qi	PROPN
fnp-6382	750	7	z	z	PROPN
fnp-6382	750	8	,	,	PUNCT
fnp-6382	750	9	wu	wu	PROPN
fnp-6382	750	10	h	h	PROPN
fnp-6382	750	11	,	,	PUNCT
fnp-6382	750	12	wang	wang	PROPN
fnp-6382	750	13	b	b	PROPN
fnp-6382	750	14	,	,	PUNCT
fnp-6382	750	15	zou	zou	PROPN
fnp-6382	750	16	f	f	PROPN
fnp-6382	750	17	,	,	PUNCT
fnp-6382	750	18	et	et	PROPN
fnp-6382	750	19	al	al	PROPN
fnp-6382	750	20	.	.	PROPN
fnp-6382	750	21	heat	heat	NOUN
fnp-6382	750	22	shock	shock	NOUN
fnp-6382	750	23	proteins	protein	NOUN
fnp-6382	750	24	:	:	PUNCT
fnp-6382	750	25	biological	biological	ADJ
fnp-6382	750	26	functions	function	NOUN
fnp-6382	750	27	,	,	PUNCT
fnp-6382	750	28	pathological	pathological	ADJ
fnp-6382	750	29	roles	role	NOUN
fnp-6382	750	30	,	,	PUNCT
fnp-6382	750	31	and	and	CCONJ
fnp-6382	750	32	therapeutic	therapeutic	ADJ
fnp-6382	750	33	opportunities	opportunity	NOUN
fnp-6382	750	34	.	.	PUNCT
fnp-6382	751	1	medcomm	medcomm	NOUN
fnp-6382	751	2	.	.	PUNCT
fnp-6382	752	1	2022	2022	NUM
fnp-6382	752	2	sep;3(3):e161	sep;3(3):e161	PROPN
fnp-6382	752	3	.	.	PUNCT
fnp-6382	753	1	https://doi.org/10.1002/mco2.161	https://doi.org/10.1002/mco2.161	PROPN
fnp-6382	753	2	98	98	NUM
fnp-6382	753	3	.	.	PUNCT
fnp-6382	754	1	bonneh	bonneh	NOUN
fnp-6382	754	2	-	-	PUNCT
fnp-6382	754	3	barkay	barkay	PROPN
fnp-6382	754	4	d	d	PROPN
fnp-6382	754	5	,	,	PUNCT
fnp-6382	754	6	wang	wang	PROPN
fnp-6382	754	7	g	g	PROPN
fnp-6382	754	8	,	,	PUNCT
fnp-6382	754	9	starkey	starkey	PROPN
fnp-6382	754	10	a	a	PRON
fnp-6382	754	11	,	,	PUNCT
fnp-6382	754	12	hamilton	hamilton	PROPN
fnp-6382	754	13	rl	rl	PROPN
fnp-6382	754	14	,	,	PUNCT
fnp-6382	754	15	wiley	wiley	PROPN
fnp-6382	754	16	ca	ca	PROPN
fnp-6382	754	17	.	.	PUNCT
fnp-6382	755	1	in	in	ADP
fnp-6382	755	2	vivo	vivo	ADJ
fnp-6382	755	3	chi3l1	chi3l1	NOUN
fnp-6382	755	4	(	(	PUNCT
fnp-6382	755	5	ykl-40	ykl-40	NOUN
fnp-6382	755	6	)	)	PUNCT
fnp-6382	755	7	expression	expression	NOUN
fnp-6382	755	8	in	in	ADP
fnp-6382	755	9	astrocytes	astrocyte	NOUN
fnp-6382	755	10	in	in	ADP
fnp-6382	755	11	acute	acute	ADJ
fnp-6382	755	12	and	and	CCONJ
fnp-6382	755	13	chronic	chronic	ADJ
fnp-6382	755	14	neurological	neurological	ADJ
fnp-6382	755	15	diseases	disease	NOUN
fnp-6382	755	16	.	.	PUNCT
fnp-6382	756	1	j	j	PROPN
fnp-6382	756	2	neuroinflammation	neuroinflammation	PROPN
fnp-6382	756	3	.	.	PUNCT
fnp-6382	757	1	2010;7(1):34	2010;7(1):34	NUM
fnp-6382	757	2	.	.	PUNCT
fnp-6382	758	1	https://doi.org/10.1186/1742-2094-7-34	https://doi.org/10.1186/1742-2094-7-34	PROPN
fnp-6382	759	1	99	99	NUM
fnp-6382	759	2	.	.	PUNCT
fnp-6382	760	1	craig	craig	PROPN
fnp-6382	760	2	-	-	PUNCT
fnp-6382	760	3	schapiro	schapiro	PROPN
fnp-6382	760	4	r	r	NOUN
fnp-6382	760	5	,	,	PUNCT
fnp-6382	760	6	perrin	perrin	PROPN
fnp-6382	760	7	rj	rj	PROPN
fnp-6382	760	8	,	,	PUNCT
fnp-6382	760	9	roe	roe	PROPN
fnp-6382	760	10	cm	cm	PROPN
fnp-6382	760	11	,	,	PUNCT
fnp-6382	760	12	xiong	xiong	PROPN
fnp-6382	760	13	c	c	PROPN
fnp-6382	760	14	,	,	PUNCT
fnp-6382	760	15	carter	carter	PROPN
fnp-6382	760	16	d	d	PROPN
fnp-6382	760	17	,	,	PUNCT
fnp-6382	760	18	cairns	cairns	PROPN
fnp-6382	760	19	nj	nj	PROPN
fnp-6382	760	20	,	,	PUNCT
fnp-6382	760	21	et	et	PROPN
fnp-6382	760	22	al	al	PROPN
fnp-6382	760	23	.	.	PUNCT
fnp-6382	761	1	ykl-40	ykl-40	PROPN
fnp-6382	761	2	:	:	PUNCT
fnp-6382	761	3	a	a	DET
fnp-6382	761	4	novel	novel	ADJ
fnp-6382	761	5	prognostic	prognostic	ADJ
fnp-6382	761	6	fluid	fluid	NOUN
fnp-6382	761	7	biomarker	biomarker	NOUN
fnp-6382	761	8	for	for	ADP
fnp-6382	761	9	preclinical	preclinical	ADJ
fnp-6382	761	10	alzheimer	alzheimer	NOUN
fnp-6382	761	11	's	's	PART
fnp-6382	761	12	disease	disease	NOUN
fnp-6382	761	13	.	.	PUNCT
fnp-6382	762	1	biol	biol	PROPN
fnp-6382	762	2	psychiatry	psychiatry	NOUN
fnp-6382	762	3	.	.	PUNCT
fnp-6382	763	1	2010	2010	NUM
fnp-6382	764	1	nov;68(10):903	nov;68(10):903	NUM
fnp-6382	764	2	-	-	SYM
fnp-6382	764	3	12	12	NUM
fnp-6382	764	4	.	.	PUNCT
fnp-6382	765	1	https://doi.org/10.1016/j.biopsych.2010.08.025	https://doi.org/10.1016/j.biopsych.2010.08.025	PROPN
fnp-6382	765	2	100	100	NUM
fnp-6382	765	3	.	.	PUNCT
fnp-6382	766	1	yu	yu	PROPN
fnp-6382	766	2	j	j	PROPN
fnp-6382	766	3	,	,	PUNCT
fnp-6382	766	4	zhu	zhu	PROPN
fnp-6382	766	5	h	h	NOUN
fnp-6382	766	6	,	,	PUNCT
fnp-6382	766	7	taheri	taheri	NOUN
fnp-6382	766	8	s	s	PROPN
fnp-6382	766	9	,	,	PUNCT
fnp-6382	766	10	mondy	mondy	PROPN
fnp-6382	766	11	w	w	PROPN
fnp-6382	766	12	,	,	PUNCT
fnp-6382	766	13	perry	perry	PROPN
fnp-6382	766	14	s	s	PROPN
fnp-6382	766	15	,	,	PUNCT
fnp-6382	766	16	kindy	kindy	PROPN
fnp-6382	766	17	ms	ms	PROPN
fnp-6382	766	18	.	.	PROPN
fnp-6382	766	19	impact	impact	NOUN
fnp-6382	766	20	of	of	ADP
fnp-6382	766	21	nutrition	nutrition	NOUN
fnp-6382	766	22	on	on	ADP
fnp-6382	766	23	inflammation	inflammation	NOUN
fnp-6382	766	24	,	,	PUNCT
fnp-6382	766	25	tauopathy	tauopathy	ADJ
fnp-6382	766	26	,	,	PUNCT
fnp-6382	766	27	and	and	CCONJ
fnp-6382	766	28	behavioral	behavioral	ADJ
fnp-6382	766	29	outcomes	outcome	NOUN
fnp-6382	766	30	from	from	ADP
fnp-6382	766	31	chronic	chronic	ADJ
fnp-6382	766	32	traumatic	traumatic	ADJ
fnp-6382	766	33	encephalopathy	encephalopathy	NOUN
fnp-6382	766	34	.	.	PUNCT
fnp-6382	767	1	j	j	PROPN
fnp-6382	767	2	neuroinflammation	neuroinflammation	PROPN
fnp-6382	767	3	.	.	PUNCT
fnp-6382	768	1	2018	2018	NUM
fnp-6382	768	2	dec;15(1):277	dec;15(1):277	PROPN
fnp-6382	768	3	.	.	PUNCT
fnp-6382	769	1	https://doi.org/10.1186/s12974-018-1312-4	https://doi.org/10.1186/s12974-018-1312-4	NUM
fnp-6382	769	2	101	101	NUM
fnp-6382	769	3	.	.	PUNCT
fnp-6382	770	1	bieniek	bieniek	PROPN
fnp-6382	770	2	kf	kf	PROPN
fnp-6382	770	3	,	,	PUNCT
fnp-6382	770	4	cairns	cairns	PROPN
fnp-6382	770	5	nj	nj	PROPN
fnp-6382	770	6	,	,	PUNCT
fnp-6382	770	7	crary	crary	PROPN
fnp-6382	770	8	jf	jf	PROPN
fnp-6382	770	9	,	,	PUNCT
fnp-6382	770	10	dickson	dickson	PROPN
fnp-6382	770	11	dw	dw	PROPN
fnp-6382	770	12	,	,	PUNCT
fnp-6382	770	13	folkerth	folkerth	PROPN
fnp-6382	770	14	rd	rd	PROPN
fnp-6382	770	15	,	,	PUNCT
fnp-6382	770	16	keene	keene	PROPN
fnp-6382	770	17	cd	cd	PROPN
fnp-6382	770	18	,	,	PUNCT
fnp-6382	770	19	et	et	PROPN
fnp-6382	770	20	al	al	PROPN
fnp-6382	770	21	.	.	PUNCT
fnp-6382	771	1	the	the	DET
fnp-6382	771	2	second	second	ADJ
fnp-6382	771	3	ninds	nind	NOUN
fnp-6382	771	4	/	/	SYM
fnp-6382	771	5	nibib	nibib	NOUN
fnp-6382	771	6	consensus	consensus	NOUN
fnp-6382	771	7	meeting	meeting	NOUN
fnp-6382	771	8	to	to	PART
fnp-6382	771	9	define	define	VERB
fnp-6382	771	10	neuropathological	neuropathological	ADJ
fnp-6382	771	11	criteria	criterion	NOUN
fnp-6382	771	12	for	for	ADP
fnp-6382	771	13	the	the	DET
fnp-6382	771	14	diagnosis	diagnosis	NOUN
fnp-6382	771	15	of	of	ADP
fnp-6382	771	16	chronic	chronic	ADJ
fnp-6382	771	17	traumatic	traumatic	ADJ
fnp-6382	771	18	encephalopathy	encephalopathy	NOUN
fnp-6382	771	19	.	.	PUNCT
fnp-6382	772	1	j	j	PROPN
fnp-6382	772	2	neuropathol	neuropathol	PROPN
fnp-6382	772	3	exp	exp	PROPN
fnp-6382	772	4	neurol	neurol	NOUN
fnp-6382	772	5	.	.	PUNCT
fnp-6382	773	1	2021	2021	NUM
fnp-6382	773	2	feb	feb	PROPN
fnp-6382	773	3	22;80(3):210	22;80(3):210	NUM
fnp-6382	773	4	-	-	SYM
fnp-6382	773	5	9	9	NUM
fnp-6382	773	6	.	.	PUNCT
fnp-6382	773	7	https://doi.org/10.1093/jnen/nlab066	https://doi.org/10.1093/jnen/nlab066	PROPN
fnp-6382	773	8	102	102	NUM
fnp-6382	773	9	.	.	PUNCT
fnp-6382	773	10	stathas	stathas	PROPN
fnp-6382	773	11	s	s	PROPN
fnp-6382	773	12	,	,	PUNCT
fnp-6382	773	13	alvarez	alvarez	PROPN
fnp-6382	773	14	ve	ve	PROPN
fnp-6382	773	15	,	,	PUNCT
fnp-6382	773	16	xia	xia	PROPN
fnp-6382	773	17	w	w	PROPN
fnp-6382	773	18	,	,	PUNCT
fnp-6382	773	19	nicks	nick	NOUN
fnp-6382	773	20	r	r	NOUN
fnp-6382	773	21	,	,	PUNCT
fnp-6382	773	22	meng	meng	PROPN
fnp-6382	773	23	g	g	PROPN
fnp-6382	773	24	,	,	PUNCT
fnp-6382	773	25	daley	daley	PROPN
fnp-6382	773	26	s	s	PROPN
fnp-6382	773	27	,	,	PUNCT
fnp-6382	773	28	et	et	PROPN
fnp-6382	773	29	al	al	PROPN
fnp-6382	773	30	.	.	PUNCT
fnp-6382	774	1	tau	tau	PROPN
fnp-6382	774	2	phosphorylation	phosphorylation	NOUN
fnp-6382	774	3	sites	site	NOUN
fnp-6382	774	4	serine202	serine202	PROPN
fnp-6382	774	5	and	and	CCONJ
fnp-6382	774	6	serine396	serine396	PROPN
fnp-6382	774	7	are	be	AUX
fnp-6382	774	8	differently	differently	ADV
fnp-6382	774	9	altered	alter	VERB
fnp-6382	774	10	in	in	ADP
fnp-6382	774	11	chronic	chronic	ADJ
fnp-6382	774	12	traumatic	traumatic	ADJ
fnp-6382	774	13	encephalopathy	encephalopathy	NOUN
fnp-6382	774	14	and	and	CCONJ
fnp-6382	774	15	alzheimer	alzheimer	PROPN
fnp-6382	774	16	's	's	PART
fnp-6382	774	17	disease	disease	NOUN
fnp-6382	774	18	.	.	PUNCT
fnp-6382	775	1	alzheimers	alzheimers	PROPN
fnp-6382	775	2	dement	dement	PROPN
fnp-6382	775	3	.	.	PUNCT
fnp-6382	776	1	2022	2022	NUM
fnp-6382	776	2	aug;18(8):1511	aug;18(8):1511	PROPN
fnp-6382	776	3	-	-	PUNCT
fnp-6382	776	4	22	22	NUM
fnp-6382	776	5	.	.	PUNCT
fnp-6382	777	1	https://doi.org/10.1002/alz.12502	https://doi.org/10.1002/alz.12502	PROPN
fnp-6382	777	2	103	103	NUM
fnp-6382	777	3	.	.	PUNCT
fnp-6382	778	1	mez	mez	PROPN
fnp-6382	778	2	j	j	PROPN
fnp-6382	778	3	,	,	PUNCT
fnp-6382	778	4	solomon	solomon	PROPN
fnp-6382	778	5	tm	tm	PROPN
fnp-6382	778	6	,	,	PUNCT
fnp-6382	778	7	daneshvar	daneshvar	NOUN
fnp-6382	778	8	dh	dh	PROPN
fnp-6382	778	9	,	,	PUNCT
fnp-6382	778	10	murphy	murphy	PROPN
fnp-6382	778	11	l	l	PROPN
fnp-6382	778	12	,	,	PUNCT
fnp-6382	778	13	kiernan	kiernan	PROPN
fnp-6382	778	14	pt	pt	PROPN
fnp-6382	778	15	,	,	PUNCT
fnp-6382	778	16	montenigro	montenigro	ADJ
fnp-6382	778	17	ph	ph	PROPN
fnp-6382	778	18	,	,	PUNCT
fnp-6382	778	19	et	et	PROPN
fnp-6382	778	20	al	al	PROPN
fnp-6382	778	21	.	.	PUNCT
fnp-6382	778	22	assessing	assess	VERB
fnp-6382	778	23	clinicopathological	clinicopathological	ADJ
fnp-6382	778	24	correlation	correlation	NOUN
fnp-6382	778	25	in	in	ADP
fnp-6382	778	26	chronic	chronic	ADJ
fnp-6382	778	27	traumatic	traumatic	ADJ
fnp-6382	778	28	encephalopathy	encephalopathy	NOUN
fnp-6382	778	29	:	:	PUNCT
fnp-6382	778	30	rationale	rationale	NOUN
fnp-6382	778	31	and	and	CCONJ
fnp-6382	778	32	methods	method	NOUN
fnp-6382	778	33	for	for	ADP
fnp-6382	778	34	the	the	DET
fnp-6382	778	35	unite	unite	NOUN
fnp-6382	778	36	study	study	NOUN
fnp-6382	778	37	.	.	PUNCT
fnp-6382	779	1	alzheimers	alzheimer	NOUN
fnp-6382	779	2	res	re	VERB
fnp-6382	779	3	ther	ther	ADV
fnp-6382	779	4	.	.	PUNCT
fnp-6382	780	1	2015	2015	NUM
fnp-6382	780	2	dec;7(1):62	dec;7(1):62	NOUN
fnp-6382	780	3	.	.	PUNCT
fnp-6382	781	1	https://doi.org/10.1186/s13195-015-0148-8	https://doi.org/10.1186/s13195-015-0148-8	NUM
fnp-6382	781	2	104	104	NUM
fnp-6382	781	3	.	.	PUNCT
fnp-6382	782	1	gard	gard	PROPN
fnp-6382	782	2	a	a	DET
fnp-6382	782	3	,	,	PUNCT
fnp-6382	782	4	vedung	vedung	PROPN
fnp-6382	782	5	f	f	PROPN
fnp-6382	782	6	,	,	PUNCT
fnp-6382	782	7	piehl	piehl	PROPN
fnp-6382	782	8	f	f	PROPN
fnp-6382	782	9	,	,	PUNCT
fnp-6382	782	10	khademi	khademi	PROPN
fnp-6382	782	11	m	m	PROPN
fnp-6382	782	12	,	,	PUNCT
fnp-6382	782	13	wernersson	wernersson	PROPN
fnp-6382	782	14	mp	mp	PROPN
fnp-6382	782	15	,	,	PUNCT
fnp-6382	782	16	rorsman	rorsman	NOUN
fnp-6382	782	17	i	i	PROPN
fnp-6382	782	18	,	,	PUNCT
fnp-6382	782	19	et	et	PROPN
fnp-6382	782	20	al	al	PROPN
fnp-6382	782	21	.	.	PUNCT
fnp-6382	782	22	cerebrospinal	cerebrospinal	ADJ
fnp-6382	782	23	fluid	fluid	ADJ
fnp-6382	782	24	levels	level	NOUN
fnp-6382	782	25	of	of	ADP
fnp-6382	782	26	neuroinflammatory	neuroinflammatory	ADJ
fnp-6382	782	27	biomarkers	biomarker	NOUN
fnp-6382	782	28	are	be	AUX
fnp-6382	782	29	increased	increase	VERB
fnp-6382	782	30	in	in	ADP
fnp-6382	782	31	athletes	athlete	NOUN
fnp-6382	782	32	with	with	ADP
fnp-6382	782	33	persistent	persistent	ADJ
fnp-6382	782	34	post	post	ADJ
fnp-6382	782	35	-	-	ADJ
fnp-6382	782	36	concussive	concussive	ADJ
fnp-6382	782	37	symptoms	symptom	NOUN
fnp-6382	782	38	following	follow	VERB
fnp-6382	782	39	sports	sport	NOUN
fnp-6382	782	40	-	-	PUNCT
fnp-6382	782	41	related	relate	VERB
fnp-6382	782	42	concussion	concussion	NOUN
fnp-6382	782	43	.	.	PUNCT
fnp-6382	783	1	j	j	PROPN
fnp-6382	783	2	neuroinflammation	neuroinflammation	PROPN
fnp-6382	783	3	.	.	PUNCT
fnp-6382	784	1	2023	2023	NUM
fnp-6382	784	2	aug	aug	PROPN
fnp-6382	784	3	17;20(1):189	17;20(1):189	NUM
fnp-6382	784	4	.	.	PUNCT
fnp-6382	784	5	https://doi.org/10.1186/s12974-023-02864-0	https://doi.org/10.1186/s12974-023-02864-0	NUM
fnp-6382	784	6	copyright	copyright	NOUN
fnp-6382	784	7	:	:	PUNCT
fnp-6382	784	8	©	©	PROPN
fnp-6382	784	9	2025	2025	NUM
fnp-6382	784	10	the	the	DET
fnp-6382	784	11	author(s	author(s	NOUN
fnp-6382	784	12	)	)	PUNCT
fnp-6382	784	13	.	.	PUNCT
fnp-6382	785	1	this	this	PRON
fnp-6382	785	2	is	be	AUX
fnp-6382	785	3	an	an	DET
fnp-6382	785	4	open	open	ADJ
fnp-6382	785	5	access	access	NOUN
fnp-6382	785	6	article	article	NOUN
fnp-6382	785	7	distributed	distribute	VERB
fnp-6382	785	8	under	under	ADP
fnp-6382	785	9	the	the	DET
fnp-6382	785	10	terms	term	NOUN
fnp-6382	785	11	of	of	ADP
fnp-6382	785	12	the	the	DET
fnp-6382	785	13	creative	creative	ADJ
fnp-6382	785	14	commons	common	NOUN
fnp-6382	785	15	attribution	attribution	NOUN
fnp-6382	785	16	4.0	4.0	NUM
fnp-6382	785	17	international	international	ADJ
fnp-6382	785	18	license	license	NOUN
fnp-6382	785	19	(	(	PUNCT
fnp-6382	785	20	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
fnp-6382	785	21	)	)	PUNCT
fnp-6382	785	22	,	,	PUNCT
fnp-6382	785	23	which	which	PRON
fnp-6382	785	24	permits	permit	VERB
fnp-6382	785	25	unrestricted	unrestricted	ADJ
fnp-6382	785	26	use	use	NOUN
fnp-6382	785	27	,	,	PUNCT
fnp-6382	785	28	distribution	distribution	NOUN
fnp-6382	785	29	,	,	PUNCT
fnp-6382	785	30	and	and	CCONJ
fnp-6382	785	31	reproduction	reproduction	NOUN
fnp-6382	785	32	in	in	ADP
fnp-6382	785	33	any	any	DET
fnp-6382	785	34	medium	medium	NOUN
fnp-6382	785	35	,	,	PUNCT
fnp-6382	785	36	provided	provide	VERB
fnp-6382	785	37	the	the	DET
fnp-6382	785	38	original	original	ADJ
fnp-6382	785	39	author	author	NOUN
fnp-6382	785	40	and	and	CCONJ
fnp-6382	785	41	source	source	NOUN
fnp-6382	785	42	are	be	AUX
fnp-6382	785	43	credited	credit	VERB
fnp-6382	785	44	,	,	PUNCT
fnp-6382	785	45	a	a	DET
fnp-6382	785	46	link	link	NOUN
fnp-6382	785	47	to	to	ADP
fnp-6382	785	48	the	the	DET
fnp-6382	785	49	creative	creative	ADJ
fnp-6382	785	50	commons	common	NOUN
fnp-6382	785	51	license	license	NOUN
fnp-6382	785	52	is	be	AUX
fnp-6382	785	53	provided	provide	VERB
fnp-6382	785	54	,	,	PUNCT
fnp-6382	785	55	and	and	CCONJ
fnp-6382	785	56	any	any	DET
fnp-6382	785	57	changes	change	NOUN
fnp-6382	785	58	are	be	AUX
fnp-6382	785	59	indicated	indicate	VERB
fnp-6382	785	60	.	.	PUNCT
fnp-6382	786	1	the	the	DET
fnp-6382	786	2	creative	creative	ADJ
fnp-6382	786	3	commons	common	NOUN
fnp-6382	786	4	public	public	ADJ
fnp-6382	786	5	domain	domain	NOUN
fnp-6382	786	6	dedication	dedication	NOUN
fnp-6382	786	7	waiver	waiver	NOUN
fnp-6382	786	8	(	(	PUNCT
fnp-6382	786	9	https://creativecommons.org/publicdomain/zero/1.0/	https://creativecommons.org/publicdomain/zero/1.0/	PROPN
fnp-6382	786	10	)	)	PUNCT
fnp-6382	786	11	applies	apply	VERB
fnp-6382	786	12	to	to	ADP
fnp-6382	786	13	the	the	DET
fnp-6382	786	14	data	datum	NOUN
fnp-6382	786	15	made	make	VERB
fnp-6382	786	16	available	available	ADJ
fnp-6382	786	17	in	in	ADP
fnp-6382	786	18	this	this	DET
fnp-6382	786	19	article	article	NOUN
fnp-6382	786	20	,	,	PUNCT
fnp-6382	786	21	unless	unless	SCONJ
fnp-6382	786	22	otherwise	otherwise	ADV
fnp-6382	786	23	stated	state	VERB
fnp-6382	786	24	.	.	PUNCT